---
document_datetime: 2023-09-21 20:33:08
document_pages: 162
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/blincyto-h-c-3731-ii-0038-epar-assessment-report-variation_en.pdf
document_name: blincyto-h-c-3731-ii-0038-epar-assessment-report-variation_en.pdf
version: success
processing_time: 258.8259395
conversion_datetime: 2025-12-17 14:19:29.357464
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

20 May 2021 EMA/CHMP/241758/2021 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## BLINCYTO

International non-proprietary name: blinatumomab

Procedure No. EMEA/H/C/003731/II/0038

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................7                                     |                                                                                                              |
|-------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation .....................................................................................................7 |                                                                                                              |
| 1.2. Steps taken for the assessment of the product                                                                            | ..........................................................8                                                  |
| 2. Scientific discussion................................................................................8                     |                                                                                                              |
| 2.1. Introduction                                                                                                             | ...........................................................................................................8 |
| 2.1.1. Problem statement...............................................................................................8      |                                                                                                              |
| 2.1.2. About the product..............................................................................................10      |                                                                                                              |
| 2.2. Non-clinical aspects...............................................................................................10    |                                                                                                              |
| 2.2.1. Ecotoxicity/environmental risk assessment...........................................................10                 |                                                                                                              |
| 2.2.2. Conclusion on the non-clinical aspects                                                                                 | .................................................................11                                          |
| 2.3. Clinical aspects.....................................................................................................11  |                                                                                                              |
| 2.3.1. Introduction.......................................................................................................11  |                                                                                                              |
| 2.3.2. Pharmacokinetics                                                                                                       | ...............................................................................................12            |
| 2.3.3. Pharmacodynamics                                                                                                       | ............................................................................................55               |
| 2.3.4. PK/PD modelling                                                                                                        | ................................................................................................55           |
| 2.3.5. Discussion on clinical pharmacology.....................................................................64             |                                                                                                              |
| 2.3.6. Conclusions on clinical pharmacology...................................................................67              |                                                                                                              |
| 2.4. Clinical efficacy                                                                                                        | .....................................................................................................67      |
| 2.4.1. Dose response study                                                                                                    | ..........................................................................................67                 |
| 2.4.2. Main study.........................................................................................................68  |                                                                                                              |
| 2.4.3. Discussion on clinical efficacy ............................................................................           | 102                                                                                                          |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................              | 106                                                                                                          |
| 2.5. Clinical safety                                                                                                          | ..................................................................................................... 107    |
| 2.5.1. Discussion on clinical safety ..............................................................................           | 144                                                                                                          |
| 2.5.2. Conclusions on clinical safety ............................................................................            | 147                                                                                                          |
| 2.5.3. PSUR cycle                                                                                                             | ...................................................................................................... 147   |
| 2.6. Risk management plan........................................................................................             | 147                                                                                                          |
| 2.7. Update of the Product information........................................................................                | 153                                                                                                          |
| 2.7.1. User consultation                                                                                                      | ............................................................................................. 154            |
| 3. Benefit-Risk Balance...........................................................................154                         |                                                                                                              |
| 3.1. Therapeutic Context............................................................................................          | 154                                                                                                          |
| 3.1.1. Disease or condition                                                                                                   | ......................................................................................... 154                |
| 3.1.2. Available therapies and unmet medical need                                                                             | ...................................................... 154                                                   |
| 3.1.3. Main clinical studies..........................................................................................        | 155                                                                                                          |
| 3.2. Favourable effects...............................................................................................        | 156                                                                                                          |
| 3.3. Uncertainties and limitations about favourable effects ............................................                      | 156                                                                                                          |
| 3.4. Unfavourable effects ...........................................................................................         | 157                                                                                                          |
| 3.5. Uncertainties and limitations about unfavourable effects                                                                 | ........................................ 158                                                                 |
| 3.6. Effects Table.......................................................................................................     | 158                                                                                                          |
| 3.7. Benefit-risk assessment and discussion.................................................................                  | 160                                                                                                          |
| 3.7.1. Importance of favourable and unfavourable effects                                                                      | ............................................. 160                                                            |
| 3.7.2. Balance of benefits and risks.............................................................................             | 161                                                                                                          |
| 3.7.3. Additional considerations on the benefit-risk balance...........................................                       | 161                                                                                                          |

<div style=\"page-break-after: always\"></div>

## 3.8. Conclusions ........................................................................................................ 161 4. Recommendations...............................................................................  161 5. EPAR changes .....................................................................................  162

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ACS American Cancer Society ADR adverse drug reaction AE adverse event AESI Adverse Events of Special Interest ALL acute lymphoblastic leukemia ALT alanine aminotransferase AMQ Amgen-defined MedDRA query AST aspartate aminotransferase bcr-abl fusion gene 9 and 22 [t(9;22) (q34:q11)] genetic mutation/translocation BiTE bispecific T-cell engager CCyR complete cytogenetic response CHR complete hematologic remission CI confidence interval CIOMS Council for International Organizations of Medical Sciences cIV continuous intravenous infusion CL clearance CML chronic myeloid leukemia CNS central nervous system CR complete response/remission CrCL creatinine clearance CRh* complete response with partial recovery of peripheral blood counts CRi complete response with incomplete recovery of peripheral blood counts CRS cytokine release syndrome CSR Clinical Study Report Css steady state concentration CSS Clinical Safety Summary CTCAE  Common Terminology Criteria for Adverse Events DMC Data Monitoring Committe ECG electrocardiogram ECOG   Eastern Cooperative Oncology Group EMA European Medicines Agency EOI event of interest

<div style=\"page-break-after: always\"></div>

| EPAR                                                | European Public Assessment Report                                                                                           |
|-----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|
| EU                                                  | European Union                                                                                                              |
| FDA                                                 | Food and Drug Administration                                                                                                |
| FISH                                                | fluorescence in-situ hybridization                                                                                          |
| GGT                                                 | gamma-glutamyltransferase                                                                                                   |
| HC                                                  | high-risk consolidation 3 chemotherapy                                                                                      |
| HC3                                                 | third block of HC chemotherapy                                                                                              |
| HR                                                  | hazard ratio                                                                                                                |
| HSCT                                                | hematopoietic stem cell transplantation                                                                                     |
| ICH                                                 | International Council on Harmonisation                                                                                      |
| IgG                                                 | immunoglobulin                                                                                                              |
| IPD                                                 | important protocol deviation                                                                                                |
| IPTW                                                | inverse probability of treatment weights                                                                                    |
| iSAP                                                | integrated Statistical Analysis Plan                                                                                        |
| IV                                                  | intravenous                                                                                                                 |
| M0                                                  | Representative bone marrow aspirate or biopsy with blasts <5%, with very low cellularity and                                |
| with no regenerating hematopoiesis                  | with no regenerating hematopoiesis                                                                                          |
| M1 with                                             | Representative bone marrow aspirate or biopsy with blasts <5%, with satisfactory cellularity and regenerating hematopoiesis |
| M2                                                  | Representative bone marrow aspirate or biopsy with ≥ 5% and <25% blasts                                                     |
| M3                                                  | Representative bone marrow aspirate or biopsy with ≥ 25% blasts                                                             |
| MAA                                                 | marketing authorization application                                                                                         |
| MaCyR                                               | Major cytogenetic response/remission                                                                                        |
| MaHR                                                | major hematologic response/remission                                                                                        |
| MedDRA Medical Dictionary for Regulatory Activities | MedDRA Medical Dictionary for Regulatory Activities                                                                         |
| MRD                                                 | minimal residual disease                                                                                                    |
| NCCN                                                | National Comprehensive Cancer Network                                                                                       |
| NE                                                  | not estimable                                                                                                               |
| OS                                                  | overall survival                                                                                                            |
| PBRER                                               | Periodic Benefit Risk Evaluation Reports                                                                                    |
| PCR                                                 | polymerase chain reaction                                                                                                   |
| PD                                                  | pharmacodynamics                                                                                                            |
| PFS                                                 | progression-free survival                                                                                                   |
| Phi +                                               | Philadelphia-positive                                                                                                       |

<div style=\"page-break-after: always\"></div>

Phi-neg  Philadelphia-negative PK pharmacokinetics PPS Per Protocol Set PSUR Periodic Safety Update Reports RFS relapse-free survival RMP Risk Management Plan RR Relapse or refractory SCS Summary of Clinical Safety SD standard deviation SmPC   Summary of Product Characteristics SMQ Standardized MedDRA Query TEAE Treatment emergent adverse event TKI tyrosine kinase inhibitor TLS Tumor lysis syndrome TRAE treatment related adverse event TTHR time to hematologic relapse TTO time to onset ULN upper limit of normal US United States WBC white blood cell

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Amgen Europe B.V. submitted to the European Medicines Agency on 13 October 2020 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include  the use of blinatumomab as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor ALL as part of the consolidation therapy; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 13 of the RMP has also been submitted.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information relating to orphan designation

BLINCYTO, was designated as an orphan medicinal product EU/3/09/650 on 24 July 2009. BLINCYTO was designated as an orphan medicinal product in the following indication: treatment of acute lymphoblastic leukaemia.

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included (an) EMA Decision(s) P/0143/2020 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0143/2020 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

## Protocol assistance

The MAH did not seek Protocol Assistance at the CHMP.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Alexandre Moreau

Co-Rapporteur:

N/A

| Timetable                                                                                             | Actual dates     |
|-------------------------------------------------------------------------------------------------------|------------------|
| Submission date                                                                                       | 13 October 2020  |
| Start of procedure:                                                                                   | 31 October 2020  |
| CHMP Rapporteur's preliminary assessment report circulated on:                                        | 21 December 2020 |
| PRAC Rapporteur's preliminary assessment report circulated on:                                        | 4 January 2021   |
| Updated PRAC Rapporteur's assessment report circulated on:                                            | 7 January 2021   |
| PRAC RMP advice and assessment overview adopted by PRAC on:                                           | 14 January 2021  |
| Updated Rapporteur's assessment report circulated on:                                                 | 25 January 2021  |
| Request for supplementary information and extension of timetable adopted by the CHMP on               | 28 January 2021  |
| MAH's responses submitted to the CHMP on:                                                             | 18 March 2021    |
| CHMP Rapporteur's preliminary assessment report on the MAH's responses circulated on:                 | 21 April 2021    |
| PRAC Rapporteur's preliminary assessment report on the MAH's responses circulated on:                 | 23 April 2021    |
| PRAC RMP advice and assessment overview adopted by PRAC on:                                           | 6 May 2021       |
| Updated CHMP Rapporteur's assessment report on the MAH's responses circulated on                      | 12 May 2021      |
| CHMP opinion adopted on:                                                                              | 20 May 2021      |
| The CHMP adopted a report on similarity of BLINCYTO with Iclusig, Xaluprine, Besponsa and Kymriah on: | 20 May 2021      |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Acute lymphoblastic leukemia is a rare aggressive cancer of the blood and bone marrow. The majority of ALL cases are B-lineage, Philadelphia-negative ALL. There are approximately 6,300 new cases diagnosed in the European Union (EU) each year (based on Forman et al, 2014). Of these, approximately half are children. B-cell precursor ALL is the most common subtype of ALL, accounting

<div style=\"page-break-after: always\"></div>

for approximately 80% to 85% of total cases of ALL in children and approximately 70% in adults (American Cancer Society, 2015 and 2014).

Among children with B-cell precursor ALL, more than 95% achieve a complete remission (CR) with front-line treatment, and 75% to 85% remain progression-free 5 years from initial diagnosis (Schrappe et al, 2013). However, approximately 15% to 20% of children with B-cell precursor ALL relapse after current front-line chemotherapy (Hunger et al, 2015).

The International Study for Children and Adolescents with Relapsed ALL (IntReALL), formed in 2010, stratified this population into two distinct risk groups, standard risk and high risk, defined by established risk factors (IntReALL, 2017; Locatelli et al, 2012). Therefore, the high-risk first relapsed ALL patient population is defined as patients with very early relapse (&lt; 18 months from initial diagnosis) at any anatomical site, early isolated bone marrow relapse (&lt; 18 months after primary diagnosis and &lt; 6 months from completion of front-line therapy), and/or MRD-positive disease.

## State the claimed therapeutic indication

The purpose of this variation application is to request the following new indication:

BLINCYTO as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor ALL as consolidation therapy.

## Management

Treatment of high-risk first relapsed ALL generally includes 3 phases, including CNS prophylaxis and treatment:

- Induction: The goal of induction therapy is to reduce tumor burden by clearing as many leukemic cells as possible from the bone marrow. Induction regimens are typically based on a standard backbone of therapy consisting of a combination of drugs including but not limited to: corticosteroids, vincristine, and anthracyclines with or without L-asparaginase and/or cyclophosphamide, 6mercaptopurine, and cytosine arabinoside.

- Consolidation: The intent of post-induction consolidation is to eliminate potential leukemic cells that remain after induction therapy, thus permitting further eradication of residual disease. The combination of drugs and duration of therapy for consolidation regimens vary between studies and patient populations.

- Allogeneic HSCT: Patients with poor outcome and high rates of subsequent relapse after conventional intensive chemotherapy have an indication for allogeneic HSCT from a matched or haplo-identical donor or in case of very high-risk also from human leukocyte antigen (HLA)-mismatched donor. For a successful allogeneic HSCT, the depth of remission is critical, which may be the case after induction and early consolidation therapy. A low MRD value before allogeneic HSCT predicts a better outcome after the allograft (Bader et al, 2009).

- CNS Prophylaxis and Treatment: The aim of CNS prophylaxis and/or treatment is to clear leukemic cells from sites that cannot be readily reached by systemic chemotherapy due to the blood-brain barrier, with the overall goal of preventing CNS disease or relapse. CNS specific therapy may include cranial irradiation and intrathecal chemotherapy (eg, methotrexate, either administered alone or in combination with cytarabine and steroids). CNS prophylaxis is typically given throughout the course of ALL therapy starting from induction and continuing through maintenance therapy.

<div style=\"page-break-after: always\"></div>

In general, pediatric treatment regimens are more intense than those used in adults and include courses of combination chemotherapy, including central nervous system (CNS) prophylaxis and treatment (eg, intrathecal chemotherapy with or without cranial radiation).

Following induction and consolidation salvage therapy, high-risk first relapsed pediatric patients who still have M1 or M2 bone marrow and those who achieve CR but remain MRD-positive prior to allogeneic HSCT will likely experience another relapse. Approximately 44% of pediatric patients with second bone marrow relapse and only 27% of those with third bone marrow relapse achieve a subsequent CR; the 5-year disease-free survival (DFS) rate in patients in third CR is reported to be 15% (Ko et al, 2010). In addition, current treatment options rely heavily on aggressive chemotherapy regimens that are generally cytotoxic and may be poorly tolerated as manifested by severe nausea, vomiting, diarrhea, and fatigue and may cause a range of toxicities including bone marrow suppression, cardiotoxicity, irreversible neuropathies, and renal toxicity. Finally, the toxicities associated with these treatments may adversely contribute to reduced effectiveness and increased treatment-related mortality of subsequent allogeneic HSCT.

## 2.1.2. About the product

Blinatumomab is a bispecific T-cell engager antibody construct that utilizes a patient's own T cells to kill CD-19-positive B cells, including malignant B cells and which binds specifically to CD19 expressed on the  surface  of  cells  of  B-lineage  origin  and  CD3  expressed  on  the  surface  of  T-cells.  It  activates endogenous T-cells by connecting CD3 in the T-cell receptor (TCR) complex with CD19 on benign and malignant B-cells.

In the European Union (EU), blinatumomab (BLINCYTO) is currently indicated as:

- monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome positive Bprecursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.
- monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%
- monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation.

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

No new data have been submitted to environmental risk assessment. According to the CHMP 2006 Guideline on the environment Risk Assessment of Medicinal Product for Human Use (EMEA/CHMP/SWP/4447/00 corr 2), in the case of proteins or peptide, due to their nature they are unlikely to result in a significant risk to the environment. As recombinant non-glycosylated protein,

<div style=\"page-break-after: always\"></div>

blinatumomab is expected to be degraded to small peptides and individual amino acids. Although the current variation may result in an increase in the total amount of blinatumomab used, due to its structure, it is not expected to result in a significant risk to environment.

## 2.2.2. Conclusion on the non-clinical aspects

Based on the accepted justification submitted in this application, the extended indication does not lead to a significant increase in environmental exposure further to the use of blinatumomab.

Considering the above data, blinatumomab is not expected to pose a risk to the environment.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

## Table 1. clinical studies

<!-- image -->

| StudyReportsofUncontrolledClinicalStudies(PediatricRelapsed/RefractoryALL)   | StudyReportsofUncontrolledClinicalStudies(PediatricRelapsed/RefractoryALL)   | StudyReportsofUncontrolledClinicalStudies(PediatricRelapsed/RefractoryALL)   | StudyReportsofUncontrolledClinicalStudies(PediatricRelapsed/RefractoryALL)                     | StudyReportsofUncontrolledClinicalStudies(PediatricRelapsed/RefractoryALL)                                                                                                                                                              | StudyReportsofUncontrolledClinicalStudies(PediatricRelapsed/RefractoryALL)   | StudyReportsofUncontrolledClinicalStudies(PediatricRelapsed/RefractoryALL)                                                                                                                                   | StudyReportsofUncontrolledClinicalStudies(PediatricRelapsed/RefractoryALL)   | StudyReportsofUncontrolledClinicalStudies(PediatricRelapsed/RefractoryALL)                                                                                                                                                                     |
|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Safety                                                                       | MT103- 205                                                                   | Efficacy Safety PK/PD                                                        | Phase1b/2 ·Non- randomized ·Non- controlled ·Single-arm ·Open-label ·Multicenter ·Dose-finding | Phase1b:Blin9 5,15,30,15-30,phase 1b and 5-15 μg/m2/day, phase 2) 4 weeks on/2 weeks off Phase 2:Up to 5 cycleswith recommended dose(from phase 1b) of blin 5 μg/m2/day (week 1, cycle 1) followed by 15 μg/m2/day for remaining period | 93(49 in and 44 in                                                           | Subjects <18 yearsofagewithblin(phase2 B-cellprecursor portion); ALL in second or1 cycle = 4 laterbone marrowrelapse, anymarrow relapseafter aHSCT,or refractory to othertreatments; >25%blastsin bonemarrow | Up to5cycles weeksofblin followed by 2 week treatment-free period            | Study completed; PA CSR; Data cutoff:12January2015; Module5.3.5.4Article46 Submission (EMEA/H/C/003731/P46/0004, Sequence 0024) FA CSR; Data cutoff: 24 May 2016; Module5.3.5.4,Article46 Submission (EMEA/H/C/003731/P46/0004, Sequence 0024) |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Study                                                                                                      | Type of Protocol No.                                                                                       | Study Objective(s) Control                                                                                 | and Type of                                                                                                | Study DesignTest Products and Dosage Regimen                                                                                                                                                                        | Number of Subjects                                                                                                  | Key Entry Criteria                                                                                                                                                      | Duration of Treatment                                                                                      | Study Status; Type of Report; Data Cutoff Date; Report Location                                                                                                                                                                                |
|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ReportsofEfficacy&SafetyStudies                                                                            | ReportsofEfficacy&SafetyStudies                                                                            | ReportsofEfficacy&SafetyStudies                                                                            | ReportsofEfficacy&SafetyStudies                                                                            | ReportsofEfficacy&SafetyStudies                                                                                                                                                                                     | ReportsofEfficacy&SafetyStudies                                                                                     | ReportsofEfficacy&SafetyStudies                                                                                                                                         | ReportsofEfficacy&SafetyStudies                                                                            | ReportsofEfficacy&SafetyStudies                                                                                                                                                                                                                |
| StudyReportsofControlledClinicalStudiesPertinenttotheClaimedIndication(PediatricHigh-riskFirstRelapsedALL) | StudyReportsofControlledClinicalStudiesPertinenttotheClaimedIndication(PediatricHigh-riskFirstRelapsedALL) | StudyReportsofControlledClinicalStudiesPertinenttotheClaimedIndication(PediatricHigh-riskFirstRelapsedALL) | StudyReportsofControlledClinicalStudiesPertinenttotheClaimedIndication(PediatricHigh-riskFirstRelapsedALL) | StudyReportsofControlledClinicalStudiesPertinenttotheClaimedIndication(PediatricHigh-riskFirstRelapsedALL)                                                                                                          | StudyReportsofControlledClinicalStudiesPertinenttotheClaimedIndication(PediatricHigh-riskFirstRelapsedALL)          | StudyReportsofControlledClinicalStudiesPertinenttotheClaimedIndication(PediatricHigh-riskFirstRelapsedALL)                                                              | StudyReportsofControlledClinicalStudiesPertinenttotheClaimedIndication(PediatricHigh-riskFirstRelapsedALL) | StudyReportsofControlledClinicalStudiesPertinenttotheClaimedIndication(PediatricHigh-riskFirstRelapsedALL)                                                                                                                                     |
| Efficacy20120215                                                                                           | Efficacy20120215                                                                                           | Efficacy Safety                                                                                            | Phase 3 ·Randomized μg/m2/day ·Open-label ·Multi-center · Controlled                                       | Blin 15 (not to exceed 28 μg/day) for 1 cycle following induction and consolidation chemotherapy or 1 cycle of HC3 following induction and consolidation chemotherapy                                               | Blin arm:54 Subjects>28                                                                                             | HC3 arm: 51 days to < 18 years of age with (1 week) of HC3 Ph- high-risk first chemotherapy relapsed B-cell precursor ALL                                               | of blin or 1 cycle                                                                                         | 1 cycle (4 weeks） Long-term follow up ongoing; PA CSR; Data cutoff: 17 July 2019; Module 5.3.5.1                                                                                                                                               |
| Safety                                                                                                     | 20130320                                                                                                   | Safety Efficacy                                                                                            | Expanded access · Single-arm · Open-label ·Multicenter                                                     | Blin 5/15 μg/m2/day (not to exceed 9/28 μg/day) if M3 marrowat screening: 15 μg/m2/day (not to exceed 28 μg/day) if M2 marrow or M1 marrow with MRD level ≥10- at screening; up to 5 cycles                         | 110                                                                                                                 | Subjects > 28 days to <18 years of age with B-cell precursorALL in second orlater bone marrow relapse, any marrowrelapse after aHSCT; or refractory to other treatments | Up to5cycles blin; 1 cycle = 4 weeks of blin followed by 2 week treatment-free period                      | Study completed; PA CSR; Data cutoff: 27Sept 2018 Module5.3.5.2,Article46 Submission (EMEA/H/C/003731/P46/013, Sequence 0119) FA CSR; Data cutoff:10Jan 2020 Module5.3.5.2,Article46 Submission (EMEA/H/C/003731/P46/013, Sequence 0119)       |
| Safety                                                                                                     | 20130265                                                                                                   | Safety Efficacy PK/PD                                                                                      | Phase 1b/2 ·Non- randomized •Non- controlled · Single-arm ·Open-label ·Multicenter · Dose-finding          | Adults: Blin 9 μg/ day (week 1, cycle 1) followed by 28 μg/m2/day for remaining period, up to 5 cycles Pediatrics: Blin 5 μg/m2/day (week 1, cycle 1) followed by 15 μg/m2/day for remaining period, up to 5 cycles | 40 adults, 26 pediatrics: Adult phase 1b: 5 Pediatric phase 1b: 9 Adult phase 2: 21 Adult exp: 14 Pediatric exp: 17 | Japanese adult subjects and pediatric subjects <18 years of age withrelapsed/ refractory Ph- B-cell precursor ALL                                                       | Up to 5 cycles blin; 1 cycle = 4 weeksof blin followed by 2 week treatment- free period                    | Study completed; PA CSR; Data cutoff:24 Aug 2017 Module 5.3.5.2, Article 46 Submission (EMEA/H/C/003731/P46/011, Sequence 0105) FA CSR; Data cutoff: 04 July 2019; Module5.3.5.2,Article46 Submission (EMEA/H/C/003731/P46/011, Sequence 0105) |

aHSCT = allogeneic hematopoietic stem cell transplantation; ALL = acute lymphoblastic leukemia;blin = blinatumomab; CSR= clinical study report;exp= expansion; FA = final analysis; HC3 = third block of high-risk consolidation chemotherapy; M1 = representative bone marrow aspirate or biopsy with blasts &lt; 5%, with satisfactory cellularityandwithregeneratinghematopoiesis;M2=representativebonemarrowaspirateorbiopsywith≥5%and&lt;25%blasts;M3=representativebonemarrow aspirateorbiopsywith≥25%blasts;MRD=minimalresidualdisease;PA=primaryanalysis;PD=pharmacodynamics;Ph-=Philadelphia-negative;PK= pharmacokinetics

## 2.3.2. Pharmacokinetics

## Introduction

To support this new indication, a phase 3, randomized, open label, controlled, multicentre study 20120215 was performed (in accordance to the PIP, EMEA-000574-PIP02-12-M03) in paediatric patients as shown in Table 2.

Page 4 of 4

<div style=\"page-break-after: always\"></div>

Table 1: Core clinical study for Blinatumomab efficacy and safety assessment for Study 20120215

<!-- image -->

|   Study Number | Study Design; Objectives                                                                                                                                                                                                                         | Test Products, Dosage Regimens, and Route of Administration                                                                                             | Key Entry Criteria                                                               | Number of Subjects Randomized                                          | PK Sampling Scheme (Number of subjects)   | Key Study & Clinical Pharmacology Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|------------------------------------------------------------------------|-------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|       20120215 | Phase 3, randomized, open-label, controlled study to investigate the efficacy, safety, and tolerability of blinatumomab versus SOC chemotherapy as consolidation therapy in pediatric subjects with high-risk first relapse B-cell precursor ALL | Blinatumomab 15 μg/m2/day clV infusion (maximum dose not to exceed 28 μg/day) for 4 weeks Third block of SOC high-risk consolidation chemotherapy (HC3) | Pediatric subjects < 18 years with high-risk first relapsed B-cell precursor ALL | 108 in the primary analysis (54 each in the blinatumomab and HC3 arms) | Sparse PK sampling (52)                   | Threshold for declaring eficacy was met for the primary endpoint of EFS at the first planned interim analysis when approximately 50%of the total EFS events had occurred. The subject incidence of EFSevents was 57.4% in the Hc3 am and 33.3% in the blinatumomab am. EFS was statistically significantly improved in the blinatumomab arm compared with HC3 arm (p<0.001). EFS hazard ratio from a stratified Cox proportional hazard model was 0.36 (95% Cl: 0.19 to 0.66), indicating a 64% risk reduction in the blinatumomab arm. PK was generally consistent with observations in the previous pediatric studies. |

The claimed dosing regimen for paediatric patients for this new indication consisted of:

- -Weight less than 45 kg (BSA-based dose): 15 µg/m 2 /day (not to exceed 28 µg/day)
- -Weight greater than 45 kg (fixed dose): 28 µg/day

Descriptive PK statistics from study 20120215 were provided. In addition, one PopPK model was developed using available PK data from adults (for other indications) and paediatric patients (for the claimed and other indication). Two exposure-response (ER) analysis were also submitted: ER efficacy and safety.

## Methods

- Analytical methods

Blinatumomab serum concentration

A validated bioassay was used to quantify serum blinatumomab concentrations. The assay is based on the principle that the CD69 activation marker is expressed on T cells in a blinatumomab concentration dependent manner, therefore the assay measures 'active form' of blinatumomab. Briefly, nominal standard ranged from 0 to 200 ng/mL (9 levels), with 3 QC samples (150/450 and 900 pg/mL). Nominal assay ranged from 50 to 1000 pg/mL (LLOQ to ULOQ).

A total of 28 analytical runs were performed for this study. Every analytical run met acceptance criteria. Samples were received between February 2016 to November 2019. 175 samples were received from which 98 were analysed.

ISR is excluded from this study because it has been already performed in the context of clinical study MT103-205 which represent the same patient population as 20120215 and uses the same assay.

Method acceptance criteria are presented in

Table 4 below. As shown below PK samples were determined in triplicates.

<div style=\"page-break-after: always\"></div>

Table 2: Bioassay for the quantification of blinatumomab across the clinical development

|              |       |                       | Pharmacokinetics                                                      | Pharmacokinetics                            | Pharmacokinetics   |
|--------------|-------|-----------------------|-----------------------------------------------------------------------|---------------------------------------------|--------------------|
| Study Number | Phase | Patient Population    | Assay description                                                     | Validation Documents                        | Performing lab     |
| MT103-104    | 1     | NHL                   | Cell-based CD69 activation assay Sensitivity: 0.05-1 ng/mL MET-003434 | VR-BIA-103-002 VR-BIA-00-009 VR-BIA-103-007 | ARMBIA PK/PD       |
| MT103-208    | 2     | NHL                   | Cell-based CD69 activation assay Sensitivity: 0.05-1 ng/mL MET-003434 | VR-BIA-103-002 VR-BIA-00-009 VR-BIA-103-007 | ARMBIA PK/PD       |
| MT103-202    | 2     | MRD+ ALL              | Cell-based CD69 activation assay Sensitivity: 0.05-1 ng/mL MET-003434 | VR-BIA-103-002 VR-BIA-00-009 VR-BIA-103-007 | ARMBIA PK/PD       |
| MT103-203    | 2     | MRD+ ALL              | Cell-based CD69 activation assay Sensitivity: 0.05-1 ng/mL MET-003434 | VR-BIA-103-002 VR-BIA-00-009 VR-BIA-103-007 | ARMBIA PK/PD       |
| MT103-206    | 2     | R/R ALL               | Cell-based CD69 activation assay Sensitivity: 0.05-1 ng/mL MET-003434 | VR-BIA-103-002 VR-BIA-00-009 VR-BIA-103-007 | ARMBIA PK/PD       |
| MT103-211    | 2     | R/R ALL               | Cell-based CD69 activation assay Sensitivity: 0.05-1 ng/mL MET-003434 | VR-BIA-103-002 VR-BIA-00-009 VR-BIA-103-007 | ARMBIA PK/PD       |
| 00103311     | 3     | R/R ALL               | Cell-based CD69 activation assay Sensitivity: 0.05-1 ng/mL MET-003434 | VR-BIA-103-002 VR-BIA-00-009 VR-BIA-103-007 | ARMBIA PK/PD       |
| 20120216     | 2     | R/R Ph+ ALL           | Cell-based CD69 activation assay Sensitivity: 0.05-1 ng/mL MET-003434 | VR-BIA-103-002 VR-BIA-00-009 VR-BIA-103-007 | ARMBIA PK/PD       |
| MT103-205    | 1/2   | R/R ALL               | Cell-based CD69 activation assay Sensitivity: 0.05-1 ng/mL MET-003434 | VR-BIA-103-002 VR-BIA-00-009 VR-BIA-103-007 | ARMBIA PK/PD       |
| 20130265     | 1b/2  | R/R ALL               | Cell-based CD69 activation assay Sensitivity: 0.05-1 ng/mL MET-003434 | VR-BIA-103-002 VR-BIA-00-009 VR-BIA-103-007 | ARMBIA PK/PD       |
| 20120215     | 3     | HR first relapsed ALL | Cell-based CD69 activation assay Sensitivity: 0.05-1 ng/mL MET-003434 | VR-BIA-103-002 VR-BIA-00-009 VR-BIA-103-007 | ARMBIA PK/PD       |

Table 3: Method acceptance criteria

| Parameter      | Assay Acceptance Criteria                                                                         |
|----------------|---------------------------------------------------------------------------------------------------|
| Standard Curve | R* Value: > 0.97                                                                                  |
| QCS            | %CV of response≤ 20; %Recovery: 70-130. A minimum of 2 out of 3 QCs must meet acceptance criteria |
| Study Samples  | %CV of response ≤ 20%.                                                                            |

%Recovery: determined by the back-calculated values

% Coefficient of Variation (%CV): determined by calculated AMG 103 concentrations of duplicates/triplicates

## Immunogenicity

Immunogenicity was assessed by a validated electrochemiluminescence (ECL)-based bridging immunoassay to determine if anti-idiotype antibodies directed against blinatumomab and/or human anti-mouse antibodies were detectable. The methodology of antibody testing was provided in the original marketing authorization application for adult relapsed/refractory ALL.

## · Pharmacokinetic data analysis

Standard non-compartmental (model independent) pharmacokinetic methods were used to calculate PK parameters, Css (steady-state serum concentrations as the observed concentrations collected after 24 hours from the start of cIV) andCL (systemic clearance calculated as CL=R0/Css, with R0 the rate of infusion) using Phoenix® WinNonlin® v.6.4 software (Certara TM , Princeton, NJ).

In addition to CL, Vz and half-life were also estimated. CL and Vz were expressed in L/h and L respectively, and normalized by BSA as L/h/m 2  and L/m 2 , respectively.

<div style=\"page-break-after: always\"></div>

Blinatumomab PK data collected from Study 20120215 in conjunction with PK data from other relevant studies (please refer to Population PK analysis section) were pooled to develop a Population PK model using the Nonmem 7.2 (ICON Development Solutions, Ellicot City, MD) software.

Exposure-response (ER) analysis for efficacy and safety were also performed using the PK exposure metrics estimated by NCA. For efficacy, the ER analysis included time to event analysis for EFS and OS using Cox proportional hazard models. For safety, ER were investigated using univariate and multivariate logistic regression models using R version 3.0.1 or higher.

## Pharmacokinetics in target population

Pivotal Study 20120215 (high-risk relapsed)

## Design

Study 20120215 is a Phase 3, randomized, open-label, controlled, multicentre study investigating the efficacy and safety profile of blinatumomab versus intensive SOC late consolidation, in paediatric patients aged &gt; 28 days to &lt; 18 years with high risk first relapsed B-cell precursor ALL.

Patients were randomized in a 1:1 ratio to either the blinatumomab arm or a third block of SOC highrisk consolidation chemotherapy arm (HC3 arm). Randomization was stratified by age, bone marrow status determined at the end of the second block of SOC chemotherapy, and MRD status determined at the end of induction.

Six strata were formed from the following 2 age categories (1 to 9 years; other [&lt; 1 year and &gt; 9 years]) and 3 bone marrow/MRD categories (M1 with MRD level ≥ 10 -3 ; M1 with MRD level &lt; 10 -3 ; and M2), where M1 was defined as representative bone marrow aspirate or biopsy with blasts &lt; 5%, with satisfactory cellularity, and with regenerating hematopoiesis, and M2 was defined as representative bone marrow aspirate or biopsy with 5% to &lt; 25% blasts.

After the screening period, eligible subjects were randomized into 1 of the following treatment arms:

- Blinatumomab arm with 1 consolidation cycle of blinatumomab, defined as a 4 weeks cIV (continuous infusion) of 15 µg/m 2 /day (maximum dose not to exceed 28 µg/day), or
- HC3 arm with 1 consolidation cycle of HC3, defined as 1 week on/ 3 weeks off

PK sampling consisted of 2 PK samples per subject collected at Day 1 and Day 15 (at least 10h after infusion start and up to 24h).

## Results

Study 20120215 is ongoing. At the cut-off date of 17 July 2019, a total of 108 eligible subjects were enrolled and randomized; both arms had 54 subjects.

During cIV infusion of 15 µg/m2/day blinatumomab to pediatric subjects, the mean (SD) serum blinatumomab concentration at steady state (Css) was 921 (1010) pg/mL (

<div style=\"page-break-after: always\"></div>

Table 5 ). The mean (SD) clearance (CL) was 0.998 (0.450) L/hr/m2. The intersubject variability, as assessed by percent coefficient of variation (CV) in the PK parameter estimates, was up to 109%. Given the high observed intersubject variability in this study, mean (SD) Css and CL of blinatumomab were generally within the ranges of those previously reported in pediatric subjects from Studies MT103-205 and 20130265 (please refer to next section).

Table 4: Descriptive statistics of Blinatumomab PK parameter estimates for cIV infusion of blinatumomab in pediatric subjects (study 20120215)

| Age Group   | Statistic   | Cycle1C 15μg/m2/day (pg/mL)   | CL (L/hr/m²)   |
|-------------|-------------|-------------------------------|----------------|
| 2years      | N           | 1                             | 1              |
| 2years      | Mean        | 334                           | 1.87           |
| 2years      | SD          | NR                            | NR             |
| 2years      | Min         | 334                           | 1.87           |
| 2years      | Median      | 334                           | 1.87           |
| 2years      | Max         | 334                           | 1.87           |
| 2years      | CV%         | NR                            | NR             |
| 2years      | Geo mean    | 334                           | 1.87           |
| 2years      | CV%Geomean  | NR                            | NR             |
| 2-6years    | N           | 24                            | 24             |
| 2-6years    | Mean        | 696                           | 1.05           |
| 2-6years    | SD          | 291                           | 0.423          |
| 2-6years    | Min         | 289                           | 0.457          |
| 2-6years    | Median      | 610                           | 1.03           |
| 2-6years    | Max         | 1370                          | 2.16           |
| 2-6years    | CV%         | 41.9                          | 40.2           |
| 2-6years    | Geo mean    | 642                           | 0.974          |
| 2-6years    | CVGeo mean  | 42.6                          | 42.6           |
| 7-17years   | N           | 15                            | 15             |
| 7-17years   | Mean        | 1320                          | 0.852          |
| 7-17years   | SD          | 1550                          | 0.431          |
| 7-17years   | Min         | 434                           | 0.113          |
| 7-17years   | Median      | 634                           | 0.986          |
| 7-17years   | Max         | 5550                          | 1.44           |
| 7-17years   | CV%         | 117.3                         | 50.7           |
| 7-17years   | Geo mean    | 904                           | 0.692          |
| 7-17years   | CV%Geo mean | 92.9                          | 92.9           |

<div style=\"page-break-after: always\"></div>

| Age Group   | Statistic   |   Cycle1C 15μg/m2/day (pg/mL) |   CL (L/hr/m²) |
|-------------|-------------|-------------------------------|----------------|
| ≤17years    | N           |                          40   |         40     |
| ≤17years    | Mean        |                         921   |       8660     |
| ≤17years    | SD          |                        1010   |          0.45  |
| ≤17years    | Min         |                         289   |          0.113 |
| ≤17years    | Median      |                         614   |          1.02  |
| ≤17years    | Max         |                        5550   |          2.16  |
| ≤17years    | CV%         |                         109.3 |         45.1   |
| ≤17years    | Geo mean    |                         718   |          0.871 |
| ≤17years    | CV%Geomean  |                          66.3 |         66.3   |

Page2of2

ALL=acute lymphoblasticleukemia;clV=continuous intravenous:CL=clearance;Css=steady state concentration;CV-coefficientofvariation;Geo mean=geometricmean;Max=maximum;Min=minimum; N-numberof subjects:NR-notreported;PK-pharmacokinetic;SD-standard deviation

PK similarity in the paediatric population (other indications)

In  this  submission  PK  data  from  study  20120215  are  included  along  with  supportive  PK  data  from previously completed studies MT103-205  (Phase 1/2 R/R  ALL) and 20130265 (Phase  1b/2 R/R  ALL Japanese)  in  paediatric  subjects.  Details  from  Studies  MT103-205  and  20130265  designs  can  be retrieved from Table 6 below.

Table 5: Supportive clinical studies for blinatumomab PK assessment

| Study Number   | Study Design; Objectives                                                                                                                            | TestProducts,Dosage Regimens,andRoute ofAdministration                                                                                                                              | Key Entry Criteria                     | Number of Subjects Enrolled   | PKSampling Scheme (Numberof subjects)       | KeyStudy&Clinical PharmacologyResults                                                                                                                                                                                                                                                     |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|-------------------------------|---------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MT103-205      | Phase 1/2, multicenter,single- armstudypreceded bydoseevaluationto investigatethe efficacy,afety,and tolerability of pediatricsubjects with R/R ALL | Blinatumomab Phase 1:5,15,30, 5/15,and15/30b μg/m²/dayclVinfusion, 4weeksonfollowedby 2weeksoff Phase2:5/15 μg/m2/day clV infusion doseregimena (recommendeddose defined inphase 1) | Pediatricsubjects <18yearswith R/R ALL | Phase1:49 Phase 2:44          | IntensivePK sampling in phase1partonly (48) | TherateofCR(M1remission) withinthefirst2treatmentcycles was38.6%。(27/70;95%Cl: 27.2%to51.0%)fordose regimenof5/15μg/m2/dayclV infusion?administeredtoeither phase1orphase2subjects. MeanCssValuesincreased approximatelydose proportionallyoverthedose rangefrom5μg/m2/dayto30 μg/m2/day. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|   Study Number | Study Design; Objectives                                                                                                                                              | Test Products,Dosage Regimens,and Route of Administration                                                                                                               | Key Entry Criteria                                 | Number of Subjects Enrolled                                                                           | PK Sampling Scheme (Number of subjects)                                                                                                | Key Study & Clinical PharmacologyResults                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|-------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|       20130265 | Phase 1b/2, multicenter, single- arm, open label study to investigate the PK, efficacy and safety of blinatumomab in Japaneseadultand pediatric subjects with R/R ALL | Adults: 9/28 μg/day*clV infusionfor4weeks followedby2weeks off drug per cycle Pediatrics: 5/15 μg/m2/daya clV infusion for 4weeksfollowed by 2 weeks off drug per cycle | Japanese adult and pediatric subjects with R/R ALL | Phase1b:5 (adults), 9 (pediatrics) Phase 2: 21 (adults) Phase 2 expansion: 14adults and 17 pediatrics | Intensive sampling in cycle 1,sparse sampling in later cycles (Phase 1b: 5 adult and 9 pediatric subjects; Phase 2: 21 adult subjects) | Phase1lb:therateofCR/CRh* withinthefirst 2treatmentcycles was 80%(4/5 subjects, 95% Cl: 28.4% to 99.5%) in adults. In pediatric subjects, the M1 remissionratewithinthefirst 2 treatment cycles was 55.6% (5/9 subjects; 95% Cl: 21.2%to 86.3%). Phase 2: the rateof CR/CRh* withinthefirst2treatmentcycles was 38.1%(8/21 subjects, 95% Cl: 18.1%to 61.6%) in adults. Phase 2 expansion: the CR/CRh*ratewithinthefirst2 cycles of treatment was 78.6% (11of 14 subjects;95%Cl: 49.2%to95.3%) in adults.In pediatric subjects, the M1 remissionratewithin thefirst 2 cycles of treatment was 29.4%(5 of 17 subjects;95%Cl:10.3%to 56.0%). PKwasconsistentwith observationsintheprevious global studies |

## Results

## Study MT103-205

Blinatumomab serum concentrations were available in total of 48 subjects including 8 subjects &lt; 2 years of age, 23 subjects 2 to 6 years of age, and 17 subjects 7 to 17 years of age. The PK of blinatumomab was assessed at doses of 5, 15, and 30 µg/m2/day.

Following the cIV infusion, Css was presumed on day 1  based on the estimated average half-life of blinatumomab (~2 hours). At a given dose, the Css was stable over time (figure 1) and the drug exposure was comparable over cycles 1 and 2 (Table 7). The mean Css values increased proportionally with increasing doses indicating linear PK. In cycle 1, the mean (SD) Css values were 162 (179), 533 (392), and 1520 (1020) pg/mL for doses of 5, 15, and 30 µg/m 2 /day, respectively, for the combined age group ( ≤ 17 years), independent of regimen. The inter-subject variability values for Css were large, ranging from 60.8% to 110.5% in the combined group. A summary of Css values by dose, cycle, and age group is presented in Table 7 .

<div style=\"page-break-after: always\"></div>

Figure 1. Mean (±SD) Serum Concentration=Time Profiles of Blinatumomab Following cIV Infusion of Blinatumomab Over 4 Weeks inCycle 1 to Pediatric Subjects With Relapse/Refractory ALL in Study MT103=205

## A. Step dosing

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 6: Descriptive Statistics of Blinatumomab Steady-State Concentrations (Css) Following cIV Infusion of Blinatumomab Over 4 Weeks to Pediatric Subjects With Relapsed/Refractory ALL in Study MT103-205

| Age Group   |              | Css (pg/mL)   | Css (pg/mL)   | Css (pg/mL)   | Css (pg/mL)   | Css (pg/mL)   | Css (pg/mL)   |
|-------------|--------------|---------------|---------------|---------------|---------------|---------------|---------------|
|             | Statistic    | Cycle 1       | Cycle 1       | Cycle 1       | Cycle 1       | Cycle 2       | Cycle 2       |
|             |              | 5 μg/m2/day   | 15 μg/m2/day  | 30 μg/m2/day  | 5 μg/m2/day   | 15 μg/m2/day  | 30 μg/m2/day  |
| 2 years     | N            | 8             | 8             | NA            | NA            | 4             | NA            |
| 2 years     | Mean         | 110           | 508           | NA            | NA            | 403           | NA            |
| 2 years     | SD           | 42.6          | 215           | NA            | NA            | 69.1          | NA            |
| 2 years     | Min          | 61.0          | 277           | NA            | NA            | 313           | NA            |
| 2 years     | Median       | 92.0          | 437           | NA            | NA            | 411           | NA            |
| 2 years     | Max          | 176           | 828           | NA            | NA            | 476           | NA            |
| 2 years     | CV%          | 38.9          | 42.3          | NA            | NA            | 17.2          | NA            |
| 2 years     | Geo mean     | 103           | 469           | NA            | NA            | 398           | NA            |
| 2 years     | CV% Ge0 mean | 37.6          | 44.6          | NA            | NA            | 18.1          | NA            |
| 2-6 years   | N            | 10            | 15            | 2             | 3             | 5             | 2             |
| 2-6 years   | Mean         | 208           | 434           | NC            | 456           | 935           | NC            |
| 2-6 years   | SD           | 275           | 353           | NC            | 288           | 648           | NC            |
| 2-6 years   | Min          | 81.0          | 58.5          | 1090          | 148           | 283           | 310           |
| 2-6 years   | Median       | 129           | 433           | 2300          | 502           | 811           | 755           |
| 2-6 years   | Max          | 987           | 1370          | 3520          | 718           | 1760          | 1200          |
| 2-6 years   | CV%          | 132.4         | 81.3          | NC            | 63.1          | 69.3          | NC            |
| 2-6 years   | Geo mean     | 146           | 303           | NC            | 377           | 740           | NC            |
| 2-6 years   | CV% Ge0 mean | 81.9          | 120.8         | NC            | 99.3          | 94.7          | NC            |
| 7-17 years  | N            | 9             | 11            | 5             | NA            | 4             | 3             |
| 7-17 years  | Mean         | 157           | 686           | 1210          | NA            | 1240          | 1420          |
| 7-17 years  | SD           | 109           | 510           | 635           | NA            | 817           | 722           |
| 7-17 years  | Min          | 53.0          | 170           | 214           | NA            | 566           | 591           |
| 7-17 years  | Median       | 130           | 559           | 1220          | NA            | 1010          | 1720          |
| 7-17 years  | Max          | 380           | 2090          | 1960          | NA            | 2380          | 1940          |
| 7-17 years  | CV%          | 69.1          | 74.3          | 52.5          | NA            | 65.8          | 51.0          |
| 7-17 years  | Geomean      | 129           | 567           | 978           | NA            | 1060          | 1250          |
| 7-17 years  | CV% Ge0 mean | 73.5          | 70.2          | 106.7         | NA            | 70.5          | 73            |

<div style=\"page-break-after: always\"></div>

|           |              | Css (pg/mL)                                                   | Css (pg/mL)   | Css (pg/mL)   | Css (pg/mL)   | Css (pg/mL)   | Css (pg/mL)   |
|-----------|--------------|---------------------------------------------------------------|---------------|---------------|---------------|---------------|---------------|
| Age Group | Statistic    | Cycle 1                                                       | Cycle 1       | Cycle 1       | Cycle 2       | Cycle 2       | Cycle 2       |
|           |              | 5 Aep/zw/bnAep/zw/bn Kep/zwybd  Aep/zw/bn Aep/zwybn Aep/zwybn | 15            | 30            | 5             | 15            | 30            |
|           | N            | 27                                                            | 34            | 7             | 3             | 13            | 5             |
|           | Mean         | 162                                                           | 533           | 1520          | 456           | 866           | 1150          |
|           | SD           | 179                                                           | 392           | 1020          | 288           | 655           | 701           |
|           | Min          | 53.0                                                          | 58.5          | 214           | 148           | 283           | 310           |
| ≤17 years | Median       | 122                                                           | 498           | 1220          | 502           | 566           | 1200          |
| ≤17 years | Max          | 987                                                           | 2090          | 3520          | 718           | 2380          | 1940          |
| ≤17 years | CV%          | 110.5                                                         | 73.6          | 67.1          | 63.1          | 75.7          | 60.8          |
| ≤17 years | Geo mean     | 126                                                           | 411           | 1190          | 377           | 684           | 940           |
| ≤17 years | CV% Ge0 mean | 66.6                                                          | 93.0          | 104.3         | 99.3          | 79.3          | 90.5          |

A summary of PK parameter estimates is provided in Table 8 .

Under  the  body  surface  area  (BSA)-based  dosing,  the  estimated  mean  (SD)  values  of  volume  of distribution based on terminal phase (Vz), systemic clearance (CL), and terminal elimination half-life (t1/2,z)  were  3.91  (3.36)  L/m2,  1.88  (1.90)  L/hr/m2,  and  2.19  (1.53)  hours,  respectively,  in  the combined age group ( ≤ 17 years). The mean (SD) blinatumomab clearance was similar in the ≤ 2 years (1.57 [0.435] L/hr/m2), 2 to 6 years (2.28 [2.47] L/hr/m2) and 7 to 17 years (1.49 [1.38] L/hr/m2) age  groups.  The  intersubject  variability  in  PK  parameter  estimates  (Vz,  t1/2,z  and  CL)  were  large, ranging from 70.1% to 101.2% in the combined group. Since no ADA was found in pediatric patients, the effect of ADA on PK was not evaluated.

<div style=\"page-break-after: always\"></div>

Table 7: Descriptive Statistics for Pharmacokinetic Parameter Estimates of Blinatumomab Following cIV Infusion of Blinatumomab Over 4 Weeks to Pediatric Subjects With Relapsed/Refractory ALL in Study MT103-205

<!-- image -->

| Age Group   |              | BlinatumomabPKParameters   | BlinatumomabPKParameters   | BlinatumomabPKParameters   | BlinatumomabPKParameters   |
|-------------|--------------|----------------------------|----------------------------|----------------------------|----------------------------|
| Age Group   | Statistic    | Cycle 1                    | Cycle 1                    | CL                         | CL                         |
| Age Group   |              | Vz (L/m²)                  | t12z (hr)                  | (L/hr/m²)                  | (L/hr)                     |
| 2 years     | N            | NA                         | NA                         | 8                          | 8                          |
| 2 years     | Mean         | NA                         | NA                         | 1.57                       | 0.680                      |
| 2 years     | SD           | NA                         | NA                         | 0.435                      | 0.154                      |
| 2 years     | Min          | NA                         | NA                         | 1.00                       | 0.371                      |
| 2 years     | Median       | NA                         | NA                         | 1.51                       | 0.718                      |
| 2 years     | Max          | NA                         | NA                         | 2.17                       | 0.868                      |
| 2 years     | CV%          | NA                         | NA                         | 27.7                       | 22.6                       |
| 2 years     | Geo mean     | NA                         | NA                         | 1.52                       | 0.662                      |
| 2 years     | CV%Ge0 mean  | NA                         | NA                         | 28.9                       | 27.1                       |
|             | N            | 6                          | 9                          | 21                         | 21                         |
|             | Mean         | 5.08                       | 2.41                       | 2.28                       | 1.75                       |
|             | SD           | 4.25                       | 1.86                       | 2.47                       | 2.05                       |
|             | Min          | 0.821                      | 0.862                      | 0.325                      | 0.277                      |
|             | Median       | 3.56                       | 1.69                       | 1.44                       | 1.05                       |
| 2-6 years   | Max          | 12.1                       | 6.04                       | 10.7                       | 8.87                       |
| 2-6 years   | CV%          | 83.6                       | 77.1                       | 108.2                      | 117.2                      |
| 2-6 years   | Geo mean     | 3.44                       | 1.96                       | 1.50                       | 1.15                       |
| 2-6 years   | CV% Ge0 mean | 132.9                      | 72.0                       | 116.0                      | 108.8                      |
| 7-17 years  | N            | 11                         | 11                         | 16                         | 16                         |
| 7-17 years  | Mean         | 2.95                       | 2.01                       | 1.49                       | 1.61                       |
| 7-17 years  | SD           | 2.18                       | 1.28                       | 1.38                       | 1.05                       |
| 7-17 years  | Min          | 0.569                      | 0.653                      | 0.604                      | 0.562                      |
| 7-17 years  | Median       | 2.24                       | 1.69                       | 1.04                       | 1.22                       |
| 7-17 years  | Max          | 6.99                       | 4.62                       | 5.84                       | 4.38                       |
| 7-17 years  | CV%          | 74.0                       | 63.5                       | 92.2                       | 65.2                       |
| 7-17 years  | Geo mean     | 2.27                       | 1.71                       | 1.17                       | 1.35                       |
| 7-17 years  | CV%Ge0 mean  | 91.8                       | 63.2                       | 72.1                       | 65.5                       |
| Age Group   |              | BlinatumomabPKParameters   | BlinatumomabPKParameters   | BlinatumomabPKParameters   | BlinatumomabPKParameters   |
|             | Statistic    | Cycle 1                    | Cycle 1                    | CL                         | CL                         |
|             | Statistic    | Vz (L/m2)                  | t12,z (hr)                 | (L/hr/m2)                  | (L/hr)                     |
|             | N            | 20                         | 20                         | 45                         | 45                         |
|             | Mean         | 3.91                       | 2.19                       | 1.88                       | 1.51                       |
|             | SD           | 3.36                       | 1.53                       | 1.90                       | 1.56                       |
|             | Min          | 0.569                      | 0.653                      | 0.325                      | 0.277                      |
| ≤17         | Median       | 2.67                       | 1.69                       | 1.29                       | 1.00                       |
| years       | Max          | 12.1                       | 6.04                       | 10.7                       | 8.87                       |
|             | CV%          | 86.0                       | 70.1                       | 101.2                      | 103.6                      |
|             | Geo mean     | 2.74                       | 1.82                       | 1.38                       | 1.10                       |
|             | CV%Ge0 mean  | 110.2                      | 65.5                       | 86.5                       | 85.8                       |

<div style=\"page-break-after: always\"></div>

## Study 20130265

Blinatumomab was administered via continuous IV infusions of 9 and 28 µg/day to adult subjects and of 5 and 15 µg/m 2 /day to pediatric subjects with relapsed/refractory B-cell precursor ALL. As shown in Table 9 , blinatumomab mean (SD) values of Css in cycle 1 were 191 (90.8) pg/mL and 948 (488) pg/mL for the 9- and 28-µg/day dosage in adults, and 113 (65.0) pg/mL and 361 (137) pg/mL for the 5- and 15-µg/m 2 /day dosage in pediatrics, respectively. The mean (SD) clearance was 1.59 (0.812) L/hour in adults and  1.88 (0.789) L/m2/hour in pediatric  subjects. Mean (SD) Css and  systemic clearance of blinatumomab in Japanese subjects in this study were within the range of those previously reported in adult and pediatric subjects in global clinical studies.

Table 8: Descriptive statistics of blinatumomab PK parameter estimates in adult and pediatric subjects with R/R ALL (Study 20130265)

| Adult Dose:9/28 μg/day         | Adult Dose:9/28 μg/day          | Adult Dose:9/28 μg/day           | Adult Dose:9/28 μg/day           | Adult Dose:9/28 μg/day           | Adult Dose:9/28 μg/day         | Adult Dose:9/28 μg/day         | Adult Dose:9/28 μg/day         |
|--------------------------------|---------------------------------|----------------------------------|----------------------------------|----------------------------------|--------------------------------|--------------------------------|--------------------------------|
| Summary Statistic              | Cycle 1 Cs fep/bn 6 (pg/mL)     | Cycle 1 Css 28 μg/day (pg/mL)    | Cycle 2 Css 28μg/day (pg/mL)     | Cycle 3+ Cs 28 μg/day (pg/mL)    | CL (L/hour)                    | ty4z (hours)                   | Vz (L)                         |
| n                              | 23                              | 25                               | 21                               | 8                                | 26                             | 24                             | 24                             |
| Mean                           | 191                             | 948                              | 1150                             | 1420                             | 1.59                           | 2.38                           | 6.02                           |
| SD                             | 90.8                            | 488                              | 575                              | 685                              | 0.812                          | 1.36                           | 6.09                           |
| Min                            | 72.4                            | 288                              | 259                              | 604                              | 0.442                          | 1.19                           | 1.75                           |
| Median                         | 173                             | 883                              | 1050                             | 1250                             | 1.42                           | 1.96                           | 3.46                           |
| Max                            | 388                             | 2390                             | 2830                             | 2620                             | 3.28                           | 6.15                           | 29.0                           |
| CV%                            | 47.5                            | 51.5                             | 49.9                             | 48.3                             | 51.0                           | 57.2                           | 101.2                          |
| Pediatric Dose: 5/15 μg/m2/day | Pediatric Dose: 5/15 μg/m2/day  | Pediatric Dose: 5/15 μg/m2/day   | Pediatric Dose: 5/15 μg/m2/day   | Pediatric Dose: 5/15 μg/m2/day   | Pediatric Dose: 5/15 μg/m2/day | Pediatric Dose: 5/15 μg/m2/day | Pediatric Dose: 5/15 μg/m2/day |
| Summary Statistic              | Cycle 1 Css 5 μg/m2/day (pg/mL) | Cycle 1 Css 15 μg/m2/day (pg/mL) | Cycle 2 Css 15 μg/m²/day (pg/mL) | Cycles 3+ C 15 μg/m2/day (pg/mL) | CL (L/m2/ hour)                | ts (hours)                     | Vz (L/m2)                      |
| N                              | 7                               | 7                                | 6                                | 1                                | 6                              | 5                              | 5                              |
| Mean                           | 113                             | 361                              | 427                              | 780                              | 1.88                           | 1.92                           | 5.05                           |
| SD                             | 65.0                            | 137                              | 66.0                             | NR                               | 0.789                          | 1.12                           | 3.35                           |
| Min                            | 57.0                            | 150                              | 354                              | 780                              | 0.820                          | 0.941                          | 1.64                           |
| Median                         | 100                             | 358                              | 429                              | 780                              | 1.75                           | 1.38                           | 3.70                           |
| Max                            | 244                             | 592                              | 540                              | 780                              | 3.65                           | 3.40                           | 8.93                           |
| CV%                            | 57.4                            | 37.9                             | 15.5                             | NR                               | 42.0                           | 58.5                           | 66.4                           |

CL = clearance; Css = steady-state concentration; Vz = volume of distribution; txz = terminal half-life Source:PKSI20130265 SAS\\_CDISC\\_V2 Base Scenanio PA (version 26)

Comparison of Pharmacokinetics between Japanese Pediatric and Adult Subjects

Blinatumomab PK parameters, Css and clearance (CL), of Japanese paediatric and adult subjects from Study 20130265 were compared (Table 10 and Table 11).  Individual PK parameters are provided in Figure 2 and Figure 3.

<div style=\"page-break-after: always\"></div>

Table 10. Descriptive Statistics of Blinatumomab Pharmacokinetic Parameters Following cIV Infusion of Blinatumomab Over 4 Weeks to Pediatric Subjects with ALL

| Summary   | GlobalPediatricR/RALL Subjects (StudyMT103-205)   | GlobalPediatricR/RALL Subjects (StudyMT103-205)   | GlobalPediatricR/RALL Subjects (StudyMT103-205)   | JapanesePediatricR/RALL Subjects (Study20130265)   | JapanesePediatricR/RALL Subjects (Study20130265)   | JapanesePediatricR/RALL Subjects (Study20130265)   |
|-----------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| Statistic | Css,15 μg/m²/day (pg/mL)a                         | CL (L/hr/m²)                                      | CL (L/hr)                                         | Css,15 μg/m2/day (pg/mL)a                          | CL (L/hr/m²)                                       | CL (L/hr)                                          |
| n         | 34                                                | 45                                                | 45                                                | 7                                                  | 9                                                  | 9                                                  |
| Mean      | 533                                               | 1.88                                              | 1.51                                              | 361                                                | 1.88                                               | 2.34                                               |
| SD        | 392                                               | 1.90                                              | 1.56                                              | 137                                                | 0.789                                              | 1.63                                               |
| CV%       | 74                                                | 101                                               | 103                                               | 38                                                 | 42                                                 | 70                                                 |

ALL=acute lymphoblasticleukemia;clV= continuous intravenous;Css= steady-state concentration;CV= coefficlent of variation;R/R =relapsed or refractory: SD =standard deviation.Body surface area-based dosing was administered to pediatric subjects in the MT103-205 and 20130265 studies.

Cycle 1

Source:MT103-205(primaryanalysis).20130265(primaryanalysis)clinicalstudyreport;IWilesrv01IPCBardRAWAQPDatalAMG103IGlobalPedliatricFiling2020IEUPediatricFiing2020LRTQsLAMG103Global PediatricFiling2020\\_Dec2020RTQ.phxproj

Table 11. Descriptive Statistics of Blinatumomab Pharmacokinetic Parameters Following cIV Infusion of Blinatumomab Over 4 Weeks to Adult Subjects with Relapsed or Refractory ALL.

| Summary   | JapaneseR/RALLSubjects (Study20130265)   | JapaneseR/RALLSubjects (Study20130265)   | GlobalR/RALLSubjects   | GlobalR/RALLSubjects   |
|-----------|------------------------------------------|------------------------------------------|------------------------|------------------------|
| Statistic | Css28μg/day (pg/mL)                      | CL (L/hr)                                | Css28μg/day (pg/mL)ab  | CL (L/hr)c             |
| n         | 25                                       | 26                                       | 410                    | 507                    |
| Mean      | 948                                      | 1.59                                     | 614                    | 3.41                   |
| SD        | 488                                      | 0.812                                    | 537                    | 3.32                   |
| CV%       | 52                                       | 51                                       | 88                     | 97                     |

ALL=acute lymphoblastic leukemia;clV=continuous intravenous;Cs=steady-state concentration;CV= coeficient of variation;R/R=relapsed orrefractory;SD=standard deviation.Fixed dosing was administeredinadult subjects inMT103-211,20120216,20130265,and00103311 studies.Body surface area-based dosing was administered in adult subjects in the MT103-206 study.

bCsvalueswerepresented forglobal subjectsadministered28μg/dayfromStudiesMT103-211,20120216, and00103311.

aCycle1

CLvalues forglobal subjectsare from StudiesMT103-206.MT103-211,20120216,and00103311. Source:Ilfilesrv01\\PCBard-RAWQPData\\AMG103\\GlobalPediatricFiling2020\\EUPediatricFiling 2020IRTQsAMG103GlobalPediatnicFiling2020Dec2020RTQ.phxDrol

<div style=\"page-break-after: always\"></div>

Figure 2. Individual Blinatumomab Steady-State Concentrations (Css) Following cIV Infusion of 28µg/Day or 15 µg/m 2 /Day Blinatumomab Over 4 weeks to Japanese Adult and Pediatric Subjects With Relapsed or Refractory ALL in Cycle 1 (Study 20130265)

<!-- image -->

Figure 3. Individual Blinatumomab Clearance Following cIV Infusion of Blinatumomab Over 4 Weeks to adult or Pediatric Subjects With Relapsed or Refractory ALL (Study 20130265)

<!-- image -->

<div style=\"page-break-after: always\"></div>

The observed mean Css value of 361 pg/mL for Japanese paediatric subjects at the 15 µg/m2/day dose level and 948 pg/mL for Japanese adult subjects at the 28 µg/day dose level (fixed dose equivalent to 15 µg/m2/day) are impacted by the PK variability of blinatumomab with a coefficient of variation (CV) up to 52% (Table 10 and Table 11). With limited data available in 7 Japanese paediatric subjects, all but 1  (86%)  had  Css  values  within  range  of  the  Css  values  from  Japanese  adult  subjects  (Figure  2). Furthermore, observed CL values in the Japanese pediatric subjects were within range of that of Japanese adult subjects (Figure 3).

## Comparison of Pharmacokinetics between Japanese and Global

## Paediatric and Adult Subjects

Blinatumomab PK parameters, Css and CL, of Japanese paediatric subjects with relapsed or refractory ALL from Study  20130265 and corresponding global  pediatric subjects from Study  MT103-205 were compared (Table 1).  The respective individual PK parameters for paediatric subjects are provided in Figure 4 and Figure 5.

Figure 4. Individual Blinatumomab Steady-State Concentration (Css) Following cIV infusion of 15 µg/m2/day Blinatumomab Over 4 Weeks to Global (Study MT103-205 and Japanese (study 20130265) Pediatric Subjects with Relapsed or Refractory ALL in Cycle 1.

<!-- image -->

ALL = acute lymphoblastic leukemiac clV = continuous intravenousc C= steady-state concentration: R/R relapsed or refractory.Black horizontal lines and red emor bars represent mean and standard deviation. respectively,ofindividuslgroups.

<div style=\"page-break-after: always\"></div>

Figure 5. Individual Blinatumomab Clearance Following cIV Infusion of Blinatumomab Over 4 Weeks to Global (Study MT103-205) and Japanese (Study 20130265) Pediatric Subjects with Relapsed or Refractory ALL.

<!-- image -->

Blinatumomab PK parameters, Css and CL, of Japanese adult subjects with relapsed or refractory ALL from  Study  20130265  and  the  corresponding  global  adult  subjects  from  several  clinical  trials  were compared (Table 11).  The respective individual PK parameters for adult subjects are provided in Figure 6 and Figure 7.

<div style=\"page-break-after: always\"></div>

Figure 6. Individual Blinatumomab Steady-State Concentration (Css) Following cIV Infusion of 28 µg/day Blinatumomab Over 4 Weeks to Japanese (Study 20130265) and Global (Study MT103-211, 20120216 and 00103311) Adult Subjects with  Relapsed  or  Refractory  ALL  in Cycle 1.

<!-- image -->

Figure 7. Individual Blinatumomab Clearance Following cIV Infusion of Blinatumomab Over 4 Weeks to Japanese (Study 20130265) and Global (Studies MT103-206, MT103-211, 20120216 and 00103311) Adult Subjects with Relapsed or refractory ALL.

<!-- image -->

At a dose of 15 µg/m2/day dose, the observed mean Css value of Japanese pediatric subjects in Study 20130265 were approximately 1.5-fold lower than that of global pediatric subjects in Study MT103-205 (Table 12).

<div style=\"page-break-after: always\"></div>

| Pediatric subjects                | MeanCat15 μg/m²/day(pg/mL)    | Fold Difference forMean Css Relative toPediatric Subjects in JapanStudy20130265   |
|-----------------------------------|-------------------------------|-----------------------------------------------------------------------------------|
| MT103-205(global) 20130265(Japan) | 533 361                       | 1.5                                                                               |
| Adult subjects                    | Mean Cat28 μg/day (pg/mL) 632 | Fold Diffcrence forMean C Rolative toAdult Subjects In JapanStudy20130265b        |
| MT103-211(global)                 |                               | 1.5                                                                               |
| 00103311 (global)                 | 587                           | 1.6                                                                               |
| 20120216 (globall)                | 673                           | 1.4                                                                               |
| 20130265(Japan)                   | 948                           |                                                                                   |

Table 12. Fold Difference in Mean Css Exposure Between Japan Study 20130265 and Global Studies for Pediatric and Adult Subjects With Relapsed or Refractory ALL.

<!-- image -->

The 1.5-fold difference in observed mean Css values between Japanese and global paediatric subjects is impacted by PK variability with CV up to 73.6%.  The mean values of the subject groups are impacted by the extreme values observed, resulting in the observed fold difference for mean Css (Figure 3). Consistent with the Css exposures, the observed CL values in Japanese pediatric subjects were within range of those in global pediatric subjects (Table 10 and Figure 5).

Likewise, the blinatumomab PK parameters for Japanese adult subjects with relapsed or refractory ALL are within range of those of corresponding adult subjects with relapsed or refractory ALL in the global studies.  At a dose of 28 µg/day dose, the observed mean Css value of Japanese adult subjects in Study 20130265 were approximately 1.4 to 1.6-fold  higher than  that of global adult subjects in 3 clinical studies, MT103-211, 00103311, and 20120216 (Table 12). When combining the Css values across the 3  global  studies,  the  fold  difference  relative  to  Japanese  subjects  is  approximately  1.5-fold.    This difference is impacted by PK variability for Css in both groups with CV up to 88% (Table 11).  In addition, the mean values of the subject groups are impacted by the extreme values in both groups, resulting in the observed fold difference for mean Css (Figure 6).  Consistent with the Css exposures, the observed CL values in Japanese adult subjects were within range of those in corresponding global subjects (Table 11 and Figure 7).

## PK across different populations

The PK of blinatumomab (Css) in pediatric subjects with relapsed/refractory or high-risk first relapsed ALL along with those estimated in adult subjects with relapsed/refractory ALL, MRD-positive ALL and non-Hodgkin's lymphoma (NHL) are presented in table 13 and table 14, respectively.

<div style=\"page-break-after: always\"></div>

Table 13. Blinatumomab Parameter Estimates Following cIV Infusion in Pediatric Subjects With Relapse/Refractory ALL and High-risk First Relapse ALL.

|           |                     |                     | Clearance (CL) (Lh)   | Clearance (CL) (Lh)   | Clearance (CL) (Uhim)   | Clearance (CL) (Uhim)   | Clearance (CL) (Uhim)   | Volume ot disinbuion (V) (L)   | Volume ot disinbuion (V) (L)   | Volume of dlstribution (V-) (Lm)   | Volume of dlstribution (V-) (Lm)   | Volume of dlstribution (V-) (Lm)   | Temlnal hai-lfe (tea) (h)   | Temlnal hai-lfe (tea) (h)   | Temlnal hai-lfe (tea) (h)   | Temlnal hai-lfe (tea) (h)   |
|-----------|---------------------|---------------------|-----------------------|-----------------------|-------------------------|-------------------------|-------------------------|--------------------------------|--------------------------------|------------------------------------|------------------------------------|------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| study     | Age                 | Dlse3se             | N                     | Mean (os)             | Mean (SD)               | Geo mean (GV)           | Medlan (range)          | N                              | Mean (SD)                      | Mean (SD)                          | (GV:) mean Geo                     | (ange)                             | N                           | Mean (os)                   | (CV%6) mean Geo             | Medlan (range)              |
| MT103-205 | 0-17 years          | RRALL               | 45                    | (1.56) 1.51           | (1.90) 1.88             | (101.2) 1.38            | (0.325 -10.7) 1.29      | 20                             | (2.85) 3.78                    | (3.35) 3.91                        | 2.74                               | (86.0)(0.569- 12.1] 2.67           | 20                          | (1.53) 2.19                 | (70.1) 1.82                 | (0.653 -6.04) 1.69          |
| 20130265  | 7-17 years          | RRALL               | 9                     | 2.34 (1.63)           | 1.88 (0.789)            | 1.74 (42.0)             | 1.75 (0.820 - 3.65)     | 5                              | 5.08 (2.43)                    | 5.05 (3.35)                        | 4.13                               | 3.70 (66.4)(1.64 -8.93]            | 5                           | 1.92 (1.12)                 | 1.67 (58.5)                 | 1.38 (0.941-3.40)           |
| 20120215  | 1-17 ye3rs          | HRfrst relapsed ALL | 40                    | 0.931 (0.499)         | 0.998 (0.450)           | 0.871 (45.1)            | 1.02 (0.113- 2.16)      |                                | NA                             | NA                                 | NA.                                | NA                                 |                             | NA                          | NA                          | NA                          |
|           | Allpedatnc subjecls | comblhed            | 94                    | 1.34 (1.29)           | 1.50 (1.43)             | 1.16 (94.9)             | 1.20 (0.113 -10.7)      | 25                             | 4.04 (2.78)                    | 4.14 (3.32)                        | 2.97                               | 3.04 (80.3)(0.559 -112.1           | 25                          | 2.14 (1.44)                 | 1.79 (67.6)                 | 1.69 (0.653 - 6.04)         |

ALL-acute lymphoblastic leukemia; clV-continuousintravenous; CL -clearance; CV-coefficient of variation(calculated as standard deviation/mean): Geo meangeometric mean; HR -high-risk; NAnot available; R/R -relapsedrefractory; SD - standard deviation; thz. = teminal half-life for cydle 1; V, - Volume of distrbution based on teminal phase in cydle 1. The mean body surface area in patients between 0 and 17 years of age was 0.04 m?

Table 14. blinatumomab Pharmacokinetic Parameter Following cIV Infusion in Adult Subject With NHL, MRD-Positive ALL, and Relapsed/Refractory ALL.

|                   |                | Clearance (CL) (Lhr)   | Clearance (CL) (Lhr)   | Clearance (CL) (Lhr)   | Clearance (CL) (Lhr)   | Volume df dstrbulion (IVn, (L)   | Volume df dstrbulion (IVn, (L)   | Volume df dstrbulion (IVn, (L)   | Volume df dstrbulion (IVn, (L)   | Temlnal haif-lfe (t .g(hr)   | Temlnal haif-lfe (t .g(hr)   | Temlnal haif-lfe (t .g(hr)   | Temlnal haif-lfe (t .g(hr)   |
|-------------------|----------------|------------------------|------------------------|------------------------|------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
| Study             | Dlsease:       |                        | Mean (SD)              | Geo mean (CV%)         | Medlan (ange)          | N                                | Mean (SD)                        | Geo mesn (CV%)                   | Medan (range)                    | N                            | Men (SD)                     | Geo mean (CV9)               | Median (range)               |
| MIT103-104        | NHL            | 66                     | 2.25 (1.17)            | 2.03 (52.0)            | 1.98 (0.714 -6.32)     | 33                               | 4.56 (2.50)                      | 4.04 (61.9)                      | 3.95 (1.86-11.6)                 | 33                           | 2.44 (1.62)                  | 2.07 (66.3)                  | 1.93 (0.906 - 8.31)          |
| MIT103-208        | NHL            | 23                     | (0.961) 1.96           | (49.1) 1.75            | (0.683 -4.41) 1.64     |                                  | NA                               | NA                               | NA                               |                              | NA                           | NA                           | NA                           |
| MIT103-202        | MRD+ ALL       | 19                     | (0.596) 1.83           | (32.6) 1.75            | (1.12-3.51) 1.66       | 18                               | (2.36) 3.98                      | (59.4) 3.45                      | (1.47- 10.8) 3.20                | 18                           | (0.530) 1.47                 | (36.1) 1.38                  | (0.660 -2.54) 1.42           |
| MT103-203         | MRD+ALL        | 32                     | 2.27 (3.02)            | 1.75 (132.8)           | 1.65 (0.815 - 18.4)    |                                  | NA.                              | NA                               | NA                               |                              | NA                           | NA.                          | NA.                          |
| MIT103-206        | RIR.ALL        | 36                     | (1.18) 2.49            | (47.4) 2.30            | (127-7.03) 2.16        |                                  | NA.                              | NA                               | NA                               |                              | NA                           | NA.                          | NA.                          |
| MIT103-211        | Ph(-)-RVR ALL  | 210                    | (3.31) 3.14            | (105.6) 225            | (0.356 - 20.5) 2.13    |                                  | NA                               | NA                               | NA                               |                              | NA                           | NA                           | NA                           |
| 00103311          | Ph-) -RuR ALL  | 224                    | 3.70 (3.34)            | 2.75 (90.3)            | 2.82 (0.154 -22.9)     |                                  | NA.                              | NA                               | NA                               |                              | NA                           | NA.                          | NA                           |
| 20120216          | Ph(+) -RR ALL  | 37                     | (4.30) 4.11            | (104.7) 2.64           | (0.526 - 18.5) 2.23    |                                  | NA                               | HA                               | NA                               |                              | NA                           | NA                           | NA                           |
| 20130265          | Ph(-) -RVR ALL | 26                     | 1.59 (0.812)           | 1.41 (51.0)            | 1.42 (0.442 - 3.28)    | 24                               | 6.02 (6.09)                      | 4.41 (101.2)                     | 3.46 (1.75 - 29.0)               | 24                           | 2.38 (1.36)                  | 2.11 (57.2)                  | 1.96 (1.19-6.15)             |
| All adult studles | combined       | 673                    | 3.08 (3.05)            | 2.30 (98.9)            | 2.17 (0.154 -22.9)     | 75                               | 4.89 (4.02)                      | 4.00 (82.3)                      | 3.58 (1.47-29.0)                 | 75                           | 2.19 (1.39)                  | 1.89 (63.6)                  | 1.73 (0.660 -8.31)           |

ALL - acule lymphoblastic leukemia: clV - continuous intravenous; CL - clearance: CV - coeficient of variation (calculaled as standard deviation/mean); Geo mean geometric mean; MRD+ = minimal residual disease positive; NA = not available; Ph+ = Fhiladelphia chromosome positive; Ph-  Philadelphia chromosome negative: NHL = non-Hodgkin's lymphoma; R/R = relapsedrefractory SD - standard devialion: taur = teminal half-life; V = volume of distribution based on teminal phase.

Css can be attained within a day and is stable over treatment cycles in both pediatric and adult subjects as shown in Table and Table, respectively. Mean Css values increased approximately dose proportionally over the dose range tested in both subject populations. The variability in Css was large in both paediatric and adult subjects regardless of BSA-based dosing or fixed dosing.

Blinatumomab PK in paediatric subjects were characterized in two distinct populations: (1) subjects with high-risk  first  relapsed  ALL  who  received  induction  therapy  and  2  blocks  of  high-risk  consolidation chemotherapy prior to blinatumomab treatment in the third consolidation course and had &lt; 25% blasts in bone marrow at enrollment in Study 20120215 and (2) subjects with relapsed/refractory ALL (defined as one of the following: second or later bone marrow relapse, any marrow relapse after allogeneic HSCT, or refractory to other treatments) with &gt; 25% blasts in the bone marrow for Study MT103- 205 or &gt; 5%

<div style=\"page-break-after: always\"></div>

blasts  in  the  bone  marrow  for  Study  20130265  where  chemotherapy  was  not  required  prior  to blinatumomab  treatment.  Given  these  differences,  the  mean  (SD)  Css  at  15  µg/m 2 /day  and  CL  of blinatumomab in paediatric subjects from Study 20120215 were generally within the ranges of those previously  reported  in  pediatric  subjects  from  Studies  MT103-205  and  20130265  when  taking  into consideration the high observed inter-subject variability.

Across the 3 clinical studies in paediatric subjects, BSA-based doses were tested over a dose range from 5 to 30 µg/m 2 /day. Based on non-compartmental analysis, the estimated mean (coefficient of variation [CV%]) Vz was 4.14 (80.3%) L/m2, indicating that blinatumomab is mainly distributed in the vascular space.  As  a  therapeutic  protein,  blinatumomab  is  likely  cleared  mainly  via  the  normal  catabolic degradation  to  small  peptides  and  individual  amino  acids  (Lin,  2009).  The  estimated  mean  (CV%) clearance (CL) under BSA-based dosing was 1.50 (94.9%) L/m2/hr, and the mean (SD) t1/2,z was 2.14 (1.44) hours, which was similar to the mean (SD) value for adults (2.19 [1.39] hours). Due to the fast CL of blinatumomab, cIV infusion is required during the treatment to maintain therapeutic concentrations in the systemic circulation.

Table 15: Blinatumomab Css by dose in pediatric subjects with RR ALL and high-risk first relapsed ALL

|                       |                        |              | Mean ± SD C: (pg/mL) (N)   | Mean ± SD C: (pg/mL) (N)   | Mean ± SD C: (pg/mL) (N)   |
|-----------------------|------------------------|--------------|----------------------------|----------------------------|----------------------------|
|                       |                        |              | Daily dose                 | Daily dose                 | Daily dose                 |
| Disease               | Study                  | Age Group    | 5 μg/m² or 9 g             | 15 μg/m² or 28 g           | 30 μg/m2                   |
| R/R ALL               | MT103-205*             | (0-17 years) | 162±179 (n=27)             | 533±392 (tc=u)             | 1520±1020 (n=7)            |
|                       | 20130265*              | (7-17 years) | 113 ±65.0 (=u)             | 361± 137 (L=u)             | NA                         |
| HR first relapsed ALL | 20120215*              | (1-17 years) | NA                         | 921 ±1010 (0t=u)           | NA                         |
|                       | All pediatric subjects | (0-17 years) | 152±162 (n=34)             | 710 ±778 (n=81)            | 1520± 1020 (=u)            |

Cs: in cycle 1 of each study is included as it contained the most subjects. Across the studies listed in the

ALL = acute lymphoblastic leukemia; C::= steady-state concentration; HR = high-risk; N = number of patients; NA = not available; R/R = relapsed/refractory; SD = standard deviation.

table, the mean body surface area in patients between 0 and 17 years of age was 0.94 m?. Sources: MT103-205 (primary analysis), 20130265 (primary analysis), 20120215 (primary analysis) clinical study reports; lifilesrv01IPCBard-RAWQPDatalAMG 1031Global Pediatric Filing 2020lEU Pediatric Filing

2020LAMG 103 EU Pediatric Filing 2020.phxproj

<div style=\"page-break-after: always\"></div>

Table16: Blinatumomab Css by dose in adult subjects with NHL, MRD-positive ALL and RR ALL

|          |                     | Mean ± SD C (pg/mL) (N)   | Mean ± SD C (pg/mL) (N)   | Mean ± SD C (pg/mL) (N)   | Mean ± SD C (pg/mL) (N)   | Mean ± SD C (pg/mL) (N)   |
|----------|---------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
|          |                     | Daily dose                | Daily dose                | Daily dose                | Daily dose                | Daily dose                |
| Disease  | Study               | 5 μg/m² 611 6 10          | 15 μg/m² or 28 μg         | 30 μg/m²                  | 60 μg/m2 or 112 μg        | 90 μg/m2                  |
| NHL      | MT103-104-          | 210±84.9 (n=32)           | 651±307 (9g=u)            | 1210±476 (g=u)            | 2730±985 (tc=u)           | 3490 ±904 (t=u)           |
|          | MT103-208*          | 277 ± 210 (oz=u)          | 565 ± 208 (n=16)          | NA                        | 2800 ±1150 (n=12)         | NA                        |
| MRD+ ALL | MT103-202*          | NA                        | 696± 147 (n=19)           | NA                        | NA                        | NA                        |
|          | MT103-203*          | NA                        | 771±312 (n=32)            | NA                        | NA                        | NA                        |
| R/R ALL  | MT103-206b          | 167 ±66.0 (n=31)          | 553 ±238 (n=34)           | 1180±820 (s=u)            | NA                        | NA                        |
|          | MT103-211           | 246 ±305 (n=178)          | 632±510 (n=188)           | NA                        | NA                        | NA                        |
|          | 00103311*           | 212±411 (n=158)           | 587 ±553d (n=194)         | NA                        | NA                        | NA                        |
|          | 20120216*           | 190 ± 99.7 (g=u)          | 673±613 (n=28)            | NA                        | NA                        | NA                        |
|          | 20130265            | 191± 90.8 (n=23)          | 948±488 (n=25)            | NA                        | NA                        | NA                        |
|          | All adult subjectsa | 224 ±318 (n=444)          | 635±491 (n=570)           | 1200 ±631 (n=11)          | 2750 ±1020 (n=46)         | 3490±904 (t=u)            |

ALL = acute lymphoblastic leukemia; C=steady-state concentration; MRD+ = minimal residual disease positive; N = number of patients; NA = not available; NHL = non-Hodgkin's lymphoma;

R/R = relapsed/refractory; SD = standard deviation

b C:: averaged over multiple cycles

* Cs in cycle 1 of each study is included as it contained the most subjects

Cycle 1 Day 2

Cycle 1 Day 15

Fixed dosing was administered at doses of 9 and 28 μg/day in the MT103-211, 00103311, 20120216, and 20130265 studies and at doses of 9, 28 and 112 μg/day in the MT103-208 study.

Sources: MT103-104 (supplementary analysis), MT103-202(primary analysis), MT103-203 (primary analysis),MT103-205(primary analysis),MT103-206(primary analysis),MT103-208(primary analysis), MT103-211(secondary analysis),20120216（finalanalysis),20130265(primaly/analysis),and 00103311 (final analysis) clinical study reports; Ifilesrv01IPCBard-RAWQPDatalAMG 103IGlobalPediatric Filing 2020IEU Pediatric Filing 2020LAMG 103 EU Pediatric Filing 2020.phxproj

Revised data not including study 20130265 are reported in table 16 and 17:

<div style=\"page-break-after: always\"></div>

Table 16. Mean (SD) Blinatumomab Steady-State Concentration (Css) by Dose in pediatric Subjects with ALL.

|                      |                        |             | Mean±SDCss(pg/mL)   | Mean±SDCss(pg/mL)   | Mean±SDCss(pg/mL)   |
|----------------------|------------------------|-------------|---------------------|---------------------|---------------------|
|                      |                        |             | Dailydose           | Dailydose           | Dailydose           |
| Disease              | Study                  | Age Group   | 5μg/m² or9g         | 15μg/m² or28μg      | 30μg/m²             |
| R/RALL               | MT103-205a             | (0-17years) | 162±179 (n=27)      | 533±392 (n=34)      | 1520±1020 (n=7)     |
| HRfirst relapsed ALL | 20120215               | (1-17years) | NA                  | 921±1010 (n=40)     | NA                  |
|                      | All pediatric subjects | (0-17years) | 162±179 (n=27)      | 743±806 (n=74)      | 1520±1020 (n=7)     |

ALL=acute lymphoblasticleukemia;C=steady state concentration;HR=high-risk:N=number of subjects;NA=notavailable:R/R-relapsed/refractory:SD=standard deviation.

Cin cycle1ofeach studyis included asit contained the most subjects.Acrossallstudieslisted in the table,the mean body surface area in patients between 0 and 17years of age was0.92m².

<div style=\"page-break-after: always\"></div>

Table 17. Mean (SD) Blinatumuab Steady-State Concentration (Css) by Dose in Adult Subjects with NHL, MRD +  ALL and R/R ALL

|          |                    | Mean±SDCss(pg/mL)   | Mean±SDCss(pg/mL)   | Mean±SDCss(pg/mL)   | Mean±SDCss(pg/mL)   | Mean±SDCss(pg/mL)   |
|----------|--------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
|          |                    | Daily dose          | Daily dose          | Daily dose          | Daily dose          | Daily dose          |
| Disease  | Study              | 5μg/m² 6ni6J0       | 15μg/m² or28μg      | 30μg/m²             | 60μg/m² or112μg     | 90μg/m2             |
| NHL      | MT103-104a         | 210±84.9 (n-32)     | 651±307 (n-36)      | 1210±476 (g-u)      | 2730±985 (n-34)     | 3490±904 (n=4)      |
|          | MT103-208a         | 277±210 (n=20)      | 565±208 (n=16)      | NA                  | 2800±1150 (n=12)    | NA                  |
| MRD+ ALL | MT103-202          | NA                  | 696±147 (n=19)      | NA                  | NA                  | NA                  |
|          | MT103-203*         | NA                  | 771±312 (n=32)      | NA                  | NA                  | NA                  |
| R/R ALL  | MT103-206b         | 167±66.0 (n=31)     | 553±238 (n=34)      | 1180±820 (S=u)      | NA                  | NA                  |
|          | MT103-211a         | 246±305a (n=178)    | 632±510 (n=188)     | NA                  | NA                  | NA                  |
|          | 00103311           | 212±411c (n=158)    | 587±553 (n=194)     | NA                  | NA                  | NA                  |
|          | 20120216           | 190±99.7 (n=6)      | 673±613 (n=28)      | NA                  | NA                  | NA                  |
|          | Alladult subjects\" | 226±325 (n=421)     | 621±486 (n=545)     | 1200±631 (n=11)     | 2750±1020 (n=46)    | 3490±904 (n=4)      |

ALL-acute lymphoblasticleukemia:C=steady state concentration;MRD+=minimalresidual disease positive;N=numberof subjects;NA=not available:NHL=non-Hodgkin'slymphoma;

R/R=relapsed/refractory:SD=standard deviation.

bCsaveragedovermultiple cycles

Cin cycle 1ofeach study isincluded as it contained themost subjects

cCycle1Day2

dCycle1Day15

Fixed dosing was administered in the MT103-208,MT103-211,00103311,and20120216studies.BSA baseddosing wasadministeredinMT103-104,MT103-202,MT103-203,andMT103-206studies. analysis),MT103-206（primary analysis).MT103-208（primaryanalysis),MT103-211(secondary analysis). 20120216(finalanalysis),and00103311(finalanalysis)clinica/studyreports;\\filesrv01\\PCBardRAWQPDatalAMG1031GlobalPediatricFiling2020\\EUPediatricFiling2020RTQs\\AMG103Global

PediaticFilina2020 Dec2020RTO.ohxDrol

Population Pharmacokinetic model

Model development

The analysis was conducted using PK data from a previous published PopPK model (Model 1) where PK data were retrieved from several clinical studies performed in adult and pediatric (MT103-104, MT103202, MT103-203, MT103-206, MT103-211, MT103-205, 20120216 and 00103311).

<div style=\"page-break-after: always\"></div>

This previous PopPK model was updated with PK data from studies 20120215 and 20130265 (Model 2). The concentration-time data of blinatumomab was modelled using a compartmental approach.

Covariates of interest in blinatumomab trials included were demographic factors (age, BSA, weight, sex, race), liver function tests (ALB, Total BILI), disease status (LDH and Hb), and baseline rating of bone marrow blast percentage(using standard classification of M1, M2 and  M3 as bone marrow biopsy or aspirate with &lt; 5% blasts, 5 to &lt; 25%, an d ≥ 25% blasts respectively).

The PopPK model was built using nonlinear mixed effects model with the first order conditional estimation with interaction method (FOCEI) in Nonmem 7 (version 7.2, ICON Development Solutions, Maryland). Covariates effects were first explored graphically, where the individual Bayesian post-hoc PK parameters were plotted against covariates. Then, testing of the covariate effects was performed using a standard stepwise forward/backward elimination method. The criterion for retention was a change in likelihood ratio  &gt;  10.83 for  1  parameter (p&lt; 0.001). Then the PopPK models were evaluated using standard diagnostic plots, and pcVPC.

## Results

The combined PK dataset includes 4043 serum samples from 760 pediatric and adult subjects across 10 studies (Model 2).

The index PK dataset consisted of PK data from study 20120215 (Pivotal Phase 3  study) and study 20130265 in  Japanese subjects (adult and  pediatric). The index PK dataset consisted of  547 serum samples from 120 adult and pediatric subjects receiving blinatumomab cIV infusion.

According to data, there were:

- 7 pre-dose samples and 59 (11%) post-dose samples below the LLOQ that were excluded
- After these exclusions, 34 subjects did not have any post-dose PK samples above the LLOQ and were excluded from the analysis
- Further, serum samples beyond 90 day post-start of first blinatumomab infusion  period (45 samples) were excluded.

The final index dataset of paediatric and adult  subjects  from these two studies included  436 serum samples from 86 subjects. A PopPK model with only these data was developed (Model 3).

An overview of the demographic covariates is provided in table 18 below. Figure 8 display the individual serum concentration vs time profiles for studies 20120215 and 20130265.

<div style=\"page-break-after: always\"></div>

Table18: Summary statistics of demographic covariates in the PopPK dataset (Model 2)

<!-- image -->

|                  |                   | Median[Min-Max]   | Median[Min-Max]   | Median[Min-Max]   |
|------------------|-------------------|-------------------|-------------------|-------------------|
|                  |                   | Study 20120215    | Study 20130265    | Combined          |
| Body Weight (kg) | Body Weight (kg)  | 23 [11.4-76.6]    | 50 [16.2-100.8]   | 68 [7.5-148.7]    |
| Age (years)      | Age (years)       | 6 [1-17]          | 40 [7-75]         | 38 [0.6-80]       |
| BSA (m²)         | BSA (m²)          | 0.88 [0.51-2.00]  | 1.49 [0.73-2.22]  | 1.8 [0.37-2.7]    |
|                  |                   | N                 | N                 | N                 |
|                  |                   | Study 20120215    | Study 20130265    | Combined          |
| Sex              | M                 | 28                | 14                | 448               |
| Sex              | F                 | 23                | 21                | 312               |
|                  | White             | 47                | 0                 | 654               |
|                  | Asian             | 1                 | 34                | 59                |
|                  | African- American | 0                 | 0                 | 14                |
|                  | Native American   | 0                 | 0                 | 3                 |
|                  | Pacific Islander  | 0                 | 0                 | 2                 |
|                  | Multiple          | 0                 | 0                 | 2                 |
|                  | Others            | 3                 | 1                 | 26                |

BSA = body surface area; F = female; Max = maximum; M = male; Min = minimum; N = number of subjects.

<div style=\"page-break-after: always\"></div>

Figure 8: Individual serum concentration-time profiles of studies 20120215 and 20130265 Study20120215

Model 1 Simulation exercise

<!-- image -->

First a simulation based exercise was performed using a VPC from model 1 to check if it was able to adequately predict the central tendency and variability of the observed PK data from studies 20120215 and 20130265. Result from this exercise is displayed in figure 9 and show the inadequacy of its predictive performance particularly on PK data from study 20120215 along the time interval and at earlier/later time points for study 20130265.

<div style=\"page-break-after: always\"></div>

Figure 9: VPC of studies 20120215 and 20130265 based on Model 1

## Study20120215

<!-- image -->

## Study20130265

<!-- image -->

Time (hours)

Model 2 (Updated PopPK model)

Since external validation suggested  that the  previous  model did  not  adequately explain the  central tendency and associated variability of blinatumomab serum concentrations for the  new dataset, the previous model was updated by using a combined dataset of 760 subjects from 10 studies.

<div style=\"page-break-after: always\"></div>

The final model is described as a one-compartment linear pharmacokinetic model and was parameterized in terms of systemic CL and V. An exponential inter-individual variability term was estimated for CL. Residual variability was modeled using an additive error model in the log-domain.

Table 19 display the final PK parameter estimates of Model 1 (left) where all parameters were estimated with a good precision (RSE &lt; 10%), and Model 3 (right) and table 20 of Model 2.

Table19: Comparison of fixed and random effect estimates for existing data (Model 1) vs New data (Model 3)

|                                   | Existing Data Only Mean (RSE1, %)   | New Data Only Mean (RSE1, %)   |
|-----------------------------------|-------------------------------------|--------------------------------|
| Pharmacokinetic Parameters        |                                     |                                |
| Volume (V, L)                     | 5.98 (8.86)                         | 8.91 (16.4)                    |
| Clearance (CL, L/h)               | 2.22 (2.95)                         | 1.50 (6.4)                     |
| Effect of BSA on CL (θ)2          | 0.620 (12.7)                        | 0.727 (23.9)                   |
| Interindividual Variability (CV%) |                                     |                                |
| WCL                               | 47.6 (16.1)                         | 12.8 (27.6)                    |
| WEPS                              | 64.3 (14.5)                         | 7.40 (65.95)                   |
| Residual Variability (CV%)        | 55.9 (3.99)                         | 62.5 (6.03)                    |

CL = Clearance from central compartment; CV = Coefficient of variation; PE = Parameter estimate;

RSE = Relative standard error; V = Volume of central compartment.

1 RSE=(SE/PE)*100.

2 Effect of BSA on CL: (BSA/1.876)** θfor existing data. (BSA/1.22)** θ for new data only

Table 20: Population PK parameters of blinatumomab (Model 2)

| Parameter (Units)                 | Typical Value [95% Cl]   | %RSE   |
|-----------------------------------|--------------------------|--------|
| Clearance (CL, L/hr)              | 2.16 [2.05-2.27]         | 2.60   |
| Effect of BSA on CL (θ)           | 0.708 [0.577-0.839]      | 9.45   |
| Volume of distribution (V, L)     | 6.41 [5.45-7.37]         | 7.64   |
| Interindividual variability (CV%) |                          |        |
| OCL                               | 52.9 [46.6-59.2]         | 6.05   |
| MEPS                              | 34.4 [31.7-37.1]         | 4.07   |
| Residual variability, o (CV%)     | 51.8 [49.2-54.4]         |        |

BSA = body surface area; Cl = confidence interval; CV = coefficient of variation; RSE = relative standard error; wcL = inter-subject variability in CL; wers = inter-subject variability in residual variability.

3 Effect of Body Surface Area (BSA) on Clearance: (BSA/1.753)** 6 Source:Study 153930

Figure 10 presented the GOF and figure 12 the pcVPC for the final model. In this figure, the observed versus predicted plots (upper panels) show random normal scatter around the identity line indicating the  absence  of  systematic  bias  and  the  adequacy  of  the  model  to  describe  the  data.  In  addition, conditional weighted residuals (middle panels) also show random normal scatter with no specific pattern suggesting model misspecification. Notably, the distribution of conditional weighted residuals versus time remains  fairly  constant,  which  indicates  the  absence  of  time-dependent  pharmacokinetics.  The

<div style=\"page-break-after: always\"></div>

histograms of the estimated random effects are presented in figure 11. Random effects estimated for CL were centered and had an acceptable shrinkage (&lt; 11%).

Figure 10: GOF of the final model (Model 2)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 11: Histograms of IIV in Final Model

<!-- image -->

Note:ETA2istheinterindividualvariabilityonCL.ETA3istheinterindividualvariabiityontheresidual variabilityparameter.Bluesolidlinesrepresentsmoothingofthedata.Reddashedlinesarethereference graphs).

Figure 12: pcVPC for the final model

VisualPredictiveCheck (PredictionCorrected) Observations vs.Time (Run 0)

<!-- image -->

Note:Redsolidlinerepresentsthemeanpredictive-correctedblinatumomabserumconcentrations. Red dashed lines represent the 5th and gh percentiles while associated shaded areas constitute the 90%confidenceinterval(Cl) forpercentilescomputedforeachbinacrosstimeandreplicates.

<div style=\"page-break-after: always\"></div>

The correlation between ETA clearance and clearance vs covariates can be found in figure 13 and figure 14, respectively.

Figure 13: Eta (CL) vs continuous covariates

<!-- image -->

Note: red solid lines represent smoothing of data using locally estimated scatterplot smoothing (LOESS). BSA -Body Surface Area; ETA2 -intenindividual variability on CL.

<div style=\"page-break-after: always\"></div>

Figure 14. CL vs continuous covariates

<!-- image -->

The effects of baseline bone marrow blast percentage may be confounded by study-specific effects and demographics in each study population. Adult and pediatric subjects with M1 bone marrow showed lower CL compared to M3 bone marrow, however subjects in M1 bone marrow were primarily composed of pediatric subjects and thus associated with lower BSA. A comparison of two pediatric studies with one composed of subjects primarily with M1 bone marrow (Study 20120215, mean BSA = 1.05 m 2 ) and the other composed of subjects primarily with M3 bone marrow (Study MT103-205, mean BSA = 0.87 m 2 ) revealed  similar  CL values  (mean  CL  1.4  L/hr  vs.  1.5  L/hr),  therefore  baseline  bone  marrow  blast percentage was not considered as a covariate on CL.

The results from the exploratory graphical and statistical analysis between the random effect of model parameters  and  the  covariates  evaluated  in  the  combined  dataset  did  not  reveal  any  remaining significant trend that explain more than 10% of the estimated between subject variability. Consequently, the final model did not include additional covariate effects other than BSA effect on CL.

<div style=\"page-break-after: always\"></div>

## Simulations of exposures between 15 µg/m 2 /day vs 28 µg/day in paediatric population patients with high risk first relapsed ALL for subjects ≥ 45 kg administered by cIV infusion

Figure 15 shows the simulated blinatumomab steady state concentration (Css) in pediatric patients with body weight ≥ 45 kg administered a body surface area (BSA) -based dose of 15 µg/m 2 /day versus a fixed dose of 28 µg/day using the updated population pharmacokinetic (PPK) model (Report 153930). The BSA values for the pediatric subjects included in this simulation were based on weight, age, and height from the National Health and Nutrition Examination Survey (NHANES) 2017-2018 demographic and body measurement  datasets.  The  figure  shows  both  dosing  regimens  resulted  in  similar  Css  in  pediatric subjects ≥ 45 kg.

For the initial PPK model, other residual unexplained variability (RUV) models were not tested. Check on a combined error model (additive + proportional) for the updated PPK model found that the additional additive error term did not improve the variability estimates.

To further evaluate the predictive performance of the updated PPK model, prediction corrected visual predicted  checks  (pcVPCs)  of  the  updated  PPK  model,  split  by  study,  are  provided  in  Figure  16. Additionally, a pcVPC for Study 20120215 alone with a different binning was presented for clarity (Figure 17).

Figure  15.  Simulated  Blinatumomab Css in Pediatric Patients With Body Weight ≥45 Kg Administered a BSA=based Dose of 15 µg/m 2 /day Versus a Fixed Dose of 28 µg/day

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 16. Prediction-correction Visual Predictive Check of the Updated PPK Model. Split by Study

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 17. Prediction-Corrected visual Predictive Check of the Updated PPK Model for study 20120215

<!-- image -->

Inclusion of inter-occasion variability (IOV) was not considered during model development under the applicant's consideration that pcVPCs demonstrated minimal bias and IOV may have limited ability to improve model predictions for pediatric subjects, as all PK samples were collected during cycle 1 for Study  20120215,  and  estimation  of  IOV  across  studies  would  be  confounded  with  study-specific differences.

The  evaluation  of  baseline  blasts  as  a  continuous  PK  covariate  was  not  feasible  as  baseline  blast numerical values were not collected in a significant portion of our population dataset (available in only 52% of pediatric subjects). While the effect of baseline blasts on PK could not be evaluated, the effects of the baseline rating of bone marrow blasts (category M1, M2, or M3) in the pediatric subject population was explored. The relationship between interindividual variability (IIV) in blinatumomab clearance (CL) and baseline rating of bone marrow blast category is presented in Figure 4. Note that only one subject in the pediatric population had a baseline rating of M2.

The PPK model have also been re-estimated using pediatric subjects only as requested. The parameter values from the PPK model based on pediatric subjects alone are presented in Table 1 alongside the parameter values for the updated PPK model from Report 153930.  The CL for a typical subject from the pediatric subject population is 1.28 L/hr.  Note that the median BSA for the pediatric subject population is 0.968 m 2 .  Based on the PPK model using pediatric subjects, the CL for a typical subject from the combined adult and pediatric subject population with a median BSA of 1.753 m 2  is 1.84 L/hr, only a 15% decrease from the previous estimate of 2.16 L/hr.  The estimated volume of central compartment (V) of 3.35 L is for a typical pediatric subject with BSA of 0.968 m 2 ; on a per m 2  basis, V is only 5.4% lower than the typical V estimated using the combined adult and pediatric population for BSA of 1.753 m 2 .

<div style=\"page-break-after: always\"></div>

The IIV on CL decreased for the PPK model using pediatric subjects compared to the updated PPK model, but  the  residual  variability  increased.    The  15%  difference  in  CL  between  the  two  models  is  small compared to the 30.1% IIV in CL.  Additionally, review of the pcVPC of the PPK model using pediatric subjects stratified by study shows that the pediatric-only PPK model performs similarly to the updated PPK model (Figure 19).

The PPK model based on pediatric subjects was used to  simulate the steady state concentrations in pediatric subjects ≥ 45 kg after a continuous infusion of either 28 μg/day or 15 μg/m 2 /day (Figure 20). Simulated Css based on the PPK model using pediatric subjects and simulated Css based on the updated PPK model are reported  in Figure 15.

Figure 18. Correlation Between categorical Baseline Rating of Bone Marrow Blast and the Individual  variability  in  Blinatumomab  Clearance  in  pediatric  Subjects  (n=106  pediatric Subjects from Studies MT103-205, 20120215, and 20130265)

<!-- image -->

M1=&lt;5%bone marrowblasts;M2=5%to&lt;25%bonemarrowblasts;M3=≥25%bonemarrow blasts.

<div style=\"page-break-after: always\"></div>

Figure  19.  Prediction-corrected  Visual  Predictive  Check  of  the  Pediatric-Only  PPK  Model, Stratifies by Study

<!-- image -->

Figure  20.  Simulated  Css  Using  pediatric-Only  PPK  Model  in  Pediatric  Patients  with  Body Weight ≥45Kg Using BSA=based Dosing of 15 µg/m2/day versus a fixed Dose of 28 µg/day

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 21. Estimated Blinatumuab PK Parameters Using Pediatric Subjects Only

<!-- image -->

| Parameter (Units)                 | Typical Value from Pediatric Only PPK Model [95%CI]   | 9RSE   | Typical Value from Updated PPK Model (Study 153930)b [95%CI]   |
|-----------------------------------|-------------------------------------------------------|--------|----------------------------------------------------------------|
| Clearance (CL, L/hr)              | 1.28 [1.11-1.45]                                      | 6.7    | 2.16 [2.05-2.27]                                               |
| Efflect of BSA on CL (θ)          | 0.613 [0.39-0.84]                                     | 18.9   | 0.708 [0.577-0.839]                                            |
| Volume of distribution (V, L)     | 3.35 [1.95-5.75]                                      | 21.2   | 6.41 [5.45-7.37]                                               |
| Interindividual variability (CV%) |                                                       |        |                                                                |
| DCL                               | 30.1 [22.6-37.6]                                      | 12.8   | 52.9 [46.6-59.2]                                               |
| OEPS                              | 32.1 [22.87-41.33]                                    | 14.7   | 34.4 [31.7-37.1]                                               |
| Residual variability, o(CV%)      | 63.4 [55.78-71.02]                                    |        | 51.8 [49.2-54.4]                                               |

## · Special populations

The effects of demographics factors on the blinatumomab PK were evaluated using individual estimated clearance  retrieve  from  the  NCA  approach.  Additional  assessment  to  quantify  these  effects  was performed with the PopPK analysis.

Relationship between weight, BSA, age, race and gender and CL of Blinatumomab were investigated at the paediatric population level (figure 21), and at both the paediatric and adult population (Figure 22)

- Weight

No  formal  PK  study  was  performed  to  investigate  the  potential  effect  of  weight  on  the  PK  of blinatumomab. The body weight ranged from 7.5 to 76.6 kg in the paediatric population, and from 7.5 to 149 kg for the full dataset. Figure 21 and 22.

- BSA

No formal PK study was performed to investigate the potential effect of BSA on the PK of blinatumomab. The BSA ranged from 0.367 to 1.99 m 2  in the paediatric population, and from 0.367 to 2.70 m 2  for the full dataset (figure 21 and 22). Based on the PopPK analysis, only BSA was found to have a significant effect on CL. Blinatumomab CL for the lowest BSA of subjects ≥ 45 kg of 1.3 m2 compared to a median BSA of 1.85 m2 is associated with a 22% reduction, and systemic CL for the highest BSA of 2.7 m2 is associated with a 31% increase. However, the magnitude of this effect is relatively low compared to the 53% unexplained between-subject variability in CL and the 34% residual variability that had a 52% between-subject variability in blinatumomab pharmacokinetics. Therefore, dose adjustments in patients ≥ 45 kg based on BSA do not appear to be necessary.

- Age, gender, race

The age ranged from 0 to 17 years in the pediatric population, and from 0 to 85 years for the full dataset. There were 78 White subjects, 9 Japanese, 3 Hispanic/latino, 1 non-Japanese Asian and 3 other races, in the pediatric population and, 570 White subjects, 35 Japanese, 82 Hispanic/latino, 24 non-Japanese Asian,  43  other  races  and  13  Black  or  African  American  for  the  full  dataset.  There  were  48/46

<div style=\"page-break-after: always\"></div>

male/female for the paediatric population and 448/319 male/female for the full dataset (figure 21 and 22).

Figure 21: Effect of demographics on blinatumomab CL in pediatric subject with ALL

## Clearance vs. Baseline Body Weight

Rsq = 0.08524, Inte1cept = 0.7809, Slope = 0.02065

<!-- image -->

Clearance vs. Age

<!-- image -->

## Clearance vs. Baseline Body Surface Area

Rsq = 0.06579,Inle1cept = 0.506, Slop9 = 0.8901

<!-- image -->

Clearance vs. Sex

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 22: Effect of demographics on blinatumomab CL in paediatric and adult subject with ALL and NHL

<!-- image -->

<div style=\"page-break-after: always\"></div>

- Immunogenicity assessment

None of the 132 paediatric subjects tested were positive for anti-blinatumomab antibodies from Study 20120215 (48 subjects tested), Study MT 103-205 (75 subjects tested), and Study 20130265 (9 subjects tested). These results are consistent with the low incidence of immunogenicity observed across adult studies with 1.4% (9 out of 663) of adult subjects showed binding or neutralizing ADA.

- Effect of baseline rating bone marrow blast percentage on Pharmacokinetic

Morphologic evidence of tumor burden in ALL subjects was assessed by percentage of blasts in the bone marrow  at  baseline.  The  effect  of  baseline  rating  of  bone  marrow  blast  percentage  on  the  CL  of blinatumomab  was  assessed  across  the  3  clinical  studies  in  pediatric  subjects  with  ALL:  Studies 20120215, MT103-205, and 20130265 ( Figure ). Baseline rating of bone marrow blast percentage was reported in subjects according to the standard classification: M1, &lt; 5% blasts; M2, 5% to &lt; 25% blasts; M3, ≥ 25% blasts.

As shown in figure 23, the level of blast infiltration in bone marrow at baseline did not show an apparent effect on drug clearance in pediatric subjects.

<div style=\"page-break-after: always\"></div>

Figure 23: Effect of baseline rating bone marrow blast percentage on blinatumomab clearance in paediatric subject

<!-- image -->

Statistical analyses were conducted using the Wilcoxon non-parametric test comparing the blinatumomab clearance (CL) values of subjects with baseline bone marrow blasts below 5% (M1) and those with baseline blasts at or above 5% (M2/M3). The results indicated that there is a low probability that the groups differ by chance. Similar statistical results are observed when comparing CL values of subjects with M1 bone marrow and those with M3 bone marr ow (≥25% blasts) at baseline (ie., removing the 1 M2 subject from the analysis).

Table  22.  Assessment  of  Effects  of  Baseline  Blast  Rating  on  Blinatumomab  Clearance (Subjects with Blinatumomab Clearance From Studies MT103-205, 20120215, and 20130265)

<!-- image -->

|                       | Blinatumomab (N=94)   | Blinatumomab (N=94)   | Blinatumomab (N=94)   |
|-----------------------|-----------------------|-----------------------|-----------------------|
| Baseline Blast Rating | n                     | Median clearance      | p-valuea              |
| Comparison 1          |                       |                       |                       |
| M1                    | 40                    | 1.02                  |                       |
| M2/M3                 | 54                    | 1.39                  |                       |
| M1 vs M2/M3           |                       |                       | 0.0006                |
| Comparison 2          |                       |                       |                       |
| M1                    | 40                    | 1.02                  |                       |
| M3                    | 53                    | 1.38                  |                       |
| M1 vs M3              |                       |                       | 0.0009                |

<div style=\"page-break-after: always\"></div>

In addition, based on the PopPK analysis, the applicant states that the effect of baseline bone marrow blast  percentage  may  be  confounded  by  study  specific  effects  and  demographics  in  each  study population. Adult and pediatric subjects with M1 bone marrow showed lower CL compared to M3 bone marrow; however, subjects with M1 bone marrow were primarily composed of pediatric subjects and thus associated with lower BSA.

A comparison of two pediatric studies with one composed of subjects primarily with M1 bone marrow (Study 20120215, mean BSA = 1.05 m2) and the other composed of subjects primarily with M3 bone marrow (study MT103-205, mean BSA = 0.87 m2) revealed similar CL values (mean CL 1.4 L/hr vs. 1.5 L/hr); therefore, baseline bone marrow blast percentage was not considered as a covariate on CL.

## 2.3.3. Pharmacodynamics

Pharmacodynamic assessments were not conducted in Study 20120215; therefore, the PD effect of blinatumomab in paediatric subjects is not discussed in this assessment report. The previous variation application for paediatric subjects with relapsed/refractory ALL in 2018 provides a description of blinatumomab PD in paediatric subjects (EMEA/H/C/003731/II/0018).

## Exposure-response Relationships

Relationships between blinatumomab Css from the target dosing regimen and the primary and secondary efficacy endpoints of EFS and OS, respectively, and adverse events of CRS, neurological events, and infections were explored in pediatric subjects with high-risk first relapsed B-cell precursor ALL treated with blinatumomab (Study 20120215). Considering that there was only 1 dosing cohort, Study 20120215 is inadequate to make conclusions about the exposure-response relationships for blinatumomab in these subjects.

## Immunogenicity

None of the 132 paediatric subjects tested were positive for anti-blinatumomab antibodies from Study 20120215 (48 subjects tested), Study MT103-205 (75 subjects tested), and Study 20130265 (9 subjects tested). These results are consistent with the low incidence (1.4%) of immunogenicity observed across adult studies

## 2.3.4. PK/PD modelling

The objectives of this analysis were to investigate the relationship between blinatumomab exposure and efficacy endpoints (duration of EFS and OS) or safety events (occurrence of CRS, neurologic events, and infections, and time to neurologic events) in paediatric subjects with high-risk first relapsed B-precursor ALL receiving blinatumomab or standard of care (SOC) chemotherapy as consolidation therapy after induction therapy.

## ER efficacy

## Methodology

Time to event analysis were conducted using Cox proportional hazard models and the hazard ratios and respective 95 th CIs are presented.

## PK data

Blinatumomab Css estimated at Day 15 was selected as the exposure metric to be investigated.

## PD data

<div style=\"page-break-after: always\"></div>

Duration of EFS and OS were considered as PD endpoints for exploratory purposes where Css (tabulated by quartiles) was available. Baseline covariates (age, weight, BSA, sex, blood counts, genetic abnormalities, extramedullar disease) were also tabulated by quartiles.

## Results

Of the 108 subjects enrolled 54 received blinatumomab (and 54 HC3). From the 54 subjects, only 40 Css at Day 15 receiving 15 µg/m2/day. (table 23, 24 and 25)

Table23: Distribution of categorical baseline covariates by quartiles of exposure in subjects treated with 15µg/m2/day cIV infusion of Blinatumomab

<!-- image -->

|                                     |               | Quartiles of exposure following 15 μg/m2/day dose   | Quartiles of exposure following 15 μg/m2/day dose   | Quartiles of exposure following 15 μg/m2/day dose   | Quartiles of exposure following 15 μg/m2/day dose   |
|-------------------------------------|---------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| Categorical Baseline Covariate      | Category      | Q1 (N=10) <490.75 pg/mL                             | Q2 (N=10) 2490.75 & <614 pg/mL                      | Q3 (N=10) 2614& <951.25 pg/mL                       | Q4 (N=10) 2951.25                                   |
| Baseline bone marrow cytomorphology | M1            | 10                                                  | 10                                                  | 10                                                  | 10                                                  |
| Baseline bone marrow cytomorphology | M2            | 0                                                   | 0                                                   | 0                                                   | 0                                                   |
| Baseline bone marrow cytomorphology | Not evaluable | 0                                                   | 0                                                   | 0                                                   | 0                                                   |
| Sex                                 | Female        | 8                                                   | 3                                                   | 6                                                   | 4                                                   |
| Sex                                 | Male          | 2                                                   | 7                                                   | 4                                                   | 6                                                   |
| B-precursor ALL subtype             | C-ALL         | 4                                                   | 7                                                   | 6                                                   | 7                                                   |
|                                     | Pre-B-ALL     | 5                                                   | 3                                                   | 4                                                   | 1                                                   |
|                                     | Pro-B-ALL     | 1                                                   | 0                                                   | 0                                                   | 2                                                   |

Table 24: Distribution of continuous baseline covariates by quartiles of exposure in subjects treated with 15µg/m2/day cIV infusion of Blinatumomab

<!-- image -->

|                               | Quartiles of exposure following 15 μg/m²/day dose   | Quartiles of exposure following 15 μg/m²/day dose   | Quartiles of exposure following 15 μg/m²/day dose   | Quartiles of exposure following 15 μg/m²/day dose   |
|-------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| Continuous baseline covariate | Q1 (N=10) <490.75 pg/mL                             | Q2 (N=10) 2490.75 & <614 pg/mL                      | Q3 (N=10) 2614 & <951.25 pg/mL                      | Q4 (N=10) 2951.25                                   |
| Weight (kg)                   | 23.1 [11.4-51]                                      | 33.5[12.3-76.6]                                     | 25.3 [12.5-53.4]                                    | 33.1 [13.3-74.5]                                    |
| Age (years)                   | 5.8 [1-12]                                          | 7.8 [2-16]                                          | 6.3 [2-17]                                          | 7.6 [2-17]                                          |
| BSA (m2)                      | 0.84 [0.49-1.49]                                    | 1.07 [0.55-1.92]                                    | 0.90 [0.53-1.6]                                     | 1.07 [0.56-2.02]                                    |
| Hemoglobin (g/L)              | 100.4 [76-117]                                      | 102.4 [87-118]                                      | 90.5 [73-110]                                       | 97.2 [77.3-114]                                     |
| Platelets (10^9/L)            | 294.4[123-583]                                      | 225.4 [59-486]                                      | 222.8 [81-351]                                      | 236.9 [151-349]                                     |

BSA: body suface area

<div style=\"page-break-after: always\"></div>

Table 25 Summary of EFS, OS and CRS, Neurological events and infections by Quartiles of Css

<!-- image -->

| EFS                       | EFS               | EFS               | EFS               | EFS                    |
|---------------------------|-------------------|-------------------|-------------------|------------------------|
| Quartile of Exposure      | Total N           | Event             | Censored          | Median (95% Cl) [days] |
| Q1 (<490.75 pg/mL)        | 10                | 4                 | 6                 | Not estimable          |
| Q2 (2490.75 & <614 pg/mL) | 10                | 2                 | 8                 | Not estimable          |
| Q3 (2614 & <951.25 pg/mL) | 10                | 3                 | 7                 | Not estimable          |
| Q4 (2951.25 pg/mL)        | 10                | 5                 | 5                 | Not estimable          |
| OS                        | OS                | OS                | OS                | OS                     |
| Quartile of Exposure      | Total N           | Event             | Censored          | Median (95% Cl) [days] |
| Q1 (<490.75 pg/mL)        | 10                | 2                 | 8                 | Not estimable          |
| Q2 (2490.75 &<614 pg/mL)  | 10                | 0                 | 10                | Not estimable          |
| Q3 (2614 &<951.25 pg/mL)  | 10                | 1                 | 9                 | Not estimable          |
| Q4 (2951.25 pg/mL)        | 10                | 3                 | 7                 | Not estimable          |
| CRS                       | CRS               | CRS               | CRS               | CRS                    |
| Quartile of Exposure      | Total N           | Event             | Censored          | Censored               |
| Q1 (<490.75 pg/mL)        | 10                | 0                 | 10                | 10                     |
| Q2 (2490.75 &<614 pg/mL)  | 10                | 0                 | 18                | 18                     |
| Q3 (2614 & <951.25 pg/mL) | 10                | 1                 | 6                 | 6                      |
| Q4 (2951.25 pg/mL)        | 10                | 1                 | 6                 | 6                      |
| Neurologic Events         | Neurologic Events | Neurologic Events | Neurologic Events | Neurologic Events      |
| Quartile of Exposure      | Total N           | Event             | Censored          | Censored               |
| Q1 (<490.75 pg/mL)        | 10                | 3                 | 7                 | 7                      |
| Q2 (2490.75 &<614pg/mL)   | 10                | 7                 | 3                 | 3                      |
| Q3 (2614 & <951.25 pg/mL) | 10                | 3                 | 7                 | 7                      |
| Q4 (2951.25 pg/mL)        | 10                | 5                 | 5                 | 5                      |
| Infections                | Infections        | Infections        | Infections        | Infections             |
| Quartile of Exposure      | Total N           | Event             | Censored          | Censored               |
| Q1 (<490.75 pg/mL)        | 10                | 5                 | 5                 | 5                      |
| Q2(2490.75&<614 pg/mL)    | 10                | 6                 | 4                 | 4                      |
| Q3 (2614 & <951.25 pg/mL) | 10                | 4                 | 6                 | 6                      |
| Q4 (2951.25 pg/mL)        | 10                | 2                 | 8                 | 8                      |

EFS: event-free sunvival. OS: overall survival. CRS: cytokine release syndrome. Cl: confidence intenval.

Of the 40 pediatric subjects with blinatumomab Css, at the time of data cutoff, 26 subjects (65%) had not progressed and 34 subjects (85%) were still alive. The median duration of EFS and OS were not estimable as &lt;50% of subjects had progressed or died at the data cut off.

Results of the univariate analysis for EFS and OS are presented in table 26 and table 27, respectively.

<div style=\"page-break-after: always\"></div>

Table 26: Results of time to event analyses of EFS (univariate)

<!-- image -->

| Univariate CoxProportional Hazard Results   | Univariate CoxProportional Hazard Results   | Hazard Ratio (95%Cl)   |   p-value |
|---------------------------------------------|---------------------------------------------|------------------------|-----------|
| Effect of treatment (N=108)                 | Blinatumomab vs. SOC Chemotherapy           | 0.39 (0.22-0.7)        |     0.002 |
| Effect of exposure1 (N=40)                  | Css (per log [pg/mL])                       | 1.104 (0.460-2.654)    |     0.824 |
| Effect ofsex (N=108)                        | Male vs.Female                              | 1.1 (0.63-1.94)        |     0.729 |
| Effect of age (N=108)                       | Continuous (per year)                       | 0.954 (0.889-1.024)    |     0.196 |
| Occurrenceofgenetic anomaly (N=108)         | True vs. False                              | 1.06 (0.6-1.86)        |     0.844 |
| Extramedullary disease at relapse (N=108)   | True vs.False                               | 1.49 (0.77-2.86)       |     0.234 |
| Effect of baseline Hemoglobin (N=108)       | Continuous (per unit)                       | 0.987 (0.966-1.008)    |     0.231 |
| Effect of baseline Platelet (N=108)         | Continuous (per unit)                       | 1.000 (0.998-1.002)    |     0.875 |

EFS:eventfreesurvival.SoC:standard-of-care

Table 27: Results of time to event analyses of OS (univariate)

<!-- image -->

| Univariate Cox Proportional Hazard Results   | Univariate Cox Proportional Hazard Results   | Hazard Ratio (95%Cl)   |   p-value |
|----------------------------------------------|----------------------------------------------|------------------------|-----------|
| Effect of treatment (N=108)                  | Blinatumomab vs. SOC Chemotherapy            | 0.42 (0.18-0.99)       |     0.046 |
| Effect of exposure1 (N=40)                   | Css (per log [pg/mL])                        | 1.699 (0.534-5.406)    |     0.37  |
| Effect of sex (N=108)                        | Male vs.Female                               | 0.91 (0.41-2.03)       |     0.812 |
| Effect of age (N=108)                        | Continuous (per year)                        | 0.965 (0.871-1.068)    |     0.487 |
| Occurrenceofgenetic anomaly (N=108)          | True vs.False                                | 1.55 (0.69-3.46)       |     0.286 |
| Extramedullarydisease at relapse (N=108)     | True vs.False                                | 1.43 (0.57—3.61)       |     0.446 |
| Effect of baseline Hemoglobin (N=108)        | Continuous (per unit)                        | 0.977 (0.946-1.01)     |     0.166 |
| Effect of baseline Platelet (N=108)          | Continuous (per unit)                        | 1.000 (0.997-1.002)    |     0.738 |

SOC:standard-of-care

Kaplan-Meier curves of EFS and OS stratified by quartiles of exposure are presented in figure 24.

<div style=\"page-break-after: always\"></div>

Figure 24: Kaplan Meier survival curves across exposure quartiles in subjects treated with blinatumomab

0.

0

6.

0

0.4

2

0.0

1st Quartile

2nd Quartile

3rd Quartile

4th Quartile

1200

Event Free Survival

0

200

400

600

800

Time(days)

<!-- image -->

Time to event analysis demonstrated improved EFS in subjects treated with blinatumomab compared to HC3 (hazard ratio = 0.39, 95% CI: 0.22-0.7, p = 0.002) as well as improved OS in subjects treated with blinatumomab compared to HC3 (hazard ratio = 0.42, 95% CI: 0.18-0.99, p = 0.046).

1000

<div style=\"page-break-after: always\"></div>

## ER safety

## Methodology

Univariate and multivariate logistic regression model and the odds ratio and respective 95 th  CIs were performed, in addition to Cox proportional hazard models.

## PK data

Observed Blinatumomab Css was selected as the exposure metric to be investigated given the large RUV and high between subjects as evident from the PopPK analysis.

## PD data

CRS (cytokine release syndrome), neurological (and time event to event analysis) and infections events were considered.

## Results

In 40 subjects with blinatumomab Css, exploratory exposure-safety analysis indicates  no difference between Css in subjects with or without a safety event of any grade for CRS, neurological events, and infections (figure 25). Further details of the univariate analysis for each safety event is presented below.

Figure 25: Comparison of Blinatumomab Css in subjects with or without adverse effects

<!-- image -->

CRS:cytokinerelease svndrome

Cytokine release syndrome (CRS)

<div style=\"page-break-after: always\"></div>

The proportion of subjects with CRS events of any grade was 5% (2 of 40 subjects) in the pediatric subjects  with  blinatumomab  Css.  There  was  no  grade ≥ 3  CRS  event  in  the  40  subjects  with blinatumomab Css. Due to the small number of events, univariate analysis exploring the association between  exposure  and  the  occurrence  of  CRS  of  any  grade  did  not  find  any  significant  association between blinatumomab Css and the occurrence of CRS.

## Neurological events

The proportion of subjects with at least 1 neurologic event of any grade was 45% (18 of 40 subjects) in the pediatric subjects with blinatumomab Css, however only 1 event (2.5%) was grade ≥ 3. Univariate analysis exploring the association between exposure and neurologic events of any grade suggested that blinatumomab Css was not associated with occurrence of neurologic events (table 28), or the time to neurologic events (hazard ratio = 1.222 per log[pg/mL], 95% CI: 0.567-2.634 per log[pg/mL], p = 0.608). Higher age was associated with higher occurrence of neurological events (odds ratio per age year = 1.18, 95% CI: 1.07-1.31 per year, p =0.001). Multivariate analysis with treatment and age also suggests higher occurrence of neurological events with higher age (table 29).

Table 28: Summary of univariate analysis by exposure for safety endpoints (Study 20120215)

| Event                |   Total N |   Nwith Events | OccurrenceofEventUnivariate Analysis Odds Ratio (95% Cl) per log (pg/mL) [p-value]   |
|----------------------|-----------|----------------|--------------------------------------------------------------------------------------|
| CRS                  |        40 |              2 | 1.730 (0.138-10.178) [0.577]                                                         |
| Neurological Event   |        40 |             18 | 1.217 (0.416-3.714) [0.713]                                                          |
| Infections           |        40 |             17 | 0.614 (0.166-1.812) [0.407]                                                          |
| Infections ≥ Grade 3 |        40 |              6 | 0.144 (0.007-1.182) [0.136]                                                          |

Table 29: Multivariate logistic regression model of neurological events

| Effect    |                                   | Odds Ratio (95% Cl)   |   p-value |
|-----------|-----------------------------------|-----------------------|-----------|
| Treatment | SoC chemotherapy vs. blinatumomab | 0.464 (0.194-1.078)   |     0.077 |
| Age       | Continuous per year               | 1.178 (1.068-1.312)   |     0.002 |

## Infections

The proportion of subjects with at least 1 infection of any grade was 42.5% (17 of 40 subjects) in the pediatric  subjects  with  blinatumomab  Css,  with  15%  (6  of  40  subjects)  categorized  as  grade ≥ 3. Univariate analysis suggested that blinatumomab Css was not associated with occurrence of infections of  any grade or grade ≥ 3 (Table 25). No significant associations were found between occurrence of infections and the covariates tested in the univariate analyses.

## Dose rationale

The rationale for the clinical dose selection for consolidation therapy of blinatumomab for the treatment of high-risk first relapsed ALL after induction therapy was based mainly on the totality of PK, efficacy, and safety information. The recommended dose regimen for this population is 15 µg/m2/day for subjects &lt; 45 kg and 28 µg/day for subjects ≥ 45 kg administered by cIV infusion.

<div style=\"page-break-after: always\"></div>

The  dose  tested  in  Study  20120215  in  paediatric  patients  with  high-risk  first  relapsed  ALL  was  15 µg/m2/day  with  a  maximum  daily  dose  not  to  exceed  28  µg/day,  whereas  the  dose  in  previous blinatumomab pediatric studies, Studies MT103-205 and 20130265, was 15 µg/m2/day (no maximum dose defined). Although an equivalent fixed dose regimen of 28 µg/day was not specified for subjects ≥ 45 kg in Study 20120215, similar exposure levels are expected with either the BSA-based dosing or fixed dosing at an equivalent dose. Similar exposure levels were observed in subjects ≥ 45 kg given the 15 µg/m2/day dose in subjects across all pediatric studies and 28 µg/day dose in adults regardless of indication (figure 26 and Table 30). In addition, the relationship between blinatumomab clearance (CL) values and body weight in subjects ≥ 45 kg was analyzed from PK data pooled from adult and pediatric subjects with relapsed/refractory ALL or high-risk first relapsed ALL (figure 27). The analyses indicate that body weight is not a sensitive factor affecting blinatumomab CL in subjects ≥ 45 kg regardless of age.

Therefore, comparable exposures of blinatumomab in subjects ≥ 45 kg are expected when receiving either a fixed dose or BSA-based dose. Body surface area has been identified as the only covariate to have a significant effect on CL  based on population PK modeling of blinatumomab PK in adult and pediatric subjects that included the impact of covariates such as demographic factors, organ function, and disease status on PK parameters. However, the BSA covariate effect was minimal, with a ≤ 31% change in CL over the range of BSA values in the combined population of pediatric and adult subjects ≥ 45 kg (1.3-2.7 m2), relative to the median BSA (1.85 m2) in this population. In addition, the magnitude of this effect is relatively low compared to the 53% unexplained between-subject variability in CL and the 34% residual variability that had a 52% between-subject variability in blinatumomab PK. Therefore, dose adjustments in pediatric patients ≥ 45 kg based on BSA do not appear to be necessary.

Figure 26: Comparison of blinatumomab Css for adult subjects ≥ 45 kg receiving 28 µg/day fixed dose and Pediatric subjects ≥ 45 kg receiving 15 µg/m 2 /day BSA based dose

<!-- image -->

N = number of patients. Boxes display mean (dashed lines), median (solid lines), 25th (bottom) percentile, and 75th (top) percentile. Whiskers represent the 10th (bottom) and 90th (top) percentiles. Source:lfilesrv01\\PCBard-RAWQPData\\AMG103IGlobalPediatricFiling 2020\\EUPediatricFiling 2020LAMG103EUPediatricFiling2020.jnb

<div style=\"page-break-after: always\"></div>

Table 30: Blinatumomab Css for adult subjects ≥ 45 kg receiving 28 µg/day fixed dose and Pediatric subjects ≥ 45 kg receiving 15 µg/m 2 /day BSA based dose

|                                  | Blinatumomab Cycle 1 Css (pg/mL)   | Blinatumomab Cycle 1 Css (pg/mL)   | Blinatumomab Cycle 1 Css (pg/mL)   | Blinatumomab Cycle 1 Css (pg/mL)   | Blinatumomab Cycle 1 Css (pg/mL)   | Blinatumomab Cycle 1 Css (pg/mL)   |
|----------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
| Subject Population, Dose         | N                                  | Median (Range)                     | Mean                               | SD                                 | CV%                                | Geo Mean                           |
| Pediatric (245 kg), 15 μg/m2/day | 11                                 | 539 (367- 4530)                    | 1020                               | 1200                               | 118.1                              | 735                                |
| Adult (≥45 kg), 28 μg/day        | 436                                | 492 (51.0 - 4450)                  | 621                                | 522                                | 84.1                               | 461                                |

ALL = acute lymphoblastic leukemia; Css = steady-state concentration; CV = coefficient of variation (calculated as standard deviation/mean); Geo mean = geometric mean; N = number of patients; SD = standard deviation.

Results from Cycle 1 Day 15 are presented from 00103311 study.

Sources: MT103-205(primary analysis),MT103-208(primary analysis), MT103-211(secondary analysis), Pediatric Filing 2020LAMG 103 EU Pediatric Filing 2020.phxproj

Figure 27 : Relationship between blinatumomab clearance values and BW (≥45 kg) in subjects with RR ALL and High-risk first relapsed ALL

Rsq=0.01102.Intercept=1.905.Slope=0.01939

<!-- image -->

ALL = acute lymphoblastic leukemia; HR = high-risk; N = number of subjects; R/R = relapsed/refractory. Source:1ifilesrv01\\PCBard-RAWQPData\\AMG 103lGlobal Pediatric Filing 2020\\EUPediatric Filing 2020LAMG 103EU PediatricFiling 2020.phxproj

From safety and efficacy perspectives, the dose of 15 µg/m2/day (maximum daily dose not to exceed 28 µg/day) was found to be safe and effective for the treatment of high-risk first relapsed ALL pediatric subjects with a reduced tumor burden of &lt; 25% blasts in the bone marrow (M1 and M2 bone marrow) in consolidation therapy after induction therapy in Study 20120215.

<div style=\"page-break-after: always\"></div>

In pediatric relapsed/refractory ALL, the recommended dose for the first cycle of treatment is a starting dose of 5 µg/m2/day (or 9 µg/day for subjects ≥ 45 kg) with escalation to 15 µg/m2/day (or 28 µg/day for subjects ≥ 45 kg) after one week to avoid CRS associated with high tumor burden. No step-dosing was needed in Study 20120215 as in the treatment in relapsed/refractory ALL, mainly because the tumor burden and related CRS events was low in the setting of consolidation after induction for the treatment of high-risk first relapsed ALL.

This rationale is identical to that of the recommended dosing for subjects with MRD positive ALL with similar  reduced  tumor  burden  and  related  CRS  risk  profile.  Given  that  comparable  exposures  are expected between fixed dosing and BSA-based dosing for subjects ≥ 45 kg, fixed dosing of 28 µg/day can be recommended for pediatric subjects ≥ 45 kg due to logistical advantages with fixed dosing such as  ease  of  administration,  reduced  risk  of  dosing  errors,  minimal  preparation  by  hospital  staff  and reduced  patient  waiting  time.  In  addition,  BSA-based  dosing  of  15  µg/m2/day  is  recommended  for pediatric subjects ≥ 45 kg to avoid excessive Css exposures.

## 2.3.5. Discussion on clinical pharmacology

Blinatumomab is currently approved for the treatment of Philadelphia-chromosome negative relapsed/refractory B-cell precursor ALL (R/R ALL) in adult and paediatric subjects and in MRD in adults only. The pharmacokinetics have been well characterized in adult and pediatric patients in R/R ALL.

The current Type II variation of extension of the indication of Blinatumomab in the paediatric population (1 to &lt; 18 years) with high-risk first relapsed Ph- B-cell precursor ALL, have been addressed according to the paediatric investigation part of Blinatumomab clinical development (EMEA000574-PIP02-12-M03). In support of this application, the applicant conducted a Phase 3 study (Study 20120215) in patients aged 1 to &lt;18 years.

Descriptive statistics were performed to support PK similarity between the observed PK metrics of interest (Css) in the target population (paediatric with high-risk), and pooled PK data from ancillary studies in adults (R/R ALL, NL, MRD, R/R ALL in Japanese) or paediatric (R/R ALL, R/R ALL in Japanese). One Population PK analysis using all available PK data and two ER analysis (efficacy/safety) using only PK data from the pivotal study were performed.

The bioanalytical assay for determination of blinatumomab in serum is considered validated and considered suitable. The same assay was used across the ancillary clinical studies (adult and pediatric populations).  The standard NCA and the population methodology are acceptable for PK data analyses.

One concern was raised with regards to the dosing regimen used in this study which should have been guided by a PopPK/PD analysis according to the PIP. Data provided showed that selected dose 15µg/m2/day was based on preliminary PK data (and efficacy/ safety data) from study MT103-206. Overall the PK data from this study are not well presented.

In study MT103-205 During cIV infusion of 15µg/m2/day blinatumomab to pediatric subjects (n=34), the mean (SD) serum blinatumomab concentration at steady state was 533 (392) pg/mL with CV of 73.6%. Median (min-max) was 498 pg/mL (58.5-2090 pg/mL). Geometric mean Css was 411 pg/mL. Interestingly, it could be observed that between cycles, Css at the same dosing regimen increase by 2fold in children from 2 to 17 years, however since only one cycle is expected for subjects with high risk first relapsed, such behavior will be difficult to observe. Overall, when PK data are split by age subgroup, it could be observed that the geometric mean CL is 2-fold higher in children aged 7-17 years compared to children ≤ 2 years (1.35 vs 0.662 L/h), therefore the applicant BSA based dose appears reasonable.

<div style=\"page-break-after: always\"></div>

A concern was raised with regards to a novel study (20130265) performed in R/R ALL Japanese adult and paediatric subject, which was used in addition to other studies to assess the PK similarity between populations. In Study 20130265 the PK data between the adult and the paediatric population are not similar at two levels, within the study (2-fold higher exposure in adult vs pediatric) and between studies (adult and paediatric from other studies). Fortunately, by providing more detailed PK data, Css in Japanese children (aged 7-17 years) were 1.5 fold lower than Css in children from Study MT103205, 361 vs 533 pg/mL, respectively. The value of 533 pg/mL probably rely on pooled Css across age cohorts, whereas the reported one 686 pg/mL rely on subjects aged 7-17 years from study MT103205. However the applicant states that age have not a significant effect on blinatumomab CL and this is not fully agreed based on the available PPK model since BSA is part as the final PPK model (BSA, age, weight are expected to be correlated, and the table which provide the covariate effect testing on PK is missing). In Japanese adult patient Css was 1.5 fold higher than Css in adult patients. Overall the applicant noted these differences but considered that PK was generally similar between population given the high CV% observed in adults 88% and in the paediatrics 76%. Moreover, the applicant state that race was not found as a significant covariate in the PPK analysis. However it should be noted that the entire PK dataset consisted of 760 subjects from which Asian accounted for 59 subjects (7.7% of the entire dataset), from which Japanese (35 subjects) accounted for 4.6% of the entire dataset (less than at least the 10% needed to detect any significant covariate). Therefore data have been provided with the exclusion of the Japanese population, nevertheless, the applicant argued that PK similarity between Japanese paediatric and adult subject, and between Japanese and other race subject can be claimed given the high IIV.

In addition, a concern was raised on the claimed PK similarity between paediatric subject from Study 20120215 and those from Study MT103-205 or adult subjects. Based on geometric mean of Css (which is considered as the best metric to consider instead of arithmetic mean, Css is related to CL and CL follow a lognormal distribution), in Study 20120215, Css is not similar between children aged 2-6 years and 7-17 years, this can be claimed only based on median Css. It should be noted that probably one (or several) outlier(s) in the group of children aged 7-17 years is probably responsible of the high CV Geo mean of 92.9%. Based on Geometric mean of CL the same trend remains. The same comments can be made with PK data from Study MT103-205 (for both Css and CL) suggesting an effect of age on blinatumomab PK. However according to the applicant, based on the PopPK model age was not found to have an effect on blinatumomab PK (this is expected since BSA is already introduce in the PK model, and both are known to be correlated).

When geometric mean Css (or CL) are compared between age cohorts from Study 20120215 and Study MT103-205, for:

-&lt;2 years, Css are not comparable

- 2-6 years old children, Css (CV%) were 642 (42.6%) vs 303 (120.8%) pg/mL, then approximately a 2.1-fold greater Css

- 7-17 years old, Css were 904 (92.9%) vs 567 (70.2%) pg/mL, then approximately a 1.6-fold greater Css

- 1-17 years (pooled), Css were 718 (66.3%) vs 411 (93%) pg/mL, then approximately a 1.7-fold greater Css

Even if the comparison is performed based on the arithmetic mean Css with pooled Css across age, Css were 921 vs 533 pg/mL, then approximately a 1.7-fold greater Css in subjects from Study 20120215.

Therefore Css in both paediatric populations from Study 20120215 and Study MT103-206 are not comparable.

<div style=\"page-break-after: always\"></div>

Now compared to adults PK data the applicant claimed that PK in the pediatric population fell within the range of corresponding values for the combined group of all adult subjects taking into consideration the large IIV of CV% of 144%. However this conclusion rely on pooled Css across all the pediatric cohort and studies by considering a mean Css, and such comparison is not considered reliable as raw PK data clearly show that PK data from Studies 20120215 and MT103-205 are not comparable and cannot be pooled.

Raw data suggest that mean Css in adults subjects is similar to the pediatric population from study MT103-205, however such conclusion cannot be claimed with mean Css from Study 20120215. Overall the applicant rely on the large IIV observed (CV of 144%) to claim the comparability between Css across the populations. However one can argue that such high CV can be reduced if instead of a BSA based fixed-dose, an adapted dose based on another metrics or maybe based on the disease status would not have led to these unexpected PK results in this pediatric population compared to others populations.

Overall, therefore statement on PK similarity is not endorsed and it has been deleted from the SmPC. Pediatric subject from Study 20120215 have a 1.7 fold increased Css compared to pediatric subjects from study 20120215 and consequently compared to adults R/R ALL.

A concern was raised with regards to the developed PopPK model and a new one has been requested with only PK data from the pediatric population to address the dosing regimen issue.

The requested simulation (based on an updated model) shows that predicted Css in children weighting more than 45 kg with the two dosing regimens (15 µg/m2 or 28 µg) are similar. Upon request, another RUV model (combined) have been investigated by the applicant with the initial PPK model (all the data except those from children) to try to correct the under-prediction of the central tendency, however no improvement of the pcVPC was observed. pcVPC split by study with the update PPK model were provided. Generally the central tendency (and variability) is well captured across the different studies except reasonable misspecifications for all the pediatric studies. The associated simulation exercise (based on an updated) was provided and shows that predicted Css in children weighting more than 45 kg with the two dosing regimens (15 µg/m2 or 28 µg) are similar. The requested PPK model was performed by the applicant without investigation of an IOV term. The evaluation of baseline blast was performed but remain uninformative since only 52% of pediatric subjects had this measure. pcVPC split by studies remain similar (with the same reasonable misspecifications) to those with the updated PPK model. This may be explained by the structure of the PK model which have not been improved and was set to be similar to that of adults even if, in general it is not expected a different structural PK model between adults and paediatrics subjects. This probably explain the inflated observed RUV, to this end the IOV term should have been of particular interest, nevertheless the issue will not be pursued, as the simulation exercise performed similarly. In conclusion, the new simulation perform similarly to that which use pooled PK data.

In addition, several concerns were raised with regards to the unclear effect of blast percentage at baseline (or after subsequent cycles) on blinatumomab clearance. Indeed results from NCA and PopPK analysis appear conflicting. Also, several studies from which PK of blinatumomab have been evaluated at subsequent cycle clearly show that as long as the number of cycles increase (and the number of percent blast is expected to decrease), Css increase suggesting that there is an effect of blast percentage on blinatumomab clearance. This behavior is observed in Study MT103-205 between Cycle 1 and Cycle 2, with geometric mean Css of 411 pg/mL and 684 pg/mL respectively, in Study 20130265, in both adult and pediatric subjects from Cycle 1 to Cycle 3, with mean Css of 948 to 1420 pg/mL in adults and 361 to 780 pg/mL in pediatric subjects. However, no such blast effect on Css was evident as demonstrated by the applicant at the individual level (data not shown). Nevertheless, it

<div style=\"page-break-after: always\"></div>

should be noted that the applicant acknowledges that the % blast at baseline have an effect on Css (and thus on CL). However, this effect is not clinically relevant.

ER analyses (efficacy/safety) were performed using estimated blinatumomab Css provided by the NCA approach and even if 54 patients were enrolled, only 40 Css from 40 patients were considered. Overall according to the applicant Css was not related to any of the efficacy or safety endpoints.

The exploratory analyses shown above suggested that the distribution of baseline covariates are similar across the exposure Css quartiles. Maintenance of EFS and OS at study cut-off as well as occurrence of CRS, neurological events, and infections is similarly distributed.

Given the small number of subjects and a single dose cohort, univariate analysis found no significant association between exposure and time to EFS and suggested that the blinatumomab Css achieved in study 20120215 using the 15 µg/m2/day dose regimen (with maximum daily dose not exceeding 28 µg/day) was sufficient to achieve EFS.

Univariate analysis also demonstrated no significant association between exposure and time to EFS or OS and the covariates tested in the univariate analyses, thus no further multivariate analyses were conducted.

In conclusion, the association between variation of Css with selected efficacy and safety responses was empirically explored for the dosing regimen evaluated in study 20120215. Blinatumomab Css achieved with the dose tested in study 20120215 was sufficient to prolong EFS and OS compared to HC3, demonstrating no significant association between exposure and duration of EFS or duration of OS. No associations were found between blinatumomab Css and the occurrence of neurologic events, CRS, or infections or the time to neurologic events. Overall, the exposure-response analyses support the dosing regimen of 15 µg/m 2 /day (maximum dose not to exceed 28 µg/day) in pediatric patients with high-risk first relapsed B-precursor ALL.

Regarding dose rational, comparable exposures of blinatumomab in subject ' s ≥ 45 kg are expected when receiving either a fixed dose or BSA-based dose in terms of median. However in terms of geometric mean pediatric subject have already a 1.6-fold higher exposure (735 vs 461 pg/mL). Nevertheless, since the safety profile remain similar between adult and pediatric subjects, the proposed dosing regimen can be considered acceptable.

## 2.3.6. Conclusions on clinical pharmacology

Exposure to blinatumomab in paediatric patients aged 1-&lt;18 years with high-risk first relapsed Ph- Bcell precursor ALL, receiving the commercial formulation following a BSA based dose regimen, has been shown to be 1.7-fold higher than both adult and paediatric with R/R ALL. Nevertheless, since the safety profile  remain  similar  between  adult  and  paediatric  subjects,  the  proposed  dosing  regimen  can  be considered acceptable.

No new PD data was included in this submission.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

No dedicated dose response study was carried out. The rationale for the clinical dose selection for consolidation therapy of blinatumomab for the treatment of high-risk first relapsed ALL after induction therapy was based mainly on the totality of PK, efficacy, and safety information.  The recommended dose regimen for this population is 15 µg/m2/day for subjects &lt; 45 kg and 28 µg/day for subjects ≥

<div style=\"page-break-after: always\"></div>

45 kg administered by continuous IV infusion. Refer to dedicated discussion in above clinical PK section.

## 2.4.2. Main study

## Title of Study

Study 20120215 is an ongoing phase 3, randomized, open-label, controlled, multicentre study investigating the efficacy and safety profile of blinatumomab versus intensive SOC late consolidation chemotherapy in paediatric subjects.

## Methods

Figure 28: Study design and treatment schedule (study 20120215)

<!-- image -->

HC = high risk consolidation; HscT = hematopoletic stem cell transplantation; R = randomlzation

The design of Study 20120215 was agreed to with PDCO as part of the PIP (EMEA-000574-PIP02-12M03).

The study consisted of a 3-week screening period, a 4-week treatment period followed by a 1-week safety follow-up period, a 12-month short-term efficacy follow-up, and a long-term follow-up that continued until the last subject on study was either followed for 36 months after receiving allogeneic HSCT or until death, whichever occurred first. After reaching the primary endpoint, subjects were to be followed in the long-term follow-up period.

After induction therapy and 2 blocks of high-risk consolidation chemotherapy (HC), paediatric subjects with high-risk first relapse B-cell ALL were randomized in a 1:1 ratio to either blinatumomab arm or a third block of standard-of-care chemotherapy (HC3 arm):

- -Blinatumomab was administered as continuous IV infusion at a constant daily flow rate of 15 µg/m2/day over 4 weeks (maximum daily dose was not to exceed 28 µg/day). Subjects randomized to HC3 arm received 1 cycle (1 week) of HC3.
- -High-risk consolidation 3 chemotherapy was administered per the IntReALL protocol.

Most subjects who were in or achieved second CR (M1 bone marrow) after completing consolidation therapy in either the blinatumomab or HC3 arm were to undergo allogeneic HSCT.

<div style=\"page-break-after: always\"></div>

## Study participants

## Key Inclusion Criteria

- Subjects with Philadelphia chromosome negative (Ph-) high-risk (HR) first relapse B-precursor ALL (as defined by I-BFM SG/IntReALL criteria) (after second consolidation after induction according to IntReALL treatment guidelines).

As per IntReALL protocol, the high-risk first relapsed ALL patient population is defined as patients with very early relapse (&lt; 18 months from initial diagnosis) at any anatomical site, early isolated bone marrow relapse (&gt; 18 months after primary diagnosis and &lt; 6 months from completion of front-line therapy), and/or MRD-positive disease.

Table 31: risk stratification per IntReALL protocol

Table 1.Definition of Time Point of Relapse (IntReALLRisk Classification)

<!-- image -->

IntReALL - Intemational Study for Children and Adolescents with Relapsed ALL Sources: IntReALL, 2017; Locatelli et al, 2012

Table 2.Definition of Site of Relapse (IntReALL Risk Classification)

<!-- image -->

| Bone marrow            |     | M1 (<5% blasts)                 | M2 (2 59% and 25% blasts)                     | M3 (2 25% blasts)                             |
|------------------------|-----|---------------------------------|-----------------------------------------------|-----------------------------------------------|
| Exlramedullary relapse | No  | No ALL relapse                  | Requires follow-up control                    | Isolated bone marrow relapse                  |
|                        | Yes | Isolated exlramedullary relapse | Combined bone marrow / extramedullary relapse | Combined bone marrow / extramedullary relapse |

IntReALL =Intemational Study for Children and Adolescents with Relapsed ALL Sources: IntReALL, 2017: Locatelli et al, 2012

According to IntReALL Risk Classification

<!-- image -->

- Very early relapse occurs &lt; 18 months from primary dlagnosis; eanly relapse occurs ≥ 18 months from primary diagnosis and &lt; 6 months after completion of primary therapy; and late relapse occurs ≥ 6 months after completion of primary therapy.

ALL = acute lymphoblastic leukemla; IntReALL =Intemational Study for Children and Adolescents with Relapsed ALL; polymerase chain reaction

- In Study 20120215, subjects with M1 or M2 bone marrow (&lt;5% blasts or ≥ 5% blasts and &lt;25% blasts) were considered high risk if blasts were confirmed to be relapse and not early regenerating normal cells
- Subjects with M1 or M2 at the time of randomization
- Age &gt; 28 days and &lt; 18 years

Sources: IntReALL, 2017; Locatelli et al, 2012

## Key Exclusion Criteria

<div style=\"page-break-after: always\"></div>

- Clinically relevant CNS pathology requiring treatment (eg, unstable epilepsy).
- Evidence of current CNS (CNS 2, CNS 3) involvement by ALL. Subjects with CNS relapse at the time of relapse are eligible if CNS is successfully treated prior to enrolment.
- Abnormal renal or hepatic function prior to start of treatment (day 1) as defined below:
- a. Serum creatinine levels above upper limit of normal, based on the normal ranges for age and gender of the local laboratories
- b. Total bilirubin &gt; 3.0 mg/dL prior to start of treatment (unless related to Gilbert's or Meulengracht disease)
- Periph eral neutrophils &lt; 500/μL prior to start of treatment
- -Peripheral platelets &lt; 50,000/μL prior to start of treatment
- Symptoms and/or clinical signs and/or radiological and/or sonographic signs that indicate an acute or uncontrolled chronic infection, any other concurrent disease or medical condition that could be exacerbated by the treatment or would seriously complicate compliance with the protocol.

## Treatments

Subjects randomized to blinatumomab arm received 1 cycle (4 weeks) of blinatumomab. Blinatumomab was administered as continuous IV infusion at a constant daily flow rate of 15 μg/m2/day over 4 weeks (maximum daily dose was not to exceed 28 μg/day) .

Table 32: Blinatunomab Treatment Cycle

<!-- image -->

| Agent        | Dosage     | Application   | Week 1                       | Week2   | Week3   | Week4   |
|--------------|------------|---------------|------------------------------|---------|---------|---------|
| Blinatumomab | 15 μg/m²/d |               | CIVI                         | CIVI    | CIVI    | CIVI    |
|              |            | Day           | 1234567123456712345671234567 |         |         |         |

Subjects randomized to HC3 arm received 1 cycle (1 week) of HC3. High-risk consolidation 3 chemotherapy was administered per the IntReALL protocol summarized in the Table below.

<div style=\"page-break-after: always\"></div>

Table 33: Successive consolidation course in paediatric HR ALL patients, as per IntReALL 2010 protocol

## IntReALL High-risk Consolidation CourseslntReALL HR 2010, HC1 Course (Modified BFM HR1)

<!-- image -->

## IntReALL HR 2010,HC2 CourSe (Modified BFM HR3)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## IntReALLHR 2010,HC3 CourSe (Modified BFM HR2)

<!-- image -->

* In case ol allergic reaction change to Erwinia-asparaginase, 20,000 units/m2 every 48 hours lor a total ol

6 doses.

** Age dependent dosages

<div style=\"page-break-after: always\"></div>

## Objectives and endpoints

Table 34: Objectives and Endpoints (pivotal study 20120215)

| Objectives                                                                                                                                                                | Endpoints                                                                                                                                                                                                                                                                        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary                                                                                                                                                                   |                                                                                                                                                                                                                                                                                  |
| To evaluate event-free survival (EFS) after blinatumomab when compared to standard of care (SoC) chemotherapy                                                             | Event-free survival, calculated from the time of randomization until the date of relapse or M2 marrow after having achieved a complete remission (CR), failure to achieve a CR at the end of treatment, secondary malignancy, or death due to any cause, whichever occurs first. |
| Key Secondary                                                                                                                                                             |                                                                                                                                                                                                                                                                                  |
| To evaluate the effect of blinatumomab on overall survival (os) when compared to Soc chemotherapy                                                                         | Overall survival, calculated from the time of randomization until death to any cause.                                                                                                                                                                                            |
| Secondary                                                                                                                                                                 |                                                                                                                                                                                                                                                                                  |
| To evaluate reduction in minimal residual disease (MRD) after blinatumomab when compared to SoC chemotherapy                                                              | MRD response, defined as MRD level < 10* at the end of treatment with investigational product(s)                                                                                                                                                                                 |
| To evaluate the safety of blinatumomab when compared to SoC chemotherapy                                                                                                  | Incidence of adverse events (both serious and nonserious). treatment-related adverse events, adverse events of interest, clinically significant changes in laboratory values Incidence of anti-blinatumomab antibody formation (blinatumomab arm only)                           |
| To evaluate cumulative incidence of relapse in blinatumomab when compared to SoC chemotherapy                                                                             | Cumulative incidence of relapse                                                                                                                                                                                                                                                  |
| To evaluate the safety of allogeneic hematopoietic stem cell transplantation (allogeneic HSCT) after blinatumomab when compared to allogeneic HSCT after SoC chemotherapy | Survival status at 100 days after allogeneic HSCT                                                                                                                                                                                                                                |
| To evaluate the pharmacokinetics (PK) of blinatumomab                                                                                                                     | Pharmacokinetic sampling for blinatumomab concentrations for population PK analysis Blinatumomab steady-state concentrations                                                                                                                                                     |

Complete remission (CR) was defined as M1 bone marrow (representative bone marrow aspirate or biopsy with &lt;5% blasts, satisfactory cellularity, and regenerating hematopoiesis), peripheral blood without blasts, and absence of extramedullary leukemic involvement. M2 was defined as

<div style=\"page-break-after: always\"></div>

representative bone marrow aspirate or biopsy with ≥ 5% and &lt; 25% blasts. M3 bone marrow was defined as representative bone marrow aspirate or biopsy with ≥ 25% blasts.

## Sample size

For EFS, an enrolment target of approximately 202 subjects and the observation of 94 events would give approximately 84% power using a 2-sided alpha level of 0.05. The calculation was based on a non-cured hazard ratio (HR) of 0.63, a control true cure rate of 40%, a control true median EFS of 7 months among non-cured patients, a true treatment cure rate of 56.2%, and a true treatment median EFS of 11.1 months among non-cured subjects.

Two interim analyses were planned to assess benefit when approximately 50% and 75% of the total number of EFS events were observed; Or when approximately 50 true cure were calculated with the use of a Lan-DeMets alpha spending function (O-Brien and Fleming, 1979; Lan and DeMets, 1983). Testing of the secondary endpoints was planned to be descriptive at the interim analyses.

As noted above, the first interim analysis was planned when approximately 50% of the total EFS events had occurred. The Data Monitoring Committee (DMC) reviewed the results of the first interim analysis and concluded that the threshold for declaring efficacy was met for the primary endpoint. Subsequently, the DMC recommended to stop enrolment for benefit in the blinatumomab arm, and only continue with treatment and long-term follow-up for those already enrolled on the study per the protocol-specified follow-up period. The MAH accepted the DMC's recommendation. The interim results met the criteria for this analysis to become the primary analysis.

## Randomisation

Upon confirmation of eligibility, study centre stuff assigned a randomization number to the subject through the Integrated Voice Response System (IVRS). Subjects were randomized in a 1:1 ratio to receive either blinatumomab or HC3. Randomization was stratified by age, bone marrow status, and MRD status. Subjects should have commenced protocol-required therapy within 3 days of randomization.

## Blinding (masking)

The study has an open label design.

## Statistical methods

No formal hypothesis testing was performed.

Blinatumomab would demonstrate a reduction in the risk of events (relapse or M2 marrow after having achieved a CR, failure to achieve a CR at the end of treatment, secondary malignancy, or death due to any cause) in this paediatric, high-risk, first relapse B-cell ALL population. It was anticipated that the risk reduction of events would be 37% in noncured subjects and a cure rate would increase from 40% to 56.2% (cure was defined as a subject having no EFS event after 36 months on study).

A sensitivity analysis assigned the planned study day rather than the actual study day to EFS events (other than deaths) to address potential evaluation-time bias resulting from the different treatment lengths between study arms. To address the potential bias of differing cycle lengths between study arms, EFS event times were grouped into discrete times as follows: as with the primary analysis,

<div style=\"page-break-after: always\"></div>

subjects who failed to achieve or maintain a CR before the disease assessment at the end of the first randomized treatment cycle (or before the assessment on day 15 for those subjects on the blinatumomab arm) were assigned an EFS duration of 1 day. An additional sensitivity analysis included allogeneic HSCT as a time-dependent covariate in a stratified Cox regression model and tested the null hypothesis using the treatment effect from that Cox model.

Testing of the secondary endpoints was planned to be descriptive at the interim analysis. Intent-totreat analysis of efficacy included all subjects who underwent randomization (the Full Analysis Set); analysis of safety included all subjects who received either blinatumomab or HC3 (the Safety Analysis Set). Time-to-event endpoints were summarized using the Kaplan-Meier method, and treatment arms were compared using two-sided stratified log-rank tests. Treatment effects were expressed as a HR with a 95% CI, estimated using a stratified Cox regression model. Percentages with exact 95% CIs summarized response endpoints. The cumulative incidence of relapse was analysed using an extension of the Cox regression model, whereby deaths that occurred before relapse and unrelated to an otherwise undocumented relapse were treated as a competing risk (Fine and Gray, 1999). Subject incidences of treatment-emergent adverse events were also summarized.

The percentage of subjects in each treatment arm with an MRD response (ie, MRD level &lt; 10 4 ) was summarized with an exact binomial 95% CI. In addition, a 2-sided Cochran Mantel-Haenszel test, which adjusted for the stratification factors at randomization, described the difference in MRD response between treatment arms. If a baseline MRD marker was found for a subject, then that subject was part of the MRD Evaluable Set. Safety analyses were descriptive in nature, and included summaries of blinatumomab administration and exposure, adverse events, concomitant medications, laboratory measurement, vital signs, and antibody testing.

An external independent DMC assessed safety approximately every 6 months provided that the enrolment rate was adequate.

## Results

Results from the primary analysis of efficacy and safety are provided below. The final analysis for the CSR of Study 20120215 is expected to be available by 2023.

## Participant flow

A total of 121 subjects were screened, of which 108 eligible subjects were randomized (54 subjects to the HC3 arm and 54 subjects to the blinatumomab arm) and comprise the Full Analysis Set.

<div style=\"page-break-after: always\"></div>

Figure 29: Subjects disposition (study 20120125)

<!-- image -->

HC3 = high-risk consolidation 3 chemotherapy

## Recruitment

Study initiation date: 10 November 2015

Study completion date: 17 July 2019 (data cut-off date for the first interim analysis; the study is ongoing). Recruitment was terminated for efficacy in blinatumomab arm, based on DMC recommendation at time of first interim analysis.

## Conduct of the study

Protocol amendments are summarized in the table below.

<div style=\"page-break-after: always\"></div>

Table 35: Protocol Amendment Summary Table (study 20120215)

<!-- image -->

| Amendment                                                                                                     | Major Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Original Protocol 27 January 2015 (0 subjects enrolled between this date and the date of the first amendment) |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Amendment 1 15 April 2015 (0 subjects enrolled between this date and the date of the next amendment)          | modified exclusion criteria to clarify that subjects with the abnormal serum creatinine were to be excluded from the study added measures to prevent and/or minimize pain and discomfort during blood draws added measures to minimize the blood volumes drawn during the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Amendment 2 29 September 2015 (11 subjects enrolled between this date and the date of the next amendment)     | added prophylactic intrathecal hydrocortisone as an alternative to prednisolone to allow United Kingdom and Australia to participate in the study changed distribution of sites participating in the study (New Zealand was removed from the list of participating countries) changed the time period for administration of intrathecal prophylaxis to align with best medical practice for the standard of care arm endpoints clarified that MRD aliquots for PCR and/or flow cytometry that are to be collected at screening, day 15 (blinatumomab arm only), and at day 29 will be analyzed at a central lab defined by the sponsor updated pregnancy, contraception, and lactation requirements to align with current risk and discomforts language                                                                                                                                                                                                                                                |
| Amendment 3 19 April 2016 (44 subjects enrolled between this date and the date of the next amendment)         | added \"population PK analysis”as a secondary endpoint corrected the time frame for administration of intrathecal prophylaxis as premedication in the HC3 arm to clarify that it could be administered either within 7 days prior to starting treatment, or be given on day 2 changed treatment-free interval from 2 weeks to 1 week when defining a cycle in the adaptive design updated number of sites from 60 to 75 in inclusion criteria, added a requirement for historical samples for central analysis of MRD updated exclusion criteria to clarify that for subjects with total bilirubin < 1.5 mg/dL, measurement of direct bilirubin was not required updated exclusion criteria to remove exclusion of other investigational procedures during study contact clarified that maximum daily dose of blinatumomab was not to exceed 28 μg/day clarified criteria for discontinuation of blinatumomab updated laboratory analyte listing updated language for pregnancy and lactation reporting |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Protocol deviations

As of the data cut-off date, 52 subjects (48.1%) had important protocol deviations (IPDs). The DMC reviewed all the IPDs and determined that they did not present a safety risk for the subjects. The most common IPD was 'missing data', most of which occurred when bone marrow samples were not sent for central review during treatment or follow up. However, bone marrow specimens at diagnosis were sent for central review for all the study subjects. Therefore, the diagnosis of B-cell ALL in all study subjects have been confirmed by central review. Moreover, all missing central lab bone marrows had local morphology reading response. For subjects without central review of the bone marrow during treatment or follow up, bone marrow MRD was assessed by either polymerase chain reaction (PCR) and/or flow cytometry. The second and third most common IPD were 'off-schedule procedures' (table 60) and 'other deviations', respectively.

<div style=\"page-break-after: always\"></div>

Table 36: Summary of Important Protocol Deviations (Full Analysis Set)

| StralificationFactor Category                                     | HC3 (N =54) n (%6)   | Blinatumomab (N = 54) n(%6)   | Total (N = 108) n(2:)   |
|-------------------------------------------------------------------|----------------------|-------------------------------|-------------------------|
| Number of subjecis with at least one important protocol deviation | 28 (51.9)            | 24 (44.4)                     | 52 (48.1)               |
| Missing data (other than TA or TC)                                | 12 (22.2)            | 15 (27.8)                     | 27 (25.0)               |
| Missed BMA slides/biopsy not sent to central lab during STFup     | 7 (13.0)             | 12 (22.2)                     | 19 (17.6)               |
| Missed same labs 2=2 consecutive times                            | 4(7.4)               | 2 (3.7)                       | 6 (5.6)                 |
| Missed BMA/biopsy during treatment phase                          | 3(5.6)               | 2(3.7)                        | 5 (4.6)                 |
| Off-schedule procedures (other than TA or TC)                     | 10 (18.5)            | 4(7.4)                        | 14 (13.0)               |
| Assessments done out of schedule at screening                     | 10 (18.5)            | 4(7.4)                        | 14 (13.0)               |
| Other deviations                                                  | 7 (13.0)             | 5 (9.3)                       | 12 (11.1)               |
| Other GCP deviation                                               | 4(7.4)               | 2(3.7)                        | 6(5.8)                  |
| Re-consent not perfommed for Level 3 risk                         | 2 (3.7)              | 4(7.4)                        | 6 (5.6)                 |
| Re-consent not pefommed for Level 1-2 risk                        | 1(1.9)               | (0'0) 0                       | 1 (0.9)                 |
| Entered study even though entry criteria Was not satisfied        | 3(5.6)               | 5 (9.3)                       | 8(7.4)                  |
| Cument CNS Pathology                                              | 1 (1.9)              | 2 (3.7)                       | 3 (2.8)                 |
| Bone Marrow Status M1 or M2                                       | 1 (1.9)              | 1(1.9)                        | 2(1.9)                  |
| High Risk first Relapse ALL                                       | 1(1.9)               | 1(1.9)                        | 2(1.9)                  |
| Hematology out of range: neutrophils                              | 0(0.0)               | 1(1.9)                        | 1 (0.9)                 |
| Received the wrong treatment orincorrect dose                     | 2 (3.7)              | 3(5.6)                        | 5 (4.6)                 |
| Use of compromised IP                                             | 2(3.7)               | 2(3.7)                        | 4 (3.7)                 |
| IP not withheld                                                   | 0 (0.0)              | 1(1.9)                        | 1 (0.9)                 |
| Received an excluded concomilant treatment                        | 3(5.6)               | 0 (0.0)                       | 3 (2.8)                 |
| Received excluded medication                                      | 3(5.6)               | 0 (0.0)                       | 3(2.8)                  |
| Other treatment compliance                                        | 0 (0.0)              | 1(1.9)                        | 1 (0.9)                 |
| CSF prophylaxis not administered                                  | 0 (0.0)              | 1 (1.9)                       | 1 (0.9)                 |

Page 1 of 1

N = Number of subjects in the analysis set. n = Number of subjecis with observed data.

Deviation categories are not mutually exclusive. Multiple deviations within the same category are counted once per subject.

Dala cut-off date: 17JUL2019

Program:

/userdata/stat/amg103/onc/20120215/analysis/primary\\_clean/tables/program/t-sum-imp-pdev-fas.sas Output: t14-03-sum-imp-pdev-fas.rtf (Date Generated: 30JAN20:02:40:50 J Source: adam. adsl, adam.addv

Table 37. Subjects with screening lumbar puncture not performed in due time in Study 20120215

|                                           | Blinatumomab N = 4 a   | HC3 N = 10   |
|-------------------------------------------|------------------------|--------------|
| Days of LP Before Treatment Start         | 9-12                   | 8-14 b       |
| CNS disease negative at primary diagnosis | 4/4                    | 9/10         |
| CNS disease negative at first relapse     | 3/4                    | 8/10         |

<div style=\"page-break-after: always\"></div>

| Baseline Marrow   |     |      |
|-------------------|-----|------|
| MRD < 10 -4       | 2/4 | 5/10 |
| M1, MRD ≥ 10 -4   | 1/4 | 3/10 |
| M1, MRD not done  | 1/4 | 1/10 |

## Non-fulfilment with inclusion/exclusion criteria

- The IPD 'Clinically relevant CNS pathology requiring treatment (eg, unstable epilepsy). Evidence of current CNS (CNS 2, CNS 3) involvement by ALL' concerned 3 subjects (2 in the blinatumomab arm, 1 in the HC3 arm). These subjects were eligible because CNS was successfully treated prior to enrolment, as allowed per study protocol. Although the screening CSF test within the study defined window was not done in these 3 subjects, the likelihood of them having CNS disease prior to cycle 1 day 1 treatment start was low given that all of them had received intense chemotherapy including induction and two blocks of consolidation chemotherapy with MRD negative (&lt; 10 -4 ) bone marrow at screening, and 2 of the 3 subjects had no history of CNS disease. In addition, the distribution of this IPD was balanced between both treatment arms.

- The IPD 'Subjects with M1, M2 marrow at the time of randomization' occurred in 1 subject in both treatment arms. It was based on local bone marrow assessment in both subjects. Central marrow results in both subjects, although showing M1 marrow, was not available to the sites at the time of enrolment.

- The IPD 'Subjects with Philadelphia chromosome negative (Ph-) high-risk (HR) first relapse Bprecursor ALL (as defined by I-BFM SG/IntReALL criteria) (after second consolidation after induction according to IntReALL treatment guidelines)'   occurred in 1 subjects in both arms. It was reported due to subjects not receiving study defined induction or consolidation chemotherapy prior to enrollment.  The variation in chemotherapy was deemed necessary and compatible with local treatment guidelines per treating physicians.

- The IPD 'Peripheral neutrophil &lt; 500/µL prior to start of treatment' concerned 1 patient for whom transplantation was scheduled with conditioning in 1 month and the BM was normal and regenerative.

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 38: Demographics and Baseline Characteristics - Study 20120215 (Full Analysis Set)

|                                           | HC3 (N = 54)   | Blinalumomab (N- 54)   | Tolal (N - 108)   |
|-------------------------------------------|----------------|------------------------|-------------------|
| Sox=n(%)                                  |                |                        |                   |
| Male                                      | 22 (40.7)      | 30 (55.6)              | 52 (48.1)         |
| Female                                    | 32 (59.3)      | 24 (44.4)              | 56 (51.9)         |
| Ehnicity -n (%%)                          |                |                        |                   |
| Hispanie/Lalino                           | 3(5.6)         | 1(1.9)                 | 4(3.7)            |
| Not Hispanic/Lalino                       | 51 (94.4)      | 53 (98.1)              | 104 (96.3)        |
| Raco -n (a)                               |                |                        |                   |
| While                                     | 43 (79.6)      | 50 (92.6)              | 93 (86.1)         |
| Othor                                     | 5 (9.3)        | 3(5.6)                 | 8(7.4)            |
| Asian                                     | 3(5.6)         | 1(1.9)                 | 4(3.7)            |
| Blackor Arican American                   | 3 (5.6)        | 0 (0.0)                | 3(2.8)            |
| American Indian or Alaska Nalive          | 0 (0.0)        | 0 (0.0)                | 0 (0.0)           |
| Native Hawaiian or Other Pacific lslander | (oo) o         | 0 (0.0)                | (oo] o            |
| Ago (yoars)                               |                |                        |                   |
| m                                         | 54             | 54                     | 108               |
| Mean                                      | 6.7            | 61                     | 7.0               |
| SD                                        | 4.4            | 4.4                    | 4.4               |
| Median                                    | 5.0            | 6.0                    | 5.0               |
| 01.03                                     | 3.0, 10.0      | 4.0, 11.0              | 4.0, 10.5         |
| Min, Max                                  | 1.17           | 1. 17                  | 1.17              |
| Ago group -n(9:)                          |                |                        |                   |
| 1 year                                    | 0 (0.0)        | 0 (0.0)                | (0'0) 0           |
| 1 to 9 years                              | 38 (70.4)      | 39 (72.2)              | 77 (71.3)         |
| 2 10 to 18 years                          | 16 (29.6)      | 15 (27.8)              | 31 (28.7)         |
| Age group for disclosure - n (%6)         |                |                        |                   |
| 28 days to 23 months                      | 2(3.7)         | 1 (1.9)                | 3(2.8)            |
| 2 to 11 years                             | 44 (81.5)      | 41 (75.9)              | 85 (78.7)         |
| 12 to 18 years                            | 8 (14.8)       | 12 (22.2)              | 20 (18.5)         |

<div style=\"page-break-after: always\"></div>

|                                                         | HC3 (N - 54)   | Blinalumomab (N- 54)   | Tolal (N - 108)   |
|---------------------------------------------------------|----------------|------------------------|-------------------|
| B-precursor subtype - n (%)                             |                |                        |                   |
| Pro-B-ALL                                               | 6 (11.1)       | 3(5.6)                 | 9(8.3)            |
| Pre-B-ALL                                               | 19 (35.2)      | 20 (37.0)              | 39 (36.1)         |
| C-ALL                                                   | 29 (53.7)      | 31 (57.4)              | 60 (55.6)         |
| Occurrence and type of any genetic abnormality - n (*%) |                |                        |                   |
| No                                                      | 29 (53.7)      | 34 (63.0)              | 63 (58.3)         |
| Yes                                                     | 25 (46.3)      | 20 (37.0)              | 45 (41.7)         |
| Hyperdiploidy                                           | 6 (11.1)       | 6 (11.1)               | 12 (11.1)         |
| Hypodiploidy                                            | 0 (0.0)        | 1 (1.9)                | 1 (0.9)           |
| (v:11q23)/MLL rearanged                                 | 4(7.4)         | (00) 0                 | 4 (3.7)           |
| (12: 21)(p13: q22)TEL-AML1                              | 3(5.6)         | 2 (3.7)                | 5 (4.6)           |
| (1: 19)(q23: p13.3)E2A-PBX1                             | 2(3.7)         | 2 (3.7)                | 4 (3.7)           |
| (5:14)(q31:32)IL3-IGH                                   | 0 (0.0)        | (0:0) 0                | 0 (0.0)           |
| Other                                                   | 10 (18.5)      | 9 (16.7)               | 19 (17.6)         |
| Exiramedullary disease - n (9%6)                        |                |                        |                   |
| At primary diagnosis                                    |                |                        |                   |
| No                                                      | 48 (88.9)      | 49 (90.7)              | 97 (89.8)         |
| Yes                                                     | 5 (9.3)        | 4(7.4)                 | 9(8.3)            |
| Missing                                                 | 1(1.9)         | 1(1.9)                 | 2(1.9)            |
| At relapse                                              |                |                        |                   |
| No                                                      | 40 (74.1)      | 44 (81.5)              | 84 (77.8)         |
| Yes                                                     | 14 (25.9)      | 10 (18.5)              | 24 (22.2)         |
| Body site*                                              |                |                        |                   |
| Central nervous system                                  | 11 (20.4)      | 11 (20.4)              | 22 (20.4)         |
| Testis                                                  | 1 (1.9)        | 1(1.9)                 | 2 (1.9)           |
| Other                                                   | 3(5.6)         | 1(1.9)                 | 4(3.7)            |

<div style=\"page-break-after: always\"></div>

|                                   | HC3 (N - 54)   | Binalumomab (N- 54)   | Tolal (N - 108)   |
|-----------------------------------|----------------|-----------------------|-------------------|
| Central bone marrow assessment    |                |                       |                   |
| Cytomorphology - n (%)            |                |                       |                   |
| MO                                | 0 (0.0)        | (0:0) 0               | 0 (0.0)           |
| M1                                | 51 (94.4)      | 54 (100.0)            | 105 (97.2)        |
| M2                                | 2(3.7)         | (0:0) 0               | 2(1.9)            |
| M3                                | 0 (0.0)        | (o:0) 0               | 0 (0.0)           |
| Not evaluable                     | 1(1.9)         | (0:0) 0               | 1 (0.9)           |
| MRD PCR value - n (%)             |                |                       |                   |
| 2 10-4                            | 13 (24.1)      | 10 (18.5)             | 23 (21.3)         |
| 10-4                              | 22 (40.7)      | 20 (37.0)             | 42 (38.9)         |
| Not done                          | 19 (35.2)      | 23 (42.6)             | 42 (38.9)         |
| Missing                           | 0 (0.0)        | 1 (1.9)               | 1 (0.9)           |
| MRD flow cytometry value - n (%%) |                |                       |                   |
| 2104                              | 13 (24.1)      | 9 (16.7)              | 22 (20.4)         |
| c10-                              | 24 (44.4)      | 27 (50.0)             | 51 (47.2)         |
| Not done                          | 17 (31.5)      | 18 (33.3)             | 35 (32.4)         |
| Hemoglobin (g/L)                  |                |                       |                   |
| Mean                              | 96.3           | 97.9                  | 97.1              |
| SD                                | 14.2           | 11.9                  | 13.0              |
| Median                            | 96.0           | 97.0                  | 97.0              |
| 01,03                             | 87.0, 102.0    | 89.0, 107.0           | 89.0, 104.0       |
| Min, Max                          | 63.137         | 73, 120               | 63.137            |
| Leukocytes (WBC) (10%/L)          |                |                       |                   |
| Mean                              | 2.900          | 3.073                 | 2.986             |
| SD                                | 1.793          | 1.747                 | 1.764             |
| Median                            | 2.430          | 2.630                 | 2.520             |
| 01.03                             | 1.700, 3.300   | 2.000,3.600           | 1.860, 3.520      |
| Min, max                          | 0.83,10.80     | 0.96,9.31             | 0.83,10.80        |
| Leukocytes (WBC) (10%/L) -n(%)    |                |                       |                   |
| ≤50                               | 54 (100.0)     | 54 (100.0)            | 108 (100.0)       |
| 09c                               | 0 (0.0)        | (0:0) 0               | 0 (0.0)           |

<div style=\"page-break-after: always\"></div>

|                                                       | HC3 (N - 54)   | Blinalumomab (N- 54)   | Tolal (N - 108)   |
|-------------------------------------------------------|----------------|------------------------|-------------------|
| Platelet counts (10%/L)                               |                |                        |                   |
| Mean                                                  | 226.5          | 256.2                  | 241.4             |
| SD                                                    | 147.0          | 121.8                  | 135.2             |
| Median                                                | 184.0          | 229.5                  | 212.0             |
| 01.03                                                 | 128.0,284.0    | 167.0.329.0            | 154.0,319.5       |
| Min, max                                              | 50.858         | 59, 613                | 50.858            |
| Peripheral blasts in blood (10/L)                     |                |                        |                   |
| n                                                     | 43             | 49                     | 92                |
| Mean                                                  | 0.01           | 0.02                   | 0.01              |
| SD                                                    | 0.03           | 0.04                   | 0.04              |
| Median                                                | 0.00           | 0.00                   | 0.00              |
| 01.03                                                 | 0.00, 0.00     | 0.00,0.00              | 0.00, 0.00        |
| Min, max                                              | 0.0, 0.1       | 0.0,0.2                | 0.0,0.2           |
| Time from first diagnosis to relapse (month)          |                |                        |                   |
| Mean                                                  | 22.80          | 21.88                  | 22.34             |
| SD                                                    | 12.25          | 8.04                   | 10.32             |
| Median                                                | 20.95          | 22.34                  | 21.74             |
| 01.03                                                 | 14.75.27.28    | 15.48.27.15            | 14.90, 27.21      |
| Min, max                                              | 9.3, 85.9      | 7.4, 42.7              | 7.4,85.9          |
| Time from first diagnosis to relapse (month) - n (%6) |                |                        |                   |
| c 18 months                                           | 22 (40.7)      | 19 (35.2)              | 41 (38.0)         |
| 2 18 months and ≤ 30 months                           | 28 (51.9)      | 32 (59.3)              | 60 (55.6)         |
| 30 months                                             | 4(7.4)         | 3 (5.6)                | 7 (6.5)           |

Page 4of 4

ALL -acute lymphoblaslic leukemia; HC3-high-risk consolidalion 3 chemotherapy: MRD -minimal residual disease; N -number of subjects in the analysis set; n -number of subjecs with observed data; PCR -- polymeraso chain reaclion; Q1 - first quarlile; O3 - hird quartile, WBC - While blood cells.

rolapse is yes.If the body sile al primary diagnosis is different from the sile at relapso, body sile at relapse is recorded.

b Mo: Representative bone mamow aspirale or biopsy with blasls  5%e, with vory low cellularity and with no rogeneraltinghemalopoiegis

M1: Representative bone marow aspirale or biopsywithblasts&lt;5%,with salisfaclory cellularity and with regeneraling homalopolosis

M2:Reprosentalivebone marow aspirale or biopsy with 2 5%and  25%: blasls

M3: Representalive bone marrow aspiralo or biopsy with 2 25%: blasls

Dala culolf dale: 17 July 2019.

Source: Table 14-2.1.1 and 14.2.2.1 of the 20120215 Primery Analysis CSR

## Numbers analysed

Full analysis set includes 108 patients (54 in each arm).

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

Primary Efficacy Endpoint  Event-Free Survival (EFS)

As of the data cu-toff date, the median follow-up time for EFS was 22.4 months. The subject incidence of EFS events was 57.4% in the HC3 arm and 33.3% in the blinatumomab arm. Event-free survival was statistically significantly improved in the blinatumomab arm when compared with HC3 arm (p &lt; 0.001 by the stratified log-rank test).

The EFS hazard ratio from a stratified Cox proportional hazard model was 0.36 (95% CI: 0.19, 0.66), indicating a 64% risk reduction in the blinatumomab arm. Results obtained with unstratified HR were similar (HR= 0.39; 95% CI: [0.22; 0.70]).

The median EFS was 7.4 months (95% CI: 4.5 to 12.7 months) in the HC3 arm and was not reached in the blinatumomab arm (95% CI: 12.5 months to not estimable [NE]). A Kaplan-Meier plot comparing EFS between the treatment arms is presented in figure below. The 36-month Kaplan-Meier estimate was 26.9% (95% CI: 13.2% to 42.8%) in the HC3 arm and 55.7% (95% CI: 37.8% to 70.4%) in the blinatumomab arm.

Figure 30: Kaplan-Meier for Event-free Survival (Full Analysis Set)

<!-- image -->

HC3 = high-risk consolidation 3 chemotherapy: NE = not estimable

Censor indicated by vertical bar. Data cutoff date 17 July 2019. Data are based on the 'as-is' database snapshot

Source: Figuwe 14-4.1.1.1

Similar results were obtained in the 'clean' snapshot, dated 16 December 2019 with data filtered up to analysis trigger date 17 July 2019.

Additional sensitivity analyses were done for EFS to evaluate potential bias of differing cycle lengths between the study arms; the results of these analyses (in 'as-in' and 'clean' analysis) were similar to the results from the primary analysis (data not shown).

To evaluate the consistency of EFS in subgroups, subgroup analyses were performed to test treatmentby-subgroup interactions in a Cox regression analysis (an interaction term with a p-value &lt; 0.10 was suggestive of an inconsistent treatment effect). Subgroup analyses for EFS included the following subgroups: age based on stratification, bone marrow/MRD status based on stratification, 6 strata formed by the combination of the stratification factors, age for disclosure, sex, and time from first diagnosis to relapse.

<div style=\"page-break-after: always\"></div>

Table 39: Subgroup Analysis - Event-free Survival (Full Analysis Set)

|                                                           | HC3 (N = 54) Events/ Subjects (%)   | Blinatumomab (N = 54) Events/ Subjects (%)   | Hazard Ratio (95% CI)   | p-value   |
|-----------------------------------------------------------|-------------------------------------|----------------------------------------------|-------------------------|-----------|
| Age based on stratification                               |                                     |                                              |                         | 0.970     |
| 1 to 9 years                                              | 23/38 (60.5)                        | 13/39 (33.3)                                 | 0.40 (0.20, 0.80)       |           |
| Other (c 1 year and > 9 years)                            | 8/16 (50.0)                         | 5/15 (33.3)                                  | 0.33 (0.10, 1.03)       |           |
| Marrow/MRD status based on stratification                 |                                     |                                              |                         | 690'0     |
| M1 with MRD level < 10-3                                  | 19/34 (55.9)                        | 13/35 (37.1)                                 | 0.49 (0.24, 1.00)       |           |
| M1 with MRD level 2 10-3                                  | 9/16 (56.3)                         | 3/15 (20.0)                                  | 0.22 (0.06, 0.82)       |           |
| M2                                                        | 3/4 (75.0)                          | 2/4 (50.0)                                   | NE                      |           |
| Strata                                                    |                                     |                                              |                         | 0.406     |
| Age 1 to 9 years + M1 with MRD level ≥ 10-3               | 7/12 (58.3)                         | 3/12 (25.0)                                  | 0.29 (0.07, 1.14)       |           |
| Age 1 to 9 years + M1 with MRD level < 10-3               | 14/24 (58.3)                        | 9/25 (36.0)                                  | 0.50 (0.22, 1.15)       |           |
| Age 1 to 9 years + M2                                     | 2/2 (100.0)                         | 1/2 (50.0)                                   | NE                      |           |
| Other (< 1 year and > 9 years) + M1 with MRD level 2 10-3 | 2/4 (50.0)                          | 0/3 (0.0)                                    | NE                      |           |
| Other (< 1 year and > 9 years) + M1 with MRD level < 10-3 | 5/10 (50.0)                         | 4/10 (40.0)                                  | 0.44 (0.12, 1.70)       |           |
| Other (< 1 year and > 9 years) + M2                       | 1/2 (50.0)                          | 1/2 (50.0)                                   | NE                      |           |
| Age for disclosure                                        |                                     |                                              |                         | 0.464     |
| 28 days to 23 months                                      | 1/2 (50.0)                          | 1/1 (100.0)                                  | NE                      |           |
| 2 to 11 years                                             | 28/44 (63.6)                        | 13/41 (31.7)                                 | 0.37 (0.19, 0.71)       |           |
| 12 to 18 years                                            | 2/8 (25.0)                          | 4/12 (33.3)                                  | 0.59 (0.10, 3.28)       |           |
| Sex                                                       |                                     |                                              |                         | 0.057     |
| Male                                                      | 14/22 (63.6)                        | 9/30 (30.0)                                  | 0.20 (0.08, 0.47)       |           |
| Female                                                    | 17/32 (53.1)                        | 9/24 (37.5)                                  | 0.61 (0.27, 1.37)       |           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Time from first diagnosis to relapse   |              |              |                   | 0.637   |
|----------------------------------------|--------------|--------------|-------------------|---------|
| c 18 months                            | 14/22 (63.6) | 7/19 (36.8)  | 0.25 (0.09, 0.66) |         |
| 2 18 months and                        | 17/28 (60.7) | 10/32 (31.3) | 0.43 (0.20, 0.95) |         |
| s 30 months                            |              |              |                   |         |
| > 30 months                            | 0/4 (0.0)    | 1/3 (33.3)   | NE                |         |
| All subjects                           | 31/54 (57.4) | 18/54 (33.3) | 0.39 (0.22, 0.70) |         |

CR = complete response: HC3 = high-risk consolidation 3 chemotherapy: MRD = minimal residual disease: N = number of subjects in the analysis set; n = number of subjects with observed data; NE = not estimable.

M1: Representalive bone marow sspirate or biopsy with blasis &lt; 5%, with salisfactory cellularity snd with regenerating hematopoiesis

M2: Representative bone mamow aspirate or biopsy with 2 5% and &lt; 25% blasts

Event-free survival is calculated from the time of randomization until the date relapse or M2 marrow after having achieved a CR, failure to achieve a CR at the end of treatment, second malignancy. or death due to any cause, whichever occurs first.

The p-value is from the test of the interaction term in an unstratified Cox regression model with terms for the covariate and treatment arm.

The hazard ratio estimate for all subjects was obtained from an unstratified Cox proportional hazard model.

Convergence not met after 25 iterations, estimates of hazard ratio and 95%6 Cl are based on the last maximum likelihood iteration.

Data cutoff date: 17 July 2019. Data are based on the 'as-is' database snapshot.

Source: Table 14-4.1.1.3

Subgroup analyses for EFS using 'as-is' and 'clean' snapshots were provided. The results were similar between the 2 snapshots. No notable treatment-by-subgroup effects were observed for any subgroups, showing that the blinatumomab treatment effect was consistent across the subgroups. The estimated hazard ratios within the treatment groups were all &lt; 1 and directionally favoured blinatumomab treatment.

Secondary Efficacy Endpoints - Overall Survival (OS)

As of the data cut-off date, the median follow-up time for OS was 19.5 months. The subject incidence of death was 29.6% in the HC3 arm and 14.8% in the blinatumomab arm; the nominal p-value from the stratified log-rank test was 0.047.

The OS hazard ratio from a stratified Cox proportional hazard model was 0.43 (95% CI: 0.18 to 1.01). The median OS was not reached in either arm. The Kaplan-Meier estimate of survival at 36 months was 55.8 months (95% CI: 36.9 to 71.0 months) in the HC3 arm and 81.1 months (95% CI: 65.5 to 90.2 months) in the blinatumomab arm.

<div style=\"page-break-after: always\"></div>

Figure 31: Kaplan-Meier for Overall Survival (Full Analysis Set)

<!-- image -->

HC3=high-risk consolidation 3 chemotherapy:NE =not estimable Censorindicated by vertical bar.Data cutoff date 17 July 2019. Source:Figure 14-4.2.1

In the Full Analysis Set, 13 subjects were randomized and treated with HC3, and then received blinatumomab treatment. After treatment with investigational product indeed, additional therapies, including blinatumomab, were allowed at the discretion of the treating investigators.  Thirteen subjects in the HC3 arm received blinatumomab following HC3 or following further lines of therapies including allogeneic hematopoietic stem cell transplantation (HSCT). Twelve of these subjects received blinatumomab due to relapsed/refractory disease (M2 or M3 bone marrow [ ≥ 5% and &lt;25% blasts or ≥ 25% blasts, respectively]), and 1 of the subjects received blinatumomab due to minimal residual disease (MRD)-positive status (M1 bone marrow [&lt; 5% blasts] with MRD ≥ 10 4 ). Seven of the 13 subjects received blinatumomab as a third line of treatment (treatment for initially diagnosed disease was considered as first line and HC3 +/- allogeneic HSCT as second line).  Six of the 13 subjects received blinatumomab as fourth or fifth line of treatment.  A sensitivity analysis was performed to estimate the treatment effect adjusted for the HC3 subjects dropping into the blinatumomab arm (Branson and Whitehead, 2002). This analysis produced a hazard ratio that was similar to that in the primary analysis (0.35 [95% CI: 0.12, 1.01; p = 0.052]).

Subgroup analysis for OS included the following subgroups: age based on stratification, marrow/MRD status based on stratification, 6 strata formed by the combination of the stratification factors, age for disclosure, sex, and time from first diagnosis to relapse. Only limited conclusions can be drawn from the OS subgroup analysis because only 24 deaths were observed overall.

<div style=\"page-break-after: always\"></div>

Table 40. Subgroup Analysis - Overall Survival (Full Analysis Set)

|                                           | HC3 (N=54) Events! Subjects (%)   | Blinatumomab (N=54) Events/ Subjects (%)   | Hazard Ratio (95% CI)   | p-value   |
|-------------------------------------------|-----------------------------------|--------------------------------------------|-------------------------|-----------|
| Age based on stratification               |                                   |                                            |                         | 0.183     |
| 1-9 years                                 | 14/38 (36.8)                      | 5/39 (12.8)                                | 0.30 (0.11, 0.83)       |           |
| Other (<1 year and >9 years)              | 2/16 (12.5)                       | 3/15 (20.0)                                | 1.30 (0.22, 7.77)       |           |
| Marrow/MRD status based on stratification |                                   |                                            |                         | 1.000     |
| M1 with MRD level < 10-3                  | 10/34 (29.4)                      | 6/35 (17.1)                                | 0.52 (0.19, 1.44)       |           |
| M1 with MRD level ≥ 10-3                  | 6/16 (37.5)                       | 0/15 (0.0)                                 | NE                      |           |
| M2                                        | 0/4 (0.0)                         | 2/4 (50.0)                                 | NE                      |           |

|                                                         | HC3 (N=54) Events/ Subjects (%)   | Blinatumomab (N=54) Events/ Subjects (%)   | Hazard Ratio (95% CI)   | p-value   |
|---------------------------------------------------------|-----------------------------------|--------------------------------------------|-------------------------|-----------|
| Strata                                                  |                                   |                                            |                         | 0.999     |
| Age 1-9 years + M1 with MRD level 2 10-3                | 6/12 (50.0)                       | 0/12 (0.0)                                 | NE                      |           |
| Age 1-9 years + M1 with MRD level < 10-3                | 8/24 (33.3)                       | 4/25 (16.0)                                | 0.46 (0.14, 1.53)       |           |
| Age 1-9 years + M2                                      | 0/2 (0.0)                         | 1/2 (50.0)                                 | NE                      |           |
| Other (<1 year and >9 years) + M1 with MRD level 2 10-  | 0/4 (0.0)                         | 0/3 (0.0)                                  | NE                      |           |
| Other (<1 year and >9 years) + M1 with MRD level < 10-* | 2/10 (20.0)                       | 2/10 (20.0)                                | 0.83 (0.12. 5.92)       |           |
| Other (<1 year and >9 years) + M2                       | 0/2 (0.0)                         | 1/2 (50.0)                                 | NE                      |           |
| Age for disclosure                                      |                                   |                                            |                         | 0.685     |
| 28 days to 23 months                                    | 1/2 (50.0)                        | 1/1 (100.0)                                | NE                      |           |
| 2 to 11 years                                           | 14/44 (31.8)                      | 5/41 (12.2)                                | 0.37 (0.13, 1.03)       |           |
| 12 to 18 years                                          | 1/8 (12.5)                        | 2/12 (16.7)                                | 0.80 (0.07, 8.92)       |           |

|                                  | HC3 (N=54) Events! Subjects (%)   | Blinatumomab (N=54) Events/ Subjects (%)   | Hazard Ratio (95% C1)   | p-value   |
|----------------------------------|-----------------------------------|--------------------------------------------|-------------------------|-----------|
| Sex                              |                                   |                                            |                         | 0.364     |
| Male                             | 7/22 (31.8)                       | 4/30 (13.3)                                | 0.29 (0.09, 1.01)       |           |
| Female                           | 9/32 (28.1)                       | 4/24 (16.7)                                | 0.61 (0.19, 1.97)       |           |
| Time from 1 diagnosis to relapse |                                   |                                            |                         | 0.713     |
| <18 months                       | 7/22 (31.8)                       | 2/19 (10.5)                                | 0.23 (0.05, 1.13)       |           |
| ≥ 18 months and ≤ 30 months      | 9/28 (32.1)                       | 5/32 (15.6)                                | 0.51 (0.17, 1.53)       |           |
| >30 months                       | 014 (0.0)                         | 1/3 (33.3)                                 | NE                      |           |
| All subjects                     | 16/54 (29.6)                      | 8/54 (14.8)                                | 0.42 (0.18, 0.99)       |           |

N = Number of subjects in the analysis set. Cl = Confidence Intenval. MRD = minimal residual disease. NE = Not estimable.

The p-value is from the test of the interaction term in an unstratified Cox regression model with temms for the covariate and treatment group.

Overall Survival (OS) time is calculated from time of randomization until death due to any cause.

The hazard ratio estimate for all subjects was obtained from an unstratified Cox Proportional Hazard model.

*Convergence not met affer 25 iterations, estimates of hazard ratio and 95% Cl are based on the last maximum likelihood iteration. Data cut-off date: 17JUL2019

<div style=\"page-break-after: always\"></div>

Secondary Efficacy Endpoints - Minimal Residual Disease Response (MRD)

The proportion of subjects who had an MRD response within 29 days of treatment initiation in the MRD evaluable set is provided in Table . An MRD response was defined as an MRD level &lt; 10 4 . Minimal residual disease response was assessed by 2 methods: quantitative PCR and flow cytometry.

Table 41: MRD Response (MRD Evaluable Set) - study 20120215

|                                | HC3 (N = 54)   | Blinatumomab (N = 54)   | Treatment Difference   |
|--------------------------------|----------------|-------------------------|------------------------|
| MRD response by PCR            |                |                         |                        |
| Subject status                 |                |                         |                        |
| Number of subjects assessed    | 48             | 49                      |                        |
| MRD response - n (%)           | 26 (54.2)      | 44 (89.8)               | 35.6                   |
| (95% CI)                       | (39.2, 68.6)   | (77.8, 96.6)            | (19.2, 52.1)           |
| p-value a                      |                |                         | <0.001                 |
| MRD response by flow cytometry |                |                         |                        |
| Subject status                 |                |                         |                        |
| Number of subjects assessed    | 53             | 53                      |                        |
| MRD response - n (%)           | 32 (60.4)      | 48 (90.6)               | 30.2                   |
| (95% CI)                       | (46.0, 73.5)   | (79.3, 96.9)            | (14.8, 45.5)           |
| p-value a                      |                |                         | <0.001                 |

Cl = exact binomial confidence interval; HC3 = high-risk consolidation 3 chemotherapy; MRD = minimal residual disease; PcR = polymerase chain reaction.

N = number of subjects in MRD evaluable set

M1: Representative bone marrow aspirate or biopsy with blasts &lt; 5%, with satisfactory cellularity and with regenerating hematopoiesis

M2: Representative bone marrow aspirate or biopsy with ≥ 5% and &lt; 25% blasts

MRD evaluable set includes subjects for which evaluable baseline MRD marker can be found with either of the MRD assessment methods of PCR or flow cytometry.

Number of subjects assessed includes subjects in the MRD evaluable set who had a baseline MRD marker for the respective assessment methods.

MRD response is analyzed at end of treatment (cycle 1 day 29) of investigational product.

Subjects who are part of MRD evaluable set and are missing end of treatment (cycle 1 day 29) assessment for respective MRD assessment methods are considered not to have achieved a response.

- PCR is used as the main method to determine MRD response, but the flow cytometry information is also analyzed.

Percentages are based on number of subjects assessed with respective methods PCR and flow cytometry.

a Cochran-Mantel-Haenszel test adjusting for the stratification factors: age (1 to 9 years vs other [&lt; 1 year and &gt; 9 years]), and marrow/MRD status (M1 with MRD level &lt; 10-3 vs M1 with MRD level ≥ 10-3 vs M2). Data cutoff date: 17 July 2019.

Source:Table 14-4.3.1

Sensitivity analysis of MRD response evaluated in subjects in MRD evaluable set who did not have any important protocol deviations that could have an impact on the efficacy evaluation of the subject was provided in CSR (Table 42 below).

<div style=\"page-break-after: always\"></div>

Table 42: Sensitivity Analysis - MRD Response (Per Protocol Analysis Set)

|                                | HC3 (N=26)   | Blinatumomab (N=30)   | Treatment Difference   |
|--------------------------------|--------------|-----------------------|------------------------|
| MRD response by PCR            |              |                       |                        |
| Subject status                 |              |                       |                        |
| Number of subjects assessed    | 23           | 27                    |                        |
| MRD response - n (%)           | 11 (47.8)    | 25 (92.6)             | 44.8                   |
| (95% CI)                       | (26.8, 69.4) | (75.7, 99.1)          | (22.1, 67.4)           |
| p-value a                      |              |                       | <0.001                 |
| MRD response by flow cytometry |              |                       |                        |
| Subject status                 |              |                       |                        |
| Number of subjects assessed    | 26           | 30                    |                        |
| MRD response - n (%)           | 13 (50.0)    | 28 (93.3)             | 43.3                   |
| (95% CI)                       | (29.9, 70.1) | (77.9, 99.2)          | (22.1, 64.5)           |
| p-value a                      |              |                       | <0.001                 |

Page 1 of 1

N = Number of subjects in per protocol analysis set. MRD = minimal residual disease. PCR = polymerase chain reaction. Cl = Exact Binomial Confidence Interval.

Per protocol set includes all subjects in the full analysis set who did not have any important protocol deviations which could have an impact on the efficacy evaluation of the subject.

the respective assessment methods.

Subjects who are part of per protocol set and are missing end of treatment (Cycle 1 Day 29) assessment for respective MRD assessment methods are considered not to have achieved a response.

PCR is used as the main method to determine MRD response, but the flow cytometry information is also analysed.

Percentages are based on number of subjects assessed with respective methods PCR and flow cytometry.

Data cut-off date: 17JUL2019

a Cochran-Mantel-Haenszel test adjusting for the stratification factors: age (1-9 years vs. other (&lt;1 year and &gt;9 years)), and marrow/MRD status (M1 with MRD level &lt; 10 -3 vs. M1 with MRD level ≥ 10 -3 vs. M2).

Sensitivity analysis of MRD response evaluated in subjects in MRD evaluable set who received investigational product is summarized in Table 43. Sensitivity analysis of MRD response evaluated in subjects in MRD evaluable set who had a baseline and at least 1 post baseline MRD assessment for the respective assessment methods is summarized in Table 44. These sensitivity analyses of MRD response showed a treatment effect that was consistent with the primary MRD analysis.

<div style=\"page-break-after: always\"></div>

Table 43. Sensitivity Analysis - MRD Response (Subjects in MRD Evaluable Set who Received Investigational Product)

<!-- image -->

|                                                  | HC3 (N=51)   | Blinatumomab (N=54)   | Treatment Difference   |
|--------------------------------------------------|--------------|-----------------------|------------------------|
| MRD response by PCR                              |              |                       |                        |
| Subject status                                   |              |                       |                        |
| Number of subjecis assessed MRD response - n (%) | 48 26 (54.2) | 49 44 (89.8)          | 35.6                   |
| (95% CI)                                         | (39.2, 68.6) | (77.8, 96.6)          | (19.2,52.1)            |
| p-value a                                        |              |                       | 0.001                  |
| MRD response by flow cytometry                   |              |                       |                        |
| Subject status                                   |              |                       |                        |
| Number of subjects assessed                      | 50           | 53                    |                        |
| MRD response - n (%)                             | 32 (64.0)    | 48 (90.6)             | 26.6                   |
| (85% (C1)                                        | (49.2, 77.1) | (79.3, 96.9)          | (11.1,42.0)            |
| p-value-                                         |              |                       | 0.001                  |

Page 1 of 1

N = Number of subjecis in MRD evaluable set who received IP. MRD = minimal residual disease. PCR = polymerase chain reaction. Cl = Exact Binomial Confidence Interval.

MRD evaluable set indludes subjects for which evaluable baseline MRD marker can be found with either of the MRD assessment methods of PCR or flow cytometry.

Number of subjects assessed indudes subjecis in MRD evaluable set who received IP' and who had a baseline MRD marker for the respective assessment methods

MRD response is analyzed at end of treatment (Cycle 1 Day 29) of investigalional product.

1 Day 29) assessment for respective MRD assessment methods are considered not to have achieved a response.

Subjecls who are part of MRD evaluable set and received IP and are missing end of treatment (Cyce

PCR is used as the main method to detemine MRD response, but the fiow cytometry infommation is also analysed.

Percentages are based on number of subjects assessed with respective methods PcR and flow cytometry.

0 Codhran-Mantel-Haensze test adjusting for the stratification faclors: age (1-9 years Vs. other (c1 year and &gt;9 years)). and mamowMRD status (M1 with MRD level &amp; 10 - vs. M1 with MRD level 2 10 - vs. M2).

Data cut-off date: 17JUL2019

<div style=\"page-break-after: always\"></div>

Table 44. Sensitivity Analysis - MRD Response (Subjects in MRD Evaluable Set Who Had at Least One Post-baseline MRD Assessment)

<!-- image -->

|                                | HC3 (N=51)   | Blinatumomab (IN=54)   | Treaiment Difference   |
|--------------------------------|--------------|------------------------|------------------------|
| MRD response by PCR            |              |                        |                        |
| Subject status                 |              |                        |                        |
| Number of subjects assessed    | 47           | 47                     |                        |
| MRD response - n (%)           | 26 (55.3)    | 44 (93.6)              | 38.3                   |
| (95% CI)                       | (40.1, 69.8) | (82.5, 98.7)           | (22.5, 54.1)           |
| p-value a                      |              |                        | 20.001                 |
| MRD response by flow cytometry |              |                        |                        |
| Subject status                 |              |                        |                        |
| Number of subjects assessed    | 46           | 50                     |                        |
| MRD response -n (%)            | 32 (69.6)    | 48 (96.0)              | 26.4                   |
| (95%% CI)                      | (54.2, 82.3) | (86.3, 99.5)           | (12.1,40.8)            |
| p-value a                      |              |                        | 0.001                  |

Page 1of 1

N = Number of subjecis in MRD evaluable set who had at least one post-baseline disease assessment. MRD = minimal residual disease. PcR = polymerase chain reacion. Cl = Exact Binomial Confidence Intenval.

MRD evaluable set includes subjecis for which evaluable baseline MRD msrker can be found with either of the MRD assessment methods of PCR or flow cytometry.

Number of subjects assessed indudes subjecis in MRD evaluable set who had a baseline and at least one post-baseline MRD assessment for the respective assessment methods.

MRD response is analyzed at end of treatment (Cyce 1 Day 29) of investigalional product.

PCR is used as the main method to detemine MRD response, but the filow cytometry infomation is also analysed.

Percentages are based on number of subjecis assessed with respective methods PcR and flow cytomeiry.

Codhran-Mantel-Haenszel test adjusting for the siralification factors: age (1-9 years Vs. other (c1 year and &gt;9 years)). and mamowiMRD status (M1 with MRD level &lt; 10 -3 vs. M1 with MRD level 2 10 -3 vs. M2L.

Data cut-off date: 17J0L2019

Secondary Efficacy Endpoints - Allogeneic Hematopoietic Stem Cell Transplantation

<div style=\"page-break-after: always\"></div>

Table 45: Summary of Allogeneic HSCT (Full Analysis Set; study 20120215)

|                                                                | HC3 (N = 54) n (%)   | Blinatumomab (#9 = N) n(%)   |
|----------------------------------------------------------------|----------------------|------------------------------|
| Subjects receiving transplant - n (%)                          |                      |                              |
| No                                                             | 8 (14.8)             | 6 (11.1)                     |
| Yes                                                            | 46 (85.2)            | 48 (88.9)                    |
| Subjects receiving transplant prior to relapse - n (%)         | 38 (70.4)            | 48 (88.9)                    |
| Time to transplant (months)b                                   |                      |                              |
| Mean (SD)                                                      | 1.9 (0.8)            | 1.9 (0.3)                    |
| Median                                                         | 1.7                  | 1.9                          |
| 01.03                                                          | 1.2                  | 2.2                          |
| Min, max                                                       | 1.3                  | 1.3                          |
| Stem cell source - n (96)c                                     |                      |                              |
| Peripheral blood                                               | 8(23.7)              | 20 (41.7)                    |
| Bone marrow                                                    | 24 (63.2)            | 24 (50.0)                    |
| pooq pop                                                       | 5 (13.2)             | 4(8.3)                       |
| Donor type - n (%)F                                            |                      |                              |
| Matched sibling                                                | 10 (26.3)            | 12 (25.0)                    |
| Mismatched sibling                                             | 1 (2.6)              | 0 (0.0)                      |
| Haploidentical (mother)                                        | 2(5.3)               | 5(10.4)                      |
| Haploidentical (father)                                        | 7 (18.4)             | 8 (16.7)                     |
| Matched unrelated                                              | 12 (31.6)            | 17 (35.4)                    |
| Mismatched unrelated                                           | 6(15.8)              | 6 (12.5)                     |
| Subjects receiving conditioning total body imadiation - n (%)c | 18 (47.4)            | 27 (56.3)                    |
| Subjects receiving conditioning chemotherapy - n (%)c          | 20 (52.6)            | 21 (43.8)                    |

N = Number of subjects in the analysis set; n = Number of subjects with obsenved data.

HC3 = high-risk consolidation 3 chemotherapy: HSCT = hematopoietic stem cell transplantation;

I Percentages are based on subjects in the Full Analysis Set.

* Percentages are based on subjects in the Full Analysis Set receiving transplant prior to relapse. Dala cutoff date: 17 July 2019.

b Months are calculated as days from randomization date to transplant date, divided by 30.5.

Source: Table 14-4.4.1

<div style=\"page-break-after: always\"></div>

Table 46: Survival Status After Allogeneic HSCT (HSCT Analysis Set) - study 20120215

|                                         | HC3 (N = 38)   | Blinatumomab (N = 48)   |
|-----------------------------------------|----------------|-------------------------|
| Mortality after allogeneic HSCT         |                |                         |
| KM estimate - %                         |                |                         |
| At time 100 daysa                       | 5.6            | 4.2                     |
| (95% C1)                                | (1.4, 20.5)    | (1.1, 15.6)             |
| Subject status                          |                |                         |
| Number of subjects with allogeneic HSCT | 38             | 48                      |
| Events - n (%)                          | 12 (31.6)      | 7 (14.6)                |
| Death from any cause                    | 12 (31.6)      | 7 (14.6)                |
| Censored - n (%)                        | 26 (68.4)      | 41 (85.4)               |
| Alive                                   | 26 (68.4)      | 41 (85.4)               |
| Time to event (KM) (days)               |                |                         |
| Median                                  | NE             | NE                      |
| 95% Cl (median)                         | (341.0, NE)    | (NE, NE)                |
| 01.03                                   | 275.0, NE      | NE. NE                  |
| Min, Max                                | 22,524         | 63.355                  |
| Time to censoring (days)ab              |                |                         |
| Median                                  | 541.0          | 652.0                   |
| 95% Cl (median)                         | (271.0, 642.0) | (465.0, 820.0)          |
| Q1.Q3                                   | 183.0,832.0    | 281.0, 973.0            |
| Min, Max                                | 1.1195         | 91.1304                 |

KM = Kaplan-Meier; N = Number of subjects in the analysis set; n = Number of subjects with observed data; NE =not estimable

HC3 = high-risk consolidation 3 chemotherapy: HSCT = hematopoietic stem cell transplantation;

Days are calculated from allogeneic HsCT date to death/censor date.

Source: Table 14-4.4.2

b Time to censoring measures follow-up time by reversing the status indicator for censored and events. Data cutoff date: 17 July 2019.

Secondary Efficacy Endpoints - Cumulative Incidence of Relapse

At the time of the data cutoff, 55.6% of subjects (30/54) in the HC3 arm and 24.1% of subjects (13/54) in the blinatumomab arm had either relapse or death due to disease progression (Table 47).

Table 47: Cumulative Incidence of Relapse With Death Due to Other Causes as a Competing Event (Full Analysis Set)

<div style=\"page-break-after: always\"></div>

|                                  | HC3 (N = 54)   | Blinatumomab (N = 54)   | Treatment Difference   |
|----------------------------------|----------------|-------------------------|------------------------|
| Cumulative incidence of relapse  |                |                         |                        |
| Subject status                   |                |                         |                        |
| Number of subjects               | t9             | 54                      |                        |
| Events -n (%)                    | 30 (55.8)      | 13 (24.1)               |                        |
| Relapse                          | 29 (53.7)      | 13 (24.1)               |                        |
| Death due to disease progression | 1 (1.9)        | 0 (0.0)                 |                        |
| Competing event - n (%)          | 1 (1.9)        | 4(7.4)                  |                        |
| Death due to other cause         | 1 (1.9)        | 4(7.4)                  |                        |
| Censored - n (%)                 | 23 (42.6)      | 37 (68.5)               |                        |
| Alive wlo relapse                | 23 (42.8)      | 37 (68.5)               |                        |
| Time to event (CIF) (months)     |                |                         |                        |
| Median                           | 7.9            | NE                      |                        |
| 95% Cl (median)                  | 5.8.23.1       | NE, NE                  |                        |
| 01.03                            | 3.9. NE        | 24.4, NE                |                        |
| Min, Max                         | 0.3, 23.1      | 3.2. 24.8               |                        |

<div style=\"page-break-after: always\"></div>

| CIF estimate - 9%6         |              |              |              |
|----------------------------|--------------|--------------|--------------|
| At time 3 months*          | 22.3         | 0.0          |              |
| (9596 C1)                  | (11.8, 34.8) | (NE. NE)     |              |
| At time 6 months?          | 42.1         | 10.7         |              |
| (95%6 C1)                  | (27.7.55.8)  | (3.9, 21.5)  |              |
| At time 12 months*         | 59.5         | 24.9         |              |
| (95% C1)                   | (43.0, 72.6) | (13.2. 38.5) |              |
| At time 18 months?         | 65.4         | 24.9         |              |
| (9596 C1)                  | (48.2, 78.1) | (13.2, 38.5) |              |
| At time 24 months?         | 70.8         | 24.9         |              |
| (95%6 C1)                  | (50.7. 83.9) | (13.2, 38.5) |              |
| At time 36 months*         | 70.8         | 33.2         |              |
| (9596 C1)                  | (50.7, 83.9) | (18.0, 49.1) |              |
| Hazard ratiob              |              |              | 0.28         |
| (95% CI)                   |              |              | (0.15, 0.53) |
| Stratified hazard ratiob.c |              |              | 0.24         |
| (95% CI)                   |              |              | (0.13, 0.46) |

Page 2 of 2

CIF = cumulative incidence function; HC3 = high-risk consolidation 3 chemotherapy: MRD = minimal residual disease; NE = not estimable; N = number of subjecis in the analysis set.

M1: Representative bone mamrow aspirate or biopsy with blasts c 5%, with satisfactory cellularity and with regenerating hematopoiesis

M2: Representative bone manrow aspirate or biopsy with 2 5% and &lt; 25% blasts

Months are calculated as days fom randomization date to event/censor date, divided by 30.5.

e Stratification factors are: age (1 to 9 years vs. other [&lt; 1 year or &gt; 9 years]). and mamow/MRD status (M1 with MRD level c 10- vs M1 with MRD level ≥ 10- vs M2).

b The subdistribution hazard ratio estimates are obtained from the subdistribution Cox model. A hazard ratio C 1.0 indicates a lower average event rate and a longer relapse-free time for blinatumomab relative to HC3.

Data cutoff date: 17 July 2019.

Soumce:Table 14-4.5.1

<div style=\"page-break-after: always\"></div>

Figure 32: Cumulative Incidence of Relapse With Death due to Other Causes as a Competing Event (Full Analysis Set)

<!-- image -->

HC3 = high-risk consolidation 3 chemotherapy: NE = not estimable Data cutoff date 17 July 2019. Source: Figure 14-4.5.1

Other Evaluations - Anti-blinatumomab Antibody Assays

Of the 54 subjects in the blinatumomab arm who were included in the Safety Analysis Set, 48 (88.9%) had a postbaseline antibody result; none of the subjects tested positive for binding or neutralizing antiblinatumomab antibodies. Therefore, analyses evaluating the effect of anti-blinatumomab antibodies on PK were not conducted.

## Ancillary analyses

Refer to sensitivity analysis provided with each endpoint.

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 48: Summary of Efficacy for Study 20120215 - Blinatumomab in Pediatric Subjects with High-risk First Relapsed ALL

Title: Phase 3, randomized, open-label, controlled, multicentre study investigating the efficacy and safety profile of blinatumomab versus intensive SOC late consolidation chemotherapy in paediatric subjects.

| Study identifier   | Study 20120215                                                 |
|--------------------|----------------------------------------------------------------|
| Design             | Phase 3, randomized, open-label, controlled, multicentre study |

<div style=\"page-break-after: always\"></div>

|                                                 | Duration of main phase:                                                                                                                                                                                                                                                                                                                                                                                                             | Duration of main phase:                                                                                                                                                                                                                                                                                                                                                                                                             | 3-week screening period 4-week treatment period followed by a 1-week safety follow-up period                                                                                                                                                                                                                                                                                                                                        | 3-week screening period 4-week treatment period followed by a 1-week safety follow-up period                                                                                                                                                                                                                                                                                                                                        |
|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hypothesis                                      | Duration of Extension phase: NA No formal hypothesis Anticipated risk reduction of events (relapse or M2 marrow after having achieved a CR, failure to achieve a CR at the end of treatment, secondary malignancy, or death due to any cause): 37% in non-cured subjects and a cure rate would increase from 40% to 56.2% with blinatumomab treatment (cure was defined as a subject having no EFS event after 36 months on study). | Duration of Extension phase: NA No formal hypothesis Anticipated risk reduction of events (relapse or M2 marrow after having achieved a CR, failure to achieve a CR at the end of treatment, secondary malignancy, or death due to any cause): 37% in non-cured subjects and a cure rate would increase from 40% to 56.2% with blinatumomab treatment (cure was defined as a subject having no EFS event after 36 months on study). | Duration of Extension phase: NA No formal hypothesis Anticipated risk reduction of events (relapse or M2 marrow after having achieved a CR, failure to achieve a CR at the end of treatment, secondary malignancy, or death due to any cause): 37% in non-cured subjects and a cure rate would increase from 40% to 56.2% with blinatumomab treatment (cure was defined as a subject having no EFS event after 36 months on study). | Duration of Extension phase: NA No formal hypothesis Anticipated risk reduction of events (relapse or M2 marrow after having achieved a CR, failure to achieve a CR at the end of treatment, secondary malignancy, or death due to any cause): 37% in non-cured subjects and a cure rate would increase from 40% to 56.2% with blinatumomab treatment (cure was defined as a subject having no EFS event after 36 months on study). |
| Treatments groups                               | Blinatumomab arm                                                                                                                                                                                                                                                                                                                                                                                                                    | Blinatumomab arm                                                                                                                                                                                                                                                                                                                                                                                                                    | - Blinatumomab, continuous IV infusion, 15  g/m2/day over, 4 weeks (maximum daily dose was not to exceed 28  g/day).                                                                                                                                                                                                                                                                                                              | - Blinatumomab, continuous IV infusion, 15  g/m2/day over, 4 weeks (maximum daily dose was not to exceed 28  g/day).                                                                                                                                                                                                                                                                                                              |
| Treatments groups                               | HC3 arm                                                                                                                                                                                                                                                                                                                                                                                                                             | HC3 arm                                                                                                                                                                                                                                                                                                                                                                                                                             | - N=54 randomized patients - HC3 arm, per IntReALL protocol - 1 week                                                                                                                                                                                                                                                                                                                                                                | - N=54 randomized patients - HC3 arm, per IntReALL protocol - 1 week                                                                                                                                                                                                                                                                                                                                                                |
| Endpoints and definitions                       | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                    | EFS                                                                                                                                                                                                                                                                                                                                                                                                                                 | - N=54 randomized patients Time from randomization until the date of relapse or M2 marrow after having achieved a CR, failure to achieve a CR at the end of treatment, secondary malignancy, or death due to any cause, whichever occurred first; FAS                                                                                                                                                                               | - N=54 randomized patients Time from randomization until the date of relapse or M2 marrow after having achieved a CR, failure to achieve a CR at the end of treatment, secondary malignancy, or death due to any cause, whichever occurred first; FAS                                                                                                                                                                               |
| Endpoints and definitions                       | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                  | OS                                                                                                                                                                                                                                                                                                                                                                                                                                  | Time from the time of randomization until death to any cause; FAS                                                                                                                                                                                                                                                                                                                                                                   | Time from the time of randomization until death to any cause; FAS                                                                                                                                                                                                                                                                                                                                                                   |
| Endpoints and definitions                       | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                  | MRD                                                                                                                                                                                                                                                                                                                                                                                                                                 | MRD response was defined as an MRD level < 10 -4 , assessed by quantitative PCR or flow cytometry; includes all subjects who had a baseline MRD marker for the respective                                                                                                                                                                                                                                                           | MRD response was defined as an MRD level < 10 -4 , assessed by quantitative PCR or flow cytometry; includes all subjects who had a baseline MRD marker for the respective                                                                                                                                                                                                                                                           |
| Endpoints and definitions                       | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                  | AlloHSCT                                                                                                                                                                                                                                                                                                                                                                                                                            | assessment method Analyzed for subjects who received allogeneic HSCT while in CR after study treatment                                                                                                                                                                                                                                                                                                                              | assessment method Analyzed for subjects who received allogeneic HSCT while in CR after study treatment                                                                                                                                                                                                                                                                                                                              |
| Database lock 17 Jul 2019                       | Database lock 17 Jul 2019                                                                                                                                                                                                                                                                                                                                                                                                           | Database lock 17 Jul 2019                                                                                                                                                                                                                                                                                                                                                                                                           | Database lock 17 Jul 2019                                                                                                                                                                                                                                                                                                                                                                                                           | Database lock 17 Jul 2019                                                                                                                                                                                                                                                                                                                                                                                                           |
| Results and Analysis                            | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                |
| Analysis description                            | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                    | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                    | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                    | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Analysis population and time point description  | FAS                                                                                                                                                                                                                                                                                                                                                                                                                                 | FAS                                                                                                                                                                                                                                                                                                                                                                                                                                 | FAS                                                                                                                                                                                                                                                                                                                                                                                                                                 | FAS                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                     | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                     | HC3 N = 54                                                                                                                                                                                                                                                                                                                                                                                                                          | Blinatumomab N = 54                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability | EFS Events, n ( % )                                                                                                                                                                                                                                                                                                                                                                                                                 | EFS Events, n ( % )                                                                                                                                                                                                                                                                                                                                                                                                                 | 31 (57.4 % )                                                                                                                                                                                                                                                                                                                                                                                                                        | 18 (33.3 % )                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | Stratified log-rank test a                                                                                                                                                                                                                                                                                                                                                                                                          | Stratified log-rank test a                                                                                                                                                                                                                                                                                                                                                                                                          | p < 0.001                                                                                                                                                                                                                                                                                                                                                                                                                           | p < 0.001                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Median EFS (95 % CI) b                                          | 7.4 months (4.5 to 12.7 months)    | NE (12.0 months to NE)             |
|-----------------------------------------------------------------|------------------------------------|------------------------------------|
| 36-month KM estimate (95 % CI)                                  | 26.9 % (13.2 % to 42.8 % )         | 55.7 % (37.8 % to 70.4 % )         |
| Median FU time                                                  | 22.4 months                        | 22.4 months                        |
| Cox stratified HR (95 % CI) c                                   | 0.36 (0.19 to 0.66)                | 0.36 (0.19 to 0.66)                |
| OS Events, n ( % )                                              | 16 (29.6 % )                       | 8 (14.8 % )                        |
| Stratified log-rank test a                                      | p = 0.047                          | p = 0.047                          |
| Median OS (95 % CI) b                                           | NE (15.7 months to NE)             | NE (NE, NE)                        |
| 36-month KM estimate (95 % CI)                                  | 55.8 % (36.9 % to 71.0 % )         | 81.1 % (65.5 % to 90.2 % )         |
| Median FU time                                                  | 19.5 months                        | 19.5 months                        |
| Cox stratified HR (95 % CI) c                                   | 0.43 (0.18, 1.01)                  | 0.43 (0.18, 1.01)                  |
| MRD response rate by PCR (95 % CI)                              | 54.2 % (26/48) (39.2 % to 68.6 % ) | 89.8 % (44/49) (77.8 % to 96.6 % ) |
| Treatment difference (95 % CI)                                  | 35.6 % (19.2 % to 52.1 % )         | 35.6 % (19.2 % to 52.1 % )         |
| Cochran-Mantel- Haenszel test d                                 | p < 0.001                          | p < 0.001                          |
| % of subjects who received allogeneic HSCT while in CR          | 82.6 % (38/46)                     | 100.0 % (48/48)                    |
| KM estimate of mortality at 100 days after HSCT e (95 % CI)     | 5.6 % (1.4 % to 20.5 % )           | 4.2 % (1.1 % to 15.6 % )           |
| % of subjects overall who died after receiving HSCT while in CR | 31.6 % (12/38)                     | 14.6 % (7/48)                      |
| Median follow- up time                                          | 17.7 months                        | 21.4 months                        |

ALL = acute lymphoblastic leukemia; CI = confidence interval; CSR = clinical study report; EFS = event-free survival; FAS = Full Analysis Set; HC3 = high-risk consolidation 3 chemotherapy; HR = hazard ratio; HSCT = hematopoietic stem cell transplantation; KM = Kaplan-Meier; M1 = &lt; 5 % blasts in bone marrow; M2 = ≥ 5 % and &lt; 25 % blasts in bone marrow; MRD = minimal residual disease; N = number of subjects in the analysis set; NE = not estimable; OS = overall survival; PA = Primary Analysis; PCR = polymerase chain reaction;

<div style=\"page-break-after: always\"></div>

- a  Stratification factors were age (1 to 9 years vs other [ &lt; 1 year and &gt; 9 years]), and marrow/MRD status (M1 with MRD level &lt; 10 -3  vs M1 with MRD level ≥ 10 -3  vs M2)
- b  Kaplan-Meier estimates; months are calculated as days from randomization date to event/censor date, divided by 30.5.
- c  The hazard ratio estimates are obtained from the Cox proportional hazard model.  A hazard ratio &lt; 1.0 indicates a lower average event rate and a longer event-free survival or overall survival for blinatumomab relative to HC3.
- d  Cochran-Mantel-Haenszel test adjusting for the stratification factors:  age (1 to 9 years vs other [ &lt; 1 year and &gt; 9 years]), and marrow/MRD status (M1 with MRD level &lt; 10 -3  vs M1 with MRD level ≥ 10 -3  vs M2)

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

## Study design and method

The pivotal study 20120215 is an ongoing phase 3, randomized, open-label, controlled, multicentre study investigating the efficacy and safety profile of blinatumomab versus intensive SOC late consolidation chemotherapy in paediatric subjects.

The randomized study design allows a comparison of results obtained versus SOC. However, a bias in investigator's assessment cannot be ruled out considering the open label design. Randomization was stratified by age, bone marrow status, and MRD status.

The inclusion/exclusion criteria of pivotal study 20120215 were designed to select a high-risk population, as per IntReALL study, OR with positive MRD after induction and 2 consolidation cycles.

Considering the treatment schedule in the study, and blinatumomab as part of consolidation therapy, the indication has been adjusted accordingly indicating that blinatumomab is considered to be part of the consolidation therapy (see final adopted indication).

Cycle length was different, with a 4 weeks cycle in blinatumomab arm and 3 weeks cycle in HC3 as per IntReALL protocol. This point is addressed in sensitivity analyses

Eligible paediatric subjects for this study should have Phi - B-precursor ALL in first relapse. High-risk (HR) population was defined as per IntReALL study, or with positive MRD after induction and 2 consolidation cycles. HR status per IntReALL protocol is defined per very early relapse (&lt; 18 months from initial diagnosis), early isolated bone marrow relapse (&gt; 18 months after primary diagnosis and &lt; 6 months from completion of front-line therapy). The HR status in IntReALL protocol didn't include MRD level. It was specified that MRD was assessed at screening and was taken into account in stratification at the end of induction therapy. Considering the data provided, MRD status was known for two thirds of the subjects, including 20% who were MRD positive. Subgroups analysis showed, regardless of the MRD level, a trend in hazard ratio in favour of the blinatumomab arm which is acceptable. Exclusion criteria follow the known safety profile for blinatumomab.

As also highlighted in Locatelli et al. publication, this classification does not consider rearrangements, which is a non-negligible limitation in this HR graduation.

IntReALL 2010 protocol allowed the implementation of study 20120125 in the continuity of InTReALL study, as follows: 'At the end of the HR consolidation, an investigational window has been implemented to allow further studies in this patient cohort.'

This study included a long-term follow-up up to 36 months until the last subject on study after HSCT or died.

<div style=\"page-break-after: always\"></div>

The primary objective was to compare EFS after blinatumomab versus SOC. EFS was calculated from randomization to relapse, M2 after having achieved CR, no CR at the end of treatment, SPM or death, whichever occurred first. This is acceptable per current guidelines for oncology treatments.

Threshold greater than 5% blasts in the bone marrow (M1) follows ESMO guidelines (2016) for the definition of haematological relapse.

The planned sample size was 202 subjects to allow 84% power using a 2-sided alpha level of 0.05. There was no formal hypothesis.

At time of first interim analysis (when 50% of the total EFS events had occurred), efficacy endpoint was met and enrolment was stopped for benefit in the blinatumomab arm. This interim analysis is adequately considered as primary analysis.

The intent-to-treat (ITT) analysis of efficacy included all subjects who underwent randomization and is referred to as the Full Analysis Set (FAS).

Blinatumomab was expected to demonstrate a reduction in the risk of events (relapse or M2 marrow after having achieved a CR, failure to achieve a CR at the end of treatment, secondary malignancy, or death due to any cause), with a risk reduction of 37% in non-cured patients and a cure rate increase from 40% to 56.2% (cure was defined as a subject having no EFS event after 36 months on study).

## Efficacy data and additional analyses

## Study conduct

The study initially planned to enrol 202 subjects but recruitment in the study was prematurely stopped on 17 July 2019, based on DMC recommendation at time of first interim analysis. Thus, study data are limited to the primary analysis, in a sample size limited to 108 enrolled patients (54 per study arm).

The study remains ongoing and the final analysis is planned by 2023. The final analysis CSR remains expected as soon as available (letter of recommendation).

At time of the data cut-off date, 75 subjects (69.4%) remained on study (32 in HC3 arm and 43 in blinatumomab arm) and 33 subjects (30.6%) discontinued the study (22 in HC3 arm and 11 in blinatumomab arm). Study discontinuation was mainly due to death (24 deaths, including 16 in HC3 arm and 8 in blinatumomab arm) and consent withdrawal (5 in HC3 arm and 2 in blinatumomab arm).

Among the 108 enrolled subjects, 105 received the study treatment (51 in the HC3 arm and 54 in the blinatumomab arm) and most of patients completed investigational treatment (99; 91.7%: 49 subjects in the HC3 arm and 50 subjects in the blinatumomab arm).

However, 52 subjects (48.1%) had important protocol deviations. A quarter of subjects had missing data, driven by bone marrow samples not sent for central review during follow up; this would not impact the diagnosis of B-cell ALL nor EFS assessment. The Applicant classified the 22 subjects with missing data due to non-sending of bone marrow samples for central review during follow-up into 3 categories/group (Group 1: Subsequent M1 BM per central lab review after missing a central BM assessment; Group 2: Subsequent M1 BM per local lab review after missing a central lab BM assessment; Group 3: Did not have a complete of set of central or local BM assessments collected at all the protocol-specified timepoints) and performed a risk analysis. The proposed categorization is acceptable. Few disease progressions were observed in Groups 1 and 2. Only the Group 3 subjects could potentially have a meaningfully impact on EFS result. Among these six subjects, four were from the blinatumomab arm while 2 were from the HC3 arm. Based on the data provided, all patients in blinatumomab arm had no event (n=3) or death of any cause (n=2), without impact of BM assessment

<div style=\"page-break-after: always\"></div>

on the timing of assessment of these events. The conclusion is that these deviations had no major impact on efficacy results.

The second most common IPD were 'off-schedule procedures'. 14 subjects had assessment not performed in due time. The development of CNS disease because following anticipated screening lumbar puncture (LP) is unlikely. Indeed, all subjects had already received intrathecal chemotherapy at the time of screening LP. 11 of the 14 subjects (except for 3 subjects [1 in the blinatumomab arm and 2 in the HC3 arm]) had no CNS disease at the time of relapse and thus had very low risk for further CNS relapse soon after induction and 2 blocks of consolidation chemotherapy. Detailed data have been provided in Table 60 (see AR above). Also 'off-schedule procedures' protocol deviations are considered not to have major impact on efficacy results.

Concerning the non-fulfilment with inclusion or exclusion criteria, the Applicant provided details on these major deviations (see above). These deviations would not have impacted study results.

## Baseline characteristics

Subjects' baselines were globally consistent between both treatment arms. The proportion of male patients was higher in blinatumomab arm (55.6% vs 40.7%) and median age was 1 year older (6 vs 5 years in HC3 arm). However, age groups were similar in both arms, with around 70% of patients aged 1 to 9 years. There was no patient below 1 year of age, which is reflected in the targeted indication.

A lower proportion of subjects had genetic abnormality in blinatumomab arm (37.0 vs 46.3%), driven by hyperdiploidy (6 patients each). MLL rearranged was only observed in HC3 arm (4 patients, 7.4%).

Extramedullar disease at diagnosis and at relapse were comparable between both arms, observed in 14 patients in HC3 arm (25.9%) and 10 patients (18.5%) in blinatumomab arm, mainly in CNS in both arms. Globally, all but 3 patients were M1 bone marrow. Baseline MRD was only available in about 2 thirds of subjects, with positive MRD in 21.3% and 20.4% globally (with PCR and flow cytometry detection respectively).

Baseline blood cell counts were similar between both arms. Median time from first diagnosis to first relapse was similar between both arms, with 20.95 and 22.34 months in HC3 and blinatumomab arms respectively. Very early relapse &lt; 18 months, as per IntReALL definition previously discussed, was observed in 22(40.7%) and 19 (35.2%) of patients in HC3 and blinatumomab arms respectively. Randomization was stratified by age, bone marrow status, and MRD status. Both arms were balanced regarding these characteristics.

## Primary endpoint - EFS

Event was defined as relapse or M2 marrow after having achieved a CR, failure to achieve a CR at the end of treatment, secondary malignancy, or death due to any cause, whichever occurs first. At time of data cut-off, median EFS was 7.4 months (95% CI: 4.5 to 12.7 months) in the HC3 arm and was not reached in the blinatumomab arm (95% CI: 12.5 months to not estimable [NE]). Median FU time was 22.4 months. EFS event incidence was 57.4% in the HC3 arm and 33.3% in the blinatumomab arm, with a statistically significant difference between both arms, in both stratified and unstratified analysis. Similar results were obtained in data analysis dated 16 December 2019 including only data until 17 July 2019 as it was the predefined date. It seems that MRD threshold applied in subgroups analysis was 10 3 , while 10 4  was used in baseline characteristic. This discrepancy is justified by the fact that MRD level at the end of induction was assessed in country local labs including those using 10 3  as the threshold due to available MRD assay sensitivity in these labs.  MRD level at baseline in Study 20120215 was assessed in central labs that utilized assays with sensitivity sufficient to allow application of 10 4  as the MRD negativity cut-off.

<div style=\"page-break-after: always\"></div>

Results in subgroups analysis confirmed trends observed in EFS, favourable with blinatumomab treatment.

The 36-month KM estimate (95 % CI) was 26.9 % (13.2 % to 42.8 % ) in HC3 arm and 55.7 % (37.8 % to 70.4 % ) in blinatumomab arm. Thus the cure rate increase, expected to raise from 40% to 56.2%, was met. However, the cure rate in the comparative arm was clearly lower than expected. In this regards the provided expected cure rate in the comparative HC3 arm was based on 2013 unpublished study data in the same population. Since then, front-line treatments have improved, suggesting that cure rate expected in second line currently would be lower. Thus, the applicant considers that cure rate was overestimated, without impact on study results nor interpretation. The applicant did not discuss if this could anyway reflect a suboptimal course of this comparative arm. However, considering cure rate obtained in blinatumomab arm (independently of the difference when compared to the comparative arm), the applicant's conclusion is endorsed; the overestimation of the cure rate do not appear to have had a major impact on study data interpretation.

## Secondary endpoints

Median OS were not reached at time of interim data cut off, with a median FU time of 19.5 months. Death incidence was 29.6% in the HC3 arm and 14.8% in the blinatumomab arm, with a significant difference in both stratified and unstratified analysis. Results in median OS remain expected in the final analysis as soon as available. KM estimates raised significant differences between both arms, favorable for blinatumomab treatment.

13 out of the 54 patients in HC3 arm received blinatumomab treatment subsequently to HC3 treatment, following R/R disease (n=12) or MRD (n=1). This did not impact the analysis.

Subgroups analysis is endorsed, with limited conclusion considering small sample size in these subgroups.

MRD response was defined as MRD level &lt; 10 4 , with 2 methods of assessment (quantitative PCR and flow cytometry). Only patients with baseline MRD were assessed for MRD response. At time of primary cut-off date (17 July 2019), with PCR method, 54.2% (26/48) in HC3 arm and 89.8% of patients (44/49) in blinatumomab arm had achieved an MRD response. The difference between both arms was significant, favorable for blinatumomab treatment.  Trends in MRD response were similar when measured by flow cytometry, with a higher number of assessable patients and a higher number of MRD response detected.

Sensitivity analysis with per protocol analysis was provided, in order to assess potential impact of protocol deviations on study results. Despite sample size sharply reduced (23 and 27 MRD evaluable patients in HC3 and blinatumomab arms respectively with PCR), results remained significantly higher in blinatumomab arm, with 89.8% (77.8; 96.6) of MRD response at the end of C1 D29. Further sensitivity analysis confirmed the favorable trend observed with blinatumomab in MRD response.

Globally, at time of primary cut-off date, a similar proportion of subjects went to alloHSCT between both arms: 85.2% in HC3 arm and 88.9% in blinatumomab arm. In blinatumomab arm, all of these patients received alloHSCT before relapse. Median time to transplant from randomization was similar between both arms (1.7 and 1.9 month in HC3 and blinatumomab arms respectively). Donor type and conditioning were quite balanced between both arms. The main stem cell source was bone marrow in both arms; however, a higher proportion of subjects received stem cell from peripheral blood in blinatumomab arm (41.7%) vs HC3 arm (23.7%).

The 100 days mortality estimate was provided in patients with alloHSCT prior relapse (n=38 in HC3 arm, n=48 in blinatumomab arm), and estimated from the date of alloHSCT: it was lower in blinatumomab arm (4.2% (1.1; 15.6) vs 5.6% (1.4; 20.5)), but not significantly different considering

<div style=\"page-break-after: always\"></div>

crossing CI. At the cut-off date (17 jul 2019), 41/48 (85.4%) of patients remained alive in blinatumomab arm, and 26/38 (68.4%) in HC3 arm. The median time to death was reached in neither arm.

The cumulative relapse, in the full analysis set (54 subjects per arm), was 53.7% of patients in HC3 arm and 24.1% in blinatumomab arm presented with LAL relapse. One additional patient in HC3 arm died due to disease progression. The discrepancy between OS death and cumulative relapse events are justified considering that the overall survival (OS) analysis reports all deaths observed on study, regardless of cause or if there was relapse prior to death.  Therefore, all 24 deaths observed on study are reported as an event in the OS analysis.  The cumulative relapse analysis reports the time to first event where the events include relapse or death due to disease progression.  For a subject that died on study but experienced a relapse prior to death, the relapse was reported as the event, not the death.  Therefore, the cumulative relapse analysis only reports deaths as events if they occurred without a prior relapse and the cause of death was due to disease progression.

Data on patients who received subsequent CAR-T cell therapy have been provided. Among the two subjects who received CAR-T cell therapy in the blinatumomab arm, one had no EFS event at last follow up in January 2021. The second subject died of ALL due to disease progression. Among the three subjects who had CAR-T in the HC3 arm, one each died of disease progression, cardiorespiratory arrest and myocardial infarction. The two last subjects had received blinatumomab after HC3 treatment. These data allow an interesting but limited analysis. Indeed, given the sample size, it is not possible to conclude on a lower response to CAR-T cells in one treatment arm or another.

Considering the cumulative incidence estimate of relapse or death due to disease progression, the difference remained significant between both arms up to 36 months from randomization, in favor of blinatumomab treatment.

None of the 48 patients with a post baseline antibody result presented with anti-blinatumomab antibodies.

## 2.4.4. Conclusions on the clinical efficacy

The pivotal study 20120215 provided results in 108 patients (54 per study arm). Median EFS in blinatumomab arm was not reached (vs 7.4 months (95% CI: 4.5; 12.7) in HC3 arm) and EFS event incidence was statistically different, in favour of blinatumomab arm (57.4% in the HC3 arm and 33.3% in the blinatumomab arm). The 36-month KM estimate EFS was 26.9 % (13.2 % to 42.8 % ) in HC3 arm and 55.7 % (37.8 % to 70.4 % ) in blinatumomab arm. The expected cure rate increase was met but the cure rate in the comparative arm was lower than expected.

Median OS were not reached at time of interim data cut off. Death incidence was 29.6% in the HC3 arm and 14.8% in the blinatumomab arm, with a significant difference in both stratified and unstratified analysis.

With PCR method, the difference in MRD response was statistically significant: 54.2% in HC3 arm vs 89.8% in blinatumomab arm. Sensitivity analysis with per protocol, despite very limited sample size, confirmed the favorable trend observed with blinatumomab in MRD response.

A similar proportion of subjects went to alloHSCT between both arms: 85.2% in HC3 arm and 88.9% in blinatumomab arm. Median time to transplant was similar between both arms (1.7 and 1.9 month in HC3 and blinatumomab arms respectively).

The 100 days mortality estimate, in patients with alloHSCT prior relapse (n=38 in HC3 arm, n=48 in blinatumomab arm), was lower in blinatumomab arm (4.2% (1.1; 15.6) vs 5.6% (1.4; 20.5)), but not

<div style=\"page-break-after: always\"></div>

significantly different considering crossing CI. At the cut off date (17 jul 2019), 41/48 (85.4%) of patients remained alive in blinatumomab arm, and 26/38 (68.4%) in HC3 arm. The median time to death was reached in neither arm.

None of the 48 patients with a post baseline antibody result presented with anti-blinatumomab antibodies.

In conclusion, considering the data provided the clinical difference remained significant between both arms, in favour of blinatumomab treatment.

## 2.5. Clinical safety

## Introduction

Safety data are provided from the pivotal Study 20120215.

Additionally, this variation application includes supporting pooled safety data from the 3 completed single-arm, open-label, multicenter blinatumomab studies in paediatric subjects with relapsed/refractory ALL (second or greater relapsed, relapsed after HSCT, and refractory to previous treatments) as a reference population for assessing the safety of blinatumomab in paediatric subjects with high-risk first relapsed ALL:

- -Study MT103-205, an open-label, single-arm, dose-finding, phase 1b/2 study in 93 paediatric subjects in second or later bone marrow relapse, in any marrow relapse after allogeneic HSCT, or refractory to other treatments
- -Study 20130320, an open-label, single-arm, expanded access study in 110 paediatric subjects with relapsed/refractory B-cell precursor ALL
- -Study 20130265, an open label, multicenter, phase 1b/2 study in 40 adult and 26 paediatric Japanese subjects with relapsed/refractory ALL. Data from the 26 paediatric subjects in this study are included in the proposed variation application.

<div style=\"page-break-after: always\"></div>

Table 49: Summary of Clinical Studies Contributing to the Safety of Blinatumomab for the Treatment Pediatric Subjects with ALL

| Study Number   | Objectives of the Study   | Study Design and Type of Control                         | Number of Subjects (Treated)/Safety Set                                                                     |
|----------------|---------------------------|----------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| MT103-205      | Efficacy Safety PK/PD     | Phase 1/2 Single-arm Open-label Multicenter Dose finding | 93 (49 in phase 1 and 44 in phase 2): 70 at the approved pediatric dose (5-15 μg/m²/day)                    |
| 20130320       | Safety Efficacy           | Expanded access Single-arm Open-label ●Multicenter       | 110                                                                                                         |
| 20130265       | Efficacy Safety PK/PD     | Phase 1b/2 Open-label ●Multicenter                       | 26 (9 in Pediatric Full Analysis Set - Phase 1b; 17 in Pediatric Expansion Analysis Set - Expansion Cohort) |
| 20120215       | Efficacy Safety PK        | Phase 3 Open-label Controlled Multicenter                | 105 (51 in the HC3 arm; 54 in the blinatumomab arm)                                                         |

ALL = acute lymphoblastic leukemia; HC3 =high-risk consolidation 3; PD =pharmacodynamics; PK=pharmacokinetics

Note: For the purposes of this submission, safety data for the high-risk first relapsed B-cell ALL population Shidiae MT1n3.2n52n13n32nand 2013n2651

For Study 20120215, the safety data cut-off date was based on the primary analysis data cut-off date of 17 July 2019. For the 3 completed studies (Studies MT103-205, 20130320, and 20130265), the safety data cut-off dates were based on the final analysis data cut-off dates for the studies.

## Method

Adverse events are defined as events that started between the start of the first infusion of investigational product (blinatumomab or HC3) and 30 days after the end of the last infusion during the study.

The safety assessment of paediatric subjects from Study 20120215 who received at least 1 infusion of blinatumomab (N = 54) is based on the primary analysis of safety data with a data cut-off date of 17 July 2019. During the treatment period, visits were performed on days 1, 15, and day 29 or end of treatment. A safety follow-up visit was required within 7 days before allogeneic hematopoietic stem cell transplantation (HSCT) or anti-cancer therapy for current malignancy not mandated by the protocol, whichever comes first.

Subjects were followed during a short-term efficacy follow-up period of 12 months after allogeneic HSCT, and then were followed in a long-term follow-up period until the last subject on study either was followed for 36 months after allogeneic HSCT or died, whichever occurred first.

For all studies summarized in the integrated safety analyses (ie, for the iSAP), the Safety Analysis Set was used to include all subjects who received any infusion of blinatumomab. Demographics, baseline

<div style=\"page-break-after: always\"></div>

disease characteristics, and disposition are summarized based on the Full Analysis Set. Adverse events, exposure, and other safety assessments are summarized based on the Safety Analysis Set.

## Patient exposure

The protocol-defined dose and regimen for each of the 4 studies that comprise the safety database are shown in the table below.

Table 50: Blinatumomab Dose Regimen by Paediatric Study

| Protocol Number   | Dose Regimen                                                                                                                                                                                                              | MaximumNumber of Cycles                             |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|
| MT103-205         | Phase 1: 5, 15, 30, 5/15a, and 15/30b μg/m2/day clVinfusion,4weekson/2weeksoff Phase2:Recommended dose(fromphase 1)of 5/15μg/m2/dayclVinfusion,4weekson/2weeks off                                                        | Up to 5 cycles; Retreatment upto 3additional cycles |
| 20130320          | 5/15a μg/m2/day (not to exceed 9/28 μg/day) clV infusion,4weekson/2weeksoff,if M3marrowat screening 15 μg/m2/day(not to exceed 28 μg/day) clV infusion,4weekson/2weeksoff,ifM2marrowor M1 marrow with an MRD level ≥ 10-3 | Up to 5 cycles                                      |
| 20130265          | Phase1b:5/15aμg/m2/dayclVinfusion,4 weeks on/2weeksoff Expansion: Recommended dose (from phase 1b) of5/15μg/m2/dayclVinfusion,4weekson/2 weeksoff                                                                         | Phase1b:upto5cycles Expansion:upto5cycles           |
| 20120215          | 15 μg/m2/day (not to exceed 28μg/day) clV infusion,4weekson,for1cycle                                                                                                                                                     | Single cycle                                        |

clV=continuous intravenous

a For 5/15 μg/m2/day dose regimen, subjects were administered blinatumomab at a dose of 5 μug/m2/day in week1,followedby15μug/m2/day inweeks 2-4ofcycle1 and15μg/m2/day inweeks1-4of subsequent cycles.

bFor15/30μg/m2/day dose regimen,subjects were administeredblinatumomab at a dose of 15 μg/m2/day in week 1, followed by 30 μg/m2/day in weeks 2-4 of cycle 1 and 30 μug/m2/day in weeks 1-4 of subsequent cycles.

c For 9/28 μug/day dose regimen, subjects were administered blinatumomab at a dose of 9 μg/day in week 1,

<div style=\"page-break-after: always\"></div>

Of the 108 subjects randomized in study 20120125, 105 subjects (51 in the HC3 arm; 54 in the blinatumomab arm) received investigational product and are included in the Safety Analysis Set. In the HC3 arm, 3 subjects did not receive treatment. Of the 105 subjects that received treatment, 99 subjects (91.7%) completed treatment (49 subjects [90.7%] in the HC3 arm; 50 subjects [92.6%] in the blinatumomab arm).

As of the data cut-off, the mean (SD) duration of blinatumomab treatment was 26.5 (6.0) days, and the mean (SD) cumulative blinatumomab dose was 378.2 (110.1) μg/m2. 50 subjects (92.6%) completed the blinatumomab treatment cycle (ie, 90% of planned duration) and 4 subjects (7.4%) discontinued the treatment cycle.

Dose modification in each arm are summarized in the table below.

Table 51: Summary of Dose Modifications to Investigational Product (Safety Analysis Set study 20120215)

|                                          | HC3 (N =51)   | Blinatumomab (N =54)   | Total (N = 105)   |
|------------------------------------------|---------------|------------------------|-------------------|
| Subjects with dose modifications - n (%) | 11 (21.6)     | 14 (25.9)              | 25 (23.8)         |
| Dose changes                             | 11 (21.6)     | 7 (13.0)               | 18 (17.1)         |
| Drug interruptions                       | 0 (0.0)       | 14 (25.9)              | 14 (13.3)         |
| Reason for Dose Change -n (%)            |               |                        |                   |
| Adverse event                            | 3 (5.9)       | 6 (11.1)               | 9 (8.6)           |
| Noncompliance                            | 0 (0.0)       | 0 (0.0)                | (0'0) 0           |
| Dose administration error                | 0 (0.0)       | 0 (0.0)                | 0 (0.0)           |
| Per protocol                             | 7 (13.7)      | 1 (1.9)                | 8 (7.6)           |
| Weight change                            | 0 (0.0)       | 0 (0.0)                | 0 (0.0)           |
| Other                                    | 1 (2.0)       | 1 (1.9)                | 2 (1.9)           |
| Reason for Drug Interruption - n (%)     |               |                        |                   |
| Adverse event                            | (0:0) 0       | 7 (13.0)               | 7 (6.7)           |
| Noncompliance                            | 0 (0.0)       | 0 (0.0)                | 0 (0.0)           |
| Dose administration error                | 0 (0.0)       | 0 (0.0)                | 0 (0.0)           |
| Weight change                            | 0 (0.0)       | 0 (0.0)                | 0 (0.0)           |
| Subject request                          | 0 (0.0)       | 0 (0.0)                | 0 (0.0)           |
| Dose re-instated                         | 0 (0.0)       | 0 (0.0)                | 0 (0.0)           |
| Device complaint                         | 0 (0.0)       | 2 (3.7)                | 2 (1.9)           |
| Compromised IP                           | 0 (0.0)       | 0 (0.0)                | (0'0) 0           |
| Infusion bag emptied prematurely         | 0 (0.0)       | 2 (3.7)                | 2 (1.9)           |
| Other                                    | 0 (0.0)       | 6 (11.1)               | 6 (5.7)           |

Page 1 of 1

N = Number of subjects in the analysis set. n = Number of subjects with observed data.

Reason for drug interuption is recorded for Blinatumomab arm alone. Reasons for drug intemuption may not be mutually exclusive.

Data cut-off date: 17JUL2019

## Program:

/userdata/stat/amg103/onc/20120215/analysis/primary\\_clean/tables/program/t-ex-sum-mod-saf.sas Output:t14-05-002-ex-sum-mod-safrtf(DateGenerated:13FEB20:23:41:19)Source:adam.adsl adam.adex

<div style=\"page-break-after: always\"></div>

Table 52: Summary of Exposure Across Blinatumomab Paediatric ALL Studies (Safety Analysis Set)

|                                                   | Pediatric ALL    | Pediatric ALL      | Pediatric ALL          | Pediatric ALL                                | Pediatric ALL                | Pediatric ALL    |
|---------------------------------------------------|------------------|--------------------|------------------------|----------------------------------------------|------------------------------|------------------|
| Core Study                                        | MT103-205 (N=93) | 20130320 (N = 110) | 20130265 (Peds) (N=26) | MT103-205a 20130320 20130265 (Peds) (N= 228) | 20120215e (Blin arm) (N= 54) | Totala (N = 282) |
| Treatment Exposure (days)                         |                  |                    |                        |                                              |                              |                  |
| n                                                 | 93               | 109                | 26                     | 228                                          | 53d                          | 281              |
| Mean                                              | 40.32            | 44.15              | 40.47                  | 42.17                                        | 26.53                        | 39.22            |
| SD                                                | 32.93            | 30.10              | 26.40                  | 30.84                                        | 6.00                         | 28.55            |
| Median                                            | 28.00            | 31.06              | 39.44                  | 28.12                                        | 27.97                        | 28.01            |
| Q1,Q3                                             | 17.82, 55.80     | 26.72, 55.87       | 21.24, 55.93           | 21.53, 55.86                                 | 27.83, 28.01                 | 27.13, 55.66     |
| Min, Max                                          | 1.6, 146.4       | 3.0, 140.2         | 8.1, 115.0             | 1.6, 146.4                                   | 0.5, 29.4                    | 0.5, 146.4       |
| Number of started cyclesb                         |                  |                    |                        |                                              |                              |                  |
| n                                                 | 93               | 109                | 26                     | 228                                          | 54                           | 282              |
| Mean                                              | 1.7              | 1.8                | 2.1                    | 1.8                                          | 1.0                          | 1.7              |
| SD                                                | 1.1              | 1.0                | 1.4                    | 1.1                                          | 0.0                          | 1.0              |
| Median                                            | 1.0              | 2.0                | 2.0                    | 1.0                                          | 1.0                          | 1.0              |
| Q1,Q3                                             | 1.0, 2.0         | 1.0, 2.0           | 1.0, 2.0               | 1.0, 2.0                                     | 1.0, 1.0                     | 1.0, 2.0         |
| Min,Max                                           | 1,6              | 1,5                | 1,7                    | 1, 7                                         | 1, 1                         | 1,7              |
| Numberof completed cyclesb                        |                  |                    |                        |                                              |                              |                  |
| n                                                 | 63               | 74                 | 17                     | 154                                          | 50                           | 204              |
| Mean                                              | 1.7              | 1.8                | 1.4                    | 1.7                                          | 1.0                          | 1.5              |
| SD                                                | 1.1              | 1.1                | 0.8                    | 1.1                                          | 0.0                          | 1.0              |
| Median                                            | 1.0              | 1.5                | 1.0                    | 1.0                                          | 1.0                          | 1.0              |
| Q1,Q3                                             | 1.0, 2.0         | 1.0, 2.0           | 1.0, 1.0               | 1.0, 2.0                                     | 1.0, 1.0                     | 1.0, 2.0         |
| Min, Max                                          | 1,5              | 1,5                | 1, 4                   | 1,5                                          | 1, 1                         | 1,5              |
| Numberofsubjectswithstudydrug interruptiondueto   | 14 (15.1)        | 25 (22.7)          | 8 (30.8)               | 47 (20.6)                                    | 6 (11.1)                     | 53 (18.8)        |
| treatment-emergent adverseevent-n(%)              |                  |                    |                        |                                              |                              |                  |
| Numberofsubjectswithstudydrugdiscontinuationdueto | 10 (10.8)        | 7 (6.4)            | 2 (7.7)                | 19 (8.3)                                     | 2 (3.7)                      | 21 (7.4)         |
| treatment-emergentadverseevent-n(%)               |                  |                    |                        |                                              |                              |                  |
| Re-treatmentc                                     |                  |                    |                        |                                              |                              |                  |
| Treatment Exposure (days)                         |                  |                    |                        |                                              |                              |                  |
| n                                                 | 2                | 1                  | 0                      | 3                                            | 0                            | 3                |
| Mean                                              | 23.52            | 139.73             |                        | 62.26                                        |                              | 62.26            |
| SD                                                | 6.31             |                    |                        | 67.24                                        |                              | 67.24            |
| Median                                            | 23.52            | 139.73             |                        | 27.98                                        |                              | 27.98            |
| Q1,Q3                                             | 19.06,27.98      | 139.73,139.73      | ，                      | 19.06,139.73                                 |                              | 19.06,139.73     |
| Min, Max                                          | 19.1, 28.0       | 139.7,139.7        | \"                      | 19.1, 139.7                                  |                              | 19.1, 139.7      |

ALL=acutelymphoblasticleukemia;Blin=blinatumomab;HSCT=hematopoieticstem cell transplant;max=maximum;min=minimum;MRD=minimal residual disease;N=Numberof subjectsinthe analysisset;n=Numberofsubjectswithobserveddata;Peds=pediatric;Q1/Q3=quartile1/quartile3

M1:Representative bone marrow aspirate or biopsy with blasts&lt;5%,with satisfactory cellularity and with regenerating hematopoiesis

M3:Representativebone marrow aspirate orbiopsy with≥25%blasts

M2:Representativebonemarrow aspirate orbiopsywith≥5%and&lt;25%blasts

StudyMT103-205:Phase1/2;≥2ndmarrowrelapse,anymarrowrelapseafterallogeneicHSCT,orrefractorytoothertreatments;M3marrow;Blinatumomab5,15,

Study20130320:Expandedaccess;≥2ndmarrowrelapse,any marrowrelapse afterallogeneicHSCT,orrefractory toothertreatments;M3orM2marrowor M1 marrow with an MRD level ≥ 10-3; Blinatumomab 5/15 μg/m2/day (not to exceed 9/28 μg/day) if M3 marrow at screening and 15 μg/m2/day (not to exceed 28 μg/day) if M2marrowor M1 marrowwith anMRDlevel≥10-3 at screeningfor up to5 cycles.

induction and consolidation chemotherapy.

aOnesubjectrolledoverfromMT103-205to20130320wasonly countedoncein thecolumn.Thesubject whichrolledoverfromMT103-205to20130320was countedasreceivingre-treatmentin20130320.

Study20130265:Phase 1b/2;≥2nd marrow relapse, any marrow relapse after allogeneic HSCT,orrefractory to other treatments;M2 or M3 marrow;Blinatumomab 5-15μg/m2/dayforup to5 cycles.

b The number of cycles includes initial and re-started cycles.

d For Study 20120215: Subject 21526002001's exposure was not calculated since dosing was ongoing at the data cutoff date. Subject 21525006003's partial exposure wasevaluateduntillatestdosingbeforethedatacutoffdate.

c Only Study MT103-205 has re-treatment period.

eData cutoffdate:17July2019.

Source:modifiedfromTable14-5.1

<div style=\"page-break-after: always\"></div>

## Adverse events

Table 53: Summary of Treatment-emergent and Treatment-related Adverse Events - Study 20120215 (Safety Analysis Set)

|                                                        | HC3 (N = 51) n (%)   | Blinatumomab (N = 54) n (%)   |
|--------------------------------------------------------|----------------------|-------------------------------|
| All treatment-emergent adverse events - n (%)          | 49 (96.1)            | 54 (100.0)                    |
| Grade ≥ 3                                              | 42 (82.4)            | 31 (57.4)                     |
| Seriousadverseevents                                   | 22 (43.1)            | 13 (24.1)                     |
| Fatal                                                  | 0 (0.0)              | 0 (0.0)                       |
| Leadingtodiscontinuationof investigationalproducta     | 0 (0.0)              | 2 (3.7)                       |
| Leading to interruption of investigational producta    | 2 (3.9)              | 6 (11.1)                      |
| Treatment-related adverse eventsb - n (%)              | 40 (78.4)            | 45 (83.3)                     |
| Grade ≥ 3                                              | 32 (62.7)            | 9 (16.7)                      |
| Seriousadverseevents                                   | 14 (27.5)            | 9 (16.7)                      |
| Fatal                                                  | 0 (0.0)              | 0 (0.0)                       |
| Leading to discontinuation of investigational producta | 0 (0.0)              | 2 (3.7)                       |
| Leading to interruption of investigational producta    | 2 (3.9)              | 5 (9.3)                       |

CTCAE = Common Terminology Criteria for Adverse Events; HC3 = high-risk consolidation 3 chemotherapy N = Number of subjects in the analysis set; n = Number of subjects with observed data.

Grading categories determined using CTCAE version 4.03.

bTreatment-related refers to the assessment of the relationship of dexamethasone, methotrexate,

a Investigational product in the HC3 arm refers to dexamethasone, methotrexate, daunorubicin, erwinase, ifosfamide, asparaginase, and vincristine. Investigational product in the blinatumomab arm refers to blinatumomab.

daunorubicin, erwinase, ifosfamide, asparaginase, and vincristine in the HC3 arm and to the assessment of therelationshipofblinatumomabintheblinatumomabarm.

Datacutoffdate:17July2019

Source:Table12-1of20120215PrimaryAnalysisCSR

<div style=\"page-break-after: always\"></div>

Table 54: Summary of Treatment-Emergent and Treatment-related Adverse Events Across Blinatumomab Paediatric ALL Studies (Safety Analysis Set)

|                                                            | Pediatric ALL     | Pediatric ALL     | Pediatric ALL           | Pediatric ALL                                | Pediatric ALL                | Pediatric ALL   |
|------------------------------------------------------------|-------------------|-------------------|-------------------------|----------------------------------------------|------------------------------|-----------------|
|                                                            | MT103-205 (N= 93) | 20130320 (N= 110) | 20130265 (Peds) (N= 26) | MT103-205* 20130320 20130265 (Peds) (N= 228) | 20120215 (Blin arm)b (N= 54) | Total (N=282)   |
| All treatment-emergent adverse events -n (%)               | 93 (100.0)        | 109 (99.1)        | 26 (100.0)              | 227 (99.6)                                   | 54 (100.0)                   | 281 (99.6)      |
| Grade 23                                                   | 83 (89.2)         | 71 (64.5)         | 24 (92.3)               | 178 (78.1)                                   | 31 (57.4)                    | 209 (74.1)      |
| Serious adverse events                                     | 54 (58.1)         | 50 (45.5)         | 4 (15.4)                | 108 (47.4)                                   | 13 (24.1)                    | 121 (42.9)      |
| Leading to discontinuation of investigational product      | 10 (10.8)         | 7 (6.4)           | 2 (7.7)                 | 19 (8.3)                                     | 2 (3.7)                      | 21 (7.4)        |
| Leading to interruption of investigational product         | 14 (15.1)         | 25 (22.7)         | 8 (30.8)                | 47 (20.6)                                    | 6 (11.1)                     | 53 (18.8)       |
| Fatal adverse events                                       | 13 (14.0)         | 9 (8.2)           | 3 (11.5)                | 25 (11.0)                                    | 0 (0.0)                      | 25 (8.9)        |
| Treatment-related treatment-emergent adverse events -n (%) | 80 (86.0)         | 81 (73.6)         | 22 (84.6)               | 182 (79.8)                                   | 45 (83.3)                    | 227 (80.5)      |
| Grade23                                                    | 56 (60.2)         | 29 (26.4)         | 17 (65.4)               | 102 (44.7)                                   | 9 (16.7)                     | 111 (39.4)      |
| Serious adverse events                                     | 23 (24.7)         | 21 (19.1)         | 0 (0.0)                 | 44 (19.3)                                    | 9 (16.7)                     | 53 (18.8)       |
| Leading to discontinuation of investigational product      | 7 (7.5)           | 4 (3.6)           | 2 (7.7)                 | 13 (5.7)                                     | 2 (3.7)                      | 15 (5.3)        |
| Leading to interruption of investigational product         | 7 (7.5)           | 18 (16.4)         | 7 (26.9)                | 32 (14.0)                                    | 5 (9.3)                      | 37 (13.1)       |
| Fatal adverse events                                       | 1 (1.1)           | 0 (0.0)           | 0 (0.0)                 | 1 (0.4)                                      | 0 (0.0)                      | 1 (0.4)         |

ALL-acutelymphoblasticleukemia;Blin-blinalumomab;CTCAE-CommonTerminologyCriteriaforAdverseEvenls;HSCT-hemalopoieticslemcell transplant;N -Numberof subjeclsin the analysis set;n-Numberof subjeclswith observed dala;MRD-minimal residual disease;Peds-pediatric

M1:Representativebonemarrowaspiraleorbiopsywithblasls5%,withsalisfaclorycellularilyandwilhregeneratinghemalopoiesis

M3:Representativebone marrow aspirale orbiopsy with≥ 25%blasts

M2: Represenlalive bone marrow aspirale or biopsy wilh2 5% and &lt; 25%blasts

Sludy MT103205: Phase 1/2; ≥ 2nd marrow relapse, any marrow relapse after allogeneic HSCT, or relraclory to other trealments; M3 marrow, Blinatumomab 5, 15, 30, 5/15, and 15/30 μg/m²/day (phase 1) and 5/15 μg/m²/day (phase 2) per cycle for up to 5 cycles.

Sludy 20120215: Phase 3; 1relapse; M1 or M2 marrow at the time of randomization. Blinatumomab 15 μg/m²/day (not to exceed 9/28 μg/day) for 1 cycle following induclion and consolidation chemotherapy.

Sludy 20130320:Expanded access;≥2ndmarrowrelapse,anymarrowrelapse aflerallogeneicHSCT,orrelraclory toother trealments;M3orM2marrow or M1 marrow with an MRD level ≥ 10-3: Blinatumomab 5/15 μg/m2/day (not to exceed 9/28 μg/day) if M3 marrow at screening and 15 μg/m2/day (not to exceed 28 μg/day) if M2 marrow or M1 marrowwilh an MRD level ≥10-3al screening for upto 5 cycles.

Sludy 20130265:Phase 1b/2;≥2ndmarrowrelapse,any marrowrelapse afterallogeneicHSCT,orrelraclory toother trealmenls;M2orM3marrow,Blinatumomab 5-15μg/m²/dayforupto5cycles.

Dala culolf dale: 17 July 2019

One subject rolled overfrom MT103-205to 20130320was only counledonce in the column.The subject which rolled overfrom MT103-205to 20130320was countedasreceivingre-lrealmentin20130320.

Severily graded using CTCAE v4.03.

Source:modlfiedfromTable14-6.1

## Common Adverse Events

For the primary analysis of Study 20120215, a summary of the most common (≥ 10% of subjects) adverse events (preferred terms) reported in either treatment arm is presented in the table below.

<div style=\"page-break-after: always\"></div>

Table 55 : Common Adverse Events by Preferred Term Reported for ≥ 10% of Subjects in Either Treatment Arm - Study 20120215 (Safety Analysis Set)

| Preferred Term                                                 | HC3 (N = 51) n(%)   | Blinatumomab (N= 54) n(%)   |
|----------------------------------------------------------------|---------------------|-----------------------------|
| Number of subjects reporting treatment-emergent adverse events | 49 (96.1)           | 54 (100.0)                  |
| Pyrexia                                                        | 10 (19.6)           | 44 (81.5)                   |
| Nausea                                                         | 9 (17.6)            | 22 (40.7)                   |
| Headache                                                       | 9 (17.6)            | 19 (35.2)                   |
| Vomiting                                                       | 11 (21.6)           | 16 (29.6)                   |
| Anaemia                                                        | 23 (45.1)           | 12 (22.2)                   |
| Diarrhoea                                                      | 9 (17.6)            | 11 (20.4)                   |
| Stomatitis                                                     | 28 (54.9)           | 10 (18.5)                   |
| Mucosal inflammation                                           | 4 (7.8)             | 9 (16.7)                    |
| Abdominal pain                                                 | 11 (21.6)           | 7 (13.0)                    |
| Rash                                                           | 4 (7.8)             | 7 (13.0)                    |
| Platelet count decreased                                       | 8 (15.7)            | 7 (13.0)                    |
| Hypokalaemia                                                   | 5 (9.8)             | 7 (13.0)                    |
| Hypertension                                                   | 4 (7.8)             | 7 (13.0)                    |
| Hypotension                                                    | 4 (7.8)             | 7 (13.0)                    |
| Erythema                                                       | 2 (3.9)             | 6 (11.1)                    |
| Pruritus                                                       | 5 (9.8)             | 6 (11.1)                    |
| Hypogammaglobulinaemia                                         | 2 (3.9)             | 6 (11.1)                    |
| Constipation                                                   | 7 (13.7)            | 5 (9.3)                     |
| Neutropenia                                                    | 16 (31.4)           | 5 (9.3)                     |
| Epistaxis                                                      | 7 (13.7)            | 5 (9.3)                     |
| Alanine aminotransferaseincreased                              | 7 (13.7)            | 4 (7.4)                     |
| Thrombocytopenia                                               | 13 (25.5)           | 4 (7.4)                     |
| Febrile neutropenia                                            | 13 (25.5)           | 3 (5.6)                     |

HC3 -high-risk consolidation 3 chemotherapy; MedDRA -Medical Dictionary lor Regulalory Activities

N - Number of subjecls in the analysis set; n - Number of subjecls with observed dala.

Coded using MedDRA version 22.1.

Dala cutoll date: 17 July 2019

Source:Table 12-2 of 20120215Primary Analysis CSR

The safety profile of blinatumomab regarding common Adverse events in the pooled RR ALL paediatric population is reported in table 56.

<div style=\"page-break-after: always\"></div>

Table 56. Common Adverse Events by Preferred Term Reported for &gt;10% of Subjects in Either the Relapsed/Refractory or High-risk First Relapsed ALL Population (Safety Analysis Set)

|                                                              | Pediatric ALL          | Pediatric ALL          | Pediatric ALL                 | Pediatric ALL                                       | Pediatric ALL                      | Pediatric ALL         |
|--------------------------------------------------------------|------------------------|------------------------|-------------------------------|-----------------------------------------------------|------------------------------------|-----------------------|
| Preferred Tem                                                | MT103-205 (N-93) n (%) | 20130320 (N-110) n (%) | 20130265 (Peds) (N- 26) n (%) | MT103-205* 20130320 20130265 (Peds) (N = 228) n (%) | 20120215 (Blin am)b (N - 54) n (%) | Totali (N =282) n (%) |
| Numberof subjecisreporting treatment-emergent adverse events | 93 (100.0)             | 109 (99.1)             | 26 (100.0)                    | 227 (99.6)                                          | 54 (100.0)                         | 281 (99.6)            |
| Pyrexia                                                      | 77 (82.8)              | 92 (83.6)              | 22 (84.6)                     | 190 (83.3)                                          | 44 (81.5)                          | 234 (83.0)            |
| Headache                                                     | 32 (34.4)              | 27 (24.5)              | 8 (30.8)                      | 67 (29.4)                                           | 19 (35.2)                          | 86 (30.5)             |
| Anaemia                                                      | 40 (43.0)              | 20 (18.2)              | 10 (38.5)                     | 70 (30.7)                                           | 12 (22.2)                          | 82 (29.1)             |
| Vomiting                                                     | 25 (26.9)              | 30 (27.3)              | 11 (42.3)                     | 66 (28.9)                                           | 16 (29.6)                          | 82 (29.1)             |
| Nausea                                                       | 28 (30.1)              | 20 (18.2)              | 4 (15.4)                      | 52 (22.8)                                           | 22 (40.7)                          | 74 (26.2)             |
| Cytokine release syndrome                                    | 16 (17.2)              | 22 (20.0)              | 11 (42.3)                     | 49 (21.5)                                           | 2 (3.7)                            | 51 (18.1)             |
| Hypertension                                                 | 26 (28.0)              | 9 (8.2)                | 6 (23.1)                      | 41 (18.0)                                           | 7 (13.0)                           | 48 (17.0)             |
| Abdominal pain                                               | 20 (21.5)              | 12 (10.9)              | 5 (19.2)                      | 37 (16.2)                                           | 7 (13.0)                           | 44 (15.6)             |
| Alanine aminotransferase increased                           | 18 (19.4)              | 11 (10.0)              | 11 (42.3)                     | 40 (17.5)                                           | 4 (7.4)                            | 44 (15.6)             |
| Hypokalaemia                                                 | 22 (23.7)              | 12 (10.9)              | 3 (11.5)                      | 37 (16.2)                                           | 7 (13.0)                           | 44 (15.6)             |
| Cough                                                        | 17 (18.3)              | 19 (17.3)              | 2 (7.7)                       | 38 (16.7)                                           | 4 (7.4)                            | 42 (14.9)             |
| Diarrhoea                                                    | 14 (15.1)              | 10 (9.1)               | 5 (19.2)                      | 29 (12.7)                                           | 11 (20.4)                          | 40 (14.2)             |
| Thrombocytopenia                                             | 22 (23.7)              | 10 (9.1)               | 3 (11.5)                      | 35 (15.4)                                           | 4 (7.4)                            | 39 (13.8)             |
| Febrileneutropenia                                           | 15 (16.1)              | 11 (10.0)              | 9 (34.6)                      | 35 (15.4)                                           | 3 (5.6)                            | 38 (13.5)             |
| Platelet count decreased                                     | 13 (14.0)              | 12 (10.9)              | 6 (23.1)                      | 31 (13.6)                                           | 7 (13.0)                           | 38 (13.5)             |
| Hypotension                                                  | 15 (16.1)              | 14 (12.7)              | 1 (3.8)                       | 30 (13.2)                                           | 7 (13.0)                           | 37 (13.1)             |
| Paininextremily                                              | 17 (18.3)              | 14 (12.7)              | 4 (15.4)                      | 35 (15.4)                                           | 2 (3.7)                            | 37 (13.1)             |

|                                     | Pediatric ALL             | Pediatric ALL            | Pediatric ALL   | Pediatric ALL                                                     | Pediatric ALL                        | Pediatric ALL        |
|-------------------------------------|---------------------------|--------------------------|-----------------|-------------------------------------------------------------------|--------------------------------------|----------------------|
| Preferred Term                      | MT103-205 (N - 93) (%6) u | 20130320 (N - 110) (%) u | (N -26) (96] u  | MT103-205 20130320 20130265(Peds) 20130265 (Peds) (N- 228) (%6) u | 20120215 (Blin arm)b (N - 54) (96] u | Totala (N-282) n (%) |
| Pain                                | 12 (12.9)                 | 18 (16.4)                | 5 (19.2)        | 35 (15.4)                                                         | 1 (1.9)                              | 36 (12.8)            |
| Aspartateaminolransferase increased | 16 (17.2)                 | 7 (6.4)                  | 10 (38.5)       | 33 (14.5)                                                         | 2 (3.7)                              | 35 (12.4)            |
| Back pain                           | 21 (22.6)                 | 10 (9.1)                 | 0 (0.0)         | 31 (13.6)                                                         | 3 (5.6)                              | 34 (12.1)            |
| Neutropenia                         | 13 (14.0)                 | 11 (10.0)                | 5 (19.2)        | 29 (12.7)                                                         | 5 (9.3)                              | 34 (12.1)            |
| Constipation                        | 8 (8.6)                   | 11 (10.0)                | 5 (19.2)        | 24 (10.5)                                                         | 5 (9.3)                              | 29 (10.3)            |
| Stomalilis                          | 5 (5.4)                   | 8 (7.3)                  | 4 (15.4)        | 17 (7.5)                                                          | 10 (18.5)                            | 27 (9.6)             |
| White blood cell count decreased    | 13 (14.0)                 | 5 (4.5)                  | 5 (19.2)        | 23 (10.1)                                                         | 4 (7.4)                              | 27 (9.6)             |
| Fatigue                             | 11 (11.8)                 | 7 (6.4)                  | 5 (19.2)        | 23 (10.1)                                                         | 3 (5.6)                              | 26 (9.2)             |
| Rash                                | 3 (3.2)                   | 12 (10.9)                | 3 (11.5)        | 18 (7.9)                                                          | 7 (13.0)                             | 25 (8.9)             |
| Pruritus                            | 3 (3.2)                   | 7 (6.4)                  | 0 (0.0)         | 10 (4.4)                                                          | 6 (11.1)                             | 16 (5.7)             |
| Mucosal inflammation                | 3 (3.2)                   | 3 (2.7)                  | 0 (0.0)         | 6 (2.6)                                                           | 9 (16.7)                             | 15 (5.3)             |
| Erythema                            | 4 (4.3)                   | 3 (2.7)                  | 0 (0.0)         | 7 (3.1)                                                           | 6 (11.1)                             | 13 (4.6)             |
| Hypogammaglobulinaemia              | 1 (1.1)                   | 3 (2.7)                  | 2 (7.7)         | 6 (2.6)                                                           | 6 (11.1)                             | 12 (4.3)             |

ALL =acute lymphoblastic leukemla; Blin =blnatumomab; CTCAE = Common Teminology Criteria for Adverse Events; HSCT -hematopoletlc stem cell transplant; MedDRA = Medical Dicllonary for Regulalory Affairs; MRD = minimal resldual dlsease; N = Number of subjecis In the analysis sel; n = Number of subjects with observed data; Peds = pedlatric

M1: Representative bone mamow aspirate or biopsy with blasts  5%, with saltistactory cellularity and with regenerating hemalopolesis

Coded using MedDRA verslon 22.1.

M2: Representative bone mamow aspirate or blopsy with ≥ 5%6 and c 25% blasts

Study MT103205: Phase 1/2; ≥2\" marrow relapse, any marrow relapse after allogenelc HSCT, or refractory to other treatments; M3 marrow, Bllnatumomab 5, 15, 30, 5/15, and 15/30 μgim?/day (phase 1) and 5/15 μg/m²/day (phase 2) per cycle for up to 5 cycles.

M3: Representative bone mamow aspirale or blopsy with 2 25%6 blasls

Study 20130320: Expanded access: ≥ 2nd marrow relapse. any mamow relapse aliter allogenelc HSCT, or refractory to other treatments; M3 or M2 mamow or M1 marrow with an MRD level ≥ 102; Blinatumomab 5/15 μg/m?lday (not to exceed 9/28 μg/day) if M3 marrow at screening and 15 μg/m?lday (notto exceed 28 μg/day) if M2 marrow or M1 marrow with an MRD level 2 10~ at screening for up to 5 cycles.

Study 20130265: Phase 1b/2; ≥ 2*dmarrow relapse, any mamow relapse aiter allogenelc HSCT, or refraclory lo other trealments; M2 or M3 marrow, Blinatumomab 5-15 μg/m?/day for up to 5 cycles.

Study 20120215: Phase 3; 1* relapse; M1 or M2 marrow at the time of randomization. Blinatumomab 15 μg/m7/day (not to exceed 9/28 μg/day) for 1 cycle followng Induclion and consolldalion chemotherapy.

One subject rolled over from MT103-205 to 20130320 was only counted once In the column. The subject whlch rolled over from MT103-205 to 20130320 was counted asreceiving re-trealment in 20130320.

bData cutoff date: 17 July 2019

<div style=\"page-break-after: always\"></div>

## TEAEs grade ≥3

For the primary analysis of Study 20120215, a summary of grade ≥ 3 adverse events (≥ 5% of subjects) reported in either treatment arm is presented in the table below.

Table 57 : Grade ≥ 3 Adverse Events by Preferred Term Reported for ≥ 5% of Subjects in Either Treatment Arm - Study 20120215 (Safety Analysis Set)

| Preferred Term                                                           | HC3 (N = 51) n (%)   | Blinatumomab (N= 54) n (%)   |
|--------------------------------------------------------------------------|----------------------|------------------------------|
| Number of subjects reporting grade ≥ 3 treatment-emergent adverse events | 42 (82.4)            | 31 (57.4)                    |
| Anaemia                                                                  | 21 (41.2)            | 8 (14.8)                     |
| Mucosal inflammation                                                     | 0 (0.0)              | 7 (13.0)                     |
| Platelet count decreased                                                 | 8 (15.7)             | 6 (11.1)                     |
| Neutropenia                                                              | 14 (27.5)            | 5 (9.3)                      |
| Thrombocytopenia                                                         | 11 (21.6)            | 4 (7.4)                      |
| Neutrophil count decreased                                               | 2 (3.9)              | 4 (7.4)                      |
| White blood cell count decreased                                         | 1 (2.0)              | 4 (7.4)                      |
| Pyrexia                                                                  | 0 (0.0)              | 3 (5.6)                      |
| Stomatitis                                                               | 16 (31.4)            | 3 (5.6)                      |
| Febrile neutropenia                                                      | 13 (25.5)            | 2 (3.7)                      |
| Aplasia                                                                  | 4 (7.8)              | 2 (3.7)                      |
| Alanine aminotransferase increased                                       | 5 (9.8)              | 1 (1.9)                      |
| Leukopenia                                                               | 3 (5.9)              | 0 (0.0)                      |
| Hypertransaminasaemia                                                    | 3 (5.9)              | 0 (0.0)                      |
| Epistaxis                                                                | 3 (5.9)              | 0 (0.0)                      |

MedDRA - Medical Dictionary for Regulatory Activities; N -- Number of subjecls in the analysis set; n --

CTCAE - Common Terminology Criteria lor Adverse Events; HC3 - high-risk consolidation 3 chemotherapy:

Number of subjecls with observed dala.

Coded using MedDRA version 22.1.

Grading calegories determined using CTCAE version 4.03.

Data cutoll date: 17 July 2019

Source:modified from Table 12-3of20120215Primary Analysis CSR

Table  58.  Grade  3  and  Above  Treatment-Related  Treatment-Emergent  Adverse  Events  by System Organ Class and Preferred Term (Safety Analysis Set)

<div style=\"page-break-after: always\"></div>

<!-- image -->

| System Organ Class Preferred Temm                                                        | HC3 (N=51) n (%)   | Blinatumomab (N = 54) n (%)   |
|------------------------------------------------------------------------------------------|--------------------|-------------------------------|
| Number of subjects reporting grade 3 and above related treatment-emergent adverse events | 32 (62.7)          | 9 (16.7)                      |
| Investigations                                                                           | 10 (19.6)          | 5 (9.3)                       |
| White blood cell count decreased                                                         | 0 (0.0)            | 2 (3.7)                       |
| Aspartate aminotransferase increased                                                     | 0 (0.0)            | 1 (1.9)                       |
| Blood immunoglobulin G decreased                                                         | 0 (0.0)            | 1(1.9)                        |
| Lymphocyte count decreased                                                               | 0 (0.0)            | 1 (1.9)                       |
| Neutrophil count decreased                                                               | 2 (3.9)            | 1(1.9)                        |
| Pancreatic enzymes increased                                                             | 0 (0.0)            | 1 (1.9)                       |
| Alanine aminotransferase increased                                                       | 3 (5.9)            | 0 (0.0)                       |
| Gamma-glutamyltransferase increased                                                      | 1 (2.0)            | 0 (0.0)                       |
| Lipase increased                                                                         | 1 (2.0)            | 0 (0.0)                       |
| Platelet count decreased                                                                 | 6 (11.8)           | 0 (0.0)                       |
| Blood and lymphatic system disorders                                                     | 29 (58.9)          | 2 (3.7)                       |
| Neutropenia                                                                              | 11 (21.6)          | 1 (1.9)                       |
| Thrombocytopenia                                                                         | 9(17.6)            | 1 (1.9)                       |
| Anaemia                                                                                  | 18 (35.3)          | 0 (0.0)                       |
| Febrle bone mamrow aplasia                                                               | 1 (2.0)            | 0 (0.0)                       |
| Febrle neutropenia                                                                       | 8 (15.7)           | 0 (0.0)                       |
| Leukopenia                                                                               | 3 (5.9)            | 0 (0.0)                       |
| Nervous system disorders                                                                 | 0 (0.0)            | 2 (3.7)                       |
| Nervous system disorder                                                                  | 0 (0.0)            | 1 (1.9)                       |
| Seizure                                                                                  | 0 (0.0)            | 1(1.9)                        |
| Vascular disorders                                                                       | 0 (0.0)            | 2 (3.7)                       |
| Hypotension                                                                              | (00) 0             | 1 (1.9)                       |
| Jugular vein thrombosis                                                                  | 0 (0.0)            | 1(1.9)                        |
| Generaldisordersandadministrationsite conditions                                         | 0 (0.0)            | 1 (1.9)                       |
| Pyrexia                                                                                  | 0 (0.0)            | 1 (1.9)                       |

| System Organ Class Preferred Temm               | HC3 (N=51) n (%)   | Blinatumomab (N= 54) n (%)   |
|-------------------------------------------------|--------------------|------------------------------|
| Hepatobiliary disorders                         | 5 (9.8)            | 1 (1.9)                      |
| Hepatocellular injury                           | 0 (0.0)            | 1 (1.9)                      |
| Hepatotoxicity                                  | 1 (2.0)            | 0 (0.0)                      |
| Hypertransaminas3emia                           | 3 (5.9)            | 0 (0.0)                      |
| Liver disorder                                  | 1 (2.0)            | 0 (0.0)                      |
| Infections and infestations                     | 3 (5.9)            | 1(1.9)                       |
| Herpes virus infection                          | 0 (0.0)            | 1 (1.9)                      |
| Bronchilis                                      | 1 (2.0)            | 0 (0.0)                      |
| Diarrhoes infectious                            | 1 (2.0)            | 0 (0.0)                      |
| Eschenichia bacteraemia                         | 1 (2.0)            | 0 (0.0)                      |
| Septic shock                                    | 1 (2.0)            | 0 (0.0)                      |
| Congenital, familial and genetic disorders      | 1 (2.0)            | 0 (0.0)                      |
| Aplasia                                         | 1 (2.0)            | 0 (0.0)                      |
| Gastrointestinal disorders                      | 13 (25.5)          | 0 (0.0)                      |
| Abdominal pain                                  | 1 (2.0)            | 0 (0.0)                      |
| Pancreatitis acute                              | 1 (2.0)            | 0 (0.0)                      |
| Stomatilis                                      | 12 (23.5)          | 0 (0.0)                      |
| Musculoskeletaland connectivetissuedisorders    | 1 (2.0)            | 0 (0.0)                      |
| Back pain                                       | 1 (2.0)            | (00) 0                       |
| Psychiatric disorders                           | 1 (2.0)            | 0 (0.0)                      |
| Confusional siate                               | 1 (2.0)            | 0 (0.0)                      |
| Respiratory, thoracic and mediastinal disorders | 3 (5.9)            | 0 (0.0)                      |
| Epislaxis                                       | 3(5.9)             | 0 (0.0)                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 59. Grade 3 and Above Adverse Events Occurring 31 Days After End of Investigational Product by System Organ Class and Preferred Term (Safety Analysis Set)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| System Orqan Class Prefered Term                    | HC3 (N-51) n (26)   | Blinalumomab (N- 54) (ee) u   |
|-----------------------------------------------------|---------------------|-------------------------------|
| Hyperleukocylosls                                   | (00) o              | 1 (1.9)                       |
| Leukopenla                                          | 1 (2.0)             | 0 (0.0)                       |
| mmune system disorders                              | 8 (15.7)            | 9(16.7)                       |
| Acute graft versus host disease                     | 3(5.9)              | 4 (7.4)                       |
| Graft versus host disease In gastrolntestinal tract | 0 (0.0)             | 2 (3.7)                       |
| Graft versus host disease In skin                   | (oo) o              | 2 (3.7)                       |
| Acule graft versus host disease In skin             | 1 (2.0)             | 1 (1.9)                       |
| Haemophagocytic lymphohistiocytosls                 | 1 (2.0)             | 1 (1.9)                       |
| Acule graft versus host disease In liver            | 1 (2.0)             | (00) 0                        |
| Drug hypersensitivity                               | 1 (2.0)             | (0'0) 0                       |
| Engrafiment syndrome                                | 1 (2.0)             | 0 (0.0)                       |
| Gastrointestinal dlsorders                          | 13 (25.5)           | 8 (14.8)                      |
| Slomatitis                                          | 8 (15.7)            | 5 (9.3)                       |
| Vomlling                                            | 3(5.9)              | 2 (3.7)                       |
| Gastritis                                           | 0 (0.0)             | 1 (1.9)                       |
| Nausea                                              | (00) 0              | 1 (1.9)                       |
| Dlarhoea                                            | 1 (2.0)             | 0 (0.0)                       |
| Enlerils                                            | 1 (2.0)             | (0'0) 0                       |
| Gastrolntestinal haemomhage                         | 2(3.9)              | (0'0) 0                       |
| Gaslrolntestinal Inllammallon                       | 1 (2.0)             | (0'0) 0                       |
| Mouth haemorrhage                                   | 1 (2.0)             | 0 (0.0)                       |
| Oesophageal haemorhage                              | 1 (2.0)             | 0 (0.0)                       |
| nvestigatlons                                       | 7 (13.7)            | 8 (14.8)                      |
| Blood Immunoglobulln G decreased                    | 0 (0.0)             | 2 (3.7)                       |
| Haemoglobln decreased                               | (00l 0              | 2 (3.7)                       |
| Platelet count decreased                            | 4 (7.8)             | 2(3.7)                        |
| Adenovlrus test positive                            | (00)0               | 1 (1.9)                       |
| Blood bilirubln increased                           | (00) 0              | 1 (1.9)                       |
| Cytomegalovlnus test posltive                       | 2(3.9)              | 1 (1.9)                       |
| Staphylococcus test posltive                        | (o0) o              | 1 (1.9)                       |
| Urne analysis abnomal                               | 0 (0.0)             | 1 (1.9)                       |
| Whitebloodcellcount decreased                       | 2(3.9)              | 1 (1.9)                       |

<div style=\"page-break-after: always\"></div>

| Svstem Organ Class Prelemed Tem                     | HC3 (N-51) n (6)   | Blinatumomab (N- 54) n (9)   |
|-----------------------------------------------------|--------------------|------------------------------|
| Alanine aminotransferase Increased                  | 1 (2.0)            | (00) o                       |
| C-reactive proteln Increased                        | 1 (2.0)            | 0 (0.0)                      |
| Epsteln-Barr virus antigen posltive                 | 1 (2.0)            | 0 (0.0)                      |
| Neulrophll count decreased                          | 1 (2.0)            | 0 (0.0)                      |
| General disorders and admnlstratlon site conditions | 11 (21.6)          | 7 (13.0)                     |
| Pyrexla                                             | 2(3.9)             | 4 (7.4)                      |
| Mucosal Inflammation                                | 8 (15.7)           | 3 (5.6)                      |
| Mucosal pain                                        | 0 (0.0)            | 1 (1.9)                      |
| Generallsed oedema                                  | 1 (2.0)            | 0 (0.0)                      |
| Influenza like illness                              | 1 (2.0)            | 0 (0.0)                      |
| Metabollsm and nutiltlon disorders                  | 6 (11.8)           | 5 (9.3)                      |
| Hypokalaemla                                        | 3 (5.9)            | 3 (5.6)                      |
| Hyperkalaemla                                       | 0 (0.0)            | 1 (1.9)                      |
| Hypemalraemla                                       | 0 (0.0)            | 1 (1.9)                      |
| Hypoglycaemla                                       | 0 (0.0)            | 1 (1.9)                      |
| Decreased appelite                                  | 2 (3.9)            | 0 (0.0)                      |
| Hyponalraemla                                       | 1 (2.0)            | 0 (0.0)                      |
| Resplratory, thoraclc and medlastinal dlsorders     | 4 (7.8)            | 4 (7.4)                      |
| Epistaxis                                           | 1 (2.0)            | 2 (3.7)                      |
| Acute resplratory fallure                           | 0 (0.0)            | 1 (1.9)                      |
| Hypoxia                                             | 1 (2.0)            | 1 (1.9)                      |
| Pneumonitis                                         | 1 (2.0)            | 1 (1.9)                      |
| Resplralory fallure                                 | 1 (2.0)            | 0 (0.0)                      |
| Skin and subculaneous tlssue disorders              | 2 (3.9)            | 3 (5.6)                      |
| Petechlae                                           | 2(3.9)             | 2 (3.7)                      |
| Prurtus                                             | 0 (0.0)            | 1 (1.9)                      |
| Vasculardisorders                                   | 2(3.9)             | 3 (5.6)                      |
| Hypertenslon                                        | 1 (2.0)            | 1 (1.9)                      |
| Hypotension                                         | 1 (2.0)            | 1 (1.9)                      |
| Venooccusive disease                                | 0 (0.0)            | 1 (1.9)                      |

<div style=\"page-break-after: always\"></div>

| Syslem Organ Class Prefered Term                                  | HC3 (N-51) n()   | Blinatumomab (N-54) n()   |
|-------------------------------------------------------------------|------------------|---------------------------|
| Hepatobllary disorders                                            | 2 (3.9)          | 2 (3.7)                   |
| Hepalocellular Injury                                             | (0°0) 0          | 1 (1.9)                   |
| Hepalotoxicity                                                    | (00) o           | 1 (1.9)                   |
| Hypertransamnassemla                                              | 1 (2.0)          | 0 (0.0)                   |
| Venooccluslve liver dlsease                                       | 1 (2.0)          | (o'0) 0                   |
| Cardlac disorders                                                 | (00) 0           | 1 (1.9)                   |
| Tachycardla                                                       | 0 (0.0)          | 1 (1.9)                   |
| Injury, poisoning and procedural complicatlons                    | 1 (2.0)          | 1(1.9)                    |
| Transplant fallure                                                | (00) 0           | 1 (1.9)                   |
| Engraft fallure                                                   | 1 (2.0)          | 0 (0.0)                   |
| Neoplasms benlgn, malignant and unspeciled (inc cysts and polyps) | 3(5.9)           | 1(1.9)                    |
| B precursor type acute leukaemla                                  | 2(3.9)           | 1 (1.9)                   |
| Acute lymphocytic leukaemia recurrent                             | 1 (2.0)          | 0 (0.0)                   |
| Nervous system dlisorders                                         | 2(3.9)           | 1 (1.9)                   |
| Hypertonla                                                        | (00) 0           | 1 (1.9)                   |
| Carotld artery occluslon                                          | 1 (2.0)          | 0 (0.0)                   |
| Seizure                                                           | 1 (2.0)          | 0 (0.0)                   |
| Congenital, famillial and genetic disorders                       | 2 (3.9)          | 0 (0.0)                   |
| Aplasla                                                           | 2(3.9)           | 0 (0.0)                   |
| Psychlatric dlsorders                                             | 1 (2.0)          | 0 (0.0)                   |
| Insomnla                                                          | 1 (2.0)          | 0 (0.0)                   |
| Renal and urinary disorders                                       | 1 (2.0)          | 0 (0.0)                   |
| Haematuria                                                        | 1 (2.0)          | 0 (0.0)                   |
| Reproductive system and breast dlsorders                          | 1 (2.0)          | 0 (0.0)                   |
| Vulvovaginal pain                                                 | 1(2.0)           | 0(0.0)                    |

N=Number ofsublecls In the analysls set.n=Number of sublects with observed data.

* AE reporting period starts 31 days alter Investigational product through 90 days alter alloHSCT.

Coded using MedDRA verslon 22.1

Grading calegorles detemlned uslng CTCAE verslon 4.03.

Data cut-off date: 17JUL2019

## Treatment-related Adverse Events

For the primary analysis of Study 20120215, the rate of treatment-related adverse events was comparable (78.4% [40/51] in the HC3 arm; 83.3% [45/54] in the blinatumomab arm).

In the HC3 arm, the related adverse events with a rate ≥ 10 % were stomatitis (41.2 % , 21/51), anemia (35.3 % , 18/51), neutropenia (25.5 % , 13/51), thrombocytopenia (21.6 % ,11/51), and febrile neutropenia (15.7 % , 8/51), and platelet count decreased (13.7 % , 7/51).  In the blinatumomab arm, the related adverse event with a rate ≥ 10 % were pyrexia (55.6 % , 30/54) and headache (18.5 % , 10/54).

Related adverse events more than 10 % higher in the HC3 arm than in the blinatumomab arm were anemia (35.3 % for HC3; 3.7 % for blinatumomab), stomatitis (41.2 % for HC3; 1.9 % for blinatumomab), platelet count decreased (13.7 % for HC3; 0 % for blinatumomab); neutropenia (25.5 % for HC3; 1.9 % for blinatumomab), and thrombocytopenia (21.6 % for HC3; 1.9 % for blinatumomab).  Related adverse events more than 10 % higher in the blinatumomab arm than in the HC3 arm were pyrexia (55.6 % for blinatumomab; 3.9 % for HC3) and headache (18.5 % for blinatumomab; 2.0 % for HC3).

## Relapsed/Refractory ALL Population:

Related adverse events that were more than 10 % higher in the relapsed/refractory ALL population compared with the high-risk first relapsed ALL population include:  Blood and Lymphatic System Disorders (24.6 % ; 56/228 versus 3.7 % ; 2/54); Investigations (31.1 % ; 71/228 versus 16.7 % ; 9/54). By System Organ Class, no related adverse events were more than 10 % higher in the high-risk first

<div style=\"page-break-after: always\"></div>

relapsed ALL population compared with the relapsed/refractory ALL population.  The following had comparable rates between relapsed/refractory and high-risk first relapsed ALL populations:  General Disorders and Administration Site Conditions (62.3 % ; 142/228 versus 59.3 % ; 32/54); Gastrointestinal Disorders, which was comparable between populations (21.5 % ; 49/228 versus 25.9 % ; 14/54); Nervous System Disorders (22.4 % ; 51/228 versus 29.6 % ; 16/54), and Immune System Disorders (20.6 % ; 47/228 versus13.0 % ; 7/54).

In the relapsed/refractory pediatric ALL population, related adverse events with a rate ≥ 10 % were pyrexia (61.8 % ; 141/228), cytokine release syndrome (19.3 % ; 44/228), anemia (11.8 % ; 27/228), headache (12.3 % ; 28/228), and ALT increased (10.5 % ; 24/228).  In the blinatumomab high-risk first relapsed population, adverse events with a rate ≥ 10 % were pyrexia (55.6 % , 30/54) and headache (18.5 % , 10/54).

Cytokine release syndrome (19.3 % for relapsed/refractory; 3.7 % for high-risk first relapsed) was the only related adverse event that was more than 10 % higher in the relapsed/refractory ALL population compared with the high-risk first relapsed ALL population, which may be attributed to a higher percentage of baseline bone marrow blasts in the relapsed/refractory ALL population compared with the high-risk first relapsed ALL population.  No related adverse events were more than 10 % higher in the high-risk first relapsed ALL population compared with the relapsed/refractory ALL population.

## Serious adverse event/deaths/other significant events

## Deaths

An overview of deaths across the blinatumomab pediatric ALL studies is presented below. Across the blinatumomab pediatric ALL studies (N = 282), a total of 96 deaths were reported.  A total of 25 subjects (8.9%) had treatment emergent fatal adverse events.

<div style=\"page-break-after: always\"></div>

Figure 33: Overview of Treatment-emergent Fatal Adverse Events in Across Blinatumomab Pediatric ALL Studies

<!-- image -->

- a One subject rolled over from MT103-205 to 20130320 was only counted once for N. This subject's data from both studies were counted once.

AnalysisCSR;Section12.5of20130265PrimaryAnalysisCSR;Section12.5of20120215Primary AnalysisCSR;Section2.1.3.2ofModule2.7.4,PediatricRelapsed/RefractoryALLFiling

## Other serious TEAEs

For the primary analysis of Study 20120215, a summary of serious adverse events is presented in the table below.

Treatment-related serious adverse events were reported for 27.5% (14/51) of subjects in the HC3 arm and 16.7% (9/54) of subjects in the blinatumomab arm. In the HC3 arm, the most frequently reported treatment-related serious adverse event was febrile neutropenia (11.8% [6/51]). In the blinatumomab arm, the most frequently reported treatment-related serious adverse events were neurological symptom and seizure (each 3.7% [2/54]).

In the HC3 arm, the most frequently reported treatment-related serious adverse events by System Organ Class were in Blood and lymphatic system disorders (17.6% [9/51]).

<div style=\"page-break-after: always\"></div>

Table 60: Serious Adverse Events by Preferred Term - Study 20120215 (Safety Analysis Set)

| Preferred Term                                                         | HC3 (N = 51) n ( % )   | Blinatumoma b (N = 54) n ( % )   |
|------------------------------------------------------------------------|------------------------|----------------------------------|
| Number of subjects reporting treatment-emergent serious adverse events | 22 (43.1)              | 13 (24.1)                        |
| Neurological symptom                                                   | 0 (0.0)                | 2 (3.7)                          |
| Seizure                                                                | 0 (0.0)                | 2 (3.7)                          |
| Nervous system disorder                                                | 0 (0.0)                | 1 (1.9)                          |
| Herpes virus infection                                                 | 0 (0.0)                | 1 (1.9)                          |
| Klebsiella infection                                                   | 0 (0.0)                | 1 (1.9)                          |
| Perineal cellulitis                                                    | 0 (0.0)                | 1 (1.9)                          |
| Blood immunoglobulin G decreased                                       | 0 (0.0)                | 1 (1.9)                          |
| Body temperature increased                                             | 0 (0.0)                | 1 (1.9)                          |
| Neurological examination abnormal                                      | 0 (0.0)                | 1 (1.9)                          |
| Stomatitis                                                             | 2 (3.9)                | 1 (1.9)                          |
| Pyrexia                                                                | 0 (0.0)                | 1 (1.9)                          |
| Accidental overdose                                                    | 0 (0.0)                | 1 (1.9)                          |
| Hypokalaemia                                                           | 0 (0.0)                | 1 (1.9)                          |
| Catheter placement                                                     | 0 (0.0)                | 1 (1.9)                          |
| Hypotension                                                            | 0 (0.0)                | 1 (1.9)                          |
| Headache                                                               | 1 (2.0)                | 0 (0.0)                          |
| Bronchitis                                                             | 1 (2.0)                | 0 (0.0)                          |
| Clostridium difficile colitis                                          | 1 (2.0)                | 0 (0.0)                          |
| Device related infection                                               | 1 (2.0)                | 0 (0.0)                          |
| Escherichia bacteraemia                                                | 1 (2.0)                | 0 (0.0)                          |
| Septic shock                                                           | 1 (2.0)                | 0 (0.0)                          |
| Lipase increased                                                       | 1 (2.0)                | 0 (0.0)                          |
| Pancreatitis acute                                                     | 1 (2.0)                | 0 (0.0)                          |
| Pneumothorax traumatic                                                 | 1 (2.0)                | 0 (0.0)                          |
| Capillary leak syndrome                                                | 1 (2.0)                | 0 (0.0)                          |
| Febrile neutropenia                                                    | 9 (17.6)               | 0 (0.0)                          |
| Leukopenia                                                             | 1 (2.0)                | 0 (0.0)                          |
| Neutropenia                                                            | 3 (5.9)                | 0 (0.0)                          |
| Thrombocytopenia                                                       | 2 (3.9)                | 0 (0.0)                          |
| Hepatotoxicity                                                         | 1 (2.0)                | 0 (0.0)                          |
| Hypertransaminasaemia                                                  | 1 (2.0)                | 0 (0.0)                          |
| Back pain                                                              | 1 (2.0)                | 0 (0.0)                          |
| Acute lymphocytic leukaemia recurrent                                  | 1 (2.0)                | 0 (0.0)                          |

HC3 = high-risk consolidation 3 chemotherapy; MedDRA = Medical Dictionary for Regulatory Activities

N = Number of subjects in the analysis set; n = Number of subjects with observed data.

Coded using MedDRA version 22.1.

Data cutoff date:  17 July 2019

Source:  Table 12-5 of 20120215 Primary Analysis CSR

<div style=\"page-break-after: always\"></div>

Table 61.  Serious Adverse Events by Preferred Term Reported for ≥ 2 % of Subjects in Either the Relapsed/Refractory or High-risk First Relapsed Pediatric ALL Population (Safety Analysis Set)

|                                                                        | Rediatric ALL          | Rediatric ALL            | Rediatric ALL                  | Rediatric ALL                                       | Rediatric ALL                      | Rediatric ALL         |
|------------------------------------------------------------------------|------------------------|--------------------------|--------------------------------|-----------------------------------------------------|------------------------------------|-----------------------|
| Preferred Term                                                         | MT103-205 (6 =N) n (%) | 20130320 (N = 110) n (%) | 20130265 (Peds) (N = 26) n (%) | MT103-205a 20130320 20130265 (Peds) (N = 228) n (%) | 20120215 (Blin arm) (N = 54) n (%) | Jotala (N =282) n (%) |
| Number of subjects reporting serious treatment-emergent adverse events | 54 (58.1)              | 50 (45.5)                | 4 (15.4)                       | 108 (47.4)                                          | 13 (24.1)                          | 121 (42.9)            |
| Neurological symptom                                                   | 0 (0.0)                | 0 (0.0)                  | 0 (0.0)                        | 0 (0.0)                                             | 2 (3.7)                            | 2 (0.7)               |
| Seizure                                                                | 2 (2.2)                | 2 (1.8)                  | 0 (0.0)                        | 4 (1.8)                                             | 2 (3.7)                            | 6 (2.1)               |
| Pyrexia                                                                | 11 (11.8)              | 11 (10.0)                | 0 (0.0)                        | 22 (9.6)                                            | 1 (1.9)                            | 23 (8.2)              |
| Febrile neutropenia                                                    | 8 (8.6)                | 5 (4.5)                  | 0 (0.0)                        | 13 (5.7)                                            | 0 (0.0)                            | 13 (4.6)              |
| Cytokine release syndrome                                              | 7 (7.5)                | 5 (4.5)                  | 0 (0.0)                        | 12 (5.3)                                            | 0 (0.0)                            | 12 (4.3)              |
| Sepsis                                                                 | 4 (4.3)                | 4 (3.6)                  | 2 (7.7)                        | 10 (4.4)                                            | 0 (0.0)                            | 10 (3.5)              |
| Respiratory failure                                                    | 6 (6.5)                | (0'0) 0                  | 0 (0.0)                        | 6 (2.6)                                             | 0 (0.0)                            | 6 (2.1)               |
| Device related infection                                               | 3 (3.2)                | 3 (2.7)                  | 0 (0.0)                        | 6 (2.6)                                             | 0 (0.0)                            | 6 (2.1)               |
| Overdose                                                               | 4 (4.3)                | 0 (0.0)                  | 1 (3.8)                        | 5 (2.2)                                             | 0 (0.0)                            | 5 (1.8)               |
| Acute lymphocytic leukaemia                                            | 0 (0.0)                | 5 (4.5)                  | 0 (0.0)                        | 5 (2.2)                                             | 0 (0.0)                            | 5 (1.8)               |

ALL = acute lymphoblastic leukemia; Blin = blinatumomab; HSCT = hematopoietic stem cell transplant; MedDRA = Medical Dictionary for  Regulatory Affairs; MRD = minimal residual disease; N = Number of subjects in the analysis set; n = Number of subjects with observed data; Peds = pediatric

Coded using MedDRA version 22.1.

Severity graded using CTCAE v4.03.

M1:  Representative bone marrow aspirate or biopsy with blasts &lt; 5 % , with satisfactory cellularity and with regenerating hematopoiesis

- M2:  Representative bone marrow aspirate or biopsy with ≥ 5 % and &lt; 25 % blasts

M3:  Representative bone marrow aspirate or biopsy with ≥ 25 % blasts

Study MT103-205: Phase 1/2; ≥ 2 nd  marrow relapse, any marrow relapse after allogeneic HSCT, or refractory to other treatments; M3 marrow; Blinatumomab 5, 15, 30, 5/15, and 15/30 μg/m 2 /day (phase 1) and 5/15 μg/m 2 /day (phase 2) per cycle for up to 5 cycles.

Study  20130320:    Expanded  access; ≥ 2 nd   marrow  relapse,  any  marrow  relapse  after  allogeneic  HSCT,  or  refractory  to  other treatments; M3 or M2 marrow or M1 marrow with an MRD level ≥ 10 -3 ; Blinatumomab 5/15 μg/m 2 /day (not to exceed 9/28 μg/day) if M3 marrow at screening and 15 μg/m 2 /day ( not to exceed 28 μg/day) if M2 marrow or M1 marrow with an MRD level ≥ 10 -3  at screening for up to 5 cycles.

Study 20120215:  Phase 3; 1 st relapse; M1 or M2 marrow at the time of randomization. Blinatumomab 15 μg/m 2 /day (not to exceed 9/28 μg/day) for 1 cy cle following induction and consolidation chemotherapy.

Study 20130265:  Phase 1b/2; ≥ 2 nd  marrow relapse, any marrow relapse after allogeneic HSCT, or refractory to other treatments; M2 or M3 marrow; Blinatumomab 515 μg/m 2 /day for up to 5 cycles.

a  One subject rolled over from MT103-205 to 20130320 was only counted once in the column. The subject which rolled over from MT103-205 to 20130320 was counted as receiving re-treatment in 20130320.

b  Data cutoff date:  17 July 2019

<div style=\"page-break-after: always\"></div>

Other Significant Adverse Events

Table  62:  Adverse  Events Leading  to  Treatment  Interruptions by  Preferred  Term  -  Study 20120215 (Safety Analysis Set)

| Preferred Term                                                                                             | HC3 (N =51) n (%)   | Blinatumomab (N = 54) n (%)   |
|------------------------------------------------------------------------------------------------------------|---------------------|-------------------------------|
| Number of subjectsreporting treatment-emergent adverse eventsleadingtointerruptionofinvestigationalproduct | 2 (3.9)             | 6 (11.1)                      |
| Neurological symptom                                                                                       | 0 (0.0)             | 2 (3.7)                       |
| Seizure                                                                                                    | 0 (0.0)             | 1 (1.9)                       |
| Abdominal pain                                                                                             | 0 (0.0)             | 1 (1.9)                       |
| Accidental overdose                                                                                        | 0 (0.0)             | 1 (1.9)                       |
| Neurologicalexaminationabnormal                                                                            | 0 (0.0)             | 1 (1.9)                       |
| Hepatotoxicity                                                                                             | 1 (2.0)             | 0 (0.0)                       |
| Agitation                                                                                                  | 1 (2.0)             | 0 (0.0)                       |
| Anxiety                                                                                                    | 1 (2.0)             | 0 (0.0)                       |
| Confusional state                                                                                          | 1 (2.0)             | 0 (0.0)                       |

HC3 =high-risk consolidation 3 chemotherapy; MedDRA = Medical Dictionary for Regulatory Activities

N = Number of subjects in the analysis set; n = Number of subjects with observed data.

InvestigationalproductintheHC3armreferstodexamethasone,methotrexate,daunorubicin,erwinase, ifosfamide, asparaginase and vincristine. Investigational product in the blinatumomab arm refers to blinatumomab.

CodedusingMedDRAversion22.1.

Datacutoffdate:17July2019

Source:Table12-4of20120215PrimaryAnalysisCSR

Table  63:  Adverse  Events  Leading  to  Treatment  Discontinuations  by  Preferred  -Study 20120215 (Safety Analysis Set)

| PreferredTerm                                              | HC3 (N = 51) n (%)   | Blinatumomab (N = 54) n (%)   |
|------------------------------------------------------------|----------------------|-------------------------------|
| Numberofsubjectsreportingtreatment-emergentadverseeventsof | 0 (0.0)              | 2 (3.7)                       |
| interestleadingtodiscontinuationofinvestigationalproduct   |                      |                               |
| Nervoussystemdisorder                                      | 0 (0.0)              | 1 (1.9)                       |
| Seizure                                                    | 0 (0.0)              | 1 (1.9)                       |

HC3=high-risk consolidation3 chemotherapy;MedDRA=Medical Dictionary for Regulatory Activities; N = Number ofsubjects intheanalysisset; n=Number of subjectswith observed data.

InvestigationalproductintheHC3armreferstodexamethasone,methotrexate,daunorubicin,erwinase, ifosfamide,asparaginase andvincristine.Investigational product intheblinatumomabarmrefers to blinatumomab.

CodedusingMedDRAversion22.1.

Datacutoffdate:17July2019

Source:Table14-6.6.3of20120215PrimaryAnalysisCSR

<div style=\"page-break-after: always\"></div>

## Events of Interest

Key  risks  for  the  blinatumomab  paediatric  program  include  neurologic  events,  cytokine  release syndrome, and medication errors. The full list of EOIs is provided below.

Table 64: Event of Interest, Search Strategy, and Search Scope

| Event of Interest                                 | Search Strategy                                                     | EOl Search Scope                                                                                           |
|---------------------------------------------------|---------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| Capillary Leak Syndrome Cytokine Release Syndrome | Capillary leak syndrome (AMQ) Cytokine release syndrome (AMQ)       | Narrow Narrow                                                                                              |
| Decreased Immunoglobulins                         | Decreased immunoglobulins (AMQ)                                     | Narrow                                                                                                     |
| Elevated Liver Enzyme                             | Liver related investigations, signs and symptoms (SMQ)              | Narrow                                                                                                     |
| Embolic and thrombotic events                     | Embolic and thrombotic events (SMQ)                                 | Narrow                                                                                                     |
| Immunogenicity Infections                         | Immunogenicity (AMQ) Infections and infestations (SOC)              | Narrow Infections and                                                                                      |
| Infusion Reactions without considering duration   | Infusion reaction (AMQ)                                             | infestations (SOC) Narrowsearch with event onset within 48 hours of drug start and no duration restriction |
| Leukoencephalopathy                               | Progressive multifocal                                              | Broad (including all terms)                                                                                |
| Medication Errors                                 | leukoencephalopathy (AMQ) Medication Errors (SMQ)                   | Broad (including all terms)                                                                                |
| Neurologic Events                                 | Central neuropsychiatric events due to direct neurotoxicities (AMQ) | Narrow                                                                                                     |
| Neutropenia and Febrile                           | Neutropenia (AMQ)                                                   | Narrow                                                                                                     |
| Pancreatitis                                      | Acute pancreatitis (SMQ)                                            | Narrow                                                                                                     |
| Tumor Lysis Syndrome                              | Tumor lysis syndrome (SMQ)                                          | Narrow                                                                                                     |

System Organ Class

Source:Table 2ofiSAP

In  study  20120215,  no  subjects  had  events  of  tumor  lysis  syndrome,  leukoencephalopathy,  or immunogenicity.

- Neurologic Adverse Events

The  analysis  of  adverse  events  suggestive  of  neurologic  and  psychiatric  events  was  based  on  a comprehensive search of sponsor-defined (AMQ) high-level arm terms from Nervous Systems Disorders and Psychiatric Disorders System Organ Classes.

Neurologic events were reported at a more than a 10 % higher rate in the blinatumomab treatment arm (48.1 % , n = 26) compared with the HC3 treatment arm (29.4 % , n = 15).

<div style=\"page-break-after: always\"></div>

Table 65: Neurologic AEs -TEAE of Interest by Preferred Term (Safety Analysis Set -)

<!-- image -->

| Event of Interest Preferred Temm                                           | HC3 (N=51) n (7%6)   | Blinatumomab (N= 54) n (%%)   |
|----------------------------------------------------------------------------|----------------------|-------------------------------|
| Number of subjecis reporting treatment-emergent adverse events of interest | 45 (88.2)            | 52 (96.3)                     |
| Neurologic events (Narow)                                                  | 15 (29.4)            | 26 (48.1)                     |
| Headache                                                                   | 9 (17.6)             | 19 (35.2)                     |
| Tremor                                                                     | 0 (0.0)              | 5 (9.3)                       |
| Agitation                                                                  | 1 (2.0)              | 4 (7.4)                       |
| Anxiety                                                                    | 2 (3.9)              | 2 (3.7)                       |
| Depression                                                                 | 1 (2.0)              | 2 (3.7)                       |
| Nenvous system disorder                                                    | 0 (0.0)              | 2 (3.7)                       |
| Neurological symptom                                                       | 0 (0.0)              | 2 (3.7)                       |
| Seizure                                                                    | 0 (0.0)              | 2 (3.7)                       |
| Depressed mood                                                             | 1 (2.0)              | 1 (1.9)                       |
| Dizziness                                                                  | 1 (2.0)              | 1 (1.9)                       |
| Encephalopathy                                                             | 0 (0.0)              | 1 (1.9)                       |
| Imitability                                                                | 1 (2.0)              | 1 (1.9)                       |
| Neuralgia                                                                  | 1 (2.0)              | 1 (1.9)                       |
| Confusional state                                                          | 1 (2.0)              | 0 (0.0)                       |
| Insomnia                                                                   | 1 (2.0)              | 0 (0.0)                       |
| Petit mal epilepsy                                                         | 1 (2.0)              | 0 (0.0)                       |

The median time to onset of neurologic events was earlier in blinatumomab arm (2.5 days; range:  1 to 51 days) compared with the HC3 arm (8.0 days; range:  1 to 46 days).  In the blinatumomab arm, a total of 52 neurologic events were reported, of which 45 events (86.5 % ) resolved.  In the HC3 arm, a total  of  25 neurologic events were reported, of which 23 events (92.0 % )  resolved.  For the resolved events,  the  median  time  to  event  resolution  was  2.5 days  (range:  1, 46 days)  for  subjects  in  the blinatumomab arm and 6.0 days (range:  1, 256 days) for subjects in the HC3 arm.

One subject (2.0 % ) in the HC3 arm and 3 subjects (5.6 % ) in the blinatumomab arm had neurologic events that were grade ≥ 3 in severity.  In the HC3 arm, the grade ≥ 3 event was confusional state. In the blinatumomab arm, the grade ≥ 3 events were nervous system disorder, seizure, and neuralgia (each in 1 subject [1.9 % ]).  The time to onset for grade ≥ 3 neurologic events was 3.0 days for the subject in the HC3 arm and 2.0 days (range:  2 to 54 days) for subjects in the blinatumomab arm.  In the HC3 arm, the 1 event resolved as of the cutoff date.  In the blinatumomab arm, 2 events resolved, and 1 event were unresolved as of the cutoff  date.  For the resolved grade ≥ 3  events,  the  time  to  event resolution was 3 days for the 1  subject in the HC3 arm and 1 and  2 days for the 2 subjects in the blinatumomab arm.

One subject (2.0 % ) in the HC3 arm and 5 subjects (9.3 % ) in the blinatumomab arm had neurological events that were deemed serious.  By preferred term, the serious adverse events were headache (2.0 % , n = 1) in the HC3 arm and neurological symptom and seizure (3.7 % , n = 2 for each), and nervous system disorder (1.9 % , n = 1) in the blinatumomab arm.  All events resolved.  The rates of neurologic events that led to treatment interruption and discontinuation were 2.0 % and 0 % , respectively, in the HC3 arm and 5.6 % and 3.7 % , respectively, in the blinatumomab arm.

## · Cytokine Release Syndrome (CRS)

One subject (2.0%) in the HC3 arm and 2 subjects (3.7%) in the blinatumomab arm had CRS. The time to onset was 30 days for 1 subject in the HC3 arm and 1 and 2 days for 2 subjects in the blinatumomab arm. All 3 events resolved; the time to resolution was 3.0 days for 1 subject in the HC3 arm and 3 and 7 days for 2 subjects in the blinatumomab arm. No events were deemed grade ≥ 3 or serious adverse events.

## · Medication errors

<div style=\"page-break-after: always\"></div>

No subjects (0.0 % ) in the HC3 arm and 1 subject (1.9 % ) in  the blinatumomab arm had a medication error.  The event was grade 2 accidental overdose, deemed serious by the investigator, and resolved. No adverse events were reported in association with the accidental overdose.

- Infections

Events of interest are defined as any adverse events in the Infections and Infestations System Organ Class.  For the assessment of opportunistic infections, a definition of opportunistic infection was applied that was  consistent with infections that occur with increased frequency  or  severity  among immunocompromised patients such as HSCT recipients, which was performed across the blinatumomab pediatric ALL studies.

In the System Organ Class of Infections and Infestations, events were reported at a more than a 10 % higher rate in the blinatumomab treatment arm (42.6 % , n = 23) compared with the HC3 treatment arm (31.4 % , n = 16).  The most frequently reported ( ≥ 3 subjects) infections by preferred term were rhinitis (9.8 % , n = 5 for HC3; 1.9 % , n = 1 for blinatumomab), nasopharyngitis (2 % , n = 1 for HC3; 5.6 % , n = 3 for blinatumomab), and paronychia (0 % for HC3; 5.6 % , n = 3 for blinatumomab).  The median time to onset of infections was earlier for subjects in the HC3 arm (10.5 days, range:  1 to 36 days) compared with subjects in the blinatumomab arm (34.0 days, range:  14 to 58 days).  In the HC3 arm, all 27 infections resolved.  In the blinatumomab arm, 42 of 45 (93.3 % ) infections resolved.   For the resolved events, the median time to event resolution was earlier for subjects in the HC3 arm (8.5 days, range: 2 to 48 days) than for subjects in the blinatumomab arm (23.0 days, range:  1 to 274 days).

The rate of grade ≥ 3 infections was more than 5 % higher for the blinatumomab arm (18.5 % , n = 10) compared with the HC3 arm (9.8 % , n = 5).  By preferred term, no grade ≥ 3 infections were reported in &gt; 1 subject in either treatment arm.  The median time to onset for grade ≥ 3 infections was earlier for subjects in the HC3 arm (13.0 days, range:  4 to 31 days) compared with subjects in the blinatumomab arm (52.5 days, range:  14 to 61 days).  In the HC3 arm, all 7 grade ≥ 3 infections resolved.  In the blinatumomab arm, 12 of 14 (85.7 % ) of grade ≥ 3 infections resolved. For the resolved grade ≥ 3 events, the median time to event resolution was 12.0 days (range:  5 to 33 days) for subjects in the HC3 arm and 16.5 days (range:  4 to 72 days) for subjects in the blinatumomab arm.  The higher incidence of grade ≥ 3 infections in the blinatumomab arm could be explained by the adverse event reporting period ending  30 days after last dose of investigational product. This period ended later for blinatumomab patients due to the duration of administration, often overlapping with subsequent anti-cancer therapy.

A post hoc analysis showed that the time from last dose of investigational product to allogeneic HSCT was 2 times earlier for subjects who received blinatumomab (mean 0.9 months) compared with subjects who  received  HC3  (mean  1.95  months).    Therefore,  any  infections  associated  with  transplant conditioning treatment were more likely reported in the blinatumomab arm since adverse event were reported up to 30 days following last dose of investigational treatment.  An additional post hoc analysis showed that the rates of infections were similar (31.4 % for HC3; 29.4 % for blinatumomab) when the reporting  time  was  on  or  before  the  safety  follow-up  visit  (ie,  before  the  start  of  the  allogeneic conditioning).    The  rates  of  grade ≥ 3  infections  were  also  similar  (9.8 % for  HC3;  13.0 % for blinatumomab) when reported on or before the safety follow-up visit. Specifically, 7 of 10 grade ≥ 3 infections in the  blinatumomab arm and 0 of  5 grade ≥ 3  infections  in  the  HC3  arm  occurred after receiving allogeneic HSCT preparative regimens (data on file).

Four subjects (7.8 % ) in the HC3 arm and 3 subjects (5.6 % ) in the blinatumomab arm had infections that were deemed serious.  By preferred term, no serious adverse event was reported in &gt; 1 subject and all serious adverse events resolved. No infections led to treatment interruption and discontinuation in either treatment arm.  No infections were fatal.

- Elevated Liver Enzymes

<div style=\"page-break-after: always\"></div>

Identification of elevated liver enzyme events was based on the narrow search strategy for the MedDRA SMQ Liver-related Investigations, Signs and Symptoms.

In addition to the narrow search, all potential cases of drug-induced liver injury were identified initially by applying the Hy's law laboratory criteria (ALT or AST ≥ 3.0 x upper limit of normal [ULN]; total bilirubin ≥ 2.0 x ULN; alkaline phosphatase &lt; 2.0 x ULN) to liver parameters reported to have occurred at any time during treatment.

Elevated liver enzyme events were reported at a more than a 10 % higher rate in the HC3 treatment arm (29.4 % , n = 15) compared with the blinatumomab treatment arm (13.0 % , n = 7). The most frequently reported ( &gt; 2 subjects) elevated liver enzymes events were increased ALT (13.7 % , n = 7 for HC3; 7.4 % , n = 4  for  blinatumomab),  increased  AST  (9.8 % ,  n = 5 for  HC3;  3.7 % ,  n = 2  for  blinatumomab), hypertransaminasemia (7.8 % , n = 4 for HC3; 1.9 % , n = 1 for blinatumomab), and increased gamma-glutamyltransferase (GGT) (3.9 % , n = 2 for HC3; 1.9 % , n = 1 for blinatumomab).

Grade ≥ 3  elevated liver enzyme events were reported at a more than 10 % higher rate in the HC3 treatment arm (17.6 % , n = 9) compared with the blinatumomab treatment arm (5.6 % , n = 3).  The most frequently reported ( &gt; 2 subjects) elevated liver enzyme events that were grade ≥ 3 in severity were increased ALT (9.8 % , n = 5 for HC3; 1.9 % , n = 1 for blinatumomab), hypertransaminasemia (5.9 % , n = 3  for  HC3;  0 % for  blinatumomab),  and  increased  GGT  (3.9 % ,  n = 2  for  HC3;  1.9 % ,  n = 1  for blinatumomab).  No events were fatal.

One subject (2.0 % ) in the HC3 arm had elevated liver enzyme event of hypertransaminasemia that was deemed serious; this event resolved. No subjects in either arm had elevated liver enzyme events that led to treatment interruption or discontinuation.

No  subjects  met  the  laboratory  criteria  of  Hy's  law  before  treatment  of  protocol-specified  therapy. Overall, 7.8 % of subjects (4/51) in the HC3 arm and 1.9 % of subjects (1/52) in the blinatumomab arm met the biochemical criteria of Hy's law at any time during treatment.

For  the  1  subject  in  the  blinatumomab  arm,  none  of  the  laboratory  values  were  elevated  during treatment.  The laboratory value criteria were met after completion of treatment with blinatumomab, between 45 days to 6 months after allogeneic HSCT.  Therefore, this subject did not meet the definitive criteria of the Hy's law during treatment.

For the 4 subjects in  the HC3 arm, not all the laboratory criteria were met during treatment.  The laboratory value criteria were met on day 29 for 1 subject and during post-HSCT period to the end of study for 3 subjects.  All 4 subjects had ≥ 1 elevated Hy's law laboratory parameter at baseline.  Elevation of laboratory parameters were episodic, did not show a discernable pattern of occurrence and did not appear to lead to progressive liver injury.  Therefore, these subjects did not meet the definitive criteria for Hy's law.

<div style=\"page-break-after: always\"></div>

Table 66.  Summary of Potential Hy's Law Cases - Study 20120215 (Safety Analysis Set)

|                                                                  | HC3 (N = 51) n/N1 ( % )   | Blinatumoma b (N = 54) n/N1 ( % )   |
|------------------------------------------------------------------|---------------------------|-------------------------------------|
| Pre-infusion                                                     |                           |                                     |
| ALT or AST > 3x ULN                                              | 21/51 (41.2)              | 14/54 (25.9)                        |
| TBL ≥ 2x ULN                                                     | 0/51 (0.0)                | 0/54 (0.0)                          |
| ALP < 2x ULN                                                     | 39/47 (83.0)              | 39/54 (72.2)                        |
| (ALT or AST) > 3x ULN & TBL ≥ 2x ULN & ALP < 2x ULN any day      | 0/47 (0.0)                | 0/54 (0.0)                          |
| (ALT or AST) > 3x ULN & TBL ≥ 2x ULN & ALP < 2x ULN within 1 day | 0/47 (0.0)                | 0/54 (0.0)                          |
| On-study                                                         |                           |                                     |
| ALT or AST > 3x ULN                                              | 30/51 (58.8)              | 19/53 (35.8)                        |
| TBL ≥ 2x ULN                                                     | 6/51 (11.8)               | 1/53 (1.9)                          |
| ALP < 2x ULN                                                     | 46/51 (90.2)              | 45/52 (86.5)                        |
| (ALT or AST) > 3x ULN & TBL ≥ 2x ULN & ALP < 2x ULN any day      | 4/51 (7.8)                | 1/52 (1.9)                          |
| (ALT or AST) > 3x ULN & TBL ≥ 2x ULN & ALP < 2x ULN within 1 day | 1/51 (2.0)                | 0/52 (0.0)                          |

ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; HC3 = high-risk consolidation 3 chemotherapy; n = number of subjects who met criteria. N1 = number of subjects with available data; TBL = total bilirubin; ULN = upper limit of normal.

Data cutoff date:  17 July 2019.

Source:  Table 14-7.10 of 20120215 Primary Analysis CSR

## · Embolic and Thrombotic Events

Adverse events suggestive of venous thrombosis and thromboembolic events were based on the narrow search strategy for the MedDRA SMQ Embolic and Thrombotic Events.

No subjects in the HC3 arm and 4 subjects (7.4 % ) in the blinatumomab arm had embolic and thrombotic events.  The adverse events were device occlusion, disseminated intravascular coagulation, jugular vein thrombosis, and veno-occlusive disease (1.9 % , n = 1 for each).  Two subjects had grade ≥ 3 events. Grade ≥ 3 events include veno-occlusive disease (1.9 % , n = 1) and jugular vein thrombosis (1.9 % , n = 1).  No subject had embolic and thrombotic events that were deemed serious, fatal, or led to treatment interruption or discontinuation.

## · Infusion Reactions

Potential infusion-related adverse events were identified by applying an AMQ narrow search strategy of preferred terms likely associated with infusion reactions.  Since an infusion reaction could represent a broad spectrum of signs and symptoms occurring within a close proximity of an infusion, many preferred terms may represent adverse events that are not an infusion related reaction.  A preferred term was considered to be an infusion reaction if it occurred within 48 hours of the infusion.

Infusion reactions were reported at a more than a 10 % higher rate for the blinatumomab treatment arm (68.5 % , n = 37) compared with the HC3 treatment arm (7.8 % , n = 4).  This is most likely explained by the dosing regimens of the 2 treatments, as blinatumomab is infused for a much longer duration than

<div style=\"page-break-after: always\"></div>

HC3.  Blinatumomab is administered as a continuous intravenous (IV) infusion over 28 days, while the chemotherapy components of HC3 are administered by IV on over 7 days.

The most frequently reported infusions reactions reported in ≥ 5 % in either treatment arm were pyrexia (0 % in HC3; 63.0 % , n = 34 in blinatumomab) and hypotension (0 % in HC3; 7.4 % , n = 4 blinatumomab).

No subjects in the HC3 arm and 2 subjects (3.7 % ) in the blinatumomab arm had an infusion reaction that was grade ≥ 3 in severity.  The adverse events were hypotension and pyrexia.  No infusion reactions were fatal.

No subjects in the HC3 arm and 1 subject (1.9 % ) in the blinatumomab arm had an infusion reaction (pyrexia)  that  was  deemed  serious;  this  event  resolved.  No  infusion  reactions  led  to  treatment interruption or discontinuation in either treatment arm.

## · Neutropenia and Febrile Neutropenia

Neutropenia events are based on the sponsor-defined narrow search strategy.

Neutropenia events were reported at a more than 10 % higher rate for the HC3 treatment arm (54.9 % , n = 28) compared with the blinatumomab treatment arm (22.2 % , n = 12). The neutropenia events were neutropenia (31.4 % , n = 16 for HC3; 9.3 % , n = 5 for blinatumomab), febrile neutropenia (25.5 % , n = 13 for HC3; 5.6 % , n = 3 for blinatumomab), and decreased neutrophil count (3.9 % , n = 2 for HC3; 9.3 % , n = 5 for blinatumomab).

The rate of grade ≥ 3 neutropenia events was more than 10 % higher in the HC3 arm (52.9 % , n = 27) compared with the blinatumomab arm (20.4 % , n = 11). The grade ≥ 3 events were neutropenia (27.5 % , n = 14 for HC3; 9.3 % , n = 5 for blinatumomab), febrile neutropenia (25.5 % , n = 13 for HC3; 3.7 % , n = 2 for  blinatumomab]),  and  decreased  neutrophil  count  (3.9 % ,  n = 2  for  HC3;  7.4 % ,  n = 4  for blinatumomab).  No neutropenia events in either treatment arm were fatal.

Twelve subjects (23.5 % ) in the HC3 arm and no subjects in the blinatumomab arm had neutropenia events that were deemed serious.  The serious adverse events reported for subjects who received HC3 were  febrile  neutropenia  (17.6 % ,  n = 9)  and  neutropenia  (5.9 % ,  n = 3).    All  events  resolved.    No neutropenia events in either treatment arm led to treatment interruption or discontinuation.

- Capillary Leak Syndrome (CLS)

One subject (2.0%) in the HC3 arm and 0 subjects (0.0%) in the blinatumomab arm had capillary leak syndrome events of interest. The event was deemed as grade 4 in severity and serious, and it resolved.

## · Pancreatitis

One subject (2.0%) in the HC3 arm and 0 subjects (0.0%) in the blinatumomab arm had pancreatitis. This event of acute  pancreatitis was deemed grade 3 and serious adverse event of interest, and it resolved.

## · Decreased Immunoglobulins

Decreased immunoglobulin events were reported at similar rate in the HC3 treatment arm (11.8 % , n = 6)  compared  with  the  blinatumomab  arm  (16.7 % ,  n = 9).  Decreased  immunoglobulin  events  were hypogammaglobulinemia  (3.9 % ,  n = 2  for  HC3;  11.1 % ,  n = 6  for  blinatumomab),  decreased  blood immunoglobulin G  (3.9 % ,  n = 2  for  HC3;  1.9 % ,  n = 1  for  blinatumomab),  decreased  globulins  (n = 0 subjects for HC3; 1.9 % , n = 1 for blinatumomab), decreased immunoglobulins (3.9 % , n = 2 for HC3; 1.9 % , n = 1 for blinatumomab).

The rates of grade ≥ 3 decreased immunoglobulin events were comparable between treatment arms: 2.0 % in  the  HC3  arm;  1.9 % in  the  blinatumomab  arm.    The  adverse  events  were  decreased

<div style=\"page-break-after: always\"></div>

immunoglobulin for the subject in the HC3 arm and decreased blood immunoglobulin G for the subject in the blinatumomab arm.  No events were fatal in either treatment arm.

One subject (1.9 % ) in the blinatumomab arm had an event of decreased blood immunoglobulin G that was  deemed  serious;  this  event  resolved.    No  decreased  immunoglobulin  events  led  to  treatment interruption or discontinuation.

In summary, a review of decreased immunoglobulin events did not reveal any additional safety concerns for subjects who received blinatumomab

## Minimum Critical Toxicities

Minimum  critical  toxicities  for  this  variation  application  include  bone  marrow  toxicity  (cytopenias), hepatotoxicity,  nephrotoxicity,  and  torsade  de  pointes/QT  prolongation,  cardiac  arrhythmias,  and convulsion.

- -Bone  marrow  toxicity  was  assessed  using  the  MedDRA  SMQ  hematopoietic  cytopenias  narrow search;
- -Hepatotoxicity was assessed using the MedDRA SMQ drug-related hepatic disorders narrow search. A review of potential hepatotoxicity was performed by Hy's law criteria;
- -Nephrotoxicity  was  assessed  by  reviewing  adverse  events  with  preferred  terms  reported  in  the MedDRA SMQ acute renal failure and Renal and Urinary Disorders System Organ Class;
- -QT prolongation was assessed by review of adverse events using the MedDRA SMQs of torsade de pointes/QT prolongation, cardiac arrhythmias, and convulsion (narrow searches).

<div style=\"page-break-after: always\"></div>

- Bone marrow toxicity

Table 67: Treatment-Emergent Adverse Events of Interest by System Organ Class and Preferred Term in Descending Frequency Bone Marrow Toxicity (Hematopoietic Cytopenias) (Narrow) (Safety Analysis Set)

| SystemOrganClass Preferred Term                                                       | HC3 (N = 51) n (%)   | Blinatumomab (N = 54) n (%)   |
|---------------------------------------------------------------------------------------|----------------------|-------------------------------|
| Number of subjects reporting Bone Marrow Toxicity (Hematopoietic Cytopenias) (Narrow) | 36 (70.6)            | 20 (37.0)                     |
| Blood and lymphaticsystemdisorders                                                    | 34 (66.7)            | 14 (25.9)                     |
| Neutropenia                                                                           | 16 (31.4)            | 5 (9.3)                       |
| Thrombocytopenia                                                                      | 13 (25.5)            | 4 (7.4)                       |
| Febrile neutropenia                                                                   | 13 (25.5)            | 3 (5.6)                       |
| Aplastic anaemia                                                                      | 0 (0.0)              | 1 (1.9)                       |
| Febrile bone marrow aplasia                                                           | 1 (2.0)              | 1 (1.9)                       |
| Cytopenia                                                                             | 2 (3.9)              | 0 (0.0)                       |
| Leukopenia                                                                            | 4 (7.8)              | 0 (0.0)                       |
| Investigations                                                                        | 9 (17.6)             | 10 (18.5)                     |
| Plateletcount decreased                                                               | 8 (15.7)             | 7 (13.0)                      |
| Neutrophil count decreased                                                            | 2 (3.9)              | 5 (9.3)                       |
| Whitebloodcellcountdecreased                                                          | 1 (2.0)              | 4 (7.4)                       |
| Lymphocytecountdecreased                                                              | 0 (0.0)              | 1 (1.9)                       |

Page 1 of 1

N = Number of subjects in the analysis set. n = Number of subjects with observed data.

CodedusingMedDRAversion22.1 Datacut-offdate:17JUL2019

- Hepatotoxicity

Hepatotoxicity (drug related hepatic disorders) was based on the narrow search strategy for the MedDRA SMQ Drug Related Hepatic Disorders - comprehensive search.

In the primary analysis, subjects who received HC3 had a more than a 10 % higher rate of hepatotoxicities than subjects who received blinatumomab (37.3 % versus 16.7 % , respectively). The following adverse events were ≥ 5 % higher in the HC3 arm compared with the blinatumomab arm:  hypertransaminasaemia (7.8 % versus 1.9 % ); ALT increased (13.7 % versus 7.4 % ); AST increased (9.8 % versus 3.7 % ).  No adverse events suggestive of hepatotoxicities were ≥ 5 % higher in the blinatumomab arm compared with HC3 arm.  The most frequently reported ( ≥ 5 % of subjects) adverse event in the blinatumomab arm was ALT increased (7.4 % , n = 4). In the HC3 arm, 3 subjects (5.9 % ) had hypertransaminasaemia that was grade ≥ 3 in severity and for 1 subject (2.0 % ) the event was deemed serious.

In summary, no new safety signal was identified from a review of these data.  In a pediatric population with  high-risk  first  relapse  ALL,  subjects  who  received  blinatumomab  are  not  at  a  higher  risk  of hepatotoxicities than subjects who received HC3.

- Nephrotoxicity

Nephrotoxicity was evaluated using the Acute Renal Failure SMQ (narrow search).

Subjects who received HC3 had a similar rate of nephrotoxicity compared with subjects who received blinatumomab (2.0 % versus 1.9 % , respectively).  The adverse event of oliguria was reported for 1 subject who received HC3 treatment and the event of acute kidney injury was reported for 1 subject who received blinatumomab.  Neither event was grade ≥ 3 in severity or deemed serious.

In summary, no new safety signal was identified from a review of these data.  In the pediatric high-risk first  relapsed  ALL  population,  subjects  who  received  blinatumomab  are  not  at  a  higher  risk  of nephrotoxicity than subjects who received HC3.

<div style=\"page-break-after: always\"></div>

- Arrhythmia, Convulsions, and Torsade de Pointes/QT Prolongation

The SMQs of torsade de pointes/QT prolongation, cardiac arrhythmias, convulsions (narrow search) were used to identify adverse events that could be secondary to QT prolongation.

Subjects  who  received  HC3  had  a  similar  rate  of  cardiac  arrhythmias  compared  with  subjects  who received blinatumomab (7.8 % , n = 4 versus 5.6 % , n = 3, respectively).  In the HC3 arm, the adverse events were sinus tachycardia (3.9 % , n = 2) and electrocardiogram QT prolongation (2.0 % , n = 1).  In the blinatumomab arm, the adverse events were sinus bradycardia (3.7 % ,  n = 2), extrasystoles and sinus arrhythmia (1.9 % , n = 1 for each); there were no event of QT prolongation or torsade de pointes reported for blinatumomab.  None of these events were grade ≥ 3 in severity or deemed serious.

Subjects who received HC3 had a similar rate of convulsions compared with subjects who received blinatumomab (2.0 % , n = 1 versus 3.7 % , n = 2, respectively).  In the HC3 arm, the adverse event was petit mal epilepsy (2.0 % , n = 1).  In the blinatumomab arm, the adverse event was seizure (3.7 % , n = 3.7 % ).  One event of seizure was grade ≥ 3 in severity and deemed serious.

Only 1 subject (2.0 % ) who received HC3 had Torsade de Pointes - QT prolongation.  The event was electrocardiogram QT prolongation; The event was neither grade ≥ 3 in severity or deemed serious.

In summary, no new safety signal was identified from a review of these data.  In the pediatric high-risk first relapsed ALL population, subjects who received blinatumomab are not at a higher risk of cardiac arrhythmias, convulsions, and torsade de pointes/QT prolongation than subjects who received HC3.

## Laboratory findings

Shifts from baselines in study 20120215 for chemistry and hematology are presented in the table below.

## Table 68: Shifts From Baseline Grade 0 or 1 to Worst Postbaseline Grade 3 or 4 (Safety Analysis Set)

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Panel Laboratory Parameter   | Direction of Toxicity   | Grade   | Baseline Postbaseline (N= 51) Grade   | HC3 Blinatumomab n (%)   | (N = 54) n (%)   | Source          |
|------------------------------|-------------------------|---------|---------------------------------------|--------------------------|------------------|-----------------|
| Chemistry                    |                         |         |                                       |                          |                  |                 |
| Potassium                    | Increase                | 0       | 3                                     | 0 (0.0)                  | 1 (1.9)          | Table 14-7.2.1  |
|                              | Decrease                | NA      | 3                                     | 2 (3.9)                  | 1 (1.9)          |                 |
|                              |                         | NA      | 4                                     | 1 (2.0)                  | 0 (0.0)          |                 |
|                              |                         | 0       | 3                                     | 4 (7.8)                  | 5 (9.3)          |                 |
|                              |                         | 0       | 4                                     | 1 (2.0)                  | 1 (1.9)          |                 |
| Albumin                      | Decrease                | 0       | 3                                     | 0 (0.0)                  | 1 (1.9)          | Table 14-7.2.2  |
| Corrected calcium            | Decrease                | 0       | 4                                     | 1 (2.0)                  | 1 (1.9)          | Table 14-7.2.3  |
| ALT                          | Increase                | 0       | 3                                     | 1 (2.0)                  | 0 (0.0)          | Table 14-7.2.5  |
|                              |                         | 1       | 3                                     | 9 (17.6)                 | 5 (9.3)          |                 |
| AST                          | Increase                | NA      | 3                                     | 1 (2.0)                  | 0 (0.0)          | Table 14-7.2.6  |
|                              |                         | 0       | 3                                     | 2 (3.9)                  | 0 (0.0)          |                 |
|                              |                         | 1       | 3                                     | 4 (7.8)                  | 1 (1.9)          |                 |
|                              |                         | 1       | 4                                     | 1 (2.0)                  | 0 (0.0)          |                 |
| GGT                          | Increase                | NA      | 3                                     | 0 (0.0)                  | 1 (1.9)          | Table 14-7.2.8  |
|                              |                         | 0       | 3                                     | 3 (5.9)                  | 4 (7.4)          |                 |
|                              |                         | 1       | 3                                     | 5 (9.8)                  | 2 (3.7)          |                 |
|                              |                         | 1       | 4                                     | 0 (0.0)                  | 3 (5.6)          |                 |
| Amylase                      | Increase                | 0       | 3                                     | 1 (2.0)                  | 1 (1.9)          | Table 14-7.2.9  |
|                              |                         | 0       | 4                                     | 1 (2.0)                  | 0 (0.0)          |                 |
|                              |                         | 1       | 3                                     | 0 (0.0)                  | 1 (1.9)          |                 |
| Lipase                       | Increase                | 0       | 3                                     | 3 (5.9)                  | 1 (1.9)          | Table 14-7.2.10 |
|                              |                         | 0       | 4                                     | 1 (2.0)                  | 2 (3.7)          |                 |
| Bilirubin                    | Increase                | 0       | 3                                     | 2 (3.9)                  | 1 (1.9)          | Table 14-7.2.11 |
|                              |                         | 0       | 4                                     | 1 (2.0)                  | 0 (0.0)          |                 |
| Hematology                   |                         |         |                                       |                          |                  |                 |
| Hemoglobin                   | Decrease                | D       | 3                                     | 1 (2.0)                  | 0 (0.0)          | Table 14-7.2.12 |
|                              |                         | 1       | 3                                     | 4 (7.8)                  | 1 (1.9)          |                 |
| Platelets                    | Decrease                | 0       | 3                                     | 5 (9.8)                  | 6 (11.1)         | Table 14-7.2.13 |
|                              |                         | 1       | 3                                     | 1 (2.0)                  | 1 (1.9)          |                 |
|                              |                         | D       | 4                                     | 13 (25.5)                | 5 (9.3)          |                 |
|                              |                         | 1       | 4                                     | 8 (15.7)                 | 2 (3.7)          |                 |
| Leukocytes                   | Increase                | D       | 3                                     | 1 (2.0)                  | 0 (0.0)          | Table 14-7.2.14 |
|                              | Decrease                | D       | 3                                     | 2 (3.9)                  | 0 (0.0)          |                 |
|                              |                         | 1       | 3                                     | 4 (7.8)                  | 4 (7.4)          |                 |
|                              |                         |         | 4                                     | 4 (7.8)                  | 0 (0.0)          |                 |
|                              |                         | 1       | 4                                     | 6 (11.8)                 | 1 (1.9)          |                 |
| Neutrophils                  | Decrease                | D       | 3                                     | 4 (7.8)                  | 10 (18.5)        | Table 14-7.2.15 |
|                              |                         |         | 4                                     | 22 (43.1)                | 3 (5.6)          |                 |
| Lymphocytes                  | Increase                | D       | 3                                     | 0 (0.0)                  | 1 (1.9)          | Table 14-7.2.16 |
|                              | Decrease                | 0       | 3                                     | 1 (2.0)                  | 3 (5.6)          |                 |
|                              |                         | D       | 4                                     | 1 (2.0)                  | 1 (1.9)          |                 |
|                              |                         | 1       | 4                                     | 1 (2.0)                  | 2 (3.7)          |                 |

<div style=\"page-break-after: always\"></div>

```
ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = Common Teminology Criteria for Adverse Events; GGT = gamma-glutamyl transferase; HC3 = high-risk consolidation 3 chemotherapy:NA.=not available n (%) = the number of subjects with observations in both categories (n) and n as a percentage (%) of all subjects in the analysis set (N) Grading categories determined using CTCAE version 4.03. Data cutoff date:17 July 2019 Source:Table14-7.2.1toTable14-7.2.16
```

## Immunoglobulins

Baseline immunoglobulin (IgG) data were available for 41 subjects in the HC3 arm and 53 subjects in the blinatumomab arm.  The median baseline IgG value was 4.68 g/L for the HC3 arm and 4.58 g/L for the blinatumomab arm.  The median IgG value for cycle 1 day 29 was 5.04 g/L for the HC3 arm and 3.00 g/L for the blinatumomab arm.  As only 3 subjects had nonmissing values for the safety follow-up visit, the sample size is too small to support any conclusions.

No new safety signal for blinatumomab was identified from the review of these data.

<div style=\"page-break-after: always\"></div>

Vital Signs, Physical Findings, and Other Observations Related to Safety

Table 69.  Abnormal Changes in Vital Signs - Study 20120215 (Safety Analysis Set)

| Vital Sign Parameter                 | HC3 (N = 51) n ( % )   | Blinatumomab (N = 54) n ( % )   |
|--------------------------------------|------------------------|---------------------------------|
| Pulse rate > 120 bpm                 | 27 (52.9)              | 29 (53.7)                       |
| Pulse rate < 50 bpm                  | 0 (0.0)                | 0 (0.0)                         |
| Systolic blood pressure ≥ 160 mmHg   | 0 (0.0)                | 0 (0.0)                         |
| Systolic blood pressure ≤ 90 mmHg    | 36 (70.6)              | 35 (64.8)                       |
| Diastolic blood pressure ≥ 105 mmHg  | 0 (0.0)                | 0 (0.0)                         |
| Diastolic blood pressure ≤ 50 mmHg   | 32 (62.7)              | 31 (57.4)                       |
| Weight decrease ≥ 10 % from baseline | 2 (3.9)                | 0 (0.0)                         |
| Weight increase ≥ 10 % from baseline | 1 (2.0)                | 4 (7.4)                         |
| Body temperature > 39 ° C            | 1 (2.0)                | 3 (5.6)                         |

N = Number of subjects in the analysis set; n = Number of subjects with observed data.

Data cut-off date: 17JUL2019

Source:  Table 14-8.2 of 20120215 Primary Analysis CSR

## Safety in special populations

The applicant provided TEAEs analysis by subgroup of age and sex.

For Study 20120215, 3 age groups were defined for subgroup analysis:  28 days to 23 months; 2 to 11 years; and 12 to 18 years

<div style=\"page-break-after: always\"></div>

Table 70.  Adverse Events by System Organ Class and Preferred Term ( ≥ 25 % in any Category): Subgroup Age - Study 20120215 (Safety Analysis Set)

|                                                                 | HC3                                  | HC3                            | HC3                            | Blinatumomab                         | Blinatumomab                   | Blinatumomab                    |
|-----------------------------------------------------------------|--------------------------------------|--------------------------------|--------------------------------|--------------------------------------|--------------------------------|---------------------------------|
| System Organ Class Preferred Term                               | 28 days to 23 months (N = 2) n ( % ) | 2 to 11 years (N = 43) n ( % ) | 12 to 18 years (N = 6) n ( % ) | 28 days to 23 months (N = 1) n ( % ) | 2 to 11 years (N = 41) n ( % ) | 12 to 18 years (N = 12) n ( % ) |
| Number of subjects reporting treatment- emergent adverse events | 2 (100.0)                            | 41 (95.3)                      | 6 (100.0)                      | 1 (100.0)                            | 41 (100.0)                     | 12 (100.0)                      |
| General disorders and administration site conditions            | 1 (50.0)                             | 16 (37.2)                      | 1 (16.7)                       | 1 (100.0)                            | 39 (95.1)                      | 8 (66.7)                        |
| Pyrexia                                                         | 0 (0.0)                              | 10 (23.3)                      | 0 (0.0)                        | 1 (100.0)                            | 37 (90.2)                      | 6 (50.0)                        |
| Mucosal inflammation                                            | 1 (50.0)                             | 3 (7.0)                        | 0 (0.0)                        | 0 (0.0)                              | 5 (12.2)                       | 4 (33.3)                        |
| Gastrointestinal disorders                                      | 0 (0.0)                              | 32 (74.4)                      | 6 (100.0)                      | 0 (0.0)                              | 25 (61.0)                      | 12 (100.0)                      |
| Nausea                                                          | 0 (0.0)                              | 7 (16.3)                       | 2 (33.3)                       | 0 (0.0)                              | 15 (36.6)                      | 7 (58.3)                        |
| Vomiting                                                        | 0 (0.0)                              | 9 (20.9)                       | 2 (33.3)                       | 0 (0.0)                              | 11 (26.8)                      | 5 (41.7)                        |
| Diarrhoea                                                       | 0 (0.0)                              | 7 (16.3)                       | 2 (33.3)                       | 0 (0.0)                              | 8 (19.5)                       | 3 (25.0)                        |
| Stomatitis                                                      | 0 (0.0)                              | 22 (51.2)                      | 6 (100.0)                      | 0 (0.0)                              | 6 (14.6)                       | 4 (33.3)                        |
| Constipation                                                    | 0 (0.0)                              | 4 (9.3)                        | 3 (50.0)                       | 0 (0.0)                              | 4 (9.8)                        | 1 (8.3)                         |
| Diarrhoea infectious                                            | 1 (50.0)                             | 0 (0.0)                        | 0 (0.0)                        | 0 (0.0)                              | 0 (0.0)                        | 0 (0.0)                         |
| Skin and subcutaneous tissue disorders                          | 1 (50.0)                             | 10 (23.3)                      | 2 (33.3)                       | 0 (0.0)                              | 17 (41.5)                      | 6 (50.0)                        |
| Pruritus                                                        | 0 (0.0)                              | 3 (7.0)                        | 2 (33.3)                       | 0 (0.0)                              | 3 (7.3)                        | 3 (25.0)                        |
| Blood and lymphatic system disorders                            | 1 (50.0)                             | 33 (76.7)                      | 4 (66.7)                       | 0 (0.0)                              | 15 (36.6)                      | 4 (33.3)                        |
| Anaemia                                                         | 0 (0.0)                              | 21 (48.8)                      | 2 (33.3)                       | 0 (0.0)                              | 10 (24.4)                      | 2 (16.7)                        |
| Neutropenia                                                     | 1 (50.0)                             | 14 (32.6)                      | 1 (16.7)                       | 0 (0.0)                              | 5 (12.2)                       | 0 (0.0)                         |
| Thrombocytopenia                                                | 0 (0.0)                              | 12 (27.9)                      | 1 (16.7)                       | 0 (0.0)                              | 4 (9.8)                        | 0 (0.0)                         |
| Febrile neutropenia                                             | 0 (0.0)                              | 12 (27.9)                      | 1 (16.7)                       | 0 (0.0)                              | 1 (2.4)                        | 2 (16.7)                        |
| Infections and infestations                                     | 2                                    | 12                             | 2                              | 1                                    | 15                             | 7 (58.3)                        |
| Staphylococcal infection                                        | (100.0) 0 (0.0)                      | (27.9) 0 (0.0)                 | (33.3) 0 (0.0)                 | (100.0) 1                            | (36.6) 1 (2.4)                 | 0 (0.0)                         |
| Catheter site infection                                         | 0 (0.0)                              | 0 (0.0)                        | 1 (16.7)                       | (100.0) 1 (100.0)                    | 0 (0.0)                        | 0 (0.0)                         |
| Infection                                                       | 1 (50.0)                             | 1 (2.3)                        | 0 (0.0)                        | 0 (0.0)                              | 0 (0.0)                        | 0 (0.0)                         |
| Pseudomonal bacteraemia                                         | 0 (0.0)                              | 0 (0.0)                        | 0 (0.0)                        | 1 (100.0)                            | 0 (0.0)                        | 0 (0.0)                         |

<div style=\"page-break-after: always\"></div>

|                                                 | HC3                                  | HC3                            | HC3                            | Blinatumomab                         | Blinatumomab                   | Blinatumomab                    |
|-------------------------------------------------|--------------------------------------|--------------------------------|--------------------------------|--------------------------------------|--------------------------------|---------------------------------|
| System Organ Class Preferred Term               | 28 days to 23 months (N = 2) n ( % ) | 2 to 11 years (N = 43) n ( % ) | 12 to 18 years (N = 6) n ( % ) | 28 days to 23 months (N = 1) n ( % ) | 2 to 11 years (N = 41) n ( % ) | 12 to 18 years (N = 12) n ( % ) |
| Splenic candidiasis                             | 0 (0.0)                              | 0 (0.0)                        | 0 (0.0)                        | 1 (100.0)                            | 0 (0.0)                        | 0 (0.0)                         |
| Staphylococcal bacteraemia                      | 0 (0.0)                              | 0 (0.0)                        | 0 (0.0)                        | 1 (100.0)                            | 0 (0.0)                        | 0 (0.0)                         |
| Nasopharyngitis                                 | 0 (0.0)                              | 1 (2.3)                        | 0 (0.0)                        | 0 (0.0)                              | 0 (0.0)                        | 3 (25.0)                        |
| Investigations                                  | 0 (0.0)                              | 20 (46.5)                      | 2 (33.3)                       | 0 (0.0)                              | 14 (34.1)                      | 7 (58.3)                        |
| Platelet count decreased                        | 0 (0.0)                              | 6 (14.0)                       | 2 (33.3)                       | 0 (0.0)                              | 6 (14.6)                       | 1 (8.3)                         |
| Nervous system disorders                        | 0 (0.0)                              | 11 (25.6)                      | 1 (16.7)                       | 0 (0.0)                              | 13 (31.7)                      | 10 (83.3)                       |
| Headache                                        | 0 (0.0)                              | 8 (18.6)                       | 1 (16.7)                       | 0 (0.0)                              | 12 (29.3)                      | 7 (58.3)                        |
| Tremor                                          | 0 (0.0)                              | 0 (0.0)                        | 0 (0.0)                        | 0 (0.0)                              | 2 (4.9)                        | 3 (25.0)                        |
| Metabolism and nutrition disorders              | 0 (0.0)                              | 13 (30.2)                      | 0 (0.0)                        | 0 (0.0)                              | 12 (29.3)                      | 7 (58.3)                        |
| Vascular disorders                              | 0 (0.0)                              | 9 (20.9)                       | 2 (33.3)                       | 0 (0.0)                              | 12 (29.3)                      | 4 (33.3)                        |
| Hypotension                                     | 0 (0.0)                              | 2 (4.7)                        | 2 (33.3)                       | 0 (0.0)                              | 5 (12.2)                       | 2 (16.7)                        |
| Immune system disorders                         | 0 (0.0)                              | 3 (7.0)                        | 0 (0.0)                        | 1 (100.0)                            | 9 (22.0)                       | 4 (33.3)                        |
| Hypogammaglobulinaemi a                         | 0 (0.0)                              | 2 (4.7)                        | 0 (0.0)                        | 1 (100.0)                            | 3 (7.3)                        | 2 (16.7)                        |
| Respiratory, thoracic and mediastinal disorders | 1 (50.0)                             | 8 (18.6)                       | 1 (16.7)                       | 0 (0.0)                              | 9 (22.0)                       | 4 (33.3)                        |
| Cough                                           | 1 (50.0)                             | 0 (0.0)                        | 0 (0.0)                        | 0 (0.0)                              | 2 (4.9)                        | 2 (16.7)                        |
| Musculoskeletal and connective tissue disorders | 0 (0.0)                              | 12 (27.9)                      | 2 (33.3)                       | 0 (0.0)                              | 6 (14.6)                       | 1 (8.3)                         |
| Psychiatric disorders                           | 0 (0.0)                              | 4 (9.3)                        | 1                              | 0 (0.0)                              | 5 (12.2)                       | 4 (33.3)                        |
| Eye disorders                                   | 0 (0.0)                              | 7 (16.3)                       | (16.7) 2 (33.3)                | 0 (0.0)                              | 2 (4.9)                        | 1 (8.3)                         |

Page 2 of 2

HC3 = high-risk consolidation 3 chemotherapy; MedDRA = Medical Dictionary for Regulatory Activities; N = Number of subjects in the analysis set; n = Number of subjects with observed data.

Coded using MedDRA version 22.1

Data cut-off date: 17JUL2019

Source:  Table 14-6.4.2 of 20120215 Primary Analysis CSR

<div style=\"page-break-after: always\"></div>

Table 71.  Adverse Events by System Organ Class and Preferred Term ( ≥ 10 % in any Category): Subgroup Sex - Study 20120215 (Safety Analysis Set)

|                                      | HC3                   | HC3                     | Blinatumomab          | Blinatumomab            |
|--------------------------------------|-----------------------|-------------------------|-----------------------|-------------------------|
| System Organ Class Preferred Term    | Male (N = 20) n ( % ) | Female (N = 31) n ( % ) | Male (N = 30) n ( % ) | Female (N = 24) n ( % ) |
| Number of subjects reporting         | 20 (100.0)            | 29 (93.5)               | 30                    | 24                      |
| treatment-emergent adverse events    |                       |                         | (100.0)               | (100.0)                 |
| Gastrointestinal disorders           | 13 (65.0)             | 25 (80.6)               | 25 (83.3)             | 12 (50.0)               |
| Nausea                               | 3 (15.0)              | 6 (19.4)                | 14 (46.7)             | 8 (33.3)                |
| Vomiting                             | 5 (25.0)              | 6 (19.4)                | 12 (40.0)             | 4 (16.7)                |
| Stomatitis                           | 7 (35.0)              | 21 (67.7)               | 8 (26.7)              | 2 (8.3)                 |
| Diarrhoea                            | 4 (20.0)              | 5 (16.1)                | 6 (20.0)              | 5 (20.8)                |
| Abdominal pain                       | 5 (25.0)              | 6 (19.4)                | 6 (20.0)              | 1 (4.2)                 |
| Constipation                         | 2 (10.0)              | 5 (16.1)                | 4 (13.3)              | 1 (4.2)                 |
| Abdominal pain upper                 | 3 (15.0)              | 0 (0.0)                 | 3 (10.0)              | 1 (4.2)                 |
| General disorders and administration | 6 (30.0)              | 12 (38.7)               | 24 (80.0)             | 24                      |
| site conditions                      |                       |                         |                       | (100.0)                 |
| Pyrexia                              | 3 (15.0)              | 7 (22.6)                | 21 (70.0)             | 23 (95.8)               |
| Mucosal inflammation                 | 2 (10.0)              | 2 (6.5)                 | 5 (16.7)              | 4 (16.7)                |
| Fatigue                              | 0 (0.0)               | 2 (6.5)                 | 3 (10.0)              | 0 (0.0)                 |
| Nervous system disorders             | 3 (15.0)              | 9 (29.0)                | 17 (56.7)             | 6 (25.0)                |
| Headache                             | 2 (10.0)              | 7 (22.6)                | 14 (46.7)             | 5 (20.8)                |
| Tremor                               | 0 (0.0)               | 0 (0.0)                 | 3 (10.0)              | 2 (8.3)                 |
| Infections and infestations          | 4 (20.0)              | 12 (38.7)               | 15 (50.0)             | 8 (33.3)                |
| Nasopharyngitis                      | 0 (0.0)               | 1 (3.2)                 | 3 (10.0)              | 0 (0.0)                 |
| Rhinitis                             | 2 (10.0)              | 3 (9.7)                 | 1 (3.3)               | 0 (0.0)                 |
| Skin and subcutaneous tissue         | 6 (30.0)              | 7 (22.6)                | 13 (43.3)             | 10 (41.7)               |
| Erythema                             | 1 (5.0)               | 1 (3.2)                 | 5 (16.7)              | 1 (4.2)                 |
| Rash                                 | 2 (10.0)              | 2 (6.5)                 | 4 (13.3)              | 3 (12.5)                |
| Pruritus                             | 2 (10.0)              | 3 (9.7)                 | 4 (13.3)              | 2 (8.3)                 |
| Investigations                       | 9 (45.0)              | 13 (41.9)               | 13 (43.3)             | 8 (33.3)                |
| Platelet count decreased             | 2 (10.0)              | 6 (19.4)                | 5 (16.7)              | 2 (8.3)                 |
| Neutrophil count decreased           | 1 (5.0)               | 1 (3.2)                 | 2 (6.7)               | 3 (12.5)                |
| Alanine aminotransferase increased   | 3 (15.0)              | 4 (12.9)                | 2 (6.7)               | 2 (8.3)                 |
| Aspartate aminotransferase increased | 2 (10.0)              | 3 (9.7)                 | 1 (3.3)               | 1 (4.2)                 |
| Blood and lymphatic system disorders | 17 (85.0)             | 21 (67.7)               | 12 (40.0)             | 7 (29.2)                |
| Anaemia                              | 10 (50.0)             | 13 (41.9)               | 7 (23.3)              | 5 (20.8)                |
| Neutropenia                          | 7 (35.0)              | 9 (29.0)                | 3 (10.0)              | 2 (8.3)                 |
| Thrombocytopenia                     | 6 (30.0)              | 7 (22.6)                | 2 (6.7)               | 2 (8.3)                 |
| Febrile neutropenia                  | 5 (25.0)              | 8 (25.8)                | 1 (3.3)               | 2 (8.3)                 |
| Cytopenia                            | 2 (10.0)              | 0 (0.0)                 | 0 (0.0)               | 0 (0.0)                 |
| Metabolism and nutrition disorders   | 5 (25.0)              | 8 (25.8)                | 10 (33.3)             | 9 (37.5)                |
| Hypokalaemia Vascular disorders      | 3 (15.0)              | 2 (6.5)                 | 4 (13.3)              | 3 (12.5)                |
| Hypertension                         | 4 (20.0) 1 (5.0)      | 7 (22.6) 3 (9.7)        | 10 (33.3)             | 6 (25.0) 2 (8.3)        |
| Hypotension                          | 0 (0.0)               |                         | 5 (16.7)              | 4                       |
|                                      |                       | 4 (12.9)                | 3 (10.0)              | (16.7)                  |

<div style=\"page-break-after: always\"></div>

|                                                 | HC3                   | HC3                     | Blinatumomab          | Blinatumomab            |
|-------------------------------------------------|-----------------------|-------------------------|-----------------------|-------------------------|
| System Organ Class Preferred Term               | Male (N = 20) n ( % ) | Female (N = 31) n ( % ) | Male (N = 30) n ( % ) | Female (N = 24) n ( % ) |
| Respiratory, thoracic and mediastinal disorders | 3 (15.0)              | 7 (22.6)                | 9 (30.0)              | 4 (16.7)                |
| Epistaxis                                       | 1 (5.0)               | 6 (19.4)                | 4 (13.3)              | 1 (4.2)                 |
| Oropharyngeal pain                              | 2 (10.0)              | 1 (3.2)                 | 2 (6.7)               | 0 (0.0)                 |
| Immune system disorders                         | 1 (5.0)               | 2 (6.5)                 | 8 (26.7)              | 6 (25.0)                |
| Hypogammaglobulinaemia                          | 1 (5.0)               | 1 (3.2)                 | 3 (10.0)              | 3 (12.5)                |
| Psychiatric disorders                           | 1 (5.0)               | 4 (12.9)                | 6 (20.0)              | 3 (12.5)                |
| Agitation                                       | 0 (0.0)               | 1 (3.2)                 | 4 (13.3)              | 0 (0.0)                 |
| Musculoskeletal and connective tissue disorders | 2 (10.0)              | 12 (38.7)               | 5 (16.7)              | 2 (8.3)                 |
| Back pain                                       | 1 (5.0)               | 4 (12.9)                | 3 (10.0)              | 0 (0.0)                 |
| Pain in extremity                               | 1 (5.0)               | 4 (12.9)                | 2 (6.7)               | 0 (0.0)                 |
| Arthralgia                                      | 0 (0.0)               | 4 (12.9)                | 0 (0.0)               | 0 (0.0)                 |
| Hepatobiliary disorders                         | 4 (20.0)              | 5 (16.1)                | 5 (16.7)              | 0 (0.0)                 |
| Hypertransaminasaemia                           | 2 (10.0)              | 2 (6.5)                 | 1 (3.3)               | 0 (0.0)                 |
| Hepatotoxicity                                  | 2 (10.0)              | 0 (0.0)                 | 0 (0.0)               | 0 (0.0)                 |
| Injury, poisoning and procedural complications  | 2 (10.0)              | 4 (12.9)                | 4 (13.3)              | 4 (16.7)                |
| Cardiac disorders                               | 1 (5.0)               | 2 (6.5)                 | 4 (13.3)              | 1 (4.2)                 |
| Renal and urinary disorders                     | 2 (10.0)              | 5 (16.1)                | 3 (10.0)              | 1 (4.2)                 |
| Eye disorders                                   | 3 (15.0)              | 6 (19.4)                | 2 (6.7)               | 1 (4.2)                 |
| Congenital, familial and genetic disorders      | 2 (10.0)              | 3 (9.7)                 | 2 (6.7)               | 0 (0.0)                 |
| Aplasia                                         | 2 (10.0)              | 2 (6.5)                 | 2 (6.7)               | 0 (0.0)                 |

HC3 = high-risk consolidation 3 chemotherapy; MedDRA = Medical Dictionary for Regulatory Activities; N = Number of subjects in the analysis set; n = Number of subjects with observed data.

Coded using MedDRA version 22.1

Data cut-off date: 17JUL2019

Source:  Table 14-6.4.1 of 20120215 Primary Analysis CSR

## Use in Pregnancy and Lactation

Cumulatively, from clinical studies, there was 1 case of pregnancy reported in the long-term follow-up phase of a clinical trial. The case described a female with MRD-positive ALL who became pregnant 6 months after the last dose of blinatumomab in Study MT103-203. Approximately 5 months into the pregnancy, an ultrasound revealed normal results with no fetal abnormalities detected. The outcome of the pregnancy was a live birth at the gestational age of 37 weeks. The investigator reported that the infant did not have any complications, medical problems, or congenital anomalies.

Cumulatively, from non-study sources, there were 2 cases of pregnancy reported. The first case described a male patient with a pregnant partner who was potentially exposed while changing the infusion bags. The birth outcome was unknown (lost to follow-up). The second case described an event of fetal death while a female patient was receiving blinatumomab. The case did not provide the patients age or obstetric history. The patient was diagnosed with B-ALL in July 2018. The patient was treated sequentially. However, the ALL was refractory to both. Subsequently, blinatumomab was started at 9 μg/day x 1 week, and the dose was escalated to 28 μg/day. On day 14 of blinatumomab treatment (approximately 26 weeks gestation), the patient had a 'spontaneous birth of a life-less child.' No details were provided as to fetal monitoring prior to the birth, autopsy, or pathology of fetus.

<div style=\"page-break-after: always\"></div>

## Safety related to drug-drug interactions and other interactions

No formal drug interaction studies have been conducted with blinatumomab.  Blinatumomab is a therapeutic protein and is not expected to affect cytochrome P450 enzyme activities and catabolism of other proteins.  Blinatumomab may induce transient cytokine elevations and the elevated cytokines, especially IL-6, may have suppressive effect on P450 enzymes.  Effect of cytokines on activities of P450 enzymes was evaluated via a physiologically based PK modelling and simulation approach, and results were provided in the original MAA submission (2015).  It was concluded that the blinatumomab mediated cytokine elevation has a low potential to affect exposure levels of other drugs and the effect is inconsequential.

## Post marketing experience

From the International Birth Date of 03 December 2014 to 02 June 2020 (data lock point for PBRER/PSUR # 9), an estimated 11 774 patients have been exposed to blinatumomab in the marketed setting (through commercialization  and  early  access  programs).    Of  these,  more  than  916  patients  were  children ( &lt; 18 years of age).

As of 02 June 2020, Amgen received a total of 5870 serious adverse drug reactions (ADRs) cumulatively from spontaneous and solicited sources. In addition, 3,227 nonserious ADRs  were  reported spontaneously.  These  events  are  consistent  with  the  known  safety  profile  of  blinatumomab  or representative of the underlying malignancy.

## 2.5.1. Discussion on clinical safety

Safety data in this extension of indication are provided from the pivotal study 20120215. The review also included pooled safety data from 3 completed single-arm, open-label, multicenter blinatumomab studies in paediatric subjects with relapsed/refractory ALL (second or greater relapsed, relapsed after HSCT, and refractory to previous treatments).

Safety analysis set in study 20120215 includes 105 patients (51 in HC3 arm, 54 in blinatumomab arm). Subjects received 1 cycle of blinatumomab treatment (4 weeks, 15 µg/m2/day through continuous IV). 50 patients completed study treatment in blinatumomab arm.

A similar proportion of patients had dose modifications in both arms (21.6% and 25.9% in HC3 and blinatumomab arms respectively). However, all modifications were dose change in HC3 arm, while all modifications included drug interruption in blinatumomab arm. The reason for drug change was driven by  protocol  requirement  in  HC3  arm  (7/11)  and  adverse  event  in  blinatumomab  arm  (6/7).  Drug interruption in blinatumomab arm was mainly due to adverse event (13.0%) and 'other' reason (11.1%).

In study 20120215, patients received only 1 cycle of blinatumomab or HC3, according to the protocol. Despite differences in protocols, which planned up to 5 cycles in additional paediatric studies, median duration of exposure is similar between study 20120215 and pooled peadiatric studies, with a median of 1 cycle.

Demographic and baseline characteristics, as previously discussed in the efficacy section, were balanced between both arms in study 20120215. Baseline demographic and disease characteristics were similar between study 20120215 and pooled paediatric ALL studies. However, it should be noted that patients in study 20120215 were slightly younger (median age of 6.0 years, vs 8.0). In blinatumomab subjects in study 20120215, baseline platelets and ANC were higher and all patients had baseline BM lasts &lt;5% when compared to pooled paediatric ALL studies, as expected according to study inclusion criteria.

<div style=\"page-break-after: always\"></div>

## Overview of safety profile

In study 20120215, most of patients presented with AEs in both arms (96.1% and 100% in HC3 and blinatumomab arms respectively). The frequency of treatment related AEs (TRAE) was also similar (78.4% and 83.3%) respectively. However, a higher proportion of patients in HC3 arm presented with TRAE grade ≥3 (62.7% vs 46.7% in blinatumomab arm) and serious TRAE (25.7% vs 16.7% in blinatumomab arm).

When compared to pooled paediatric safety studies, the frequency of grade ≥3 AEs (78.1% in pooled studies vs 57.4% in blinatumomab arm 20150215) and serious AEs (47.4% vs 24.1%) was higher in pooled paediatric stu dy. Similarly, TRAE grade ≥3 (44.7% vs 16.7%) were more frequent in pooled paediatric studies.

In study 20120215, the highest increase in blinatumomab arm was reported in the following SOCs: General disorders and administration site conditions (35.3% in HC3 arm vs 88.9% in blinatumomab arm), Nervous system disorders (23.5% vs 42.6%) and Skin and subcutaneous tissue disorders (25.5% vs 42.6%). The highest increase in TEAEs reporting in HC3 arm concerned Blood and lymphatic system disorders SOC (74.5% vs 35.2%).

Common TEAEs were defined as TEAEs observed in at least 10% of subjects in any of both study arms. In study 20120215, TAEs with at least 10% higher frequency in blinatumomab arm were pyrexia (81.5% versus 19.6%), nausea (40.7% for versus 17.6%), and headache (35.2% versus 17.6%), while a higher frequency for the following AEs was reported in HC3 arm: anaemia (45.1% vs 22.2%), neutropenia (31.4% vs 9.3%), thrombocytopenia (25.5% vs 7.4%), febrile neutropenia (25.5% vs 5.6%) and stomatitis (54.9% vs 18.5%). These safety results are coherent with the known safety profile of both treatments. The safety profile of blinatumomab was similar to pooled RR ALL paediatric population (refer to table 13 is CSS), despite a higher frequency of nausea (40.7% for high-risk first relapsed; 22.8% for relapsed/refractory), stomatitis (18.5% for high-risk first relapsed; 7.5% for relapsed/refractory), and mucosal inflammation (16.7% for high-risk first relapsed; 2.6% for relapsed/refractory) in blinatumomab arm in study 20120215. The implication of previous consolidation cycles in the onset of these TEAEs, as well as HSCT conditioning, in this population cannot be ruled out.

In study 20120215, grade ≥3 TEAEs were reported in 82.4% of patients in HC3 arm, and 57.4% in blinatum omab arm. A similar trend was observed in related grade ≥3 TEAEs (62.7% vs 16.7%). The safety profile in grade ≥3 TEAEs appeared to be more favourable in blinatumomab arm, with the following grade ≥3 TEAEs more frequent in HC3: anaemia (41.2% in HC3 arm vs 14.8% in blinatumomab arm), neutropenia (27.5% vs 9.3%), febrile neutropenia (25.5% vs 3.7%) and stomatitis (31.4% vs 5.6%). The safety profile for grade≥3 TEAEs of blinatumomab in study 20120215 was similar to pooled RR ALL paediatric population (refer to table 15 is CSS), despite a higher frequency of mucosal inflammation (13.0% versus none).

In study 20120215, the frequency of TRAEs was similar between both arms (78.4% in the HC3 arm; 83.3% in the blinatumomab arm). The following TRAEs were more frequent in HC3 arm: anaemia (35.3 % for HC3; 3.7 % for blinatumomab), stomatitis (41.2% vs 1.9 % ), platelet count decreased (13.7 % vs 0 % ), neutropenia (25.5 % vs 1.9 % ), and thrombocytopenia (21.6 % vs 1.9 % ). TRAEs of pyrexia (55.6 % for blinatumomab; 3.9 % for HC3) and headache (18.5 % vs 2.0 % for HC3) were more frequent in blinatumomab arm.

No unexpected safety signal was raised comparing blinatumomab arm to pooled paediatric safety data. Of note, mucosal inflammation was no longer reported as TRAEs with blinatumomab. A decrease in TRAE of CSR was noted; applicant's hypothesis that this could be related to lower blast count in study 20120215 is acknowledged.

<div style=\"page-break-after: always\"></div>

The applicant provided data on TEAEs occurred after 31 days after treatment stopped in study 20120215. Among them, serious GVHD events were more frequently reported in blinatumomab arm: acute GVHD (none in HC3; 1 in blinatumomab arm), GVHD in gastrointestinal tract (1 each) and GVHD in skin (none in HC3; 1 in blinatumomab arm) . Delayed neutrophil/platelet engraftment were discucssed based on ANC ≤ 5 x10 9 /L and Platelet Count ≤ 20 x 10 9 /L at 45 days Post-transplant. Based on cases retrieved, no risk of delayed neutrophil/platelet engraftment was identified following blinatumomab treatment pre HSCT. Infections post HCT were reported in 67 patients gobally (n=36, 75.0% of patients with HSCT in blinatumomab arm; n=31, 67.4% in HC3 arm). No significant difference in these infections between both arms was identified. Two cases of graft failure were reported, one in each arm. Based on case narratives provided, no unexpected safety finding was raised from these two cases. GvHD was only reported in blinatumomab arm, in 3 patients. Of note, two of them had received HSCT from match-sibling donor. The applicant considered that, based on blinatumomab half life, a causal relationship is poorly probable. However, considering the 3 cases described, and the absence of case in HC3 arm, this point remains of concern. Supportive data were provided, from a previous phase 2 study, without higher risk of GvHD identified. Based on data provided, a causal relationship or a higher potential risk between blinatumomab treatment and GvHD seems not being supported. However, the risk of GvHD should remain closely monitored in the routine pharmacovigilance. To be noted, the risk of Hematopoietic stem cell transplantation-related toxicity in children remains one of the important potential risks, described in the RMP.

No fatal TEAE was reported in study 20120215. T he frequency of serious TEAEs was lower in blinatumomab arm (24.1% vs 43.1%); a similar trend was observed among treatment related serious AEs ('16.7% vs 27.5%). No unexpected safety finding was retrieved among serious AEs.

No unexpected trend in AEs leading to Treatment Interruptions and treatment discontinuation was observed in study 20120215.

Prespecified AESIs were neurologic events, cytokine release syndrome (CRS), infections, elevated liver enzymes, infusion reactions, tumor lysis syndrome (TLS), capillary leak syndrome (CLS), medication errors, decreased immunoglobulins, embolic and thrombotic events (including disseminated intravascular coagulation [DIC]), leukoencephalopathy including progressive multifocal leukoencephalopathy (PML), neutropenia and febrile neutropenia, lymphopenia, immunogenicity, and pancreatitis. Additionally, the following minimum critical toxicities were reviewed: bone marrow toxicity (cytopenias), hepatotoxicity, nephrotoxicity, and torsade de pointes/QT prolongation, cardiac arrhythmias, and convulsion.

No unexpected safety signal was raised from these AESIs and critical toxicities.

No safety signal was raised from changes in haematology laboratory parameters, immunoglobulins nor from vital signs. Regarding clinical chemistry, a review of the events in the blinatumomab arm of potassium decrease from grade 0 to grade 3 or 4. The review identified 6 AEs with switch in laboratory values, including 3 without temporal relationship with blinatumomab and 3 with confonding concomitant treatments. Theree addiontal cases were retrieved from clinical AEs reported, including 2 without temporal relationship with blinatumomab and 1 with confonding medical condition. Based on these data, and the absence of significant difference in incidence between both arms, no new safety signal was identified.

## Subgroup analysis

The applicant provided a subgroup analysis with 3 age groups in study 20120215: 28 days to 23 months; 2 to 11 years; and 12 to 18 years. Despite limited conclusion due to very small sample size, no difference in safety profile was identified across age groups in blinatumomab arm, nor when comparing each age group between blinatumomab and HC3 arms.

<div style=\"page-break-after: always\"></div>

No significant difference in safety profile was evidenced between male and female patients in blinatumomab arm, nor when comparing each sex group between blinatumomab and HC3 arms.

## 2.5.2. Conclusions on clinical safety

No  unexpected  safety  signal  was  raised  in  high-risk  first  relapse  paediatric  patients  treated  with blinatumomab in consolidation in study 20120215, when  compared to HC3 arm in the study and to pooled safety data in paediatric RR ALL patients.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 15 is acceptable.

The CHMP endorsed the Risk Management Plan version 15 with the following content:

## Safety concerns

Table 72 : Summary of safety concerns

| Important identified risks   | Neurologic events Opportunistic Infections Cytokine release syndrome Medication errors                                                                                                                                                              |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks    | Hematopoietic stem cell transplantation-related toxicity in children                                                                                                                                                                                |
| Missing information          | Use in patients after recent HSCT Recent or concomitant treatment with other anti-cancer therapies (including radiotherapy) Recent or concomitant treatment with other immunotherapy Long-term safety and efficacy                                  |
| Missing information          | Development impairment in children including neurological, endocrine, and immune system Subsequent relapse of leukemia in children including in the central nervous system Long-term toxicity in children Secondary malignant formation in children |

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

Table 73 : Ongoing and Planned Additional Pharmacovigilance Activities

| Study Status                                                                                                                                                                                                        | Summary of Objectives Safety Concerns Addressed                                                                                                                                                                                                                                                                                                                                                | Due Dates                                                                                                                                   |                                                                                                                            |                                                                                                                            |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                          | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                                                                                                                                                                                     | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                  | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization |
| Study 20180130:                                                                                                                                                                                                     | Primary objective: • To estimate incidence of neuropsychomoto r developmental impairment, endocrine impairment, neurological impairment, and immune system impairment (including auto-immune Hematopoietic stem                                                                                                                                                                                | Q1 2020                                                                                                                                     |                                                                                                                            |                                                                                                                            |
| Evaluation of long-term follow- up for developmental, HSCT, and secondary malignancy toxicity in pediatric patients with B-precursor ALL who have been treated with either blinatumomab or chemotherapy followed by | cell transplantation-relate d toxicity in children Long-term safety and efficacy Development impairment in children including neurological, endocrine, and immune system Subsequent relapse leukemia in children                                                                                                                                                                               | Every 2 years from start of data collection                                                                                                 |                                                                                                                            |                                                                                                                            |
| transplantation. Planned Observational Patient Study Study 20150136: An observational study of blinatumomab safety and                                                                                              | including in the central nervous system toxicity in malignant in children events, cytokine                                                                                                                                                                                                                                                                                                     | Q4 2038                                                                                                                                     |                                                                                                                            |                                                                                                                            |
| effectiveness, utilization and treatment practices. Ongoing                                                                                                                                                         | Primary objective: • To characterize the safety profile of blinatumomab in routine clinical practice in countries in Europe by characterizing specific adverse events (neurological events and opportunistic infections) • To estimate the frequency and types of blinatumomab medication errors identified in patient charts Secondary objectives: • To estimate the incidence of all errors, | Submission: 22 January 20 16 Pharmacovigil ance Risk Assessment Committee (PRAC) adoption of draft protocol on 02 September 2016 Enrollment |                                                                                                                            |                                                                                                                            |
|                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                | update will be provided in each PSUR/Periodic Benefit-Risk Evaluation Report (PBRER) Annual interim reports will be provided with           |                                                                                                                            |                                                                                                                            |
|                                                                                                                                                                                                                     | after recent                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                             |                                                                                                                            |                                                                                                                            |
|                                                                                                                                                                                                                     | with other                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                             |                                                                                                                            |                                                                                                                            |
|                                                                                                                                                                                                                     | therapies                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                             |                                                                                                                            |                                                                                                                            |
|                                                                                                                                                                                                                     | recent                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                             |                                                                                                                            |                                                                                                                            |
|                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                | corresponding                                                                                                                               |                                                                                                                            |                                                                                                                            |
|                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                | PSUR/PBRER                                                                                                                                  |                                                                                                                            |                                                                                                                            |
| adverse                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                             |                                                                                                                            |                                                                                                                            |
| events                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                             |                                                                                                                            |                                                                                                                            |
| starting with                                                                                                                                                                                                       | starting with                                                                                                                                                                                                                                                                                                                                                                                  | starting with                                                                                                                               | starting with                                                                                                              | starting with                                                                                                              |
|                                                                                                                                                                                                                     | or efficacy                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                             |                                                                                                                            |                                                                                                                            |
|                                                                                                                                                                                                                     | or                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                             |                                                                                                                            |                                                                                                                            |
|                                                                                                                                                                                                                     | vaccine failure)                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                             |                                                                                                                            |                                                                                                                            |
|                                                                                                                                                                                                                     | Secondary formation Neurologic opportunistic infections, release syndrome, medication use in recent                                                                                                                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                            |                                                                                                                            |
|                                                                                                                                                                                                                     | and                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                             |                                                                                                                            |                                                                                                                            |
|                                                                                                                                                                                                                     | Long-term children                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                             |                                                                                                                            |                                                                                                                            |
| and                                                                                                                                                                                                                 | and                                                                                                                                                                                                                                                                                                                                                                                            | and                                                                                                                                         | and                                                                                                                        | and                                                                                                                        |
|                                                                                                                                                                                                                     | patients HSCT, concomitant treatment anti-cancer (including radiotherapy), concomitant treatment                                                                                                                                                                                                                                                                                               |                                                                                                                                             |                                                                                                                            |                                                                                                                            |
| with other immunotherapy, long-term safety                                                                                                                                                                          | with other immunotherapy, long-term safety                                                                                                                                                                                                                                                                                                                                                     | with other immunotherapy, long-term safety                                                                                                  | with other immunotherapy, long-term safety                                                                                 | with other immunotherapy, long-term safety                                                                                 |
|                                                                                                                                                                                                                     | disorders and                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                             |                                                                                                                            |                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                  | • To estimate the incidence of the specified adverse events and all adverse events collected in this study among patient subgroups defined by demographic and clinical factors • To evaluate efficacy endpoint overall and among patient subgroups defined by demographic and clinical factors • To describe blinatumomab utilization and select healthcare resource use in routine clinical   |                                                               |                                                               | PSUR/PBRER # 3                                                |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                                                                                                                                                                                  | • To estimate the incidence of the specified adverse events and all adverse events collected in this study among patient subgroups defined by demographic and clinical factors • To evaluate efficacy endpoint overall and among patient subgroups defined by demographic and clinical factors • To describe blinatumomab utilization and select healthcare resource use in routine clinical   |                                                               | Final report                                                  | Anticipated Q1 2024                                           |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                    | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                  | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities |
| Observational Cohort Study Study 20170610:                                                                                                                                       | Primary objective: • Describe 100-day and mortality • Estimate the incidence of graft versus host disease (GVHD) (acute and                                                                                                                                                                                                                                                                    | Long-term safety and efficacy                                 | Final Protocol                                                | Q1 2020                                                       |
| Overall survival and incidence of adverse events in B-cell acute lymphoblastic leukemia (ALL) patients after allogeneic stem cell transplant: induction with blinatumomab versus | chronic)                                                                                                                                                                                                                                                                                                                                                                                       | Long-term safety and efficacy                                 | Interim CSR                                                   | Q2 2025                                                       |
| non-blinatumoma b chemotherapy - an analysis of the Center for International Blood and Marrow Transplant Research Database.                                                      | Primary objective: • Describe 100-day and mortality • Estimate the incidence of graft versus host disease (GVHD) (acute and                                                                                                                                                                                                                                                                    | Long-term safety and efficacy                                 | Final CSR                                                     | Anticipated Q1 2030                                           |
| Planned A Randomized, Open-label, Controlled phase 3 Adaptive Trial                                                                                                              | To evaluate EFS in the blinatumomab arm versus EFS in the standard consolidation chemotherapy arm                                                                                                                                                                                                                                                                                              | Long-term safety and efficacy                                 | CSR                                                           | July 2024                                                     |

<div style=\"page-break-after: always\"></div>

| A randomized, open-label, controlled phase 3 adaptive trial to investigate the efficacy, safety, and tolerability of the bi-specific T-cell engager (BiTE  ) antibody blinatumomab as consolidation therapy versus conventional chemotherapy in pediatric patients with high-risk first relapse of B-precursor acute lymphoblastic leukemia (ALL) Ongoing   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## Risk minimisation measures

Table  74: Summary Table of Pharmacovigilance Activities and Risk Minimization Activities by Safety Concern

| Safety Concern             | Risk Minimization Measures                                                                                                                                                                                                                                                                                                     | Pharmacovigilance Activities                                                                                                                                                         |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks | Important Identified Risks                                                                                                                                                                                                                                                                                                     | Important Identified Risks                                                                                                                                                           |
| Neurologic events          | Routine risk minimization measures: • SmPC Section 4.2 • SmPC Section 4.4 • SmPC Section 4.7 • SmPC Section 4.8 • PIL Section 2 • PIL Section 4 Additional risk minimization measures: • Educational materials for physicians, nurses, pharmacists and patients (including caregivers), and patient alert card (see Part V.2). | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational patient Study 20150136 |

<div style=\"page-break-after: always\"></div>

| Opportunistic infections                                             | Routine risk minimization measures: • SmPC Section 4.4 • SmPC Section 6.6 • PIL Section 4 Additional risk minimization measures: • None                                                                                                                                                            | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational patient Study 20150136   |
|----------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cytokine release syndrome                                            | Routine risk minimization measures: • SmPC Section 4.2 • SmPC Section 4.4 • SmPC Section 4.5 • SmPC Section 4.8 • SmPC Section 5.1 • SmPC Section 5.3 • PIL Section 4 Additional risk minimization measures:                                                                                       | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational patient Study 20150136   |
| Medication errors                                                    | Routine risk minimization measures: • SmPC Section 4.4 • SmPC Section 4.9 • SmPC Section 6.6 Additional risk minimization measures: • Educational Materials for Physicians, Pharmacists, Nurses, and Patients (Including Caregivers). In addition, patients will also receive a patient alert card | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational Patient Study 20150136   |
| Important Potential Risks                                            | Important Potential Risks                                                                                                                                                                                                                                                                          | Important Potential Risks                                                                                                                                                              |
| Hematopoietic stem cell transplantation-related toxicity in children | Routine risk minimization measures: • None Additional risk minimization measures: • None                                                                                                                                                                                                           | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational cohort Study 20180130    |

<div style=\"page-break-after: always\"></div>

| Missing Information                                                                       | Missing Information                                                                      | Missing Information                                                                                                                                                                                                                                                                                         |
|-------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Use in patients after recent HSCT                                                         | Routine risk minimization measures: • None Additional risk minimization measures: • None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational patient Study 20150136                                                                                                                        |
| Recent or concomitant treatment with other anti-cancer therapies (including radiotherapy) | Routine risk minimization measures: • None Additional risk minimization measures: • None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational patient Study 20150136                                                                                                                        |
| Recent or concomitant treatment with other immunotherapy                                  | Routine risk minimization measures: • None Additional risk minimization measures: • None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational patient Study 20150136                                                                                                                        |
| Long-term safety and efficacy                                                             | Routine risk minimization measures: • None Additional risk minimization measures: • None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • An open-label, controlled Study 20120215 • Observational patient Study 20150136 • Observational cohort Study 20170610 • Observational cohort Study 20180130 |

<div style=\"page-break-after: always\"></div>

HSCT = hematopoietic stem cell transplantation; PIL = patient information leaflet; SmPC = summary of product characteristics

| Development impairment in children including neurological, endocrine, and immune system   | Routine risk minimization measures: • None Additional risk minimization measures: • None   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational cohort Study 20180130   |
|-------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Subsequent relapse of leukemia in children including in the central nervous system        | Routine risk minimization measures: • None Additional risk minimization measures: • None   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational cohort Study 20180130   |
| Long-term toxicity in children                                                            | Routine risk minimization measures: • None Additional risk minimization measures: • None   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational cohort Study 20180130   |
| Secondary malignant formation in children                                                 | Routine risk minimization measures: • None Additional risk minimization measures: • None   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational cohort Study 20180130   |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.8, 5.1, 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

Changes were also made to the PI to bring it in line with the current Agency/QRD template, SmPC guideline and other relevant guideline(s) [e.g. Excipients guideline, storage conditions, Braille, etc…] and to improve readability in section 6.6 pf the SmPC, which were reviewed and accepted by the CHMP.

for full changes please see the appended final approved Product information

<div style=\"page-break-after: always\"></div>

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

No full user consultation with target patient groups on the package leaflet has been performed on the basis of a bridge to the results of the user consultation performed for the initial MAA. The changes to the package leaflet are minimal and do not require user consultation with target patient groups.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

The purpose of this variation application is to include:

BLINCYTO as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor ALL as part of the consolidation therapy.

## 3.1.1. Disease or condition

Acute lymphoblastic leukemia is a rare aggressive cancer of the blood and bone marrow. The majority of ALL cases are B-lineage, Philadelphia-negative ALL. There are approximately 6,300 new cases diagnosed in the European Union (EU) each year (based on Forman et al, 2014). Of these, approximately half are children. B-cell precursor ALL is the most common subtype of ALL, accounting for approximately 80% to 85% of total cases of ALL in children (American Cancer Society, 2015 and 2014).

Among children with B-cell precursor ALL, more than 95% achieve a complete remission (CR) with front-line treatment, and 75% to 85% remain progression-free 5 years from initial diagnosis (Schrappe et al, 2013). However, approximately 15% to 20% of children with B-cell precursor ALL relapse after current front-line chemotherapy (Hunger et al, 2015).

The International Study for Children and Adolescents with Relapsed ALL (IntReALL), formed in 2010, stratified this population into two distinct risk groups, standard risk and high risk, defined by established risk factors (IntReALL, 2017; Locatelli et al, 2012). Therefore, the high-risk first relapsed ALL patient population is defined as patients with very early relapse (&lt; 18 months from initial diagnosis) at any anatomical site, early isolated bone marrow relapse (&lt; 18 months after primary diagnosis and &lt; 6 months from completion of front-line therapy), and/or MRD-positive disease.

## 3.1.2. Available therapies and unmet medical need

Pediatric treatment regimens are more intense than those used in adults and include courses of combination chemotherapy, including central nervous system (CNS) prophylaxis and treatment (eg, intrathecal chemotherapy with or without cranial radiation).

Treatment of high-risk first relapsed ALL generally includes 3 phases, including CNS prophylaxis and treatment:

<div style=\"page-break-after: always\"></div>

- Induction: The goal of induction therapy is to reduce tumor burden. Induction regimens are typically based on corticosteroids, vincristine, and anthracyclines with or without L-asparaginase and/or cyclophosphamide, 6-mercaptopurine, and cytosine arabinoside.

- Consolidation: The intent of post-induction consolidation is to eliminate potential leukemic cells that remain after induction therapy, thus permitting further eradication of residual disease. The combination of drugs and duration of therapy for consolidation regimens vary between studies and patient populations.

- Allogeneic HSCT: Patients with poor outcome and high rates of subsequent relapse after conventional intensive chemotherapy have an indication for allogeneic HSCT.

- CNS Prophylaxis and Treatment: CNS prophylaxis is typically given throughout the course of ALL therapy starting from induction and continuing through maintenance therapy.

Current treatment options rely heavily on aggressive chemotherapy regimens that are generally cytotoxic and may be poorly tolerated. Toxicities associated with these treatments may adversely contribute to reduced effectiveness and increased treatment-related mortality of subsequent allogeneic HSCT.

## 3.1.3. Main clinical studies

This extension of indication is mainly based on Study 20120215, a phase 3, randomized, open-label, controlled, multicenter study investigating the efficacy and safety profile of blinatumomab as part of the consolidation therapy versus intensive standard late consolidation chemotherapy in pediatric high-risk first relapsed ALL subjects. The randomized study design allows a comparison of results obtained versus SOC.

After induction therapy and 2 blocks of consolidation chemotherapy, patients were randomized (1:1) to:

- blinatumomab arm: continuous IV infusion, 15 µg/m²/day over 4 weeks (and maximum daily dose of 28 µg/day);

- or a third block of standard-of-care (SOC) chemotherapy (HC3 arm), per the IntReALL protocol.

Eligible paediatric subjects for this study should have Phi - B-precursor ALL in first relapse. High-risk (HR) population was defined as per IntReALL study, or with positive MRD after induction and 2 consolidation cycles. HR status per IntReALL protocol is defined per very early relapse (&lt; 18 months from initial diagnosis), early isolated bone marrow relapse (&gt; 18 months after primary diagnosis and &lt; 6 months from completion of front-line therapy).

This study included a long-term FU up to 36 months until the last subject on study after HSCT or died.

The planned sample size was 202 subjects to allow 84% power using a 2-sided alpha level of 0.05. However, the recruitment in the study was prematurely stopped on 17 July 2019 for efficacy in blinatumomab arm, based on DMC recommendation at time of first interim analysis. Thus, study data are limited to primary analysis, in a sample size limited to 108 enrolled patients (54 per study arm).

Most of patients completed investigational treatment (99; 91.7%: 49 subjects in the HC3 arm and 50 subjects in the blinatumomab arm).

<div style=\"page-break-after: always\"></div>

## 3.2. Favourable effects

Median EFS in blinatumomab arm was not reached (vs 7.4 months (95% CI: 4.5; 12.7) in HC3 arm) and EFS event incidence was statistically different, in favour of blinatumomab arm (57.4% in the HC3 arm and 33.3% in the blinatumomab arm). Results in subgroups analysis confirmed trends observed in EFS, favourable with blinatumomab treatment. The 36-month KM estimate EFS was 26.9 % (13.2 % to 42.8 % ) in HC3 arm and 55.7 % (37.8 % to 70.4 % ) in blinatumomab arm.

Median OS were not reached at time of interim data cut off. Death incidence was 29.6% in the HC3 arm and 14.8% in the blinatumomab arm, with a significant difference in both stratified and unstratified analysis.

With PCR method, the difference in MRD response was statistically significant: 54.2% in HC3 arm vs 89.8% in blinatumomab arm. Trends in MRD response were similar when measured by flow cytometry. Sensitivity analysis with per protocol, despite very limited sample size, confirmed the favorable trend observed with blinatumomab in MRD response.

The cumulative relapse, in the full analysis set (54 subjects per arm), was 53.7% of patients in HC3 arm and 24.1% in blinatumomab arm presented with LAL relapse. Considering the cumulative incidence estimate of relapse or death due to DP, the difference remained significant between both arms up to 36 months from randomization, in favor of blinatumomab treatment.

At the cutoff date (17 July 2019), 41/48 (85.4%) of patients remained alive in blinatumomab arm, and 26/38 (68.4%) in HC3 arm. The median time to death was reached in neither arm.

None of the 48 patients with a post baseline antibody result presented with anti-blinatumomab antibodies.

## 3.3. Uncertainties and limitations about favourable effects

The randomized study design allows a comparison of results obtained versus SOC. However, the following limitations should be taken into account:

- -A bias in investigator's assessment cannot be ruled out considering the open label design;
- -Recruitment in the study was prematurely stopped on 17 July 2019 for efficacy in blinatumomab arm, based on DMC recommendation. Thus, study data are limited to primary analysis, in a sample size limited to 108 enrolled patients (54 per study arm). The final analysis remains expected, planned by 2023;
- -Results in median OS remain expected in the final analysis, to be completed by may 2023.

The expected cure rate increase, in terms of 36-month KM EFS estimate, was met. However, the cure rate in the comparative arm was lower than expected. This point was further clarified: the expected cure rate in the comparative arm, based on 2013 unpublished study data, could have been overestimated, considering current improvements in first-line treatments. However, considering results raised in blinatumomab arm, this would not have impacted efficacy results, nor their interpretation.

About one half of patients had important protocol deviations. However, these deviations had no major impact on the results assessment. Moreover, assessment not performed in due time for 14 subjects and non-fulfilment with inclusion/exclusion criteria for 8 patients (3 in HC3 arm, 5 in Blinatumomab arm) bear no impact on study results nor on the robustness of the study conduct.

While high risk of relapse in patients with MRD is acknowledged, HR status per MRD level is not clearly described in IntReALL protocol, and not clearly specified in inclusion criteria. Nevertheless, MRD level

<div style=\"page-break-after: always\"></div>

was not part of HR status but was assessed at screening and considered as risk factor in stratification at the end of the induction therapy.

Exposure to blinatumomab in pediatric patients aged 1-&lt;18 years with high-risk first relapsed Ph- Bcell precursor ALL, receiving the commercial formulation following a BSA based dose regimen, has been shown to be 1.7 fold higher than both adult and pediatric with R/R ALL.

No evaluation of quality of life was provided. Considering the 4 weeks IV continuous treatment with blinatumomab, vs one week of HC3 course, this would have been helpful to complete the assessment.

No increase in allo HSCT was obtained: 85.2% in HC3 arm and 88.9% in blinatumomab arm. Median time to transplant from randomization was similar between both arms (1.7 and 1.9 month in HC3 and blinatumomab arms respectively).

No significant difference in 100-days mortality was observed: 4.2% (1.1; 15.6) in blinatumomab arm vs 5.6% (1.4; 20.5) in HC3 arm.

Very few data have been provided on response to CAR-T cells after blinatumomab considering that this could have been of concern, but very preliminary exploratory analysis did not confirm this risk at this point in time.

## 3.4. Unfavourable effects

Safety data in this extension of indication are provided from the pivotal study 20120215: ongoing phase 3, randomized, open-label, controlled, multicentre study investigating the efficacy and safety profile of blinatumomab versus intensive SOC late consolidation chemotherapy in paediatric subjects.

The review also included pooled safety data from 3 completed single-arm, open-label, multicenter blinatumomab studies in paediatric subjects with relapsed/refractory ALL (second or greater relapsed, relapsed after HSCT, and refractory to previous treatments).

Safety analysis set in study 20120215 includes 105 patients (51 in HC3 arm, 54 in blinatumomab arm). Subjects received 1 cycle of blinatumomab treatment (4 weeks, 15 µg/m²/day through continuous IV). 50 patients completed study treatment in blinatumomab arm.

## Overview of safety profile

In study 20120215, most of patients presented with AEs in both arms (96.1% and 100% in HC3 and blinatumomab arms respectively). The frequency of treatment related AEs (TRAE) was also similar (78.4% and 83.3%) respectively. However, a higher proportion of patients in HC3 arm presented with TRAE grade ≥3 (62.7% vs 46.7% in blinatumomab arm) and serious TRAE (25.7% vs 16.7% in blinatumomab arm).

In study 20120215, TAEs in blinatumomab arm were driven by pyrexia (81.5% versus 19.6%), nausea (40.7% for versus 17.6%), and headache (35.2% versus 17.6%), while a higher frequency for the following AEs was reported in HC3 arm: anaemia (45.1% vs 22.2%), neutropenia (31.4% vs 9.3%), thrombocytopenia (25.5% vs 7.4%), febrile neutropenia (25.5% vs 5.6%) and stomatitis (54.9% vs 18.5%).

The safety profile in grade ≥3 TEAEs appeared to be more favourable in blinatumomab arm, with the following grade ≥3 TEAEs more frequent in HC3: anaemia (41.2% in HC3 arm vs 14.8% in blinatumomab arm), neutropenia (27.5% vs 9.3%), febrile neutropenia (25.5% vs 3.7%) and stomatitis (31.4% vs 5.6%). The safety profile for grade≥3 TEAEs of blinatumomab in study 20120215 was similar to pooled RR ALL paediatric population.

<div style=\"page-break-after: always\"></div>

The following TRAEs were more frequent in HC3 arm: anaemia (35.3 % for HC3; 3.7 % for blinatumomab), stomatitis (41.2% vs 1.9 % ), platelet count decreased (13.7 % vs 0 % ), neutropenia (25.5 % vs 1.9 % ), and thrombocytopenia (21.6 % vs 1.9 % ). TRAEs of pyrexia (55.6 % for blinatumomab; 3.9 % for HC3) and headache (18.5 % vs 2.0 % for HC3) were more frequent in blinatumomab arm.

No fatal TEAE was reported in study 20120215. T he frequency of serious TEAEs was lower in blinatumomab arm (24.1% vs 43.1%); a similar trend was observed among treatment related serious AEs (16.7% vs 27.5%). No unexpected safety finding was retrieved among serious AEs.

No unexpected trend in AEs leading to Treatment Interruptions and treatment discontinuation was observed in study 20120215.

## Adverse Events of Special Interest (AESIs)

Prespecified AESIs were neurologic events, cytokine release syndrome (CRS), infections, elevated liver enzymes, infusion reactions, tumor lysis syndrome (TLS), capillary leak syndrome (CLS), medication errors, decreased immunoglobulins, embolic and thrombotic events (including disseminated intravascular coagulation [DIC]), leukoencephalopathy including progressive multifocal leukoencephalopathy (PML), neutropenia and febrile neutropenia, lymphopenia, immunogenicity, and pancreatitis.

Additionally, the following minimum critical toxicities were reviewed: bone marrow toxicity (cytopenias), hepatotoxicity, nephrotoxicity, and torsade de pointes/QT prolongation, cardiac arrhythmias, and convulsion.

No unexpected safety signal was raised from these AESIs and critical toxicities.

No safety signal was raised from changes in haematology laboratory parameters, immunoglobulins nor from vital signs.

## 3.5. Uncertainties and limitations about unfavourable effects

The safety profile of blinatumomab was similar to pooled RR ALL paediatric population, despite a higher frequency of nausea (40.7% for high-risk first relapsed; 22.8% for relapsed/refractory), stomatitis (18.5% for high-risk first relapsed; 7.5% for relapsed/refractory), and mucosal inflammation (16.7% for high-risk first relapsed; 2.6% for relapsed/refractory) in blinatumomab arm in study 20120215. The implication of previous consolidation cycles in the onset of these TEAEs, as well as HSCT conditioning, in this population cannot be ruled out.

The applicant provided a summary table of TEAEs occurred after 31 days after treatment stopped in study 20120215. Among them, serious GVHD events were more frequently reported in blinatumomab arm: acute GVHD (none in HC3; 1 in blinatumomab arm), GVHD in gastrointestinal tract (1 each) and GVHD in skin (none in HC3; 1 in blinatumomab arm). Nevertheless, no safety signal was raised but this risk remains to be closely monitored.

## 3.6. Effects Table

Table 75. Effects Table for blinatumomab in paediatric patients with high-risk first relapsed Phi neg CD19 +  B-precursor ALL as consolidation therapy

| Effect             | Short description   | Unit   | Control   | Treatment   | Uncertainties / Strength of evidence   | Refere nces   |
|--------------------|---------------------|--------|-----------|-------------|----------------------------------------|---------------|
| Favourable Effects | Favourable Effects  |        |           |             |                                        |               |

<div style=\"page-break-after: always\"></div>

| Effect                                                | Short description                                                                                                                                                                                                          | Unit                 | Control                            | Treatment                          | Uncertainties / Strength of evidence                                                                                       | Refere nces          |
|-------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|------------------------------------|------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------|
| EFS Events, n ( % ) Median, months (95%CI )           | Time from randomization until the date of relapse or M2 marrow after having achieved a CR, failure to achieve a CR at the end of treatment, secondary malignancy, or death due to any cause, whichever occurred first; FAS |                      | 31 (57.4 % ) 7.4 (4.5, 12.7)       | 18 (33.3 % ) NE (12.0, NE)         | p < 0.001 HR (95% CI): 0.36 [0.19, 0.66] open label limited sample size about half patients with major protocol deviations | Study 201202 15      |
| 36-month KM estimate (95 % CI)                        |                                                                                                                                                                                                                            | Months               |                                    |                                    | Expected cure rate increase was met.                                                                                       | Study 201202 15      |
|                                                       |                                                                                                                                                                                                                            |                      | 26.9 % (13.2 % to 42.8 % )         | 55.7 % (37.8 % to 70.4 % )         | But the cure rate in the comparative arm was lower than expected.                                                          |                      |
| OS Number of death (%) 36-month estimate (%) [95% CI] |                                                                                                                                                                                                                            |                      | 16 (29.6) 55.8 [36.9, 71.0]        | 8 (14.8) 81.1 [65.5, 90.2]         | P 0.047 HR (95% CI): 0.43 [0.18, 1.01]                                                                                     |                      |
| Median OS (95 % CI) b                                 | Time from the time of randomization until death to any cause                                                                                                                                                               | Months               | NE (15.7 months to                 | NE (NE, NE)                        | Results in median OS remain expected in the                                                                                | Study 201202 15      |
| MRD                                                   | MRD level < 10 -4 , by quantitative PCR or flow cytometry                                                                                                                                                                  |                      | 54.2 % (26/48) (39.2 % to 68.6 % ) | 89.8 % (44/49) (77.8 % to 96.6 % ) | p < 0.001                                                                                                                  | Study 201202 15      |
| 100 days mortality (KM estimate)                      | in subjects who received allogeneic HSCT while in CR after study treatment                                                                                                                                                 |                      | 5.6 % (1.4 % to 20.5 % )           | 4.2 % (1.1 % to 15.6 % )           | No significant difference                                                                                                  | Study 201202 15      |
| Unfavourable Effects                                  | Unfavourable Effects                                                                                                                                                                                                       | Unfavourable Effects | Unfavourable Effects               | Unfavourable Effects               | Unfavourable Effects                                                                                                       | Unfavourable Effects |
| TRAEs SAEs                                            |                                                                                                                                                                                                                            |                      | 78.4% 43.1%                        | 83.3% 24.1%                        | No fatal AEs                                                                                                               |                      |
| AESIs                                                 |                                                                                                                                                                                                                            |                      |                                    |                                    | No unexpected safety signal in AESIs and critical toxicities.                                                              |                      |

Abbreviations: TEAE: treatment related adverse event, CI: confidence interval; EFS: event free survival; OS: overall survival, MRD: minimal residual disease

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The pivotal study, 20120215, enrolled 108 patients (54 per study arm). Most of patients completed investigational treatment (99; 91.7%).

Considering treatment schedule, blinatumomab is part of consolidation therapy. The indication was reviewed to clearly reflect this point.

Median EFS in blinatumomab arm was not reached (vs 7.4 months (95% CI: 4.5; 12.7) in HC3 arm) and EFS event incidence was statistically different, in favour of blinatumomab arm (57.4% in the HC3 arm and 33.3% in the blinatumomab arm). The 36-month KM estimate EFS was 26.9 % (13.2 % to 42.8 % ) in HC3 arm and 55.7 % (37.8 % to 70.4 % ) in blinatumomab arm.

Median OS were not reached at time of interim data cut off. Death incidence was 29.6% in the HC3 arm and 14.8% in the blinatumomab arm, with a significant difference in both stratified and unstratified analysis.

With PCR method, the difference in MRD response was statistically significant: 54.2% in HC3 arm vs 89.8% in blinatumomab arm.

At the cut off date (17 July 2019), 41/48 (85.4%) of patients remained alive in blinatumomab arm, and 26/38 (68.4%) in HC3 arm. The median time to death was reached in neither arm.

No increase in allo HSCT was obtained: 85.2% in HC3 arm and 88.9% in blinatumomab arm. Median time to transplant from randomization was similar between both arms (1.7 and 1.9 month in HC3 and blinatumomab arms respectively).

No significant difference in 100-days mortality was observed: 4.2% (1.1; 15.6) in blinatumomab arm vs 5.6% (1.4; 20.5) in HC3 arm.

The safety profile was similar between both arms, and coherent with the known safety profile of blinatumomab.

The randomized study design allows a comparison of results obtained versus SOC. However, the following limitations should be taken into account:

- -A bias in investigator's assessment cannot be ruled out considering the open label design;
- -Recruitment in the study was prematurely stopped on 17 July 2019 for efficacy in blinatumomab arm, based on DMC recommendation. Thus, study data are limited to primary analysis, in a sample size limited to 108 enrolled patients (54 per study arm). The final analysis remains expected, planned by 2023.

Exposure to blinatumomab in the target population was 1.7-fold higher than both adult and pediatric with R/R ALL, however the safety profile remain similar between both populations.

The expected cure rate increase, in terms of 36-month KM EFS estimate, was met. The cure rate in the comparative arm was lower than expected, probably overestimated due to treatment improvements since protocol design.

No evaluation of quality of life was provided. Considering the 4 weeks IV continuous treatment with blinatumomab, vs one week of HC3 course, this would have been helpful to complete the assessment.

<div style=\"page-break-after: always\"></div>

## 3.7.2. Balance of benefits and risks

Despite limitations due to limited sample size, open-label design and deviations, efficacy results in the target indication are favourable to blinatumomab vs HC3, in terms of EFS and OS estimate, as well as RMD response. No significant difference in allo HSCT was obtained.

The safety profile was similar between both arms, and coherent with the known safety profile of blinatumomab.

## 3.7.3. Additional considerations on the benefit-risk balance

N/A

## 3.8. Conclusions

The overall B/R of blinatumomab in the claimed indication is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of indication to include  the use of blinatumomab as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor ALL as part of the consolidation therapy; as a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 of the SmPC are updated. In addition, section 6.6 of the SmPC is updated to improve readability of the instructions for preparation. The Package Leaflet is updated in accordance. Version 15 of the RMP has also been submitted.

The variation leads to amendments to the Summary of Product Characteristics, Annex II, Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

<div style=\"page-break-after: always\"></div>

## Paediatric data

Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan P/0143/2020 and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Blincyto is not similar to Iclusig, (ponatinib), Xaluprine (Mercaptopurine), Besponsa (inotuzumab ozogamicin) and Kymriah (tisagenlecleucel) within the meaning of Article 3 of Commission Regulation (EC) No. 847/200.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Blincyto-H-C-3731-II-0038'